{NP_1}PMID{/NP_1} - {CP_2}19018287{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}The <p>LIM-only protein FHL2</p>{/NP_P_4} {VP_act_5}mediates{/VP_act_5} {NP_6}ras-induced transformation{/NP_6} through {NP_7}<p>cyclin D1</p> and <p>p53</p> pathways{/NP_7} .

{NP_8}AB{/NP_8} - {NP_9}BACKGROUND{/NP_9} :

{NP_P_10}<p>Four and a half LIM-only protein 2 ( FHL2 )</p>{/NP_P_10} {VP_pass_11}has been implicated{/VP_pass_11} in {NP_12}multiple signaling pathways{/NP_12} {NP_13}that{/NP_13} {VP_act_14}regulate{/VP_act_14} {NP_15}<Bpcl>cell</Bpcl> growth and <Bpcl>tissue</Bpcl> homeostasis{/NP_15} .

{NP_16}We{/NP_16} {VP_act_17}reported{/VP_act_17} {AV_18}previously{/AV_18} that {NP_P_19}<p>FHL2</p>{/NP_P_19} {VP_act_20}regulates{/VP_act_20} {NP_21}<p>cyclin D1</p> expression{/NP_21} and that {NP_S_22}immortalized <S>FHL2-null <s>mouse</s> embryo fibroblasts ( MEFs )</S>{/NP_S_22} {VP_act_23}display{/VP_act_23} {NP_24}reduced levels{/NP_24} of {NP_P_25}<p>cyclin D1</p>{/NP_P_25} and {NP_26}low proliferative activity{/NP_26} .

{NP_B_27}<B>METHODOLOGY/PRINCIPAL FINDINGS</B>{/NP_B_27} : {AV_28}Here{/AV_28} {NP_29}we{/NP_29} {VP_act_30}address{/VP_act_30} {NP_31}the contribution{/NP_31} of {NP_P_32}<p>FHL2</p>{/NP_P_32} in {NP_33}<Bpcl>cell</Bpcl> transformation{/NP_33} by {VP_act_34}investigating{/VP_act_34} {NP_35}the effects{/NP_35} of {NP_P_36}oncogenic <p>Ras</p>{/NP_P_36} in {NP_37}<B>FHL2-null</B> context{/NP_37} .

{NP_38}We{/NP_38} {VP_act_39}show{/VP_act_39} that {NP_B_40}<B>H-RasV12</B>{/NP_B_40} {VP_act_41}provokes{/VP_act_41} {NP_42}cell cycle arrest{/NP_42} {VP_pass_43}accompanied{/VP_pass_43} by {NP_44}accumulation{/NP_44} of {NP_P_45}<p>p53</p> and <p>p16 (INK4a)</p>{/NP_P_45} in {NP_S_46}immortalized <S><p>FHL2</p>(-/-) MEFs</S>{/NP_S_46} .

{NP_47}These features{/NP_47} {VP_act_48}contrast{/VP_act_48} {AV_49}sharply{/AV_49} with {NP_P_50}<p>Ras</p>{/NP_P_50} {VP_act_51}transforming{/VP_act_51} {NP_52}activity{/NP_52} in {NP_53}wild <Bpcl>type cell lines</Bpcl>{/NP_53} .

{NP_54}We{/NP_54} {NP_55}further{/NP_55} {VP_act_56}show{/VP_act_56} that {NP_57}establishment{/NP_57} of {NP_S_58}<S>FHL2-null cell lines</S>{/NP_S_58} {VP_act_59}differs{/VP_act_59} from {NP_60}conventional immortalization scheme{/NP_60} by {VP_act_61}retaining{/VP_act_61} {NP_P_62}functional <p>p19</p>{/NP_P_62} ( {NP_63}<p>ARF )/p53</p> checkpoint{/NP_63} {NP_64}that{/NP_64} {VP_pass_65}is required{/VP_pass_65} for {NP_66}cell cycle arrest{/NP_66} {VP_pass_67}imposed{/VP_pass_67} by {NP_P_68}<p>Ras</p>{/NP_P_68} .

OUTPUT 0
PTM = ({NP_74};phosphorylation)
	HasAgentTheme="<p>Rb</p>" in "{NP_74}<B>D-type cyclins</B> and <p>Rb</p> phosphorylation{/NP_74}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>p19</p>" in "{NP_P_79}the <p>p19</p>{/NP_P_79}" 	(Features:dist=0)
		Candidate="<p>FHL2</p>" in "{NP_S_71}<S>Ras-expressing <p>FHL2</p>(-/-) cells</S>{/NP_S_71}" 	(Features:dist=0|in-prefix_modifier)
Substrate = ({NP_74}<p>Rb</p>{/NP_74};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_74}<B>D-type cyclins</B> and <p>Rb</p> phosphorylation{/NP_74}16..17|<p>Rb</p>]
Site = (-;-;UNK)

{AV_69}However{/AV_69} , after {NP_70}serial passages{/NP_70} of {NP_S_71}<S>Ras-expressing <p>FHL2</p>(-/-) cells</S>{/NP_S_71} , {VP_pass_72}dramatic increase{/VP_pass_72} in {NP_73}the levels{/NP_73} of {NP_74}<B>D-type cyclins</B> and <p>Rb</p> phosphorylation{/NP_74} {VP_act_75}correlates{/VP_act_75} with {NP_76}the onset{/NP_76} of {NP_77}<Bpcl>cell</Bpcl> proliferation and transformation{/NP_77} without {VP_act_78}disrupting{/VP_act_78} {NP_P_79}the <p>p19</p>{/NP_P_79} ( {NP_80}<p>ARF )/p53</p> pathway{/NP_80} .

{AV_81}Interestingly{/AV_81} , {NP_S_82}primary <S>FHL2-null cells</S>{/NP_S_82} {VP_act_83}overexpressing{/VP_act_83} {NP_P_84}<p>cyclin D1</p>{/NP_P_84} {VP_act_85}undergo{/VP_act_85} {NP_86}a classical immortalization process{/NP_86} {VP_act_87}leading{/VP_act_87} to {NP_88}loss{/NP_88} of {NP_P_89}the <p>p19</p>{/NP_P_89} ( {NP_90}<p>ARF )/p53 checkpoint</p> and susceptibility{/NP_90} to {NP_91}<p>Ras</p> transformation{/NP_91} .

{NP_C_92}<c>CONCLUSIONS/SIGNIFICANCE</c>{/NP_C_92} : {NP_93}Our findings{/NP_93} {VP_act_94}uncover{/VP_act_94} {NP_95}a novel aspect{/NP_95} of {NP_96}cellular responses{/NP_96} {VP_act_97}to mitogenic{/VP_act_97} {NP_98}stimulation{/NP_98} and {VP_act_99}illustrate{/VP_act_99} {NP_100}a critical role{/NP_100} of {NP_P_101}<p>FHL2</p>{/NP_P_101} in {NP_102}the signalling network{/NP_102} {NP_103}that{/NP_103} {VP_act_104}implicates{/VP_act_104} {NP_P_105}<p>Ras</p> , <p>cyclin D1</p> and <p>p53</p>{/NP_P_105} .


{NP_1}PMID{/NP_1} - {CP_2}19001261{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Polyphosphate -dependent synthesis{/NP_4} of {NP_P_5}<p>ATP</p> and <p>ADP</p>{/NP_P_5} by {NP_P_6}the <p>family -2 polyphosphate kinases</p>{/NP_P_6} in {NP_7}<Bpcl>bacteria</Bpcl>{/NP_7} .

{NP_8}AB{/NP_8} - {NP_P_9}Inorganic <p>polyphosphate ( polyP )</p>{/NP_P_9} {VP_act_10}is{/VP_act_10} {NP_11}a linear polymer{/NP_11} of {NP_12}tens{/NP_12} or {NP_13}hundreds{/NP_13} of {NP_PP_14}<pp>phosphate residues</pp>{/NP_PP_14} {VP_pass_15}linked{/VP_pass_15} by {NP_16}high-energy bonds{/NP_16} .

{NP_17}It{/NP_17} {VP_pass_18}is found{/VP_pass_18} in {NP_19}all organisms{/NP_19} and {VP_pass_20}has been proposed{/VP_pass_20} {VP_act_21}to serve{/VP_act_21} as {NP_22}an energy source{/NP_22} in {NP_23}a <B>pre-ATP</B> world{/NP_23} .

{NP_24}This ubiquitous and abundant biopolymer{/NP_24} {VP_act_25}plays{/VP_act_25} {NP_26}numerous and vital roles{/NP_26} in {NP_27}metabolism and regulation{/NP_27} in {NP_28}prokaryotes{/NP_28} and {NP_29}eukaryotes{/NP_29} , but {NP_30}the underlying molecular mechanisms{/NP_30} for {NP_31}most activities{/NP_31} of {NP_P_32}<p>polyP</p>{/NP_P_32} {VP_act_33}remain{/VP_act_33} {JP_34}unknown{/JP_34} .

In {NP_35}prokaryotes{/NP_35} , {NP_36}the synthesis and utilization{/NP_36} of {NP_P_37}<p>polyP</p>{/NP_P_37} {VP_pass_38}are catalyzed{/VP_pass_38} by {NP_39}2 <Bpf>families</Bpf>{/NP_39} of {NP_P_40}<p>polyP kinases</p> , <p>PPK1</p> and <p>PPK2</p>{/NP_P_40} , and {NP_P_41}<p>polyphosphatases</p>{/NP_P_41} .

{AV_42}Here{/AV_42} , {NP_43}we{/NP_43} {NP_44}present structural and functional characterization{/NP_44} of {NP_B_45}the <B><p>PPK2</p> family</B>{/NP_B_45} .

OUTPUT 0
PTM = ({NP_47};phosphorylation)
Inducer = ({NP_47}<p>polyP</p>{/NP_47};-)
	Method=rule: (inducer) for phrase=[{NP_47}a single <p>PPK2</p> domain catalyze <p>polyP</p> -dependent phosphorylation{/NP_47}25..29|<p>polyP</p>]
Kinase = (-;-)
Substrate = (-;-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_48}<p>ADP</p>{/NP_P_48}]
	Filtered={NP_P_48}<p>ADP</p>{/NP_P_48}	(Category=others)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_48}<p>ADP</p>{/NP_P_48}]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({VP_act_55};phosphorylate)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>PPK2</p>" in "{NP_47}a single <p>PPK2</p> domain catalyze <p>polyP</p> -dependent phosphorylation{/NP_47}" 	(Features:dist=0)
		Candidate="<pp><p>PPK2</p> domains</pp>" in "{NP_PP_54}<pp><p>PPK2</p> domains</pp>{/NP_PP_54}" 	(Features:dist=0)
		Candidate="<p>PPK2</p>" in "{NP_PP_54}<pp><p>PPK2</p> domains</pp>{/NP_PP_54}" 	(Features:dist=0)
		Candidate="{NP_P_46}<Bppf>Proteins</Bppf>{/NP_P_46}" 	(Features:dist=0|subject_main)
		Candidate="{NP_P_48}<p>ADP</p>{/NP_P_48}" 	(Features:dist=0|is-substrate_elsewhere|pparg)
Substrate = ({NP_P_56}<p>AMP</p>{/NP_P_56};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_56}<p>AMP</p>{/NP_P_56}]
Site = (-;-;UNK)

{NP_P_46}<Bppf>Proteins</Bppf>{/NP_P_46} with {NP_47}a single <p>PPK2</p> domain catalyze <p>polyP</p> -dependent phosphorylation{/NP_47} of {NP_P_48}<p>ADP</p>{/NP_P_48} to {NP_P_49}<p>ATP</p>{/NP_P_49} , whereas {NP_P_50}<Bppf>proteins</Bppf>{/NP_P_50} {VP_act_51}containing{/VP_act_51} {CP_52}2{/CP_52} {VP_act_53}fused{/VP_act_53} {NP_PP_54}<pp><p>PPK2</p> domains</pp>{/NP_PP_54} {VP_act_55}phosphorylate{/VP_act_55} {NP_P_56}<p>AMP</p>{/NP_P_56} to {NP_P_57}<p>ADP</p>{/NP_P_57} .

{NP_58}Crystal <Bpf>structures</Bpf>{/NP_58} of {NP_P_59}2 representative <Bppf>proteins</Bppf>{/NP_P_59} , {NP_B_60}<B>SMc02148</B>{/NP_B_60} from {NP_61}<s>Sinorhizobium meliloti</s>{/NP_61} and {NP_B_62}<B>PA3455</B>{/NP_B_62} from <s>{NP_63}Pseudomonas{/NP_63} {VP_act_64}aeruginosa{/VP_act_64}</s> , {VP_act_65}revealed{/VP_act_65} {NP_66}a <p>3-layer alpha/beta/alpha</p> sandwich fold{/NP_66} with {NP_67}an alpha-helical lid{/NP_67} {JP_68}similar{/JP_68} to {NP_69}the <Bpf>structures</Bpf>{/NP_69} of {NP_P_70}microbial <p>thymidylate kinases</p>{/NP_P_70} , {VP_act_71}suggesting{/VP_act_71} that {NP_P_72}these <Bppf>proteins</Bppf>{/NP_P_72} {VP_act_73}share{/VP_act_73} {NP_74}a common evolutionary origin and catalytic mechanism{/NP_74} .

{NP_75}Alanine replacement mutagenesis{/NP_75} {VP_act_76}identified{/VP_act_76} {NP_PP_77}9 conserved <Bppp>residues</Bppp>{/NP_PP_77} , {NP_78}which{/NP_78} {VP_pass_79}are required{/VP_pass_79} for {NP_80}activity{/NP_80} and {VP_act_81}include{/VP_act_81} {NP_PP_82}the <Bppp>residues</Bppp>{/NP_PP_82} from {NP_B_83}both <B>Walker A</B> and <B>B motifs</B>{/NP_B_83} and {NP_84}the lid{/NP_84} .

{AV_85}Thus{/AV_85} , {NP_P_86}the <p>PPK2s</p>{/NP_P_86} {VP_act_87}represent{/VP_act_87} {NP_88}a molecular mechanism{/NP_88} , {NP_89}which{/NP_89} {VP_act_90}potentially allow{/VP_act_90} {NP_91}<Bpcl>bacteria</Bpcl>{/NP_91} {VP_act_92}to use{/VP_act_92} {NP_P_93}<p>polyP</p>{/NP_P_93} as {NP_94}an intracellular energy reserve{/NP_94} for {NP_95}the generation{/NP_95} of {NP_96}<p>ATP</p> and survival{/NP_96} .


{NP_1}PMID{/NP_1} - {CP_2}19004803{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>ATR kinase</p>{/NP_P_4} {VP_pass_5}is required{/VP_pass_5} for {NP_6}global genomic nucleotide excision repair{/NP_6} {AV_7}exclusively{/AV_7} during {NP_8}S phase{/NP_8} in {NP_9}<s>human</s> <Bpcl>cells</Bpcl>{/NP_9} .

{NP_10}AB{/NP_10} - {NP_B_11}<B>Global-genomic nucleotide excision repair ( GG-NER )</B>{/NP_B_11} {VP_act_12}is{/VP_act_12} {NP_13}the only pathway{/NP_13} {JP_14}available{/JP_14} to {NP_15}<s>humans</s>{/NP_15} for {NP_16}removal{/NP_16} , from {NP_P_17}the <Bppf>genome</Bppf>{/NP_P_17} {JP_18}overall{/JP_18} , of {NP_B_19}highly genotoxic <B>helix-distorting DNA adducts</B>{/NP_B_19} {VP_pass_20}generated{/VP_pass_20} by {NP_21}many environmental mutagens{/NP_21} and {NP_22}certain chemotherapeutic agents{/NP_22} , {NP_23}e.g.{/NP_23} , UV -induced <B>6-4 photoproducts ( 6-4PPs )</B> and <p>cyclobutane pyrimidine dimers ( CPDs )</p> .

OUTPUT 0
PTM = ({VP_act_28};phosphorylate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_P_24}The ataxia telangiectasia and rad-3-related <p>kinase (ATR)</p>{/NP_P_24} {VP_pass_25}is rapidly activated{/VP_pass_25} in {NP_26}response{/NP_26} to UV -induced replication stress and {NP_27}proceeds{/NP_27} {VP_act_28}to phosphorylate{/VP_act_28} {NP_29}a plethora{/NP_29} of {NP_P_30}<Bppf>downstream effectors</Bppf>{/NP_P_30} {NP_31}that{/NP_31} {VP_act_32}modulate{/VP_act_32} {NP_33}primarily <Bpcl>cell</Bpcl> cycle checkpoints{/NP_33} but {VP_act_34}also apoptosis{/VP_act_34} and {NP_35}DNA repair{/NP_35} .

{VP_act_36}To investigate{/VP_act_36} whether {NP_P_37}this critical <Bppf>kinase</Bppf>{/NP_P_37} {VP_act_38}might participate{/VP_act_38} in {NP_39}the regulation{/NP_39} of {NP_B_40}<B>GG-NER</B>{/NP_B_40} , {NP_41}we{/NP_41} {VP_act_42}developed{/VP_act_42} {NP_43}a novel flow cytometry-based DNA repair assay{/NP_43} {NP_44}that{/NP_44} {VP_act_45}allows{/VP_act_45} {NP_46}precise evaluation{/NP_46} of {NP_47}<B>GG-NER</B> kinetics{/NP_47} as {NP_48}a function{/NP_48} of {NP_49}<Bpcl>cell</Bpcl> cycle{/NP_49} .

{AV_50}Remarkably{/AV_50} , {NP_51}inhibition{/NP_51} of {NP_52}<p>ATR</p> signaling{/NP_52} in {NP_S_53}primary <s>human</s> lung <S>fibroblasts</S>{/NP_S_53} by {NP_54}treatment{/NP_54} with {NP_55}caffeine{/NP_55} , or with {NP_B_56}<B>siRNA</B>{/NP_B_56} {VP_act_57}specifically targeting{/VP_act_57} {NP_P_58}<p>ATR</p>{/NP_P_58} , {VP_pass_59}resulted{/VP_pass_59} in {NP_60}total inhibition{/NP_60} of {NP_61}<B>6-4PP</B> removal{/NP_61} during {NP_B_62}<B>S phase</B>{/NP_B_62} , whereas {NP_63}<Bpcl>cells</Bpcl>{/NP_63} {VP_act_64}repaired{/VP_act_64} {AV_65}normally{/AV_65} during {NP_66}either <B>G(0)/G(1)</B> or G(2)/M{/NP_66} .

{NP_67}Similarly striking S-phase-specific defects{/NP_67} in {NP_B_68}<B>GG-NER</B>{/NP_B_68} of {NP_P_69}both <p>6-4PPs</p> and <p>CPDs</p>{/NP_P_69} {VP_pass_70}were documented{/VP_pass_70} in {NP_S_71}<S>ATR-deficient Seckel syndrome skin fibroblasts</S>{/NP_S_71} .

{AV_72}Finally{/AV_72} , among {NP_73}six diverse model <s>human</s> tumor <Bpcl>strains</Bpcl>{/NP_73} {VP_act_74}investigated{/VP_act_74} , {CP_75}three{/CP_75} {VP_act_76}manifested{/VP_act_76} {NP_77}complete abrogation{/NP_77} of {NP_78}<B>6-4PP</B> repair{/NP_78} {AV_79}exclusively{/AV_79} in {NP_80}S-phase populations{/NP_80} .

{NP_81}Our data{/NP_81} {VP_act_82}reveal{/VP_act_82} {NP_83}a highly novel role{/NP_83} for {NP_P_84}<p>ATR</p>{/NP_P_84} in {NP_85}the regulation{/NP_85} of {NP_B_86}<B>GG-NER</B>{/NP_B_86} {AV_87}uniquely{/AV_87} during {NP_B_88}<B>S phase</B>{/NP_B_88} of {NP_89}the <Bpcl>cell</Bpcl> cycle{/NP_89} , and {VP_act_90}indicate{/VP_act_90} that {NP_91}many <s>human</s> cancers{/NP_91} {VP_pass_92}may be characterized{/VP_pass_92} by {NP_93}a defect{/NP_93} in {NP_94}this regulation{/NP_94} .


{NP_1}PMID{/NP_1} - {CP_2}19008353{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Dynamic equilibrium engagement{/NP_4} of {NP_5}a <Bpf>polyvalent ligand</Bpf>{/NP_5} with {NP_6}a single{/NP_6} - {NP_P_7}<Bppf>site receptor</Bppf>{/NP_P_7} .

{NP_8}AB{/NP_8} - {NP_P_9}Intrinsically disordered <Bppf>proteins</Bppf>{/NP_P_9} {VP_act_10}play{/VP_act_10} {JP_11}critical{/JP_11} but {VP_act_12}often poorly understood{/VP_act_12} {NP_13}roles{/NP_13} in {VP_act_14}mediating{/VP_act_14} {NP_15}<Bppf>protein</Bppf> interactions{/NP_15} .

{NP_16}The interactions{/NP_16} of {NP_P_17}disordered <Bppf>proteins</Bppf>{/NP_P_17} {VP_act_18}studied{/VP_act_18} {VP_act_19}to date{/VP_act_19} {VP_act_20}typically entail{/VP_act_20} {NP_21}structural stabilization{/NP_21} , whether as {NP_22}a global disorder-to-order transition or minimal ordering{/NP_22} of {NP_PP_23}short linear <Bppp>motifs</Bppp>{/NP_PP_23} .

OUTPUT 0
PTM = ({NP_29};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_30}<pp><B>CDK</B> sites</pp>{/NP_PP_30})
	Method=rule: (siteother) for phrase=[{NP_PP_30}its multiple dispersed <pp><B>CDK</B> sites</pp>{/NP_PP_30}20..27|<pp><B>CDK</B> sites</pp>]

{NP_P_24}The disordered <p>cyclin-dependent kinase ( CDK ) inhibitor Sic1</p>{/NP_P_24} {VP_act_25}interacts{/VP_act_25} with {NP_PP_26}a single <Bppp>site</Bppp>{/NP_PP_26} on {NP_P_27}its <Bppf>receptor</Bppf> <p>Cdc4</p>{/NP_P_27} {AV_28}only{/AV_28} upon {NP_29}phosphorylation{/NP_29} of {NP_PP_30}its multiple dispersed <pp><B>CDK</B> sites</pp>{/NP_PP_30} .

{NP_31}The molecular basis{/NP_31} for {NP_32}this multisite -dependent interaction{/NP_32} with {NP_PP_33}a single <Bppp>receptor site</Bppp>{/NP_PP_33} {VP_pass_neg_34}is not known{/VP_pass_neg_34} .

OUTPUT 1
PTM = ({NP_PP_38};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<Bppp>sites</Bppp>" in "{NP_PP_38}multiple phosphorylated <Bppp>sites</Bppp>{/NP_PP_38}" 	(Features:dist=0)
		Candidate="<Bppp>site</Bppp>" in "{NP_PP_44}each <Bppp>site</Bppp>{/NP_PP_44}" 	(Features:dist=0)
Substrate = ({NP_P_39}<p>Sic1</p>{/NP_P_39};-)
	Method=link (substrate) for phrase=[{NP_P_39}<p>Sic1</p>{/NP_P_39}]
		From: {NP_PP_38}multiple phosphorylated <Bppp>sites</Bppp>{/NP_PP_38}
		Path: whole
Site = (-;-;{NP_PP_38}<Bppp>sites</Bppp>{/NP_PP_38})
	Method=rule: (siteother) for phrase=[{NP_PP_38}multiple phosphorylated <Bppp>sites</Bppp>{/NP_PP_38}22..26|<Bppp>sites</Bppp>]

By {NP_35}NMR analysis{/NP_35} , {NP_36}we{/NP_36} {VP_act_37}show{/VP_act_37} that {NP_PP_38}multiple phosphorylated <Bppp>sites</Bppp>{/NP_PP_38} on {NP_P_39}<p>Sic1</p>{/NP_P_39} {VP_act_40}interact{/VP_act_40} with {NP_P_41}<p>Cdc4</p>{/NP_P_41} in {NP_42}dynamic equilibrium{/NP_42} with {NP_43}only local ordering{/NP_43} around {NP_PP_44}each <Bppp>site</Bppp>{/NP_PP_44} .

OUTPUT 2
PTM = ({NP_46};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{AV_45}Regardless{/AV_45} of {NP_46}phosphorylation status{/NP_46} , {NP_P_47}<p>Sic1</p>{/NP_P_47} {VP_act_48}exists{/VP_act_48} in {NP_49}an intrinsically disordered state{/NP_49} but {VP_pass_50}is surprisingly compact{/VP_pass_50} with {NP_51}transient <Bpf>structure</Bpf>{/NP_51} .

{NP_52}The observation{/NP_52} of {NP_53}this unusual binding mode{/NP_53} between {NP_P_54}<p>Sic1</p> and <p>Cdc4</p>{/NP_P_54} {VP_act_55}extends{/VP_act_55} {NP_56}the understanding{/NP_56} of {NP_57}<Bppf>protein</Bppf> interactions{/NP_57} from {NP_58}predominantly static <Bpf>complexes</Bpf>{/NP_58} {VP_act_59}to include{/VP_act_59} {NP_60}dynamic ensembles{/NP_60} of {NP_61}intrinsically disordered states{/NP_61} .


{NP_1}PMID{/NP_1} - {CP_2}19008357{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}The <p>G-protein -coupled receptor kinase 5</p>{/NP_P_4} {VP_act_5}inhibits{/VP_act_5} {NP_6}<p>NFkappaB</p> transcriptional activity{/NP_6} by {VP_act_7}inducing{/VP_act_7} {NP_8}nuclear accumulation{/NP_8} of {NP_P_9}<p>IkappaB alpha</p>{/NP_P_9} .

{NP_10}AB{/NP_10} - {NP_P_11}<p>G-protein-coupled receptor ( GPCR ) kinases</p>{/NP_P_11} , {NP_P_12}<p>GRKs</p>{/NP_P_12} , {VP_pass_13}are known{/VP_pass_13} as {NP_P_14}<Bppf>serine/threonine kinases</Bppf>{/NP_P_14} {NP_15}that{/NP_15} {VP_act_16}regulate{/VP_act_16} {NP_17}<p>GPCR</p> signaling{/NP_17} , but {NP_18}recent findings{/NP_18} {VP_act_19}propose{/VP_act_19} {NP_20}functions{/NP_20} for {NP_P_21}these <Bppf>kinases</Bppf>{/NP_P_21} besides {NP_22}<Bppf>receptor</Bppf> desensitization{/NP_22} .

{AV_23}Indeed{/AV_23} , {NP_P_24}<p>GRK5</p>{/NP_P_24} {VP_act_25}can translocate{/VP_act_25} to {NP_26}the nucleus{/NP_26} by {NP_27}means{/NP_27} of {NP_PP_28}a nuclear <Bppp>localization sequence</Bppp>{/NP_PP_28} , {VP_act_29}suggesting{/VP_act_29} that {NP_P_30}this <Bppf>kinase</Bppf>{/NP_P_30} {VP_act_31}regulates{/VP_act_31} {NP_32}transcription events{/NP_32} in {NP_33}the nucleus{/NP_33} .

{VP_act_34}To evaluate{/VP_act_34} {NP_35}the effect{/NP_35} of {NP_36}<p>GRK5-IkappaB alpha</p> interaction{/NP_36} on {NP_37}<p>NFkappaB</p> signaling{/NP_37} , {NP_38}we{/NP_38} {VP_act_39}induced{/VP_act_39} {NP_40}the overexpression{/NP_40} and {NP_41}the knockdown{/NP_41} of {NP_P_42}<p>GRK5</p>{/NP_P_42} in {NP_43}<Bpcl>cell cultures</Bpcl>{/NP_43} .

{NP_44}<p>GRK5</p> overexpression causes nuclear accumulation{/NP_44} of {NP_P_45}<p>IkappaB alpha</p>{/NP_P_45} , {VP_act_46}leading{/VP_act_46} to {NP_47}the inhibition{/NP_47} of {NP_48}<p>NFkappaB</p> transcriptional activity{/NP_48} .

Opposite {NP_49}results{/NP_49} {VP_pass_50}are achieved{/VP_pass_50} by {NP_51}<p>GRK5</p> knockdown{/NP_51} through {NP_B_52}<B>siRNA</B>{/NP_B_52} .

{NP_53}A physical interaction{/NP_53} between {NP_P_54}<p>GRK5</p> and <p>IkappaB alpha</p>{/NP_P_54} , {AV_55}rather{/AV_55} than {NP_56}<c>phosphorylative</c> events{/NP_56} , {VP_act_57}appears{/VP_act_57} as {NP_58}the underlying mechanism{/NP_58} .

{NP_59}We{/NP_59} {VP_act_60}identify{/VP_act_60} {NP_61}the <Bpf>regulator</Bpf>{/NP_61} of {NP_PP_62}<Bppf>gene protein</Bppf> signaling homology <Bppp>domain</Bppp>{/NP_PP_62} of {NP_P_63}<p>GRK5 (RH)</p>{/NP_P_63} and {NP_PP_64}the <pp>N-terminal domain</pp>{/NP_PP_64} of {NP_P_65}<p>IkappaB alpha</p>{/NP_P_65} as {NP_PP_66}the <Bppp>regions</Bppp>{/NP_PP_66} {VP_pass_67}involved{/VP_pass_67} in {NP_68}such interaction{/NP_68} .

{VP_act_69}To confirm{/VP_act_69} {NP_70}the biological relevance{/NP_70} of {NP_71}this mechanism{/NP_71} of {NP_72}regulation{/NP_72} for {NP_P_73}<p>NFkappaB</p>{/NP_P_73} , {NP_74}we{/NP_74} {VP_act_75}evaluated{/VP_act_75} {NP_76}the effects{/NP_76} of {NP_P_77}<p>GRK5-RH</p>{/NP_P_77} on {NP_78}<p>NFkappaB</p> -dependent phenotypes{/NP_78} .

In {JP_79}particular{/JP_79} , {NP_80}<p>GRK5-RH</p> overexpression{/NP_80} {VP_act_81}impairs{/VP_act_81} {VP_act_82}apoptosis{/VP_act_82} {NP_83}protection and <p>cytokine</p> production{/NP_83} in {NP_84}vitro{/NP_84} and {NP_85}inflammation and <Bpcl>tissue</Bpcl> regeneration{/NP_85} in {NP_86}vivo{/NP_86} .

{NP_87}Our results{/NP_87} {VP_act_88}reveal{/VP_act_88} {NP_89}an unexpected role{/NP_89} for {NP_P_90}<p>GRK5</p>{/NP_P_90} in {NP_91}the regulation{/NP_91} of {NP_92}<p>NFkappaB</p> transcription activity{/NP_92} .

{VP_act_93}Placing{/VP_act_93} {NP_94}these findings{/NP_94} in {NP_95}perspective{/NP_95} , {NP_96}this mechanism{/NP_96} {VP_act_97}may represent{/VP_act_97} {NP_98}a therapeutic target{/NP_98} for {NP_99}all those conditions{/NP_99} {VP_act_100}involving{/VP_act_100} {NP_101}excessive <p>NFkappaB</p> activity{/NP_101} .


{NP_1}PMID{/NP_1} - {CP_2}19018012{/CP_2}

{NP_3}TI{/NP_3} - {NP_B_4}<B>PCTA</B>{/NP_B_4} : {NP_5}a new player{/NP_5} in {NP_6}<p>TGF-beta</p> signaling{/NP_6} .

{NP_7}AB{/NP_7} - {NP_P_8}<p>Transforming growth factor beta ( TGF-beta )</p>{/NP_P_8} {VP_act_9}regulates{/VP_act_9} {NP_10}a wide variety{/NP_10} of {NP_11}biological activities{/NP_11} by {NP_12}binding{/NP_12} to {NP_P_13}<Bpcl>cell</Bpcl> surface <p>serine/threonine kinase receptors</p>{/NP_P_13} .

{NP_14}Canonical <p>TGF-beta</p> signaling{/NP_14} {VP_pass_15}is mediated{/VP_pass_15} by {NP_P_16}<p>Smad proteins</p>{/NP_P_16} , {NP_17}which{/NP_17} {VP_act_18}transduce{/VP_act_18} {NP_19}the <p>TGF-beta</p> signal{/NP_19} from {NP_20}the <Bpcl>cell</Bpcl> surface{/NP_20} into {NP_21}the nucleus{/NP_21} {VP_act_22}to regulate{/VP_act_22} {NP_23}transcription{/NP_23} .

OUTPUT 0
PTM = ({VP_act_26};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_25}<p>TGF-beta receptor</p>{/NP_P_25};-)
	Method=rule: (kinase) for phrase=[{NP_P_25}the <p>TGF-beta receptor</p>{/NP_P_25}3..18|<p>TGF-beta receptor</p>]
Substrate = ({NP_P_27}<p>Smad3</p>{/NP_P_27};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_27}<p>Smad2</p> and <p>Smad3</p>{/NP_P_27}0..4|<p>Smad2</p>]
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_27}<p>Smad2</p> and <p>Smad3</p>{/NP_P_27}8..12|<p>Smad3</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({VP_act_26};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_25}<p>TGF-beta receptor</p>{/NP_P_25};-)
	Method=rule: (kinase) for phrase=[{NP_P_25}the <p>TGF-beta receptor</p>{/NP_P_25}3..18|<p>TGF-beta receptor</p>]
Substrate = ({NP_P_27}<p>Smad2</p>{/NP_P_27};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_27}<p>Smad2</p> and <p>Smad3</p>{/NP_P_27}0..4|<p>Smad2</p>]
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_27}<p>Smad2</p> and <p>Smad3</p>{/NP_P_27}8..12|<p>Smad3</p>]
Site = (-;-;UNK)

Upon {NP_24}<p>TGF-beta</p> binding and <Bppf>receptor</Bppf> activation{/NP_24} , {NP_P_25}the <p>TGF-beta receptor</p>{/NP_P_25} {VP_act_26}phosphorylates{/VP_act_26} {NP_P_27}<p>Smad2</p> and <p>Smad3</p>{/NP_P_27} .

OUTPUT 2
PTM = ({NP_30};phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_31}<p>TGF-beta receptor</p>{/NP_P_31};-)
	Method=rule: (kinase) for phrase=[{NP_P_31}the <p>TGF-beta receptor</p>{/NP_P_31}3..18|<p>TGF-beta receptor</p>]
Substrate = (-;-)
Site = (-;-;UNK)

{NP_28}SARA ( <p>Smad</p> anchor{/NP_28} for {NP_P_29}receptor activation ) and <p>cPML ( cytoplasmic promyelocytic leukemia protein ) recruit Smad2</p> and <p>Smad3</p>{/NP_P_29} for {NP_30}phosphorylation{/NP_30} by {NP_P_31}the <p>TGF-beta receptor</p>{/NP_P_31} .

{NP_P_32}<p>cPML</p>{/NP_P_32} {VP_pass_33}is sequestered{/VP_pass_33} in {NP_34}the nucleus{/NP_34} by {NP_P_35}the <p>homeodomain protein TGIF ( TG-interacting factor )</p>{/NP_P_35} , {NP_36}a negative <Bpf>regulator</Bpf>{/NP_36} of {NP_37}<p>TGF-beta</p> signaling{/NP_37} .

OUTPUT 3
PTM = ({NP_56};phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_58}<p>TGF-beta receptor</p>{/NP_P_58};-)
	Method=rule: (kinase) for phrase=[{NP_P_58}the <p>TGF-beta receptor</p>{/NP_P_58}3..18|<p>TGF-beta receptor</p>]
Substrate = ({NP_P_57}<p>Smad3</p>{/NP_P_57};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_57}<p>Smad2</p> and <p>Smad3</p>{/NP_P_57}0..4|<p>Smad2</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_57}<p>Smad2</p> and <p>Smad3</p>{/NP_P_57}8..12|<p>Smad3</p>]
Site = (-;-;UNK)

OUTPUT 4
PTM = ({NP_56};phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_58}<p>TGF-beta receptor</p>{/NP_P_58};-)
	Method=rule: (kinase) for phrase=[{NP_P_58}the <p>TGF-beta receptor</p>{/NP_P_58}3..18|<p>TGF-beta receptor</p>]
Substrate = ({NP_P_57}<p>Smad2</p>{/NP_P_57};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_57}<p>Smad2</p> and <p>Smad3</p>{/NP_P_57}0..4|<p>Smad2</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_57}<p>Smad2</p> and <p>Smad3</p>{/NP_P_57}8..12|<p>Smad3</p>]
Site = (-;-;UNK)

{AV_38}Recently{/AV_38} , {NP_39}PCTA ( PML competitor{/NP_39} for {NP_B_40}<p>TGIF</p> association ){/NP_B_40} {VP_pass_41}has been shown{/VP_pass_41} {VP_act_42}to compete{/VP_act_42} with {NP_P_43}<p>cPML</p>{/NP_P_43} for {NP_44}binding{/NP_44} to {NP_P_45}<p>TGIF</p>{/NP_P_45} , {VP_act_46}resulting{/VP_act_46} in {NP_47}the accumulation{/NP_47} of {NP_P_48}<p>cPML</p>{/NP_P_48} in {NP_49}the cytoplasm{/NP_49} , {NP_50}where{/NP_50} {NP_51}it{/NP_51} {VP_act_52}mediates{/VP_act_52} {NP_53}the interaction{/NP_53} between {NP_P_54}<p>Smad2/3</p> and <p>SARA</p>{/NP_P_54} and {VP_act_55}coordinates{/VP_act_55} {NP_56}the phosphorylation{/NP_56} of {NP_P_57}<p>Smad2</p> and <p>Smad3</p>{/NP_P_57} by {NP_P_58}the <p>TGF-beta receptor</p>{/NP_P_58} .

{AV_59}Accordingly{/AV_59} , {NP_B_60}<B>PCTA</B>{/NP_B_60} {VP_act_61}promotes{/VP_act_61} {NP_62}<p>TGF-beta</p> -mediated transcriptional regulation and growth inhibition{/NP_62} .

{AV_63}Thus{/AV_63} , {NP_B_64}<B>PCTA</B>{/NP_B_64} {VP_act_65}defines{/VP_act_65} {NP_66}a new <Bpf>regulator</Bpf>{/NP_66} in {NP_67}<p>TGF-beta</p> signaling{/NP_67} .


{NP_1}PMID{/NP_1} - {CP_2}19020135{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Nicorandil{/NP_4} , {NP_5}an <p>adenosine triphosphate-sensitive potassium channel</p> opener{/NP_5} , {VP_act_6}inhibits{/VP_act_6} {NP_7}muscarinic <p>acetylcholine receptor</p> -mediated activation{/NP_7} of {NP_P_8}extracellular signal-regulated <Bppf>kinases</Bppf>{/NP_P_8} in {NP_S_9}<S>PC12 cells</S>{/NP_S_9} .

{NP_10}AB{/NP_10} - {NP_11}BACKGROUND{/NP_11} :

{NP_12}Nicorandil{/NP_12} , {NP_13}an <p>adenosine triphosphate-sensitive potassium channel</p> opener{/NP_13} , {VP_pass_14}is reported{/VP_pass_14} {VP_act_15}to have{/VP_act_15} {NP_16}an antinociceptive effect{/NP_16} by {NP_17}hyperpolarization{/NP_17} through {NP_P_18}the <p>K(+) channel</p>{/NP_P_18} .

{NP_19}The activation{/NP_19} of {NP_P_20}<p>extracellular signal-regulated kinase ( ERK )</p>{/NP_P_20} , {NP_21}a <Bpf>family</Bpf>{/NP_21} of {NP_P_22}<p>mitogen -activated protein kinases</p>{/NP_P_22} , {VP_act_23}plays{/VP_act_23} {NP_24}an important role{/NP_24} in {NP_25}synaptic plasticity{/NP_25} and {NP_26}noxious stimulation{/NP_26} in {NP_27}the dorsal root ganglion{/NP_27} , and {NP_28}spinal neurons{/NP_28} {VP_pass_29}have been reported{/VP_pass_29} {VP_act_30}to induce{/VP_act_30} {NP_31}its activation{/NP_31} .

{VP_act_32}To understand{/VP_act_32} {NP_33}the biological mechanisms{/NP_33} of {NP_34}nicorandil{/NP_34} , {NP_35}we{/NP_35} {VP_act_36}examined{/VP_act_36} {NP_37}the effects{/NP_37} of {NP_38}nicorandil{/NP_38} on {NP_39}muscarinic <p>acetylcholine ( ACh ) receptor</p> -mediated activation{/NP_39} of {NP_P_40}<p>ERK</p>{/NP_P_40} in {NP_41}a neuronal model <Bpcl>cell</Bpcl>{/NP_41} , {NP_S_42}<s>rat</s> pheochromocytoma <S>PC12 cells</S>{/NP_S_42} .

OUTPUT 0
PTM = ({NP_49};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_50}<p>ERK</p>{/NP_P_50};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_50}<p>ERK</p>{/NP_P_50}]
Site = (-;-;UNK)

{NP_43}METHODS{/NP_43} : {NP_S_44}<S>PC12 cells</S>{/NP_S_44} {VP_pass_45}were stimulated{/VP_pass_45} with {NP_S_46}<S>ACh</S>{/NP_S_46} in {NP_47}the presence or absence{/NP_47} of {NP_48}nicorandil{/NP_48} , and {NP_49}phosphorylation{/NP_49} of {NP_P_50}<p>ERK</p>{/NP_P_50} {VP_pass_51}was examined{/VP_pass_51} by {NP_52}a Western blot analysis{/NP_52} .

{NP_53}We{/NP_53} {VP_act_54}also examined{/VP_act_54} {NP_55}the effects{/NP_55} of {NP_56}nicorandil{/NP_56} on {NP_57}the <p>ERK</p> activation{/NP_57} {VP_pass_58}induced{/VP_pass_58} by {NP_C_59}<c>4beta-phorbol 12-myristate 13-acetate</c>{/NP_C_59} , {NP_60}an <Bpf>activator</Bpf>{/NP_60} of {NP_P_61}<p>protein kinase C</p>{/NP_P_61} , or {NP_C_62}<c>ionomycin</c>{/NP_C_62} , {NP_C_63}a <c>calcium ionophore</c>{/NP_C_63} .

{NP_B_64}Intracellular <B>Ca(2+)</B>{/NP_B_64} {VP_act_65}increase{/VP_act_65} {VP_pass_66}was visualized{/VP_pass_66} in {NP_S_67}fluo-3-loaded <S>PC12 cells</S>{/NP_S_67} {VP_act_68}using{/VP_act_68} {NP_69}fluorescence microscopy{/NP_69} .

{NP_70}RESULTS{/NP_70} : {NP_71}Nicorandil{/NP_71} {VP_act_72}inhibited{/VP_act_72} {NP_73}<S>ACh</S> -induced <p>ERK</p> activation{/NP_73} in {NP_74}a concentration -dependent manner{/NP_74} .

{NP_75}The inhibition{/NP_75} {VP_pass_76}was abolished{/VP_pass_76} by {NP_C_77}<c>glibenclamide</c>{/NP_C_77} , {NP_78}an <p>adenosine triphosphate-sensitive potassium channel</p> blocker{/NP_78} .

{NP_79}Nicorandil{/NP_79} {VP_act_80}suppressed{/VP_act_80} {NP_81}the <p>ERK</p> activation{/NP_81} {VP_pass_82}induced{/VP_pass_82} by {NP_C_83}<c>ionomycin</c>{/NP_C_83} but not {NP_C_84}<c>4beta-phorbol 12-myristate 13-acetate</c>{/NP_C_84} .

{NP_85}Pretreatment{/NP_85} of {NP_S_86}<S>PC12 cells</S>{/NP_S_86} with {NP_87}nicorandil{/NP_87} {VP_act_88}reduced{/VP_act_88} {NP_89}the intracellular <B>Ca(2+)</B> concentration{/NP_89} {VP_pass_90}stimulated{/VP_pass_90} by {NP_S_91}<S>ACh</S>{/NP_S_91} .

{NP_92}CONCLUSIONS{/NP_92} : {NP_93}Nicorandil{/NP_93} {VP_act_94}inhibits{/VP_act_94} {NP_95}muscarinic activation{/NP_95} of {NP_96}the <p>ERK</p> signaling pathway{/NP_96} by {VP_act_97}reducing{/VP_act_97} {NP_98}the intracellular <B>Ca(2+)</B> concentration{/NP_98} .


{NP_1}PMID{/NP_1} - {CP_2}19020770{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Essential nutrients{/NP_4} {VP_act_5}suppress{/VP_act_5} {NP_6}inflammation{/NP_6} by {VP_act_7}modulating{/VP_act_7} {NP_8}key inflammatory <Bppf>gene</Bppf> expression{/NP_8} .

{NP_9}AB{/NP_9} - {NP_10}We{/NP_10} {VP_act_11}investigated{/VP_act_11} {NP_12}the effects{/NP_12} of {NP_B_13}a <B>nutrient mixture ( NM )</B>{/NP_B_13} {VP_act_14}consisting{/VP_act_14} of {NP_P_15}<p>ascorbic acid</p>{/NP_P_15} , {NP_B_16}<B>quercetin</B>{/NP_B_16} , {NP_B_17}<B>naringenin</B>{/NP_B_17} , {NP_B_18}<B>hesperetin</B>{/NP_B_18} , {NP_PP_19}tea <pp>catechins</pp> , <pp>lysine</pp> , <pp>proline</pp> , <pp>arginine</pp> and <pp>N-acetylcysteine</pp>{/NP_PP_19} on {NP_20}experimental{/NP_20} in {NP_21}vivo{/NP_21} and {NP_22}in vitro inflammation{/NP_22} {VP_pass_23}triggered{/VP_pass_23} by {NP_B_24}bacterial <B>lipopolysaccharide ( LPS )</B>{/NP_B_24} .

{NP_25}<c>BALB/c</c> <s>mice</s>{/NP_25} ( {NP_26}n{/NP_26} = {CP_27}36{/CP_27} ) {VP_pass_28}were administered{/VP_pass_28} {NP_B_29}<c>NM</c> ( 200 mg/kg <B>BW</B> ){/NP_B_29} or {NP_B_30}<c>ibuprofen</c> ( 20 mg/kg <B>BW</B> ){/NP_B_30} for {NP_31}two weeks{/NP_31} .

{NP_32}Blood plasma{/NP_32} , {VP_act_33}collected{/VP_act_33} {NP_34}three hours{/NP_34} after {NP_35}a single intraperitoneal injection{/NP_35} with {NP_B_36}<c>LPS</c> ( 1 mg/kg <B>BW</B> ){/NP_B_36} , {VP_pass_37}was analyzed{/VP_pass_37} with {NP_38}14 <p>cytokine</p> microarray{/NP_38} .

OUTPUT 0
PTM = ({VP_act_47};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_39}<c>LPS</c> inflammatory effects{/NP_39} {VP_pass_40}were analyzed{/VP_pass_40} in {NP_S_41}<s>human</s> <S>U937 macrophages</S>{/NP_S_41} by {NP_42}<p>cytokine</p> release{/NP_42} , {NP_43}<p>cyclooxygenase ( COX )</p> enzymatic activity{/NP_43} , {NP_44}<p>COX protein</p> expression (Western blot analysis){/NP_44} , {NP_B_45}specific mRNA levels <B>(RT-PCR)</B>{/NP_B_45} , and {NP_46}<p>nuclear factor kappabeta ( NFkappabeta )</p> activation{/NP_46} ( {VP_act_47}phosphorylated{/VP_act_47} {NP_48}<p>p65</p> immunoassay{/NP_48} ) .

{NP_49}Nutrient supplementation{/NP_49} in {NP_50}<s>mice</s>{/NP_50} {VP_act_51}altered{/VP_act_51} {NP_52}the <c>LPS</c> -induced <p>cytokine</p> response{/NP_52} in {NP_53}a manner{/NP_53} {JP_54}similar{/JP_54} to {NP_C_55}<c>ibuprofen</c>{/NP_C_55} ( {NP_56}r{/NP_56} = {NP_57}0.4157{/NP_57} , {NP_58}p{/NP_58} = {CP_59}0.139{/CP_59} ) .

{NP_60}<p>Cytokine</p> response{/NP_60} to {NP_C_61}<c>LPS</c>{/NP_C_61} in {NP_S_62}cultured <S>macrophages</S>{/NP_S_62} {VP_pass_63}was similar{/VP_pass_63} to {NP_64}the in vivo study{/NP_64} ( {NP_65}r{/NP_65} = {NP_66}0.718{/NP_66} , {NP_67}p{/NP_67} = {NP_68}0.023{/NP_68} ) .

{NP_C_69}<c>NM</c>{/NP_C_69} {VP_act_70}inhibited{/VP_act_70} {NP_P_71}<B><p>COX-2</p> enzymatic</B> activity , and <p>COX-2</p>{/NP_P_71} and {NP_72}pro-inflammatory <p>cytokine</p> protein expression levels{/NP_72} {VP_pass_73}were downregulated{/VP_pass_73} by {NP_C_74}<c>NM</c>{/NP_C_74} at {NP_75}the transcription level{/NP_75} {VP_act_76}complementing{/VP_act_76} {NP_77}a blockade{/NP_77} in {NP_78}<p>NFkappabeta</p> activation{/NP_78} .

{NP_C_79}<c>NM</c>{/NP_C_79} {VP_act_80}demonstrated{/VP_act_80} {NP_81}strong beneficial effects{/NP_81} on {NP_82}the experimental inflammation{/NP_82} by {VP_act_83}targeting{/VP_act_83} {NP_84}multiple responsible mechanisms{/NP_84} in {NP_85}the <Bpf>complex</Bpf> process{/NP_85} {VP_pass_86}involved{/VP_pass_86} in {NP_87}the inflammatory reaction{/NP_87} to {NP_88}pathogens{/NP_88} .


{NP_1}PMID{/NP_1} - {CP_2}19020771{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Maturation-induced down-regulation{/NP_4} of <p>MFG-E8</p> impairs {NP_5}apoptotic <Bpcl>cell</Bpcl> clearance{/NP_5} and {VP_act_6}enhances{/VP_act_6} {NP_7}<B>endotoxin</B> response{/NP_7} .

{NP_8}AB{/NP_8} - In {NP_9}sepsis{/NP_9} , {NP_10}phagocytosis{/NP_10} and {NP_11}the killing{/NP_11} of {NP_12}<Bpcl>bacteria</Bpcl>{/NP_12} by {NP_S_13}<S>phagocytes</S>{/NP_S_13} {VP_pass_14}are important{/VP_pass_14} .

{AV_15}Similarly{/AV_15} , {NP_16}the clearance{/NP_16} of {VP_act_17}accumulating{/VP_act_17} {NP_18}apoptotic <Bpcl>cells</Bpcl>{/NP_18} {VP_pass_19}is critical{/VP_pass_19} in {VP_act_20}maintaining{/VP_act_20} {NP_21}normal immunity{/NP_21} .

Upon {NP_22}maturation{/NP_22} , {NP_S_23}<S>peritoneal macrophages ( PM )</S>{/NP_S_23} {VP_pass_24}become{/VP_pass_24} {NP_25}a major source{/NP_25} of {NP_P_26}proinflammatory <p>cytokines</p>{/NP_P_26} , while {VP_act_27}losing{/VP_act_27} {NP_28}their efficacy{/NP_28} of {NP_29}phagocytosis{/NP_29} .

{AV_30}However{/AV_30} , {NP_31}the underlying mechanism{/NP_31} {VP_act_32}remains{/VP_act_32} {JP_33}unknown{/JP_33} .

{AV_34}Here{/AV_34} {NP_35}we{/NP_35} {VP_act_36}investigated{/VP_act_36} {NP_37}the differential effects{/NP_37} of {NP_S_38}<S>apoptotic thymocytes ( AoTC )</S>{/NP_S_38} on {NP_39}<p>TNF-alpha</p> release{/NP_39} in {NP_P_40}immature <c>thioglycolate-elicited PM ( TGPM )</c> and <p>mature resident PM ( RPM )</p>{/NP_P_40} in {NP_41}vitro{/NP_41} by {VP_act_42}culturing{/VP_act_42} {NP_43}them{/NP_43} with or without {NP_P_44}<p>AoTC and/or LPS</p>{/NP_P_44} .

{NP_45}<p>MFG-E8</p> expression{/NP_45} {VP_pass_46}was assessed{/VP_pass_46} {VP_act_47}using{/VP_act_47} {NP_48}Western{/NP_48} {VP_act_49}blotting{/VP_act_49} and {NP_50}the ability{/NP_50} {VP_act_51}to engulf{/VP_act_51} {NP_S_52}<S>AoTC</S>{/NP_S_52} {VP_pass_53}was determined{/VP_pass_53} {AV_54}histologically{/AV_54} .

{NP_55}<p>Cytokine</p> secretion{/NP_55} {VP_pass_56}was measured{/VP_pass_56} by {NP_B_57}<B>ELISA</B>{/NP_B_57} .

OUTPUT 0
PTM = ({NP_58};phosphorylation)
	HasAgentTheme="<p>MAP kinase</p>" in "{NP_58}<p>MAP kinase</p> phosphorylation{/NP_58}"
Inducer = (-;-)
Kinase = ({NP_58}<p>MAP kinase</p>{/NP_58};-)
	Method=agent_or_theme_but_known_as_kinase (kinase) for phrase=[{NP_58}<p>MAP kinase</p> phosphorylation{/NP_58}0..8|<p>MAP kinase</p>]
Substrate = (-;-)
Site = (-;-;UNK)

{NP_58}<p>MAP kinase</p> phosphorylation{/NP_58} {VP_pass_59}was assessed{/VP_pass_59} {VP_act_60}using{/VP_act_60} {NP_61}Western{/NP_61} {VP_act_62}blotting{/VP_act_62} .

{NP_P_63}Mature <p>RPM</p>{/NP_P_63} {VP_act_64}express{/VP_act_64} {NP_65}&lt{/NP_65} ; {NP_66}50%{/NP_66} of {NP_67}<p>TGPM MFG-E8</p> levels{/NP_67} and {VP_act_68}have{/VP_act_68} {NP_69}a 30% lower capacity{/NP_69} {VP_act_70}to clear{/VP_act_70} {NP_S_71}<S>AoTC</S>{/NP_S_71} .

{NP_72}The proinflammatory response ( <p>TNF-alpha</p> release ){/NP_72} to {NP_P_73}<p>LPS</p>{/NP_P_73} {VP_act_74}is{/VP_act_74} {NP_75}5 times{/NP_75} {JP_76}higher{/JP_76} , and {NP_77}the capability{/NP_77} {VP_act_78}to phagocytose{/VP_act_78} {VP_pass_79}is decreased{/VP_pass_79} along with {NP_80}further down-regulation{/NP_80} of {NP_P_81}<p>MFG-E8</p>{/NP_P_81} after {NP_82}LPS-stimulation{/NP_82} .

{NP_P_83}<p>RPMs</p>{/NP_P_83} {VP_act_84}also lack{/VP_act_84} {NP_85}phagocytosis-induced inhibition{/NP_85} of {NP_86}<p>TNF-alpha</p> release{/NP_86} after {NP_87}<p>LPS</p> stimulation{/NP_87} .

OUTPUT 1
PTM = ({NP_88};phosphorylation)
Inducer = ({NP_88}<p>LPS</p>{/NP_88};-)
	Method=rule: (inducer) for phrase=[{NP_88}<p>LPS</p> -induced phosphorylation{/NP_88}0..2|<p>LPS</p>]
Kinase = (-;-)
Substrate = ({NP_P_89}<p>p38</p>{/NP_P_89};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}0..5|<p>ERK1/2</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}13..15|<p>JNK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}7..9|<p>p38</p>]
Site = (-;-;UNK)

OUTPUT 2
PTM = ({NP_88};phosphorylation)
Inducer = ({NP_88}<p>LPS</p>{/NP_88};-)
	Method=rule: (inducer) for phrase=[{NP_88}<p>LPS</p> -induced phosphorylation{/NP_88}0..2|<p>LPS</p>]
Kinase = (-;-)
Substrate = ({NP_P_89}<p>JNK</p>{/NP_P_89};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}0..5|<p>ERK1/2</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}13..15|<p>JNK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}7..9|<p>p38</p>]
Site = (-;-;UNK)

OUTPUT 3
PTM = ({NP_88};phosphorylation)
Inducer = ({NP_88}<p>LPS</p>{/NP_88};-)
	Method=rule: (inducer) for phrase=[{NP_88}<p>LPS</p> -induced phosphorylation{/NP_88}0..2|<p>LPS</p>]
Kinase = (-;-)
Substrate = ({NP_P_89}<p>ERK1/2</p>{/NP_P_89};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}0..5|<p>ERK1/2</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}13..15|<p>JNK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89}7..9|<p>p38</p>]
Site = (-;-;UNK)

{NP_88}<p>LPS</p> -induced phosphorylation{/NP_88} of {NP_P_89}<p>ERK1/2</p> , <p>p38</p> and <p>JNK</p>{/NP_P_89} {VP_pass_90}is more enhanced{/VP_pass_90} in {NP_P_91}<p>RPM</p>{/NP_P_91} {VP_act_92}compared{/VP_act_92} to {NP_C_93}<c>TGPM</c>{/NP_C_93} .

<p>MFG-E8</p> -mediated {NP_94}apoptotic <Bpcl>cell</Bpcl> phagocytosis results{/NP_94} in {NP_95}an inhibition{/NP_95} of {NP_96}<p>MAPK</p> and <p>NFkappaB</p> signaling pathways{/NP_96} .

{NP_97}Differential <p>MAPK</p> activation{/NP_97} {VP_act_98}may play{/VP_act_98} {NP_99}a role{/NP_99} in {NP_100}the enhanced <p>LPS</p> responsiveness{/NP_100} of {NP_P_101}<p>RPM</p>{/NP_P_101} and {NP_102}the lack{/NP_102} of {NP_P_103}<p>MFG-E8</p>{/NP_P_103} {VP_act_104}impedes{/VP_act_104} {NP_105}post-phagocytic suppression{/NP_105} of {NP_B_106}<B>LPS-response</B>{/NP_B_106} through {NP_107}the inhibition{/NP_107} of {NP_108}those signaling pathways{/NP_108} .

{NP_109}These results{/NP_109} {VP_act_110}provide{/VP_act_110} {NP_111}a potential mechanistic insight{/NP_111} into {NP_112}the benefit{/NP_112} of {VP_act_113}promoting{/VP_act_113} {NP_114}apoptotic <Bpcl>cell</Bpcl> clearance{/NP_114} via {NP_P_115}<p>MFG-E8</p>{/NP_P_115} under {NP_116}inflammatory conditions{/NP_116} .


{NP_1}PMID{/NP_1} - {CP_2}19020776{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}<p>LC3-I</p> conversion{/NP_4} to {NP_P_5}<p>LC3-II</p>{/NP_P_5} {VP_pass_neg_6}does not necessarily result{/VP_pass_neg_6} in {NP_7}complete autophagy{/NP_7} .

{NP_8}AB{/NP_8} - {NP_9}Autophagy{/NP_9} {VP_pass_10}was induced{/VP_pass_10} in {NP_S_11}<s>human</s> neuroblastoma <s><S>SH-SY5Y cells</S></s>{/NP_S_11} by {NP_12}two different procedures{/NP_12} :

{NP_13}deprivation{/NP_13} of {NP_14}fetal serum{/NP_14} in {NP_15}<Bpcl>culture</Bpcl> medium{/NP_15} , or {NP_16}treatment{/NP_16} with {NP_C_17}dopamine. <c>3-methyladenine</c>{/NP_C_17} {VP_act_18}prevented{/VP_act_18} {NP_19}autophagy{/NP_19} in {NP_20}the two procedures{/NP_20} .

Although {NP_21}it{/NP_21} {VP_pass_22}is usually considered{/VP_pass_22} that {NP_23}the conversion{/NP_23} of {NP_P_24}soluble <p>LC3-I</p>{/NP_P_24} to {NP_25}<Bpcf>lipid</Bpcf>{/NP_25} {VP_act_26}bound{/VP_act_26} {NP_P_27}<p>LC3-II</p>{/NP_P_27} {VP_pass_28}is associated{/VP_pass_28} with {NP_29}the formation{/NP_29} of {NP_30}autophagosomes{/NP_30} , {NP_31}the inhibition{/NP_31} of {NP_32}autophagy{/NP_32} with {NP_C_33}<c>3-methyladenine</c>{/NP_C_33} {VP_act_34}prevented{/VP_act_34} {NP_35}this transformation{/NP_35} in {JP_36}serum-deprived{/JP_36} but {AV_37}not{/AV_37} in {NP_38}dopamine -treated <Bpcl>cells</Bpcl>{/NP_38} .

OUTPUT 0
PTM = ({NP_44};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_45}<p>Akt</p>{/NP_P_45};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_45}<p>Akt</p>{/NP_P_45}]
Site = (-;-;UNK)

While {NP_39}the <p>PI3K-mTOR</p> pathway{/NP_39} {VP_pass_40}was inhibited{/VP_pass_40} by {NP_41}serum deprivation{/NP_41} , {NP_42}dopamine{/NP_42} {VP_act_43}increased{/VP_act_43} {NP_44}the phosphorylation{/NP_44} of {NP_P_45}<p>Akt</p>{/NP_P_45} but {VP_act_46}inhibited{/VP_act_46} {NP_47}<p>mTOR</p> activity{/NP_47} in {NP_48}a similar way{/NP_48} to {NP_C_49}<c>rapamycin</c>{/NP_C_49} .

{NP_50}Dopamine{/NP_50} and {NP_C_51}<c>rapamycin</c>{/NP_C_51} {VP_act_52}increased{/VP_act_52} {NP_53}<p>LC3-II</p> levels{/NP_53} by {NP_54}a mechanism{/NP_54} {VP_pass_neg_55}not prevented{/VP_pass_neg_55} by {NP_C_56}<c>3-methyladenine</c>{/NP_C_56} .

{NP_57}The activation{/NP_57} of {NP_P_58}<p>LC3-I</p>{/NP_P_58} to {NP_P_59}<p>LC3-II</p>{/NP_P_59} {VP_act_60}may then be necessary{/VP_act_60} but not {JP_61}sufficient{/JP_61} {VP_act_62}to trigger{/VP_act_62} {NP_63}<Bpcl>cell</Bpcl> autophagy{/NP_63} .

{AV_64}Thus{/AV_64} , the {VP_pass_65}increase{/VP_pass_65} in {NP_P_66}<p>LC3-II</p>{/NP_P_66} , as {NP_67}the main <Bpcf>biochemical</Bpcf> parameter{/NP_67} for {NP_68}autophagy{/NP_68} at {JP_69}present{/JP_69} , {VP_pass_70}should be considered{/VP_pass_70} with {NP_71}caution{/NP_71} .


{NP_1}PMID{/NP_1} - {CP_2}19020779{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Impact{/NP_4} of {NP_5}<p>insulin</p> resistance{/NP_5} on {NP_6}the progression{/NP_6} of {NP_7}chronic liver diseases{/NP_7} .

{NP_8}AB{/NP_8} - {NP_9}Recent studies{/NP_9} {VP_act_10}have revealed{/VP_act_10} {NP_11}a close relationship{/NP_11} between {NP_B_12}<B><p>insulin</p> resistance ( IR )</B>{/NP_B_12} and {NP_13}the progression{/NP_13} of {NP_14}chronic liver diseases{/NP_14} , although {VP_pass_15}relatively little is known{/VP_pass_15} {VP_act_16}regarding{/VP_act_16} {NP_17}the possible mechanisms{/NP_17} {VP_act_18}involved{/VP_act_18} .

{NP_19}The aim{/NP_19} of {NP_20}this study{/NP_20} {VP_pass_21}was{/VP_pass_21} {VP_act_22}to elucidate{/VP_act_22} {NP_23}the impact{/NP_23} of {NP_B_24}<B>IR</B>{/NP_B_24} on {NP_25}the development{/NP_25} of {NP_26}liver fibrosis and hepatocarcinogenesis{/NP_26} {VP_act_27}using{/VP_act_27} {NP_28}obese diabetic <B>Otsuka Long-Evans Tokushima Fatty ( OLETF )</B> <s>rats</s>{/NP_28} .

{NP_29}Liver fibrosis development and <p>glutathione-S-transferase placental form ( GST-P )</p>- positive pre-neoplastic lesions{/NP_29} {VP_pass_30}were{/VP_pass_30} both {JP_31}markedly accelerated{/JP_31} in {NP_32}<B>OLETF</B> <s>rats</s>{/NP_32} , {VP_pass_33}being induced{/VP_pass_33} by {NP_C_34}<s>pig</s> serum and <c>diethylnitrosamine ( DEN )</c>{/NP_C_34} , {AV_35}respectively{/AV_35} .

In {NP_36}the fibrosis experiment{/NP_36} , {NP_37}alpha-smooth muscle{/NP_37} {VP_act_38}actin-positive activated{/VP_act_38} {NP_P_39}<p>hepatic stellate cells ( HSCs )</p>{/NP_P_39} {VP_pass_40}also significantly increased{/VP_pass_40} in {NP_41}<B>OLETF</B> <s>rats</s>{/NP_41} along with {NP_42}augmentation{/NP_42} of {NP_43}the hepatic collagen content{/NP_43} and {VP_act_44}transforming{/VP_act_44} {NP_P_45}<Bppf>growth factor -beta1</Bppf>{/NP_P_45} .

{NP_46}Our in vitro study{/NP_46} {VP_act_47}showed{/VP_act_47} that {NP_P_48}both <c>glucose</c> and <p>insulin</p>{/NP_P_48} {VP_act_49}stimulated{/VP_act_49} {NP_50}the proliferation{/NP_50} of {NP_P_51}activated <p>HSCs</p>{/NP_P_51} , and {NP_52}the combination treatment{/NP_52} {VP_act_53}exerted{/VP_act_53} {NP_54}an additive effect{/NP_54} .

In {NP_55}the <c>DEN</c> model{/NP_55} , {NP_56}neovascularization{/NP_56} , {NP_57}which{/NP_57} {VP_act_58}plays{/VP_act_58} {NP_59}a pivotal role{/NP_59} in {NP_60}hepatocarcinogenesis{/NP_60} , {VP_pass_61}was up-regulated{/VP_pass_61} in {NP_62}<B>OLETF</B> <s>rats</s>{/NP_62} {AV_63}almost{/AV_63} in {JP_64}parallel{/JP_64} with {NP_65}pre-neoplastic lesion development{/NP_65} and {NP_P_66}a potent angiogenic <Bppf>factor</Bppf>{/NP_P_66} , {NP_P_67}vascular endothelial <Bppf>growth factor</Bppf>{/NP_P_67} .

OUTPUT 0
PTM = ({NP_71};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_P_68}High <c>glucose</c> and <p>insulin</p>{/NP_P_68} {VP_act_69}also significantly augmented{/VP_act_69} {NP_70}the in vitro neovascularization{/NP_70} via {NP_71}extracellular signal-regulated <Bppf>kinase</Bppf> 1/2 phosphorylation{/NP_71} .

{JP_72}Similar{/JP_72} to {NP_73}the effect{/NP_73} on {NP_P_74}the activated <p>HSCs</p>{/NP_P_74} , {NP_75}co-existence{/NP_75} of {NP_P_76}both <Bppf>factors</Bppf>{/NP_P_76} {VP_act_77}exerted{/VP_act_77} {NP_78}a more potent effect{/NP_78} than {NP_P_79}either single <Bppf>factor</Bppf>{/NP_P_79} .

In {NP_80}conclusion{/NP_80} , {NP_81}these results{/NP_81} {VP_act_82}indicated{/VP_act_82} that {NP_83}the <B>IR</B> status{/NP_83} {VP_act_84}directly accelerated{/VP_act_84} {NP_85}liver fibrosis development and hepatocarcinogenesis{/NP_85} {AV_86}atleast partly{/AV_86} through {NP_87}the stimulation{/NP_87} of {NP_88}activated <p>HSC</p> proliferation and hepatic neovascularization{/NP_88} , {AV_89}respectively{/AV_89} , in {NP_90}the <s>rat</s>{/NP_90} .


{NP_1}PMID{/NP_1} - {CP_2}19020780{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Modulation{/NP_4} of <p>TNF-alpha</p> -induced {NP_5}endothelial <Bpcl>cell</Bpcl> activation{/NP_5} by {NP_6}glucosamine{/NP_6} , {NP_C_7}a naturally occurring <c>amino monosaccharide</c>{/NP_C_7} .

{NP_8}AB{/NP_8} - {NP_9}Atherosclerosis{/NP_9} {VP_pass_10}is now considered{/VP_pass_10} {NP_11}a chronic inflammatory disease{/NP_11} , and {NP_12}glucosamine{/NP_12} {VP_act_13}has{/VP_act_13} the {JP_14}potential{/JP_14} {VP_act_15}to exhibit{/VP_act_15} {NP_16}an anti-inflammatory action{/NP_16} .

{AV_17}Thus{/AV_17} , {NP_18}we{/NP_18} {VP_act_19}investigated{/VP_act_19} {NP_20}the effect{/NP_20} of {NP_21}glucosamine{/NP_21} on <p>tumor necrosis factor alpha ( TNF-alpha )</p>- induced {NP_22}endothelial <Bpcl>cell</Bpcl> activation{/NP_22} .

{NP_S_23}<S><s>Human</s> umbilical vein endothelial cells ( HUVECs )</S>{/NP_S_23} {VP_pass_24}were stimulated{/VP_pass_24} by {NP_P_25}<p>TNF-alpha</p>{/NP_P_25} in {NP_26}the presence or absence{/NP_26} of {NP_27}glucosamine{/NP_27} or {NP_28}its <Bpf>analogue</Bpf>{/NP_28} , {NP_C_29}<c>N-acetylglucosamine</c>{/NP_C_29} .

{NP_30}mRNA expression{/NP_30} of {NP_P_31}<p>MCP-1 ( a chemoattractant protein )</p> and <p>ICAM-1 ( an adhesion molecule )</p>{/NP_P_31} {VP_pass_32}was evaluated{/VP_pass_32} by {NP_B_33}real-time <B>RT-PCR</B>{/NP_B_33} , and {NP_34}their <Bppf>protein</Bppf> levels{/NP_34} {VP_pass_35}were analyzed{/VP_pass_35} by {NP_36}<B>ELISA</B> and Western{/NP_36} {VP_act_37}blotting{/VP_act_37} , {AV_38}respectively{/AV_38} .

OUTPUT 0
PTM = ({NP_42};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>p38MAPK</p>" in "{NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>NF-kappaB</p>" in "{NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_43}<p>p38MAPK</p>{/NP_P_43};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43}0..6|<p>p38MAPK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43}10..18|<p>NF-kappaB</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_42};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>p38MAPK</p>" in "{NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>NF-kappaB</p>" in "{NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_43}<p>NF-kappaB</p>{/NP_P_43};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43}0..6|<p>p38MAPK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43}10..18|<p>NF-kappaB</p>]
Site = (-;-;UNK)

{AV_39}Furthermore{/AV_39} , {NP_40}the effects{/NP_40} of {NP_41}glucosamine{/NP_41} on {NP_42}the phosphorylation{/NP_42} of {NP_P_43}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_43} , and {NP_44}<c>O-N-acetylglucosamine ( O-GlcNAc )</c> modification{/NP_44} {VP_pass_45}were evaluated{/VP_pass_45} by {NP_46}Western{/NP_46} {VP_act_47}blotting{/VP_act_47} .

{NP_48}The results{/NP_48} {VP_act_49}demonstrated{/VP_act_49} that {NP_C_50}glucosamine but not <c>N-acetylglucosamine</c>{/NP_C_50} {VP_act_51}suppressed{/VP_act_51} {NP_52}<p>TNF-alpha</p> -induced expression{/NP_52} of {NP_P_53}<p>MCP-1</p> and <p>ICAM-1</p>{/NP_P_53} at both {NP_54}the mRNA and <Bppf>protein</Bppf> levels{/NP_54} .

OUTPUT 2
PTM = ({NP_58};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>p38MAPK</p>" in "{NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>NF-kappaB</p>" in "{NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_59}<p>p38MAPK</p>{/NP_P_59};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59}0..6|<p>p38MAPK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59}10..18|<p>NF-kappaB</p>]
Site = (-;-;UNK)

OUTPUT 3
PTM = ({NP_58};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>p38MAPK</p>" in "{NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>NF-kappaB</p>" in "{NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_59}<p>NF-kappaB</p>{/NP_P_59};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59}0..6|<p>p38MAPK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59}10..18|<p>NF-kappaB</p>]
Site = (-;-;UNK)

{AV_55}Furthermore{/AV_55} , {NP_56}glucosamine{/NP_56} {VP_act_57}abrogated{/VP_act_57} {NP_58}the phosphorylation{/NP_58} of {NP_P_59}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_59} .

OUTPUT 4
PTM = ({NP_68};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_67}<p>MCP-1</p> and <p>ICAM-1</p>{/NP_P_67}" 	(Features:dist=0|pparg)
		Candidate="<p>MCP-1</p>" in "{NP_P_67}<p>MCP-1</p> and <p>ICAM-1</p>{/NP_P_67}" 	(Features:dist=0)
		Candidate="<p>ICAM-1</p>" in "{NP_P_67}<p>MCP-1</p> and <p>ICAM-1</p>{/NP_P_67}" 	(Features:dist=0)
		Candidate="<p>p38MAPK</p>" in "{NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>NF-kappaB</p>" in "{NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_69}<p>p38MAPK</p>{/NP_P_69};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69}0..6|<p>p38MAPK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69}10..18|<p>NF-kappaB</p>]
Site = (-;-;UNK)

OUTPUT 5
PTM = ({NP_68};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_67}<p>MCP-1</p> and <p>ICAM-1</p>{/NP_P_67}" 	(Features:dist=0|pparg)
		Candidate="<p>MCP-1</p>" in "{NP_P_67}<p>MCP-1</p> and <p>ICAM-1</p>{/NP_P_67}" 	(Features:dist=0)
		Candidate="<p>ICAM-1</p>" in "{NP_P_67}<p>MCP-1</p> and <p>ICAM-1</p>{/NP_P_67}" 	(Features:dist=0)
		Candidate="<p>p38MAPK</p>" in "{NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>NF-kappaB</p>" in "{NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_69}<p>NF-kappaB</p>{/NP_P_69};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69}0..6|<p>p38MAPK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69}10..18|<p>NF-kappaB</p>]
Site = (-;-;UNK)

To {VP_act_neg_60}note{/VP_act_neg_60} , {NP_61}glucosamine{/NP_61} {VP_act_62}induced{/VP_act_62} {NP_63}O-GlcNAc modification{/NP_63} , {NP_64}which{/NP_64} {VP_pass_65}was negatively correlated{/VP_pass_65} with {NP_66}the expression{/NP_66} of {NP_P_67}<p>MCP-1</p> and <p>ICAM-1</p>{/NP_P_67} , and {NP_68}phosphorylation{/NP_68} of {NP_P_69}<p>p38MAPK</p> and <p>NF-kappaB</p>{/NP_P_69} .

{AV_70}Thus{/AV_70} , {NP_71}glucosamine{/NP_71} {VP_pass_72}is likely{/VP_pass_72} {VP_act_73}to suppress{/VP_act_73} {NP_74}endothelial <Bpcl>cell</Bpcl> activation ( <p>TNF-alpha</p> -induced <p>ICAM-1</p> and <p>MCP-1</p> expression ){/NP_74} {AV_75}possibly{/AV_75} by {VP_act_76}affecting{/VP_act_76} {NP_77}<p>p38MAPK</p> and <p>NF-kappaB</p> signaling{/NP_77} via {NP_78}O-GlcNAc modification{/NP_78} .


{NP_1}PMID{/NP_1} - {CP_2}19020748{/CP_2}

OUTPUT 0
PTM = ({NP_4};phosphorylation)
	HasAgentTheme="<p>Annexin A2</p>" in "{NP_4}<p>Annexin A2</p> expression and phosphorylation{/NP_4}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_4}<p>Annexin A2</p>{/NP_4};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_4}<p>Annexin A2</p> expression and phosphorylation{/NP_4}0..8|<p>Annexin A2</p>]
Site = ({NP_4}2{/NP_4};{NP_4}Ala{/NP_4};UNK)
	Method=site_in_argument_proteins (site) for phrase=[{NP_4}<p>Annexin A2</p> expression and phosphorylation{/NP_4}7..8|A2|Ala2]

{NP_3}TI{/NP_3} - {NP_4}<p>Annexin A2</p> expression and phosphorylation{/NP_4} {VP_pass_5}are up-regulated{/VP_pass_5} in {NP_6}hepatocellular carcinoma{/NP_6} .

{NP_7}AB{/NP_7} - {NP_P_8}<p>Annexins ( ANXs )</p>{/NP_P_8} {VP_act_9}constitute{/VP_act_9} {NP_10}a <Bpf>family</Bpf>{/NP_10} of {NP_P_11}<p>Ca2+ -dependent membrane-binding proteins</p>{/NP_P_11} ; {JP_12}atleast{/JP_12} {CP_13}20{/CP_13} of {NP_14}them{/NP_14} {VP_pass_15}have been described{/VP_pass_15} {VP_act_16}to date{/VP_act_16} .

Among these , {NP_P_17}<p>Annexin A2 ( ANXA2 )</p>{/NP_P_17} {VP_pass_18}has been revealed{/VP_pass_18} as {NP_P_19}a multi-functional <Bppf>protein</Bppf>{/NP_P_19} in {NP_20}vitro{/NP_20} .

{NP_21}Its actual role{/NP_21} in {NP_22}vivo{/NP_22} , {AV_23}however{/AV_23} , {VP_act_24}requires{/VP_act_24} {NP_25}further investigation{/NP_25} .

{NP_26}We{/NP_26} {VP_act_27}already reported{/VP_act_27} that {NP_P_28}<p>ANX-I ( ANXA1 )</p>{/NP_P_28} {VP_pass_29}was up-regulated{/VP_pass_29} in {NP_S_30}<S>hepatocellular carcinoma ( HCC )</S>{/NP_S_30} .

{NP_31}The role{/NP_31} of {NP_P_32}<p>ANXA2</p>{/NP_P_32} in {NP_33}various liver diseases{/NP_33} {VP_act_34}including{/VP_act_34} {NP_S_35}<S>HCC</S>{/NP_S_35} {VP_act_36}remains{/VP_act_36} {JP_37}obscure{/JP_37} .

In {NP_38}the present study{/NP_38} , {NP_39}the <Bppf>protein</Bppf> and mRNA levels{/NP_39} of {NP_P_40}<p>ANXA2</p>{/NP_P_40} , as well as {NP_41}its localization{/NP_41} , {VP_pass_42}were determined{/VP_pass_42} for {NP_43}the normal <s>human</s> liver{/NP_43} , {NP_44}chronic hepatitis liver{/NP_44} , and {NP_45}non-tumorous and tumorous portions{/NP_45} of {NP_S_46}<S>HCC tissues</S>{/NP_S_46} .

{NP_P_47}<p>ANXA2</p>{/NP_P_47} {VP_pass_48}was rarely detected{/VP_pass_48} in {NP_49}either normal or chronic hepatitis liver <Bpcl>tissues</Bpcl>{/NP_49} , whereas {NP_50}it{/NP_50} {VP_pass_51}was overexpressed{/VP_pass_51} at both {NP_52}the transcriptional and translational levels{/NP_52} in {NP_PP_53}tumorous and non-tumorous <Bppp>regions</Bppp>{/NP_PP_53} of {NP_S_54}<S>HCC</S>{/NP_S_54} .

In {NP_55}addition{/NP_55} , in {NP_56}many cases{/NP_56} , {NP_P_57}more <p>ANXA2</p>{/NP_P_57} {VP_pass_58}was expressed{/VP_pass_58} in {NP_59}the tumorous portion{/NP_59} than in {NP_60}the non-tumorous portion{/NP_60} of {NP_S_61}<S>HCC</S>{/NP_S_61} .

{NP_62}The expression{/NP_62} of {NP_P_63}<p>ANXA2</p>{/NP_P_63} {VP_pass_64}was mainly localized{/VP_pass_64} in {NP_65}<Bpcl>cancer cells</Bpcl>{/NP_65} , {AV_66}especially{/AV_66} in {NP_S_67}poorly differentiated <S>HCC</S>{/NP_S_67} .

OUTPUT 1
PTM = ({VP_pass_70};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="tyrosine" in "{VP_pass_70}was <pp>tyrosine</pp>-phosphorylated{/VP_pass_70}" 	(Features:dist=0)
Substrate = ({NP_P_69}<p>ANXA2</p>{/NP_P_69};-)
	Method=rule:1.3.1.1.0.1 (substrate) for phrase=[{NP_P_69}<p>ANXA2</p>{/NP_P_69}]
Site = (-;{VP_pass_70}Tyr{/VP_pass_70};UNK)
	Method=rule: (site) for phrase=[{VP_pass_70}was <pp>tyrosine</pp>-phosphorylated{/VP_pass_70}3..10|tyrosine|Tyr]

{AV_68}Furthermore{/AV_68} , {NP_P_69}<p>ANXA2</p>{/NP_P_69} {VP_pass_70}was <pp>tyrosine</pp>-phosphorylated{/VP_pass_70} in {NP_S_71}<S>HCC</S>{/NP_S_71} .

OUTPUT 2
PTM = ({NP_74};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>tyrosine</pp>" in "{NP_74}overexpression and <pp>tyrosine</pp> phosphorylation{/NP_74}" 	(Features:dist=0)
		Candidate="tyrosine" in "{NP_74}overexpression and <pp>tyrosine</pp> phosphorylation{/NP_74}" 	(Features:dist=0)
Substrate = ({NP_P_75}<p>ANXA2</p>{/NP_P_75};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_75}<p>ANXA2</p>{/NP_P_75}]
Site = (-;{NP_74}Tyr{/NP_74};UNK)
	Method=rule: (site) for phrase=[{NP_74}overexpression and <pp>tyrosine</pp> phosphorylation{/NP_74}17..24|tyrosine|Tyr]

{NP_72}These data{/NP_72} {VP_act_73}suggest{/VP_act_73} that {NP_74}overexpression and <pp>tyrosine</pp> phosphorylation{/NP_74} of {NP_P_75}<p>ANXA2</p>{/NP_P_75} {VP_act_76}play{/VP_act_76} {NP_77}important roles{/NP_77} in {NP_78}the malignant transformation process{/NP_78} {VP_act_79}leading{/VP_act_79} to {NP_S_80}<S>HCC</S>{/NP_S_80} and {VP_pass_81}are related{/VP_pass_81} to {NP_82}the histological grade{/NP_82} of {NP_S_83}<S>HCC</S>{/NP_S_83} .


{NP_1}PMID{/NP_1} - {CP_2}19020749{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Growth and molecular interactions{/NP_4} of {NP_P_5}the <p>anti-EGFR antibody cetuximab</p>{/NP_P_5} and {NP_B_6}the <B>DNA cross-linking agent cisplatin</B>{/NP_B_6} in {NP_S_7}gefitinib-resistant <s><S>MDA-MB-468 cells</S></s>{/NP_S_7} : {NP_8}new prospects{/NP_8} in {NP_9}the treatment{/NP_9} of {NP_10}triple-negative/basal-like breast cancer{/NP_10} .

{NP_11}AB{/NP_11} - {NP_12}Three prominent hallmarks{/NP_12} of {NP_13}triple-negative/basal-like breast carcinomas{/NP_13} , {NP_14}a subtype{/NP_14} of {NP_P_15}breast <Bppf>cancer gene phenotype</Bppf>{/NP_P_15} {VP_act_16}associated{/VP_act_16} {NP_17}<B>with</B> poor relapse-free and overall survival{/NP_17} , {VP_act_18}are overexpression{/VP_act_18} of {NP_P_19}the <p>epidermal growth factor receptor ( EGFR )</p>{/NP_P_19} , {NP_20}hyperactivation{/NP_20} of {NP_21}the <p>MEK/ERK</p> transduction pathway and high sensitivity{/NP_21} to {NP_22}<B>DNA-damaging</B> agents{/NP_22} .

{NP_23}The cytotoxic interaction{/NP_23} between {NP_P_24}<Bppf><p>EGFR</p> inhibitors</Bppf>{/NP_P_24} ( {NP_P_25}monoclonal <Bppf>antibodies</Bppf>{/NP_P_25} {JP_26}such{/JP_26} as {NP_P_27}<Bppf>cetuximab</Bppf> and <Bppf>small molecule tyrosine kinase inhibitors</Bppf>{/NP_P_27} {JP_28}such{/JP_28} as {NP_29}gefitinib{/NP_29} ) and {NP_30}DNA cross-linking agents ( e.g. <B>platinum derivatives</B> ){/NP_30} {VP_act_31}might represent{/VP_act_31} {NP_32}a promising combination{/NP_32} for {NP_33}the treatment{/NP_33} of {NP_34}triple-negative/basal-like breast tumors{/NP_34} {NP_35}that{/NP_35} {VP_pass_36}are dependent{/VP_pass_36} upon {NP_37}<p>EGFR/MEK/ERK</p> signaling{/NP_37} .

{NP_38}We{/NP_38} {VP_act_39}evaluated{/VP_act_39} {NP_40}the growth and molecular interactions{/NP_40} of {NP_P_41}the <p>anti-EGFR antibody cetuximab</p> ( erbitux ){/NP_P_41} and {NP_B_42}the <B>DNA cross-linking agent cisplatin</B>{/NP_B_42} ( {NP_C_43}<c>cis-diammedichloroplatinum</c>{/NP_C_43} ; {NP_B_44}<B>CDDP</B>{/NP_B_44} ) in {NP_45}the gefitinib-resistant <B>MDA-MB-468</B> breast <Bpcl>cancer cell line</Bpcl>{/NP_45} , {NP_46}an in vitro model system{/NP_46} {NP_47}that{/NP_47} {VP_act_48}shows{/VP_act_48} {NP_49}many{/NP_49} of {NP_50}the recurrent basal-like molecular abnormalities{/NP_50} {VP_act_51}including{/VP_act_51} {NP_52}<B>ER-PR-HER2-negative</B> status{/NP_52} , {NP_53}<p>TP53</p> deficiency{/NP_53} , {NP_54}<p>EGFR</p> overexpression{/NP_54} , {NP_55}<p>PTEN</p> loss{/NP_55} and {NP_56}constitutive activation{/NP_56} of {NP_57}the <p>MEK/ERK</p> pathway{/NP_57} .

Unlike {NP_58}other basal-like breast cancer models{/NP_58} , {NP_S_59}<s><S>MDA-MB-468 cells</S></s>{/NP_S_59} {VP_act_neg_60}do not carry{/VP_act_neg_60} {NP_61}mutations{/NP_61} of {NP_P_62}the key <p>DNA repair gene BRCA1</p>{/NP_P_62} .

{NP_63}Concurrent treatment <B>with</B> sub-optimal doses{/NP_63} of {NP_B_64}<B>cetuximab</B>{/NP_B_64} {VP_act_65}significantly enhanced{/VP_act_65} <B>CDDP</B> -induced {NP_66}apoptotic <Bpcl>cell</Bpcl> death{/NP_66} .

{AV_67}However{/AV_67} , {NP_68}an isobologram-based mathematical assessment{/NP_68} of {NP_69}the nature{/NP_69} of {NP_70}the interaction{/NP_70} {VP_act_71}revealed{/VP_act_71} {NP_72}a loss{/NP_72} of {NP_73}synergism{/NP_73} when {VP_act_74}employing{/VP_act_74} {NP_75}a high-dose{/NP_75} of {NP_B_76}<B>cetuximab</B>{/NP_B_76} .

Since {NP_B_77}<B><p>BRCA1</p> depletion has been</B>{/NP_B_77} {VP_act_78}found{/VP_act_78} {VP_act_79}to decrease{/VP_act_79} {NP_80}DNA damage repair{/NP_80} and {NP_81}<Bpcl>cell</Bpcl> survival{/NP_81} in {NP_S_82}<s><S>MDA-MB-468 cells</S></s>{/NP_S_82} when {VP_act_83}treated{/VP_act_83} {NP_C_84}<c>with DNA-damaging drugs</c>{/NP_C_84} , {NP_85}we{/NP_85} {VP_act_86}employed{/VP_act_86} {NP_87}<B>ELISA-based</B> quantitative analyses{/NP_87} {VP_act_88}to measure{/VP_act_88} {NP_89}<p>BRCA1 protein</p> levels{/NP_89} in {NP_S_90}<S>CDDP+/- cetuximab-treated cells</S>{/NP_S_90} .

{NP_B_91}<B>Cetuximab</B>{/NP_B_91} as {NP_92}single agent{/NP_92} {VP_pass_93}was as efficient{/VP_pass_93} as {NP_B_94}<B>CDDP</B>{/NP_B_94} at {VP_act_95}increasing{/VP_act_95} {NP_96}<p>BRCA1 protein</p> expression{/NP_96} .

{AV_97}Interestingly{/AV_97} , {NP_B_98}<B>cetuximab</B>{/NP_B_98} {VP_act_99}co-exposure significantly antagonized{/VP_act_99} {NP_100}the ability{/NP_100} of {NP_B_101}<B>CDDP</B>{/NP_B_101} to {NP_102}up-regulate <p>BRCA1</p> expression{/NP_102} .

OUTPUT 0
PTM = ({NP_107};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_117};hyper-phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>MAPKs</p>" in "{NP_B_103}Low-scale phosphor-proteomic approaches [i.e. phospho-receptor tyrosine kinase ( RTK ) and phospho-<B>mitogen-activated protein kinases ( <p>MAPKs</p> ) Array Proteome Profiler</B>{/NP_B_103}" 	(Features:dist=0|subject_main_modifier)
		Candidate="<p>MAPKs</p>" in "{NP_P_109}23 different <p>MAPKs</p>{/NP_P_109}" 	(Features:dist=0)
		Candidate="{NP_P_110}other <Bppf>serine/threonine kinases</Bppf>{/NP_P_110}" 	(Features:dist=0|is-kinase_inherently)
Substrate = ({NP_P_118}<p>EGFR</p>{/NP_P_118};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_118}<p>EGFR</p>{/NP_P_118}]
Site = (-;-;UNK)

{NP_B_103}Low-scale phosphor-proteomic approaches [i.e. phospho-receptor tyrosine kinase ( RTK ) and phospho-<B>mitogen-activated protein kinases ( <p>MAPKs</p> ) Array Proteome Profiler</B>{/NP_B_103} {JP_104}capable{/JP_104} of {VP_act_105}simultaneously identifying{/VP_act_105} {NP_106}the relative levels{/NP_106} of {NP_107}phosphorylation{/NP_107} of {NP_B_108}42 different <B>RTKs</B>{/NP_B_108} and {NP_P_109}23 different <p>MAPKs</p>{/NP_P_109} and {NP_P_110}other <Bppf>serine/threonine kinases</Bppf>{/NP_P_110} , {NP_111}respectively]{/NP_111} {VP_act_112}revealed{/VP_act_112} {NP_113}the ability{/NP_113} of {NP_B_114}<B>Cetuximab</B>{/NP_B_114} , as {NP_115}single agent{/NP_115} , {VP_act_116}to paradoxically induce{/VP_act_116} {NP_117}hyper-phosphorylation{/NP_117} of {NP_P_118}<p>EGFR</p>{/NP_P_118} while {VP_act_119}concomitantly deactivating{/VP_act_119} {NP_P_120}<p>p42/44 (ERK1/ERK2) MAPK</p>{/NP_P_120} .

{AV_121}Unexpectedly{/AV_121} , {NP_122}<B>ELISA-based</B> quantitative analyses{/NP_122} of {NP_123}<p>EGFR protein</p> content{/NP_123} {VP_act_124}demonstrated{/VP_act_124} that {NP_125}simultaneous exposure{/NP_125} to {NP_B_126}<B>cetuximab</B>{/NP_B_126} and {NP_127}optimal doses{/NP_127} of {NP_B_128}<B>CDDP</B>{/NP_B_128} {VP_act_129}completely depleted{/VP_act_129} {NP_P_130}<p>EGFR protein</p>{/NP_P_130} in {NP_S_131}<s><S>MDA-MB-468 cells</S></s>{/NP_S_131} .

{NP_P_132}THIS <p>LINE WITH 600 OR MORE CHARS HAS BEEN REMOVED.</p>{/NP_P_132}


{NP_1}PMID{/NP_1} - {CP_2}19020753{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Ectopic <p>cyclin D1</p> overexpression{/NP_4} {VP_act_5}increases{/VP_act_5} {VP_act_6}chemosensitivity{/VP_act_6} but not {NP_7}<Bpcl>cell</Bpcl> proliferation{/NP_7} in {NP_8}multiple myeloma{/NP_8} .

{NP_9}AB{/NP_9} - {NP_10}We{/NP_10} {VP_act_11}established{/VP_act_11} {NP_B_12}a myeloma <Bpcl>cell line</Bpcl> (RPMI8226){/NP_B_12} with {NP_13}<p>cyclin D1</p> overexpression{/NP_13} in {NP_14}which{/NP_14} {NP_P_15}the transfected <p>cyclin D1 gene</p>{/NP_P_15} {VP_pass_16}was stably expressed{/VP_pass_16} .

{NP_17}<c>D1</c> transfectants{/NP_17} {VP_act_18}showed{/VP_act_18} {NP_19}down-regulation{/NP_19} of {NP_P_20}<p>cyclin D2</p>{/NP_P_20} .

{NP_21}Cell proliferation analysis{/NP_21} {VP_act_neg_22}did not show{/VP_act_neg_22} {NP_23}any differences{/NP_23} among {NP_B_24}<B>RPMI8226</B>{/NP_B_24} , {NP_25}mock control{/NP_25} , and {NP_26}<c>D1</c> transfectants{/NP_26} .

{NP_27}The number{/NP_27} of {NP_28}<Bpcl>S-phase cells</Bpcl>{/NP_28} {VP_act_29}increased{/VP_act_29} while {NP_30}the number{/NP_30} of {NP_B_31}<B>G0/G1</B>{/NP_B_31} - and {NP_S_32}<S>G2/M-phase cells</S>{/NP_S_32} {VP_pass_33}decreased{/VP_pass_33} in {NP_34}<c>D1</c> transfectants{/NP_34} , {NP_35}which{/NP_35} {VP_act_36}indicates{/VP_act_36} {NP_37}a prolonged S-phase{/NP_37} {VP_pass_38}caused{/VP_pass_38} by {NP_39}<p>cyclin D1</p> transfection{/NP_39} .

{NP_40}A decreased number{/NP_40} of {NP_S_41}<S>G2/M-phase cells</S>{/NP_S_41} {VP_pass_42}was also detected{/VP_pass_42} in {NP_43}myeloma <Bpcl>cells</Bpcl>{/NP_43} of {NP_44}patients{/NP_44} with {NP_45}translocation t{/NP_45} ( {CP_46}11{/CP_46} ; {CP_47}14{/CP_47} ) ( {CP_48}q13{/CP_48} ; {NP_P_49}<p>q32</p>{/NP_P_49} ) .

OUTPUT 0
PTM = ({NP_P_53};hyperphosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_58}<p>p53</p> , <p>p16</p> , <p>Bax</p> , <p>Bad</p> , <p>Bcl-2</p> , and <p>Mcl-1</p>{/NP_P_58}" 	(Features:dist=0|pparg)
		Candidate="<p>p53</p>" in "{NP_P_58}<p>p53</p> , <p>p16</p> , <p>Bax</p> , <p>Bad</p> , <p>Bcl-2</p> , and <p>Mcl-1</p>{/NP_P_58}" 	(Features:dist=0)
		Candidate="<p>Bad</p>" in "{NP_P_58}<p>p53</p> , <p>p16</p> , <p>Bax</p> , <p>Bad</p> , <p>Bcl-2</p> , and <p>Mcl-1</p>{/NP_P_58}" 	(Features:dist=0)
		Candidate="<p>Bcl-2</p>" in "{NP_P_58}<p>p53</p> , <p>p16</p> , <p>Bax</p> , <p>Bad</p> , <p>Bcl-2</p> , and <p>Mcl-1</p>{/NP_P_58}" 	(Features:dist=0)
		Candidate="<p>Mcl-1</p>" in "{NP_P_58}<p>p53</p> , <p>p16</p> , <p>Bax</p> , <p>Bad</p> , <p>Bcl-2</p> , and <p>Mcl-1</p>{/NP_P_58}" 	(Features:dist=0)
		Candidate="<p>p16</p>" in "{NP_P_58}<p>p53</p> , <p>p16</p> , <p>Bax</p> , <p>Bad</p> , <p>Bcl-2</p> , and <p>Mcl-1</p>{/NP_P_58}" 	(Features:dist=0)
		Candidate="<p>Bax</p>" in "{NP_P_58}<p>p53</p> , <p>p16</p> , <p>Bax</p> , <p>Bad</p> , <p>Bcl-2</p> , and <p>Mcl-1</p>{/NP_P_58}" 	(Features:dist=0)
Substrate = ({NP_P_54}<p>retinoblastoma ( Rb ) protein</p>{/NP_P_54};-)
	Method=link (substrate) for phrase=[{NP_P_54}<p>retinoblastoma ( Rb ) protein</p>{/NP_P_54}]
		From: {NP_P_53}the hyperphosphorylated <Bppf>form</Bppf>{/NP_P_53}
		Path: identity
Site = (-;-;UNK)

{NP_50}Western blot analysis{/NP_50} {VP_act_51}revealed{/VP_act_51} an {VP_pass_52}increase{/VP_pass_52} in {NP_P_53}the hyperphosphorylated <Bppf>form</Bppf>{/NP_P_53} of {NP_P_54}<p>retinoblastoma ( Rb ) protein</p>{/NP_P_54} in {NP_55}<c>D1</c> transfectants{/NP_55} ; {AV_56}however{/AV_56} , {NP_57}the expression{/NP_57} of {NP_P_58}<p>p53</p> , <p>p16</p> , <p>Bax</p> , <p>Bad</p> , <p>Bcl-2</p> , and <p>Mcl-1</p>{/NP_P_58} {VP_act_neg_59}did not significantly change{/VP_act_neg_59} .

{NP_60}Treatment{/NP_60} with {NP_61}<Bpcf>anti-myeloma drugs</Bpcf>{/NP_61} ( {NP_62}melphalan{/NP_62} , {NP_C_63}<c>dexamethasone</c>{/NP_C_63} , {NP_64}bortezomib{/NP_64} and {NP_65}immunomodulatory <Bpcf>compounds</Bpcf>{/NP_65} ) {VP_act_66}induced{/VP_act_66} {NP_67}apoptosis{/NP_67} {AV_68}earlier{/AV_68} in {NP_69}<c>D1</c> transfectants{/NP_69} {VP_act_70}compared{/VP_act_70} with {NP_B_71}<B>RPMI8226</B>{/NP_B_71} and {NP_72}mock control{/NP_72} via {NP_73}the activation{/NP_73} of {NP_P_74}both <p>caspase-8</p>{/NP_P_74} and {CP_75}-9{/CP_75} .

{AV_76}However{/AV_76} , {NP_77}we{/NP_77} {VP_act_neg_78}could not detect{/VP_act_neg_78} {NP_79}a relationship{/NP_79} between {NP_80}<p>cyclin D1</p> expression{/NP_80} and {NP_81}the response{/NP_81} to {NP_82}treatment{/NP_82} with {NP_P_83}<p>VAD</p>{/NP_P_83} and {NP_84}bortezomib{/NP_84} .

{AV_85}Therefore{/AV_85} , {NP_86}we{/NP_86} {VP_act_87}assume{/VP_act_87} that {NP_88}high sensitivity{/NP_88} to {NP_89}<Bpcf>anti-myeloma drugs</Bpcf>{/NP_89} {VP_act_90}depends{/VP_act_90} on {NP_91}the duration{/NP_91} of {NP_92}the S-phase{/NP_92} , but {NP_93}a clinical response{/NP_93} {VP_act_94}might depend{/VP_act_94} on {NP_95}the number{/NP_95} of {NP_96}myeloma <Bpcl>cells</Bpcl>{/NP_96} with {NP_97}<p>cyclin D1</p> overexpression{/NP_97} .


{NP_1}PMID{/NP_1} - {CP_2}19020765{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}<B>Pleurotus</B> ostreatus{/NP_4} {VP_act_5}inhibits{/VP_act_5} {NP_6}proliferation{/NP_6} of {NP_7}<s>human</s> breast and <Bpcl>colon cancer cells</Bpcl>{/NP_7} through {NP_8}<p>p53</p> -dependent as well{/NP_8} as {NP_9}<p>p53</p> -independent pathway{/NP_9} .

{NP_10}AB{/NP_10} - In {NP_11}spite{/NP_11} of {NP_12}the global consumption{/NP_12} of {NP_13}mushrooms{/NP_13} , {NP_14}only two epidemiological studies{/NP_14} {VP_act_15}demonstrated{/VP_act_15} {NP_16}an inverse correlation{/NP_16} between {NP_17}mushroom intake{/NP_17} and {NP_18}the risk{/NP_18} of {NP_19}cancer{/NP_19} .

{AV_20}Therefore{/AV_20} , in {NP_21}the present study{/NP_21} {NP_22}we{/NP_22} {VP_act_23}evaluated{/VP_act_23} whether {NP_24}extracts{/NP_24} from {NP_25}edible mushrooms <B>Agaricus</B> bisporus ( portabella ){/NP_25} , {NP_26}<B>Flammulina</B> velutipes ( enoki ){/NP_26} , {NP_27}<B>Lentinula</B> edodes ( shiitake ){/NP_27} and {NP_28}<B>Pleurotus</B> ostreatus ( oyster ) affect{/NP_28} {NP_29}the growth{/NP_29} of {NP_30}breast and <Bpcl>colon cancer cells</Bpcl>{/NP_30} .

{AV_31}Here{/AV_31} , {NP_32}we{/NP_32} {VP_act_33}identified{/VP_act_33} as the {JP_34}most potent{/JP_34} , {NP_B_35}<s><B>P.ostreatus</B></s> ( <s>oyster mushroom</s> ){/NP_B_35} {NP_36}which{/NP_36} {VP_act_37}suppressed{/VP_act_37} {NP_38}proliferation{/NP_38} of {NP_39}breast cancer{/NP_39} ( {NP_B_40}<B>MCF-7</B>{/NP_B_40} , {NP_B_41}<B>MDA-MB-231</B>{/NP_B_41} ) and {NP_42}colon cancer{/NP_42} ( {NP_P_43}<p>HT-29</p>{/NP_P_43} , {NP_P_44}<p>HCT-116</p>{/NP_P_44} ) {NP_45}<Bpcl>cells</Bpcl>{/NP_45} , without {VP_act_46}affecting{/VP_act_46} {NP_47}proliferation{/NP_47} of {NP_S_48}<B>epithelial mammary MCF-10A</B> and normal colon <s><S>FHC cells</S></s>{/NP_S_48} .

{NP_49}Flow cytometry{/NP_49} {VP_act_50}revealed{/VP_act_50} that {NP_51}the inhibition{/NP_51} of {NP_52}<Bpcl>cell</Bpcl> proliferation{/NP_52} by {NP_B_53}<s><B>P.ostreatus</B></s>{/NP_B_53} {VP_pass_54}was associated{/VP_pass_54} with {NP_55}the cell cycle arrest{/NP_55} at {NP_56}<B>G0/G1</B> phase{/NP_56} in {NP_S_57}<B>MCF-7</B> and <s><S><p>HT-29</p> cells</S></s>{/NP_S_57} .

OUTPUT 0
PTM = ({NP_64};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>tumor suppressor p53</p>" in "{NP_B_62}the <p>tumor suppressor p53</p> and <B>cyclin-dependent kinase inhibitor <p>p21</p> ( CIP1/WAF1 )</B>{/NP_B_62}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="<p>p21</p>" in "{NP_B_62}the <p>tumor suppressor p53</p> and <B>cyclin-dependent kinase inhibitor <p>p21</p> ( CIP1/WAF1 )</B>{/NP_B_62}" 	(Features:dist=0)
Substrate = ({NP_P_65}<p>Rb protein</p>{/NP_P_65};-)
	Method=rule: (substrate) for phrase=[{NP_P_65}retinoblastoma <p>Rb protein</p>{/NP_P_65}14..22|<p>Rb protein</p>]
Site = (-;-;UNK)

{AV_58}Moreover{/AV_58} , {NP_B_59}<s><B>P.ostreatus</B></s>{/NP_B_59} {VP_act_60}induced{/VP_act_60} {NP_61}the expression{/NP_61} of {NP_B_62}the <p>tumor suppressor p53</p> and <B>cyclin-dependent kinase inhibitor <p>p21</p> ( CIP1/WAF1 )</B>{/NP_B_62} , whereas {JP_63}inhibited{/JP_63} {NP_64}the phosphorylation{/NP_64} of {NP_P_65}retinoblastoma <p>Rb protein</p>{/NP_P_65} in {NP_S_66}<s><S>MCF-7 cells</S></s>{/NP_S_66} .

OUTPUT 1
PTM = ({NP_71};phosphorylation)
	HasAgentTheme="<p>Rb</p>" in "{NP_71}<p>Rb</p> phosphorylation{/NP_71}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_69}<p>p21</p>{/NP_P_69}" 	(Features:dist=0|pparg)
		Candidate="<p>HT-29</p>" in "{NP_S_72}<s><S><p>HT-29</p> cells</S></s>{/NP_S_72}" 	(Features:dist=0)
Substrate = ({NP_71}<p>Rb</p>{/NP_71};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_71}<p>Rb</p> phosphorylation{/NP_71}0..1|<p>Rb</p>]
Site = (-;-;UNK)

In {NP_67}addition{/NP_67} , {NP_68}<s><B>P.ostreatus</B></s> also up-regulated expression{/NP_68} of {NP_P_69}<p>p21</p>{/NP_P_69} and {VP_act_70}inhibited{/VP_act_70} {NP_71}<p>Rb</p> phosphorylation{/NP_71} in {NP_S_72}<s><S><p>HT-29</p> cells</S></s>{/NP_S_72} , {VP_act_73}suggesting{/VP_act_73} that {NP_B_74}that <s><B>P.ostreatus</B></s>{/NP_B_74} {VP_act_75}suppresses{/VP_act_75} {NP_76}the proliferation{/NP_76} of {NP_77}breast and <Bpcl>colon cancer cells</Bpcl>{/NP_77} via {NP_78}<p>p53</p> -dependent as well{/NP_78} as {NP_79}<p>p53</p> -independent pathway{/NP_79} .

In {NP_80}conclusion{/NP_80} , {NP_81}our results{/NP_81} {VP_act_82}indicated{/VP_act_82} that {NP_83}the edible <s>oyster mushroom</s>{/NP_83} {VP_act_84}has{/VP_act_84} {NP_85}potential therapeutic/preventive effects{/NP_85} on {NP_86}breast and colon cancer{/NP_86} .


{NP_1}PMID{/NP_1} - {CP_2}19001498{/CP_2}

{NP_3}TI{/NP_3} - {NP_S_4}<B>uPAR-deficient</B> <s>mouse</s> <S>keratinocytes</S>{/NP_S_4} {VP_act_5}fail{/VP_act_5} {VP_act_6}to produce{/VP_act_6} {NP_7}<p>EGFR</p> -dependent{/NP_7} {JP_8}laminin-5{/JP_8} , {VP_act_9}affecting{/VP_act_9} {NP_10}migration{/NP_10} in {NP_11}vivo{/NP_11} and {NP_12}in vitro{/NP_12} .

{NP_13}AB{/NP_13} - {NP_P_14}The <p>urokinase receptor ( uPAR )</p>{/NP_P_14} {VP_pass_15}is involved{/VP_pass_15} in {NP_16}a series{/NP_16} of {NP_17}pathological processes{/NP_17} , from {NP_18}inflammation{/NP_18} to {NP_19}cancer{/NP_19} .

{NP_20}We{/NP_20} {VP_pass_21}have analyzed{/VP_pass_21} in {NP_PP_22}<Bppp>detail</Bppp>{/NP_PP_22} {NP_23}the role{/NP_23} of {NP_P_24}<p>uPAR</p>{/NP_P_24} and {NP_25}the mechanisms{/NP_25} {VP_pass_26}involved{/VP_pass_26} in {NP_27}<S>keratinocyte</S> behavior{/NP_27} during {NP_28}wound healing{/NP_28} by {VP_act_29}exploiting{/VP_act_29} {NP_30}<B>uPAR-knockout ( KO )</B> <s>mice</s>{/NP_30} .

{NP_31}In vivo{/NP_31} , {NP_32}<p>uPAR-KO</p> <s>mice</s>{/NP_32} {VP_act_33}showed{/VP_act_33} {NP_34}delayed wound healing{/NP_34} , with {NP_35}<S>abnormal keratinocyte</S> migration and proliferation{/NP_35} .

{NP_36}In vitro{/NP_36} , unlike {NP_37}<Bpcl>wild-type cells</Bpcl>{/NP_37} , {NP_S_38}primary <S><p>uPAR-KO</p> keratinocytes</S>{/NP_S_38} {VP_pass_neg_39}did not proliferate{/VP_pass_neg_39} in {NP_40}response{/NP_40} to {NP_P_41}<p>epidermal growth factor ( EGF )</p>{/NP_P_41} , {NP_42}their growth and migration{/NP_42} {VP_pass_neg_43}were not inhibited{/VP_pass_neg_43} by {NP_P_44}<Bppf>EGF-receptor ( <p>EGFR</p> ) inhibitors</Bppf>{/NP_P_44} , and {NP_45}they{/NP_45} {VP_act_neg_46}did not adhere{/VP_act_neg_46} to {NP_47}uncoated surfaces{/NP_47} .

OUTPUT 0
PTM = ({NP_52};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)
	Method=rule: (site) for phrase=[{NP_52}no <pp>tyrosine</pp> phosphorylation{/NP_52}2..9|tyrosine|Tyr]

Whereas {NP_48}<p>EGFR</p> levels{/NP_48} in {NP_S_49}<S><p>uPAR-KO</p> keratinocytes</S>{/NP_S_49} {VP_pass_50}were normal{/VP_pass_50} , there {VP_pass_51}was{/VP_pass_51} {NP_52}no <pp>tyrosine</pp> phosphorylation{/NP_52} upon {NP_53}addition{/NP_53} of {NP_P_54}<p>EGF</p>{/NP_P_54} , and {NP_P_55}its <Bppf>downstream targets</Bppf>{/NP_P_55} , {NP_P_56}<p>extracellular-signal-regulated kinases 1 and 2 ( ERK1/2 )</p>{/NP_P_56} , {VP_pass_neg_57}were not activated{/VP_pass_neg_57} .

{NP_58}Re-introduction{/NP_58} of {NP_P_59}<s>mouse</s> <p>uPAR</p>{/NP_P_59} {VP_act_60}rescued{/VP_act_60} {NP_61}all phenotypes{/NP_61} .

{NP_62}In vitro adhesion and migration defects{/NP_62} {VP_pass_63}were associated{/VP_pass_63} with {NP_64}the failure{/NP_64} of {NP_S_65}<S><p>uPAR-KO</p> keratinocytes</S>{/NP_S_65} {VP_act_66}to normally produce{/VP_act_66} and {NP_P_67}secrete <p>laminin-5 ( LN5 )</p>{/NP_P_67} , {NP_68}an event{/NP_68} {NP_69}that{/NP_69} {VP_act_70}requires{/VP_act_70} {NP_71}<p>EGFR</p> signaling{/NP_71} .

{NP_72}These results{/NP_72} {VP_pass_73}were confirmed{/VP_pass_73} in {NP_74}vivo{/NP_74} , with {NP_P_75}<p>LN5</p>{/NP_P_75} {VP_pass_76}being upregulated{/VP_pass_76} during {NP_77}wound healing{/NP_77} in {JP_78}wild-type{/JP_78} but {AV_79}not{/AV_79} in {NP_80}<p>uPAR-KO</p> epidermis{/NP_80} .


{NP_1}PMID{/NP_1} - {CP_2}19001499{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>TRPC1</p>{/NP_P_4} {VP_act_5}regulates{/VP_act_5} {NP_6}<S>skeletal myoblast</S> migration and differentiation{/NP_6} .

{NP_7}AB{/NP_7} - {NP_8}<S>Myoblast</S> migration{/NP_8} {VP_act_9}is{/VP_act_9} {NP_10}a key step{/NP_10} in {NP_11}myogenesis and regeneration{/NP_11} .

{NP_12}It{/NP_12} {VP_act_13}allows{/VP_act_13} {NP_14}<S>myoblast</S> alignment{/NP_14} and {NP_15}their fusion{/NP_15} into {NP_16}myotubes{/NP_16} .

{NP_17}The process{/NP_17} {VP_pass_18}has been shown{/VP_pass_18} {VP_act_19}to involve{/VP_act_19} {JP_20}m-calpain or mu-calpain{/JP_20} , {NP_P_21}two <p><pp>Ca(2+)- dependent cysteine</pp> proteases</p>{/NP_P_21} .

{AV_22}Here{/AV_22} {NP_23}we{/NP_23} {VP_act_24}measure{/VP_act_24} {VP_act_25}calpain{/VP_act_25} {NP_26}activity{/NP_26} in {NP_27}cultured <Bpcl>cells</Bpcl>{/NP_27} and {VP_act_28}show{/VP_act_28} {NP_29}a peak{/NP_29} of {NP_30}activity{/NP_30} at {NP_31}the beginning{/NP_31} of {NP_32}the differentiation process{/NP_32} .

{NP_33}We{/NP_33} {VP_act_34}also observed{/VP_act_34} {NP_35}a concomitant and transient increase{/NP_35} of {NP_36}the influx{/NP_36} of {NP_37}<B>Ca(2+)</B> and expression{/NP_37} of {NP_P_38}<p>TRPC1 protein</p>{/NP_P_38} .

{NP_39}Calpains{/NP_39} {VP_pass_40}are specifically activated{/VP_pass_40} by {NP_41}a store-operated entry{/NP_41} of {NP_B_42}<B>Ca(2+)</B>{/NP_B_42} in {NP_43}adult skeletal muscle fibres{/NP_43} .

{NP_44}We{/NP_44} {VP_act_45}therefore repressed{/VP_act_45} {NP_46}the expression{/NP_46} of {NP_P_47}<p>TRPC1</p>{/NP_P_47} in {NP_S_48}<S>myoblasts</S>{/NP_S_48} and {VP_act_49}studied{/VP_act_49} {NP_50}the effects{/NP_50} on {NP_51}<B>Ca(2+)</B> fluxes{/NP_51} and on {NP_52}differentiation{/NP_52} .

{NP_S_53}<S>TRPC1-depleted myoblasts</S>{/NP_S_53} {VP_act_54}presented{/VP_act_54} {NP_55}a largely reduced store-operated entry{/NP_55} of {NP_B_56}<B>Ca(2+)</B>{/NP_B_56} and {NP_57}a significantly diminished transient influx{/NP_57} of {NP_B_58}<B>Ca(2+)</B>{/NP_B_58} at {NP_59}the beginning{/NP_59} of {NP_60}differentiation{/NP_60} .

{NP_61}The concomitant peak{/NP_61} of {NP_62}calpain activity{/NP_62} {VP_pass_63}was abolished{/VP_pass_63} .

OUTPUT 0
PTM = ({NP_P_66};substrate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_66}<p>myristoylated alanine-rich C-kinase substrate ( MARCKS )</p>{/NP_P_66};-)
	Method=rule:1.7.2.1 (substrate) for phrase=[{NP_P_66}<p>myristoylated alanine-rich C-kinase substrate ( MARCKS )</p>{/NP_P_66}]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_P_67};substrate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_S_64}<S>TRPC1-knockdown myoblasts</S>{/NP_S_64} {VP_act_65}also accumulated{/VP_act_65} {NP_P_66}<p>myristoylated alanine-rich C-kinase substrate ( MARCKS )</p>{/NP_P_66} , {NP_P_67}an <Bppf>actin-binding protein</Bppf> and <Bppf>substrate</Bppf>{/NP_P_67} of {NP_68}calpain{/NP_68} .

{NP_69}Their fusion{/NP_69} into {NP_70}myotubes{/NP_70} {VP_pass_71}was significantly slowed{/VP_pass_71} {AV_72}down{/AV_72} as {NP_73}a result{/NP_73} of {NP_74}the reduced speed{/NP_74} of {NP_75}<Bpcl>cell</Bpcl> migration{/NP_75} .

{AV_76}Accordingly{/AV_76} , {NP_77}migration{/NP_77} of {NP_S_78}control <S>myoblasts</S>{/NP_S_78} {VP_pass_79}was inhibited{/VP_pass_79} by {NP_80}2-5 microM GsMTx4 toxin{/NP_80} , {NP_P_81}an <Bppf>inhibitor</Bppf>{/NP_P_81} of {NP_P_82}<p>TRP channels</p>{/NP_P_82} or by {CP_83}50{/CP_83} microM <pp>Z-Leu-Leu</pp> , {NP_P_84}an <Bppf>inhibitor</Bppf>{/NP_P_84} of {NP_85}calpain{/NP_85} .

By {NP_86}contrast{/NP_86} , {NP_87}stimulation{/NP_87} of {NP_S_88}control <S>myoblasts</S>{/NP_S_88} with {NP_P_89}<p>IGF-1</p>{/NP_P_89} {VP_act_90}increased{/VP_act_90} {NP_91}the basal influx{/NP_91} of {NP_B_92}<B>Ca(2+)</B>{/NP_B_92} , {VP_act_93}activated{/VP_act_93} {NP_94}calpain{/NP_94} and {VP_act_95}accelerated{/VP_act_95} {NP_96}migration{/NP_96} .

{NP_97}These effects{/NP_97} {VP_pass_neg_98}were not observed{/VP_pass_neg_98} in {NP_S_99}<S>TRPC1-knockdown cells</S>{/NP_S_99} .

{NP_100}We{/NP_100} {VP_act_101}therefore suggest{/VP_act_101} that {NP_102}entry{/NP_102} of {NP_B_103}<B>Ca(2+)</B>{/NP_B_103} through {NP_P_104}<p>TRPC1 channels</p>{/NP_P_104} {VP_act_105}induces{/VP_act_105} {NP_106}a transient activation{/NP_106} of {NP_107}calpain{/NP_107} and {NP_108}subsequent proteolysis{/NP_108} of {NP_P_109}<p>MARCKS</p>{/NP_P_109} , {NP_110}which{/NP_110} {VP_act_111}allows{/VP_act_111} {AV_112}in turn{/AV_112} , {NP_113}<S>myoblast</S> migration and fusion{/NP_113} .


{NP_1}PMID{/NP_1} - {CP_2}19001501{/CP_2}

OUTPUT 0
PTM = ({VP_act_5};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_4}<p>NIMA-family kinase Nek6</p>{/NP_P_4};-)
	Method=rule: (kinase) for phrase=[{NP_P_4}The <p>NIMA-family kinase Nek6</p>{/NP_P_4}3..23|<p>NIMA-family kinase Nek6</p>]
Substrate = (-;-)
Site = (-;-;{NP_PP_7}<Bppp>site</Bppp>{/NP_PP_7})
	Method=rule: (siteother) for phrase=[{NP_PP_7}a novel <Bppp>site</Bppp>{/NP_PP_7}6..9|<Bppp>site</Bppp>]

{NP_3}TI{/NP_3} - {NP_P_4}The <p>NIMA-family kinase Nek6</p>{/NP_P_4} {VP_act_5}phosphorylates{/VP_act_5} {NP_B_6}the <B>kinesin <p>Eg5</p></B>{/NP_B_6} at {NP_PP_7}a novel <Bppp>site</Bppp>{/NP_PP_7} {JP_8}necessary{/JP_8} for {NP_9}mitotic spindle formation{/NP_9} .

{NP_10}AB{/NP_10} - {NP_P_11}<p>Nek6</p> and <p>Nercc1</p>{/NP_P_11} ( {VP_act_12}also known{/VP_act_12} as {NP_P_13}<p>Nek9</p>{/NP_P_13} ) {VP_pass_14}belong{/VP_pass_14} to {NP_B_15}the <B>NIMA family</B>{/NP_B_15} of {NP_P_16}<Bppf>protein kinases</Bppf>{/NP_P_16} .

OUTPUT 1
PTM = ({VP_act_22};phosphorylates)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_17}<p>Nercc1</p>{/NP_P_17}" 	(Features:dist=0|subject_main)
		Candidate="<p>Nercc1</p>" in "{NP_P_17}<p>Nercc1</p>{/NP_P_17}" 	(Features:dist=0|subject_main|subject_main_modifier)
Substrate = ({NP_P_23}<p>Nek6</p>{/NP_P_23};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_23}<p>Nek6</p>{/NP_P_23}]
Site = (-;-;UNK)

{NP_P_17}<p>Nercc1</p>{/NP_P_17} {VP_pass_18}is activated{/VP_pass_18} in {NP_19}mitosis{/NP_19} , whereupon {NP_20}it{/NP_20} {VP_act_21}binds{/VP_act_21} , {VP_act_22}phosphorylates and activates{/VP_act_22} {NP_P_23}<p>Nek6</p>{/NP_P_23} .

{NP_24}Interference{/NP_24} with {NP_P_25}<p>Nek6</p> or <p>Nercc1</p>{/NP_P_25} in {NP_26}mammalian <Bpcl>cells</Bpcl> causes prometaphase-metaphase arrest , and depletion{/NP_26} of {NP_P_27}<p>Nercc1</p>{/NP_P_27} from {NP_28}<B>Xenopus</B> egg extracts{/NP_28} {VP_act_29}prevents{/VP_act_29} {NP_30}normal spindle assembly{/NP_30} .

{NP_31}Herein{/NP_31} {NP_32}we{/NP_32} {VP_act_33}show{/VP_act_33} that {NP_P_34}<p>Nek6</p>{/NP_P_34} {VP_pass_35}is constitutively associated{/VP_pass_35} with {NP_P_36}<p>Eg5</p>{/NP_P_36} ( {VP_act_37}also known{/VP_act_37} as {NP_P_38}<p>Kinesin-5</p> and <p>Kif11</p>{/NP_P_38} ) , {NP_B_39}a <B>kinesin</B>{/NP_B_39} {NP_40}that{/NP_40} {VP_pass_41}is necessary{/VP_pass_41} for {NP_42}spindle bipolarity{/NP_42} .

OUTPUT 2
PTM = ({VP_act_44};phosphorylated)
Inducer = (-;-)
Kinase = ({NP_P_43}<p>Nek6</p>{/NP_P_43};-)
	Method=rule:1.11.1.1.1 (kinase) for phrase=[{NP_P_43}<p>Nek6</p>{/NP_P_43}]
Substrate = ({NP_P_45}<p>Eg5</p>{/NP_P_45};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_45}<p>Eg5</p>{/NP_P_45}]
Site = (-;-;{NP_PP_46}<Bppp>sites</Bppp>{/NP_PP_46})
({NP_PP_50}1033{/NP_PP_50};{NP_PP_50}Ser{/NP_PP_50};UNK)
	Method=unclaimed_site_or_shared_substrate (site) for phrase=[{NP_PP_50}<pp>Ser1033</pp>{/NP_PP_50}0..6|Ser1033|Ser1033]
	Method=rule: (siteother) for phrase=[{NP_PP_46}several <Bppp>sites</Bppp>{/NP_PP_46}7..11|<Bppp>sites</Bppp>]
	Candidates (Site):
		Candidate="{NP_PP_50}<pp>Ser1033</pp>{/NP_PP_50}" 	(Features:is-aa)

OUTPUT 3
PTM = ({VP_pass_51};phosphorylated)
Inducer = (-;-)
Kinase = ({NP_P_43}<p>Nek6</p>{/NP_P_43};-)
	Method=from_other_triggers_in_the_same_sentence (kinase) for phrase=[{NP_P_43}<p>Nek6</p>{/NP_P_43}]
Substrate = ({NP_P_45}<p>Eg5</p>{/NP_P_45};-)
	Method=link (substrate) for phrase=[{NP_P_45}<p>Eg5</p>{/NP_P_45}]
		From: {CP_48}one{/CP_48}
		Path: collection,refer,whole
Site = (-;-;{NP_PP_46}several <Bppp>sites</Bppp>{/NP_PP_46})
({NP_PP_50}1033{/NP_PP_50};{NP_PP_50}Ser{/NP_PP_50};UNK)
	Method=unclaimed_site_or_shared_substrate (site) for phrase=[{NP_PP_50}<pp>Ser1033</pp>{/NP_PP_50}0..6|Ser1033|Ser1033]
	Candidates (Site):
		Candidate="{NP_PP_50}<pp>Ser1033</pp>{/NP_PP_50}" 	(Features:is-aa)

{NP_P_43}<p>Nek6</p>{/NP_P_43} {VP_act_44}phosphorylated{/VP_act_44} {NP_P_45}<p>Eg5</p>{/NP_P_45} at {NP_PP_46}several <Bppp>sites</Bppp>{/NP_PP_46} in {NP_47}vitro{/NP_47} and {CP_48}one{/CP_48} of {NP_PP_49}these <Bppp>sites</Bppp>{/NP_PP_49} , {NP_PP_50}<pp>Ser1033</pp>{/NP_PP_50} , {VP_pass_51}is phosphorylated{/VP_pass_51} in {NP_52}vivo{/NP_52} during {NP_53}mitosis{/NP_53} .

OUTPUT 4
PTM = ({VP_act_55};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_54}<p>CDK1</p>{/NP_P_54};-)
	Method=rule:1.11.1.1.1 (kinase) for phrase=[{NP_P_54}<p>CDK1</p>{/NP_P_54}]
Substrate = ({NP_P_57}<p>Eg5</p>{/NP_P_57};-)
	Method=rule: (substrate) for phrase=[{NP_P_57}all <p>Eg5</p>{/NP_P_57}3..5|<p>Eg5</p>]
Site = ({NP_PP_58}926{/NP_PP_58};{NP_PP_58}Thr{/NP_PP_58};UNK)
	Method=rule: (site) for phrase=[{NP_PP_58}<pp>Thr926</pp>{/NP_PP_58}0..5|Thr926|Thr926]

OUTPUT 5
PTM = ({VP_act_61};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_60}<p>Nek6</p>{/NP_P_60};-)
	Method=rule:1.11.1.1.1 (kinase) for phrase=[{NP_P_60}<p>Nek6</p>{/NP_P_60}]
Substrate = ({NP_P_63}<p>Eg5</p>{/NP_P_63};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_63}<p>Eg5</p>{/NP_P_63}]
Site = ({NP_PP_58}926{/NP_PP_58};{NP_PP_58}Thr{/NP_PP_58};UNK)
	Method=unclaimed_site_or_shared_substrate (site) for phrase=[{NP_PP_58}<pp>Thr926</pp>{/NP_PP_58}0..5|Thr926|Thr926]
	Candidates (Site):
		Candidate="{NP_PP_58}<pp>Thr926</pp>{/NP_PP_58}" 	(Features:is-aa|is-site)

Whereas {NP_P_54}<p>CDK1</p>{/NP_P_54} {VP_act_55}phosphorylates{/VP_act_55} {AV_56}nearly{/AV_56} {NP_P_57}all <p>Eg5</p>{/NP_P_57} at {NP_PP_58}<pp>Thr926</pp>{/NP_PP_58} during {NP_59}mitosis{/NP_59} , {NP_P_60}<p>Nek6</p>{/NP_P_60} {VP_act_61}phosphorylates{/VP_act_61} {NP_62}approximately 3%{/NP_62} of {NP_P_63}<p>Eg5</p>{/NP_P_63} , {AV_64}primarily{/AV_64} at {NP_65}the spindle poles{/NP_65} .

{NP_66}<p>Eg5</p> depletion{/NP_66} {VP_act_67}caused{/VP_act_67} {NP_68}mitotic arrest{/NP_68} , {VP_act_69}resulting{/VP_act_69} in {NP_70}<Bpcl>cells</Bpcl>{/NP_70} with {NP_71}a monopolar spindle{/NP_71} .

{NP_72}This arrest{/NP_72} {VP_pass_73}could be rescued{/VP_pass_73} by {NP_P_74}<Bppf>wild-type</Bppf> <p>Eg5</p>{/NP_P_74} but {AV_75}not{/AV_75} by {NP_PP_76}<pp><p>Eg5</p>[<pp>Thr926</pp>Ala]</pp>{/NP_PP_76} .

Despite {NP_77}substantial overexpression{/NP_77} , {NP_PP_78}<pp><p>Eg5</p>[<pp>Ser1033</pp>Ala]</pp>{/NP_PP_78} {VP_act_79}rescued{/VP_act_79} {NP_80}50%{/NP_80} of {NP_81}<Bpcl>cells</Bpcl>{/NP_81} {VP_act_82}compared{/VP_act_82} with {NP_P_83}<Bppf>wild-type</Bppf> <p>Eg5</p>{/NP_P_83} , whereas {NP_P_84}an <Bppf><p>Eg5</p>[<pp>Ser1033</pp>Asp] mutant</Bppf>{/NP_P_84} {VP_pass_85}was nearly as effective{/VP_pass_85} as {NP_86}wild type{/NP_86} .

OUTPUT 6
PTM = ({VP_act_89};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_88}<p>Nek6</p>{/NP_P_88};-)
	Method=rule: (kinase) for phrase=[{NP_P_88}mitosis <p>Nek6</p>{/NP_P_88}7..10|<p>Nek6</p>]
Substrate = ({NP_PP_91}<p>Eg5</p>{/NP_PP_91};-)
	Method=rule: (substrate) for phrase=[{NP_PP_91}<pp><p>Eg5</p> polypeptides</pp>{/NP_PP_91}0..2|<p>Eg5</p>]
Site = (-;-;{NP_PP_91}<pp><p>Eg5</p> polypeptides</pp>{/NP_PP_91})
	Method=rule: (siteother) for phrase=[{NP_PP_91}<pp><p>Eg5</p> polypeptides</pp>{/NP_PP_91}]

OUTPUT 7
PTM = ({NP_93};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{AV_87}Thus{/AV_87} , during {NP_P_88}mitosis <p>Nek6</p>{/NP_P_88} {VP_act_89}phosphorylates{/VP_act_89} {NP_90}a subset{/NP_90} of {NP_PP_91}<pp><p>Eg5</p> polypeptides</pp>{/NP_PP_91} at {NP_PP_92}a conserved <Bppp>site</Bppp>{/NP_PP_92} , {NP_93}the phosphorylation{/NP_93} of {NP_94}which{/NP_94} {VP_pass_95}is crucial{/VP_pass_95} for {NP_96}the mitotic function{/NP_96} of {NP_P_97}<p>Eg5</p>{/NP_P_97} .

NORM=eg 5
SYNONYM=Eg5

NORM=nek 6
SYNONYM=NIMA-family kinase Nek6
SYNONYM=Nek6


{NP_1}PMID{/NP_1} - {CP_2}19001503{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}<p>BMP2</p> induction{/NP_4} of {NP_5}<B>actin cytoskeleton</B> reorganization and <S>cell</S> migration{/NP_5} {VP_act_6}requires{/VP_act_6} {NP_7}<p>PI3-kinase</p> and <p>Cdc42</p> activity{/NP_7} .

{NP_8}AB{/NP_8} - {NP_P_9}<p>Bone morphogenetic proteins ( BMPs )</p>{/NP_P_9} {VP_pass_10}are{/VP_pass_10} {NP_11}potent <Bpf>regulators</Bpf>{/NP_11} of {NP_12}several cellular events{/NP_12} .

{NP_13}We{/NP_13} {VP_act_14}report{/VP_act_14} that {NP_15}exposure{/NP_15} of {NP_S_16}<S>C2C12 cells</S>{/NP_S_16} to {NP_P_17}<p>BMP2</p>{/NP_P_17} {VP_act_18}leads{/VP_act_18} to an {VP_pass_19}increase{/VP_pass_19} in {NP_20}<Bpcl>cell</Bpcl> migration{/NP_20} and {NP_21}a rapid rearrangement{/NP_21} of {NP_P_22}the <p>actin filaments</p>{/NP_P_22} into {NP_23}cortical protrusions{/NP_23} .

{NP_24}These effects{/NP_24} {VP_act_25}required{/VP_act_25} {NP_26}independent and parallel activation{/NP_26} of {NP_P_27}the <p>Cdc42</p> small <p>GTPase</p>{/NP_P_27} and {NP_P_28}the <Bppf>alpha-isoform</Bppf>{/NP_P_28} of {NP_P_29}the <p>phosphoinositide 3-kinase ( PI3Kalpha )</p>{/NP_P_29} , because {NP_30}ectopic expression{/NP_30} of {NP_31}a dominant-negative form{/NP_31} of {NP_P_32}<p>Cdc42</p>{/NP_P_32} or {NP_P_33}distinct pharmacological <Bppf><p>PI3K</p> inhibitors</Bppf>{/NP_P_33} {VP_act_34}abrogated{/VP_act_34} {NP_35}these responses{/NP_35} .

{AV_36}Furthermore{/AV_36} , {NP_37}we{/NP_37} {VP_act_38}demonstrate{/VP_act_38} that {NP_P_39}<p>BMP2</p>{/NP_P_39} {VP_act_40}activates{/VP_act_40} {NP_P_41}different <c>group I</c> and <p>group II PAK isoforms</p>{/NP_P_41} as well as {NP_P_42}<p>LIMK1</p>{/NP_P_42} with {NP_43}similar kinetics{/NP_43} to {NP_44}<p>Cdc42</p> or <p>PI3K</p> activation{/NP_44} .

OUTPUT 0
PTM = ({NP_PP_51};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_51}<Bppp>residues</Bppp>{/NP_PP_51})
	Method=rule: (siteother) for phrase=[{NP_PP_51}phosphorylated <Bppp>residues</Bppp>{/NP_PP_51}14..21|<Bppp>residues</Bppp>]

{NP_45}<p>BMP2</p> activation{/NP_45} of {NP_P_46}<p>PAK</p> and <p>LIMK1</p>{/NP_P_46} , {VP_pass_47}measured{/VP_pass_47} by {NP_48}either <Bppf>kinase</Bppf> activity{/NP_48} or with {NP_P_49}<Bppf>antibodies</Bppf>{/NP_P_49} {VP_act_50}raised{/VP_act_50} against {NP_PP_51}phosphorylated <Bppp>residues</Bppp>{/NP_PP_51} at {NP_52}their activation loops{/NP_52} , {VP_pass_53}were abolished{/VP_pass_53} by {VP_act_54}blocking{/VP_act_54} {NP_55}<p>PI3K</p> -signaling pathways{/NP_55} .

{AV_56}Together{/AV_56} , {NP_57}these findings{/NP_57} {VP_act_58}suggest{/VP_act_58} that {NP_59}<p>Cdc42</p> and <p>PI3K</p> signals{/NP_59} {VP_act_60}emanating{/VP_act_60} from {NP_P_61}<p>BMP receptors</p>{/NP_P_61} {VP_pass_62}are involved{/VP_pass_62} in {NP_63}specific regulation{/NP_63} of {NP_B_64}<B>actin assembly</B>{/NP_B_64} and {NP_65}<S>cell</S> migration{/NP_65} .


{NP_1}PMID{/NP_1} - {CP_2}19020305{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>ATR</p> and <p>Rad17</p>{/NP_P_4} {VP_pass_5}collaborate{/VP_pass_5} in {VP_act_6}modulating{/VP_act_6} {NP_7}<p>Rad9</p> localisation{/NP_7} at {NP_PP_8}<Bppp>sites</Bppp>{/NP_PP_8} of {NP_9}DNA damage{/NP_9} .

OUTPUT 0
PTM = ({VP_pass_12};phosphorylated)
Inducer = (-;-)
Kinase = ({NP_P_13}<p>ATR</p>{/NP_P_13};-)
	Method=rule:1.13.1.1 (kinase) for phrase=[{NP_P_13}<p>ATR</p>{/NP_P_13}]
Substrate = ({NP_P_11}<p>Chk1</p>{/NP_P_11};-)
	Method=rule: (substrate) for phrase=[{NP_P_11}The <Bpcl>cell</Bpcl> cycle checkpoint kinase <p>Chk1</p>{/NP_P_11}28..31|<p>Chk1</p>]
Site = (-;-;UNK)

{NP_10}AB{/NP_10} - {NP_P_11}The <Bpcl>cell</Bpcl> cycle checkpoint kinase <p>Chk1</p>{/NP_P_11} {VP_pass_12}is phosphorylated and activated{/VP_pass_12} by {NP_P_13}<p>ATR</p>{/NP_P_13} in {NP_14}response{/NP_14} to {NP_15}DNA damage{/NP_15} and {VP_pass_16}is crucial{/VP_pass_16} for {VP_act_17}initiating{/VP_act_17} {NP_18}the DNA damage response{/NP_18} .

OUTPUT 1
PTM = ({NP_25};phosphorylation)
	HasAgentTheme="<p>Chk1</p>" in "{NP_25}<p>Chk1</p> phosphorylation{/NP_25}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_20}<Bppf>factors</Bppf>{/NP_P_20}" 	(Features:dist=0|subject_main)
		Candidate="<p>TopBP1</p>" in "{NP_P_28}the <p>Rad9-Rad1-Hus1 complex</p> , <p>TopBP1</p> and <p>Claspin</p>{/NP_P_28}" 	(Features:dist=0)
		Candidate="<p>Rad9-Rad1-Hus1 complex</p>" in "{NP_P_28}the <p>Rad9-Rad1-Hus1 complex</p> , <p>TopBP1</p> and <p>Claspin</p>{/NP_P_28}" 	(Features:dist=0)
		Candidate="<p>Claspin</p>" in "{NP_P_28}the <p>Rad9-Rad1-Hus1 complex</p> , <p>TopBP1</p> and <p>Claspin</p>{/NP_P_28}" 	(Features:dist=0)
Substrate = ({NP_25}<p>Chk1</p>{/NP_25};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_25}<p>Chk1</p> phosphorylation{/NP_25}0..3|<p>Chk1</p>]
Site = (-;-;UNK)

{NP_19}A number{/NP_19} of {NP_P_20}<Bppf>factors</Bppf>{/NP_P_20} {VP_pass_21}act{/VP_pass_21} in {NP_22}concert{/NP_22} with {NP_P_23}<p>ATR</p>{/NP_P_23} {VP_act_24}to facilitate{/VP_act_24} {NP_25}<p>Chk1</p> phosphorylation{/NP_25} , {VP_act_26}including{/VP_act_26} {NP_P_27}<p>Rad17-RFC</p>{/NP_P_27} , {NP_P_28}the <p>Rad9-Rad1-Hus1 complex</p> , <p>TopBP1</p> and <p>Claspin</p>{/NP_P_28} .

{NP_P_29}<p>Rad17</p>{/NP_P_29} {VP_pass_30}is required{/VP_pass_30} for {NP_31}loading{/NP_31} of {NP_B_32}<B>Rad9-Rad1-Hus1</B> ( 9-1-1 ){/NP_B_32} onto {NP_PP_33}<Bppp>sites</Bppp>{/NP_PP_33} of {NP_34}DNA damage{/NP_34} .

OUTPUT 2
PTM = ({NP_35};phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_37}<p>ATR</p>{/NP_P_37};-)
	Method=rule:1.12.1.1.0.2 (kinase) for phrase=[{NP_P_37}<p>ATR</p>{/NP_P_37}]
Substrate = ({NP_P_36}<p>Rad17</p>{/NP_P_36};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_36}<p>Rad17</p>{/NP_P_36}]
Site = (-;-;UNK)

Although {NP_35}phosphorylation{/NP_35} of {NP_P_36}<p>Rad17</p>{/NP_P_36} by {NP_P_37}<p>ATR</p>{/NP_P_37} {VP_pass_38}is required{/VP_pass_38} for {NP_39}checkpoint function{/NP_39} , how {NP_40}this{/NP_40} {VP_act_41}affects{/VP_act_41} {NP_42}9-1-1 regulation{/NP_42} {VP_act_43}remains{/VP_act_43} {JP_44}unclear{/JP_44} .

{NP_45}We{/NP_45} {VP_act_46}report{/VP_act_46} that {NP_47}exposure{/NP_47} of {NP_48}<Bpcl>cells</Bpcl>{/NP_48} to {NP_49}DNA damage or replication stress results{/NP_49} in {NP_50}<p>Rad17</p> -dependent immobilisation{/NP_50} of {NP_P_51}<p>Rad9</p>{/NP_P_51} into {NP_52}nuclear foci{/NP_52} .

OUTPUT 3
PTM = ({VP_pass_neg_57};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{AV_53}Furthermore{/AV_53} , {NP_54}expression{/NP_54} of {NP_P_55}<Bppf>mutant</Bppf> <p>Rad17</p>{/NP_P_55} {NP_56}that{/NP_56} {VP_pass_neg_57}cannot be phosphorylated{/VP_pass_neg_57} by {NP_P_58}<p>ATR (Rad17 (AA))</p>{/NP_P_58} , or {NP_59}downregulation{/NP_59} of {NP_P_60}<p>ATR</p>{/NP_P_60} , {VP_act_61}results{/VP_act_61} in {NP_62}a decreased number{/NP_62} of {NP_63}<Bpcl>cells</Bpcl>{/NP_63} {NP_64}that{/NP_64} {VP_act_65}display{/VP_act_65} {NP_66}<p>Rad9</p> foci{/NP_66} .

{VP_act_67}Photobleaching{/VP_act_67} {NP_68}experiments{/NP_68} {VP_act_69}reveal{/VP_act_69} an {VP_pass_70}increase{/VP_pass_70} in {NP_71}the dynamic behaviour{/NP_71} of {NP_P_72}<p>Rad9</p>{/NP_P_72} within {VP_act_73}remaining{/VP_act_73} {NP_74}foci{/NP_74} in {NP_75}the absence{/NP_75} of {NP_P_76}<p>ATR</p>{/NP_P_76} or {VP_act_77}following{/VP_act_77} {NP_78}expression{/NP_78} of {NP_P_79}<p>Rad17 (AA)</p>{/NP_P_79} .

{AV_80}Together{/AV_80} , {NP_81}these data{/NP_81} {VP_act_82}suggest{/VP_act_82} {NP_83}a model{/NP_83} in {NP_84}which{/NP_84} {NP_P_85}<p>Rad17</p> and <p>ATR</p>{/NP_P_85} {VP_pass_86}collaborate{/VP_pass_86} in {VP_act_87}regulating{/VP_act_87} {NP_88}<p>Rad9</p> localisation and association{/NP_88} at {NP_PP_89}<Bppp>sites</Bppp>{/NP_PP_89} of {NP_90}DNA damage{/NP_90} .

NORM=chk 1
SYNONYM=Chk1


{NP_1}PMID{/NP_1} - {CP_2}19020281{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>Complement C5a receptors</p>{/NP_P_4} in {NP_5}the pituitary gland{/NP_5} : {NP_6}expression and function{/NP_6} .

{NP_7}AB{/NP_7} - {NP_8}Communication{/NP_8} between {NP_9}the immune and endocrine system{/NP_9} {VP_pass_10}is important{/VP_pass_10} for {NP_11}the control{/NP_11} of {NP_12}inflammation{/NP_12} {NP_13}that{/NP_13} {VP_pass_14}is primarily mediated{/VP_pass_14} through {NP_15}the hypothalamic-pituitary-adrenal axis{/NP_15} .

{NP_16}The innate immune system{/NP_16} {VP_act_17}rapidly responds{/VP_act_17} to {NP_18}pathogens{/NP_18} by {VP_act_19}releasing{/VP_act_19} {NP_P_20}<Bppf>complement proteins</Bppf>{/NP_P_20} {NP_21}that{/NP_21} {VP_act_22}include{/VP_act_22} {NP_P_23}the <p>anaphylatoxins C3a</p> and <p>C5a</p>{/NP_P_23} .

{NP_24}We{/NP_24} {VP_act_25}previously reported{/VP_act_25} {NP_26}the existence{/NP_26} of {NP_P_27}<p>C3a receptors</p>{/NP_P_27} in {NP_28}the anterior pituitary gland{/NP_28} and {VP_act_29}now describe{/VP_act_29} {NP_30}the presence{/NP_30} of {NP_P_31}<p>C5a receptors</p>{/NP_P_31} in {NP_32}the gland{/NP_32} .

{NP_P_33}<p>C5a and its less active derivative ( C5adR )</p>{/NP_P_33} {VP_act_34}can bind{/VP_act_34} to {NP_P_35}its own <Bppf>receptor</Bppf>{/NP_P_35} and to {NP_P_36}another <Bppf>receptor</Bppf>{/NP_P_36} {VP_act_37}called{/VP_act_37} {NP_P_38}<p>C5L2</p>{/NP_P_38} .

{VP_act_39}Using{/VP_act_39} {NP_B_40}<B>RT-PCR</B>{/NP_B_40} and {NP_41}immunocytochemistry{/NP_41} , {NP_P_42}<p>C5a receptors</p> and <p>C5L2</p>{/NP_P_42} {VP_pass_43}were demonstrated{/VP_pass_43} in {NP_44}the <s>rat</s> anterior pituitary gland{/NP_44} and in {NP_45}several rodent anterior pituitary <Bpcl>cell lines</Bpcl>{/NP_45} .

OUTPUT 0
PTM = ({NP_51};phosphorylation)
Inducer = ({NP_P_49}<p>C5a</p>{/NP_P_49};-)
	Method=rule: (inducer) for phrase=[{NP_P_49}<p>C5a</p>{/NP_P_49}]
Kinase = (-;-)
Substrate = ({NP_P_52}<p>AKT</p>{/NP_P_52};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_52}<p>MAPK</p> and <p>AKT</p>{/NP_P_52}0..3|<p>MAPK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_52}<p>MAPK</p> and <p>AKT</p>{/NP_P_52}7..9|<p>AKT</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_51};phosphorylation)
Inducer = ({NP_P_49}<p>C5a</p>{/NP_P_49};-)
	Method=rule: (inducer) for phrase=[{NP_P_49}<p>C5a</p>{/NP_P_49}]
Kinase = (-;-)
Substrate = ({NP_P_52}<p>MAPK</p>{/NP_P_52};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_52}<p>MAPK</p> and <p>AKT</p>{/NP_P_52}0..3|<p>MAPK</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_52}<p>MAPK</p> and <p>AKT</p>{/NP_P_52}7..9|<p>AKT</p>]
Site = (-;-;UNK)

{VP_act_46}Western blotting{/VP_act_46} {NP_47}analysis{/NP_47} {VP_act_48}showed{/VP_act_48} that {NP_P_49}<p>C5a</p>{/NP_P_49} {VP_act_50}stimulated{/VP_act_50} {NP_51}the phosphorylation{/NP_51} of {NP_P_52}<p>MAPK</p> and <p>AKT</p>{/NP_P_52} but {NP_P_53}not <p>p38</p>{/NP_P_53} ; {NP_P_54}<p>C5adR</p>{/NP_P_54} on {NP_55}the other hand{/NP_55} , {VP_act_56}had{/VP_act_56} {NP_57}no effect{/NP_57} on any of {NP_P_58}the <Bppf>signal molecules</Bppf>{/NP_P_58} {VP_act_59}investigated{/VP_act_59} .

{NP_60}The effects{/NP_60} of {NP_P_61}<p>C5a</p> and <p>C5adR</p>{/NP_P_61} on {NP_62}the secretion{/NP_62} of {NP_P_63}the inflammatory <Bppf>molecule</Bppf>{/NP_P_63} , {NP_P_64}<p>macrophage migration inhibitory factor ( MIF )</p>{/NP_P_64} {VP_pass_65}were investigated{/VP_pass_65} by {NP_B_66}<B>ELISA</B>{/NP_B_66} .

{NP_67}Both <Bpcf>compounds</Bpcf>{/NP_67} {VP_act_68}showed{/VP_act_68} {NP_69}a dose -dependent inhibition{/NP_69} of {NP_70}<p>MIF</p> release{/NP_70} , {NP_71}30-40% inhibition{/NP_71} at around {NP_C_72}35-70 <c>nM agonist</c>{/NP_C_72} with {NP_73}<B>IC50</B> values{/NP_73} of around {NP_74}20 nM{/NP_74} .

{NP_P_75}<p>C5a</p> and <p>C5adR</p>{/NP_P_75} {VP_act_76}also stimulated{/VP_act_76} {NP_77}<p>ACTH</p> secretion{/NP_77} ( up to {NP_78}25%{/NP_78} ) from {NP_S_79}<S>AtT-20DV16 cells</S>{/NP_S_79} .

{NP_80}These data{/NP_80} {VP_act_81}show{/VP_act_81} that {NP_P_82}functional <p>C5a receptors</p> ( <p>C5a</p> and <p>C5L2</p> ){/NP_P_82} {VP_pass_83}are present{/VP_pass_83} in {NP_84}the anterior pituitary gland{/NP_84} and {NP_85}they{/NP_85} {VP_act_86}may play{/VP_act_86} {NP_87}a role{/NP_87} in {NP_88}dampening down inflammation{/NP_88} by {VP_act_89}inhibiting{/VP_act_89} {NP_90}the release{/NP_90} of {NP_P_91}<p>MIF</p>{/NP_P_91} and {VP_act_92}stimulating{/VP_act_92} {NP_93}the release{/NP_93} of {NP_P_94}<p>ACTH</p>{/NP_P_94} .


{NP_1}PMID{/NP_1} - {CP_2}19020017{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>RANTES</p>{/NP_P_4} {VP_act_5}modulates{/VP_act_5} {NP_6}the release{/NP_6} of {NP_C_7}<c>glutamate</c>{/NP_C_7} in {NP_8}<s>human</s> neocortex{/NP_8} .

{NP_9}AB{/NP_9} - {NP_10}The effects{/NP_10} of {NP_P_11}the recombinant <s>human</s> <p>chemokine RANTES ( hRANTES )</p>{/NP_P_11} on {NP_12}the release{/NP_12} of {NP_C_13}<c>glutamate</c>{/NP_C_13} from {NP_14}<s>human</s> neocortex <c>glutamatergic</c> nerve endings{/NP_14} {VP_pass_15}were investigated{/VP_pass_15} .

OUTPUT 0
PTM = ({NP_25};phosphorylations)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_P_16}<p>hRANTES</p>{/NP_P_16} {VP_act_17}facilitated{/VP_act_17} {NP_18}the spontaneous release{/NP_18} of {NP_B_19}d <B>[(3) H]D-aspartate ([(3) H]DASP-)</B>{/NP_B_19} by {NP_P_20}binding Pertussis toxin-sensitive G-protein-coupled receptors ( GPCRs ){/NP_P_20} , {NP_21}whose activation{/NP_21} {VP_act_22}caused{/VP_act_22} {NP_23}<B>Ca(2+)</B> mobilization{/NP_23} from {NP_24}<c>inositol trisphosphate-sensitive</c> stores{/NP_24} and {NP_25}cytosolic <Bppf>tyrosine kinase</Bppf> -mediated phosphorylations{/NP_25} .

{NP_26}Facilitation{/NP_26} of {NP_27}release{/NP_27} {VP_act_28}switched{/VP_act_28} to {NP_29}inhibition{/NP_29} when {NP_30}the effects{/NP_30} of {NP_P_31}<p>hRANTES</p>{/NP_P_31} on {NP_32}the 12 mM K(+)- evoked [(3) H]D-ASP exocytosis{/NP_32} {VP_pass_33}were studied{/VP_pass_33} .

{NP_34}Inhibition{/NP_34} of {NP_35}exocytosis{/NP_35} {VP_pass_36}relied{/VP_pass_36} on {NP_37}activation{/NP_37} of {NP_P_38}<p>Pertussis toxin-sensitive GPCRs</p>{/NP_P_38} {VP_act_39}negatively coupled{/VP_act_39} to {NP_P_40}<p>adenylyl cyclase</p>{/NP_P_40} .

{NP_41}Both <p>hRANTES</p> effects{/NP_41} {VP_pass_42}were prevented{/VP_pass_42} by {NP_B_43}<B>met-RANTES</B>{/NP_B_43} , {NP_44}an <Bpcf>antagonist</Bpcf>{/NP_44} at {NP_P_45}the <p>chemokine receptors ( CCRs )</p>{/NP_P_45} of {NP_B_46}the <p>CCR1</p> , <p>CCR3</p> , and <B><p>CCR5</p> subtypes</B>{/NP_B_46} .

{AV_47}Interestingly{/AV_47} , {NP_48}<s>human</s> neocortex <c>glutamatergic</c> nerve endings{/NP_48} {VP_act_49}seem{/VP_act_49} {VP_act_50}to possess{/VP_act_50} {NP_P_51}all three <Bppf>receptor subtypes</Bppf>{/NP_P_51} .

{NP_52}Blockade{/NP_52} of {NP_P_53}<p>CCR1</p> and <p>CCR5</p>{/NP_P_53} by {NP_P_54}<Bppf>antibodies</Bppf>{/NP_P_54} against {NP_PP_55}the extracellular <Bppp>domain</Bppp>{/NP_PP_55} of {NP_P_56}<p>CCRs</p>{/NP_P_56} {VP_act_57}prevented{/VP_act_57} both {NP_P_58}the <p>hRANTES</p>{/NP_P_58} {VP_pass_59}effect{/VP_pass_59} on {NP_60}<B>[(3) H]D-ASP</B> release{/NP_60} , whereas {NP_61}blockade{/NP_61} of {NP_P_62}<p>CCR3</p>{/NP_P_62} {VP_act_63}prevented{/VP_act_63} {NP_64}inhibition{/NP_64} , but not {VP_act_neg_65}facilitation{/VP_act_neg_65} , of {NP_66}release{/NP_66} .

{NP_67}The effects{/NP_67} of {NP_P_68}<p>RANTES</p>{/NP_P_68} on the {JP_69}spontaneous{/JP_69} and {NP_70}the evoked release{/NP_70} of {NP_B_71}<B>[(3) H]D-ASP</B>{/NP_B_71} {VP_pass_72}were also observed{/VP_pass_72} in {NP_73}experiments{/NP_73} with {NP_74}<s>mouse</s> cortical synaptosomes{/NP_74} , {NP_75}which{/NP_75} {VP_act_76}may therefore represent{/VP_act_76} {NP_77}an appropriate animal model{/NP_77} {VP_act_78}to study{/VP_act_78} {NP_79}<p>RANTES</p> -induced effects{/NP_79} on {NP_80}neurotransmission{/NP_80} .

{NP_81}It{/NP_81} {VP_pass_82}is concluded{/VP_pass_82} that {NP_83}<c>glutamate</c> transmission{/NP_83} {VP_pass_84}can be modulated{/VP_pass_84} in {NP_85}<Bppp>opposite</Bppp> directions{/NP_85} by {NP_P_86}<p>RANTES</p>{/NP_P_86} {VP_act_87}acting{/VP_act_87} at {NP_P_88}distinct <p>CCR receptor subtypes</p>{/NP_P_88} {VP_act_89}coupled{/VP_act_89} to {NP_90}different transduction pathways{/NP_90} , {JP_91}consistent{/JP_91} with the {JP_92}multiple{/JP_92} and {VP_act_93}sometimes contrasting{/VP_act_93} {NP_94}effects{/NP_94} of {NP_P_95}the <p>chemokine</p>{/NP_P_95} .


{NP_1}PMID{/NP_1} - {CP_2}19020018{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Marked <p>calpastatin</p> <p>(CAST)</p> depletion{/NP_4} in {NP_5}Alzheimer's disease{/NP_5} {VP_act_6}accelerates{/VP_act_6} {NP_7}cytoskeleton disruption and neurodegeneration{/NP_7} : {NP_8}neuroprotection{/NP_8} by {NP_9}<p>CAST</p> overexpression{/NP_9} .

{NP_10}AB{/NP_10} - {VP_act_11}Increased{/VP_act_11} {NP_12}activity{/NP_12} of {NP_13}calpains{/NP_13} {VP_pass_14}is implicated{/VP_pass_14} in {NP_15}synaptic dysfunction and neurodegeneration{/NP_15} in {NP_B_16}<B>Alzheimer's disease ( AD )</B>{/NP_B_16} .

{NP_17}The molecular mechanisms{/NP_17} {JP_18}responsible{/JP_18} for {NP_19}increased calpain activity{/NP_19} in {NP_B_20}<B>AD</B>{/NP_B_20} {VP_pass_neg_21}are not known{/VP_pass_neg_21} .

{AV_22}Here{/AV_22} , {NP_23}we{/NP_23} {VP_act_24}demonstrate{/VP_act_24} that {NP_25}disease progression{/NP_25} {VP_pass_26}is propelled{/VP_pass_26} by {NP_27}a marked depletion{/NP_27} of {NP_P_28}the endogenous calpain <Bppf>inhibitor</Bppf>{/NP_P_28} , {NP_P_29}<p>calpastatin ( CAST )</p>{/NP_P_29} , from {NP_30}<B>AD</B> neurons{/NP_30} , {NP_31}which{/NP_31} {VP_pass_32}is mediated{/VP_pass_32} by {NP_P_33}<p>caspase-1</p>{/NP_P_33} , {NP_P_34}<p>caspase-3</p>{/NP_P_34} , and {NP_35}calpains{/NP_35} .

OUTPUT 0
PTM = ({NP_45};hyperphosphorylation)
	HasAgentTheme="<Bppf>neurofilament</Bppf>" in "{NP_45}<Bppf>neurofilament</Bppf> hyperphosphorylation{/NP_45}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>CAST</p>" in "{NP_36}Initial <p>CAST</p> depletion{/NP_36}" 	(Features:dist=0|in-title_elsewhere|subject_main_modifier)
		Candidate="<p>calpain II</p>" in "{NP_41}<p>calpain II</p> and <p>ERK</p> 1/2 activation{/NP_41}" 	(Features:dist=0)
		Candidate="<p>calpain II</p>|<p>ERK</p>" in "{NP_41}<p>calpain II</p> and <p>ERK</p> 1/2 activation{/NP_41}" 	(Features:dist=0)
		Candidate="<p>ERK</p>" in "{NP_41}<p>calpain II</p> and <p>ERK</p> 1/2 activation{/NP_41}" 	(Features:dist=0)
Substrate = ({NP_45}<Bppf>neurofilament</Bppf>{/NP_45};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_45}<Bppf>neurofilament</Bppf> hyperphosphorylation{/NP_45}0..12|<Bppf>neurofilament</Bppf>]
Site = (-;-;UNK)

{NP_36}Initial <p>CAST</p> depletion{/NP_36} {AV_37}focally{/AV_37} along {NP_38}dendrites{/NP_38} {VP_act_39}coincides{/VP_act_39} {AV_40}topographically{/AV_40} with {NP_41}<p>calpain II</p> and <p>ERK</p> 1/2 activation{/NP_41} , {NP_42}<p>tau</p> cleavage{/NP_42} by {NP_P_43}<p>caspase-3</p>{/NP_P_43} , and {NP_P_44}<p>tau</p>{/NP_P_44} and {NP_45}<Bppf>neurofilament</Bppf> hyperphosphorylation{/NP_45} .

{NP_46}These same changes{/NP_46} , {AV_47}together{/AV_47} with {NP_48}cytoskeletal proteolysis and <Bpcl>neuronal cell</Bpcl> death{/NP_48} , {VP_act_49}accompany{/VP_act_49} {NP_50}<p>CAST</p> depletion{/NP_50} after {NP_51}intrahippocampal <p>kainic acid</p> administration{/NP_51} to {NP_52}<s>mice</s>{/NP_52} , and {VP_pass_53}are substantially reduced{/VP_pass_53} in {NP_54}<s>mice</s>{/NP_54} {VP_act_55}overexpressing{/VP_act_55} {NP_P_56}<s>human</s> <p>CAST</p>{/NP_P_56} .

{AV_57}Moreover{/AV_57} , {NP_58}<p>CAST</p> reduction{/NP_58} by {NP_B_59}<B>shRNA</B>{/NP_B_59} in {NP_60}neuronal <Bpcl>cells</Bpcl> causes calpain-mediated death{/NP_60} at {NP_61}levels{/NP_61} of {NP_62}calcium-induced injury{/NP_62} {NP_63}that{/NP_63} {VP_pass_64}are sublethal{/VP_pass_64} to {NP_65}<Bpcl>cells</Bpcl>{/NP_65} {VP_act_66}normally expressing{/VP_act_66} {NP_P_67}<p>CAST</p>{/NP_P_67} .

{NP_68}Our results{/NP_68} {VP_act_69}strongly support{/VP_act_69} {NP_70}a novel hypothesis{/NP_70} that {NP_71}<p>CAST</p> depletion{/NP_71} by {NP_P_72}multiple abnormally activated <Bppf>proteases</Bppf>{/NP_P_72} {VP_act_73}accelerates{/VP_act_73} {NP_74}calpain dysregulation{/NP_74} in {NP_B_75}<B>AD</B>{/NP_B_75} {VP_act_76}leading{/VP_act_76} {VP_act_77}to cytoskeleton{/VP_act_77} {NP_78}disruption and neurodegeneration{/NP_78} .

{NP_79}<p>CAST</p> mimetics{/NP_79} {VP_act_80}may{/VP_act_80} , {AV_81}therefore{/AV_81} , {VP_pass_82}be neuroprotective{/VP_pass_82} in {NP_B_83}<B>AD</B>{/NP_B_83} .


{NP_1}PMID{/NP_1} - {CP_2}19020019{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Imaging{/NP_4} of {NP_5}peripheral <p>benzodiazepine receptor</p> expression{/NP_5} as {NP_6}biomarkers{/NP_6} of {JP_7}detrimental{/JP_7} versus {NP_8}beneficial glial responses{/NP_8} in {NP_9}<s>mouse</s> models{/NP_9} of {NP_10}Alzheimer's{/NP_10} and {NP_11}other <B>CNS</B> pathologies{/NP_11} .

{NP_12}AB{/NP_12} - {NP_13}We{/NP_13} {VP_act_14}demonstrate{/VP_act_14} {NP_15}the significance{/NP_15} of {NP_16}<p>peripheral benzodiazepine receptor ( PBR )</p> imaging{/NP_16} in {VP_act_17}living{/VP_act_17} {NP_18}<s>mouse</s> models{/NP_18} of {NP_B_19}<B>Alzheimer's disease ( AD )</B>{/NP_B_19} as {NP_20}biomarkers{/NP_20} and {NP_21}functional signatures{/NP_21} of {NP_22}glial activation{/NP_22} .

OUTPUT 0
PTM = ({VP_act_36};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>AD-like Abeta</p>" in "{NP_29}<p>AD-like Abeta</p> deposition{/NP_29}" 	(Features:dist=0|subject_subnc_modifier)
		Candidate="<p>PBR</p>" in "{NP_31}astrocyte-dominant <p>PBR</p> expression{/NP_31}" 	(Features:dist=0)
		Candidate="<p>PBR</p>" in "{NP_33}nonastroglial <p>PBR</p> upregulation{/NP_33}" 	(Features:dist=0)
Substrate = ({NP_P_37}<p>tau</p>{/NP_P_37};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_37}<p>tau</p>{/NP_P_37}]
Site = (-;-;UNK)

By {VP_act_23}radiochemically and immunohistochemically analyzing{/VP_act_23} {NP_24}<s>murine</s> models{/NP_24} of {NP_25}the two pathological hallmarks{/NP_25} of {NP_B_26}<B>AD</B>{/NP_B_26} , {NP_27}we{/NP_27} {VP_act_28}found{/VP_act_28} that {NP_29}<p>AD-like Abeta</p> deposition{/NP_29} {VP_pass_30}is concurrent{/VP_pass_30} with {NP_31}astrocyte-dominant <p>PBR</p> expression{/NP_31} , in {NP_32}striking contrast{/NP_32} with {NP_33}nonastroglial <p>PBR</p> upregulation{/NP_33} in {NP_34}accumulations{/NP_34} of {NP_B_35}<B>AD-like</B>{/NP_B_35} {VP_act_36}phosphorylated{/VP_act_36} {NP_P_37}<p>tau</p>{/NP_P_37} .

Because {NP_38}tau-induced massive neuronal loss{/NP_38} {VP_pass_39}was distinct{/VP_pass_39} from {NP_40}the marginal neurodegeneration{/NP_40} {VP_act_41}associated{/VP_act_41} with {NP_42}<p>Abeta</p> plaques{/NP_42} in {NP_43}these models{/NP_43} , {NP_44}cellular localization{/NP_44} of {NP_P_45}<p>PBR</p>{/NP_P_45} {VP_act_46}reflected{/VP_act_46} {NP_47}deleterious and beneficial glial reactions{/NP_47} to {NP_P_48}<p>tau</p>{/NP_P_48} versus {NP_49}<p>Abeta</p> pathologies{/NP_49} , {AV_50}respectively{/AV_50} .

{NP_51}This notion{/NP_51} {VP_pass_52}was subsequently examined{/VP_pass_52} in {NP_53}models{/NP_53} of {NP_54}various <B>non-AD</B> neuropathologies{/NP_54} , {VP_act_55}revealing{/VP_act_55} {NP_56}the following reactive glial dynamics{/NP_56} {VP_act_57}underlying{/VP_act_57} {NP_58}differential <p>PBR</p> upregulation{/NP_58} : (1) {NP_59}<B><p>PBR</p>(-)</B> astrogliosis{/NP_59} {JP_60}uncoupled{/JP_60} with {NP_61}microgliosis{/NP_61} or {VP_act_62}coupled{/VP_act_62} with {NP_63}<B><p>PBR</p>(+)</B> microgliosis{/NP_63} {VP_act_64}associated{/VP_act_64} with {NP_65}irreversible neuronal insults{/NP_65} ; and (2) {NP_66}<B><p>PBR</p>(+)</B> astrogliosis{/NP_66} {VP_act_67}coupled{/VP_act_67} with {NP_P_68}<p>PBR</p>{/NP_P_68} ( - or {NP_69}+/-{/NP_69} ) {NP_70}microgliosis{/NP_70} {VP_act_71}associated{/VP_act_71} with {NP_72}minimal or reversible neuronal toxicity{/NP_72} .

{NP_73}Intracranial transplantation{/NP_73} of {NP_74}microglia{/NP_74} {VP_act_75}also indicated{/VP_act_75} that {NP_76}nontoxic microglia drives astroglial <p>PBR</p> expression{/NP_76} .

{AV_77}Moreover{/AV_77} , {VP_act_78}levels{/VP_act_78} of {NP_P_79}<p>glial cell line-derived neurotrophic factor ( GDNF )</p>{/NP_P_79} in {NP_S_80}<S>astrocytes</S>{/NP_S_80} {VP_pass_81}were correlated{/VP_pass_81} with {NP_P_82}astroglial <p>PBR</p>{/NP_P_82} , except for {NP_P_83}increased <p>GDNF</p>{/NP_P_83} in {NP_S_84}<S><p>PBR</p>(-) astrocytes</S>{/NP_S_84} in {NP_85}the model{/NP_85} of {NP_86}<p>AD-like tau</p> pathology{/NP_86} , {VP_act_87}thereby suggesting{/VP_act_87} that {NP_88}<p>PBR</p> upregulation{/NP_88} in {NP_S_89}<S>astrocytes</S>{/NP_S_89} {VP_act_90}is{/VP_act_90} {NP_91}an indicator{/NP_91} of {NP_92}neurotrophic{/NP_92} {VP_act_93}support{/VP_act_93} .

{AV_94}Together{/AV_94} , {NP_95}<p>PBR</p> expressions{/NP_95} in {NP_96}<S>astrocytes</S> and microglia{/NP_96} {VP_act_97}reflect{/VP_act_97} {NP_98}beneficial and deleterious glial reactions{/NP_98} , {AV_99}respectively{/AV_99} , in {NP_100}diverse neurodegenerative disorders{/NP_100} {VP_act_101}including{/VP_act_101} {NP_B_102}<B>AD</B>{/NP_B_102} , {VP_act_103}pointing{/VP_act_103} to {NP_104}new applications{/NP_104} of {NP_105}<p>PBR</p> imaging{/NP_105} for {VP_act_106}monitoring{/VP_act_106} {NP_107}the impact{/NP_107} of {NP_108}gliosis{/NP_108} on {NP_109}the pathogenesis and treatment{/NP_109} of {NP_B_110}<B>AD</B>{/NP_B_110} .


{NP_1}PMID{/NP_1} - {CP_2}19020030{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>Kalirin-7</p>{/NP_P_4} {VP_pass_5}is required{/VP_pass_5} for {NP_6}<Bpf>synaptic structure</Bpf> and function{/NP_6} .

{NP_7}AB{/NP_7} - {NP_B_8}Rho <B>GTPases</B>{/NP_B_8} {VP_pass_9}activated{/VP_pass_9} by {NP_P_10}<p>GDP/GTP exchange factors ( GEFs )</p>{/NP_P_10} {VP_act_11}play{/VP_act_11} {NP_12}key roles{/NP_12} in the {JP_13}developing{/JP_13} and {NP_14}adult nervous system{/NP_14} .

{NP_P_15}<p>Kalirin-7 ( Kal7 )</p>{/NP_P_15} , {NP_16}the predominant adult splice form{/NP_16} of {NP_P_17}the multifunctional <p>Kalirin RhoGEF</p>{/NP_P_17} , {VP_act_18}includes{/VP_act_18} {NP_B_19}a <B>LONGTOKEN</B>{/NP_B_19} ] {NP_PP_20}<Bppp>binding domain</Bppp>{/NP_PP_20} and {VP_act_21}localizes{/VP_act_21} to {NP_22}the postsynaptic side{/NP_22} of {NP_23}excitatory synapses{/NP_23} .

{NP_24}In vitro studies{/NP_24} {VP_act_25}demonstrated{/VP_act_25} that {NP_26}overexpression{/NP_26} of {NP_P_27}<p>Kal7</p>{/NP_P_27} {VP_act_28}increased{/VP_act_28} {NP_29}dendritic spine density{/NP_29} , whereas {NP_30}reduced expression{/NP_30} of {NP_P_31}endogenous <p>Kal7</p>{/NP_P_31} {VP_act_32}decreased{/VP_act_32} {NP_33}spine density{/NP_33} .

{VP_act_34}To evaluate{/VP_act_34} {NP_35}the role{/NP_35} of {NP_P_36}<p>Kal7</p>{/NP_P_36} in {NP_37}vivo{/NP_37} , {NP_38}<s>mice</s>{/NP_38} {VP_act_39}lacking{/VP_act_39} {NP_40}the <Bppp>terminal</Bppp> exon{/NP_40} {JP_41}unique{/JP_41} to {NP_P_42}<p>Kal7</p>{/NP_P_42} {VP_pass_43}were created{/VP_pass_43} .

{NP_44}<s>Mice</s>{/NP_44} {VP_act_45}lacking{/VP_act_45} {NP_46}both copies{/NP_46} of {NP_P_47}the <p>Kal7</p> exon ( <p>Kal7 ( KO )</p> ){/NP_P_47} {VP_act_48}grew{/VP_act_48} and {VP_act_49}reproduced{/VP_act_49} {AV_50}normally{/AV_50} .

{NP_51}Golgi impregnation and electron microscopy{/NP_51} {VP_act_52}revealed{/VP_act_52} {NP_53}decreased hippocampal spine density{/NP_53} in {NP_54}<p>Kal7 ( KO )</p> <s>mice</s>{/NP_54} .

{AV_55}Behaviorally{/AV_55} , {NP_56}<p>Kal7 ( KO )</p> <s>mice</s>{/NP_56} {VP_act_57}showed{/VP_act_57} {NP_58}decreased anxiety-like behavior{/NP_58} in {NP_C_59}the elevated <c>zero maze</c>{/NP_C_59} and {VP_act_60}impaired{/VP_act_60} {NP_61}acquisition{/NP_61} of {NP_62}a passive avoidance task{/NP_62} , but {NP_63}normal behavior{/NP_63} in {NP_64}open field{/NP_64} , {NP_65}object recognition{/NP_65} , and {NP_66}radial arm <c>maze</c> tasks{/NP_66} .

{NP_67}<p>Kal7 ( KO )</p> <s>mice</s>{/NP_67} {VP_pass_68}were deficient{/VP_pass_68} in {NP_69}hippocampal long-term potentiation{/NP_69} .

{NP_70}Western blot analysis{/NP_70} {VP_act_71}confirmed{/VP_act_71} {NP_72}the absence{/NP_72} of {NP_P_73}<p>Kal7</p>{/NP_P_73} and {VP_act_74}revealed{/VP_act_74} {NP_75}compensatory increases{/NP_75} in {NP_P_76}larger <Bppf>Kalirin isoforms</Bppf>{/NP_P_76} .

OUTPUT 0
PTM = ({VP_act_86};phosphorylate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_87}<p>Kal7</p>{/NP_P_87};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_87}<p>Kal7</p>{/NP_P_87}]
Site = (-;-;UNK)

{NP_P_77}<p>PSDs</p>{/NP_P_77} {VP_act_78}purified{/VP_act_78} from {NP_79}the cortices{/NP_79} of {NP_80}<p>Kal7 ( KO )</p> <s>mice</s>{/NP_80} {VP_act_81}showed{/VP_act_81} {NP_82}a deficit{/NP_82} in {NP_P_83}<p>Cdk5</p>{/NP_P_83} , {NP_P_84}a <Bppf>kinase</Bppf>{/NP_P_84} {VP_act_85}known{/VP_act_85} {VP_act_86}to phosphorylate{/VP_act_86} {NP_P_87}<p>Kal7</p>{/NP_P_87} and {VP_act_88}play{/VP_act_88} {NP_89}an essential role{/NP_89} in {NP_90}synaptic function{/NP_90} .

{NP_91}The early stages{/NP_91} of {NP_92}excitatory synaptic development{/NP_92} {VP_pass_93}proceeded{/VP_pass_93} {AV_94}normally{/AV_94} in {NP_95}cortical neurons{/NP_95} {VP_act_96}prepared{/VP_act_96} from {NP_97}<p>Kal7 ( KO )</p> <s>mice</s>{/NP_97} , with {NP_98}decreased excitatory synapses{/NP_98} {AV_99}apparent only{/AV_99} after {NP_100}21 d{/NP_100} in {NP_101}vitro{/NP_101} .

{NP_102}Expression{/NP_102} of {NP_P_103}exogenous <p>Kal7</p>{/NP_P_103} in {NP_104}<p>Kal7 ( KO )</p> neurons{/NP_104} {VP_act_105}rescued{/VP_act_105} {NP_106}this deficit{/NP_106} .

{NP_P_107}<p>Kal7</p>{/NP_P_107} {VP_act_108}plays{/VP_act_108} {NP_109}an essential role{/NP_109} in {NP_110}<Bpf>synaptic structure</Bpf> and function{/NP_110} , {VP_act_111}affecting{/VP_act_111} {NP_112}a subset{/NP_112} of {NP_113}cognitive processes{/NP_113} .


{NP_1}PMID{/NP_1} - {CP_2}19020034{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}Novel leptin-regulated <Bppf>genes</Bppf>{/NP_P_4} {VP_pass_5}revealed{/VP_pass_5} by {VP_act_6}transcriptional profiling{/VP_act_6} of {NP_7}the hypothalamic paraventricular nucleus{/NP_7} .

{NP_8}AB{/NP_8} - {NP_P_9}<p>Leptin</p>{/NP_P_9} {VP_act_10}plays{/VP_act_10} {NP_11}a major role{/NP_11} in {VP_act_12}coordinating{/VP_act_12} {NP_13}the integrated response{/NP_13} of {NP_B_14}the <B>CNS</B>{/NP_B_14} to {NP_15}changes{/NP_15} in {NP_16}nutritional state{/NP_16} .

{NP_17}Neurons{/NP_17} within {NP_B_18}the <B>paraventricular nucleus ( PVN )</B>{/NP_B_18} of {NP_P_19}the hypothalamus <p>express leptin receptors</p>{/NP_P_19} and {VP_act_20}receive{/VP_act_20} {NP_21}dense innervation{/NP_21} from {NP_22}<p>leptin receptor</p> -expressing neurons{/NP_22} in {NP_23}the arcuate nucleus{/NP_23} .

{VP_act_24}To obtain{/VP_act_24} {NP_25}new insights{/NP_25} into {NP_26}the effects{/NP_26} of {VP_act_27}circulating{/VP_act_27} {NP_P_28}<p>leptin</p>{/NP_P_28} on {NP_29}<B>PVN</B> function{/NP_29} , {NP_30}we{/NP_30} {VP_act_31}compared{/VP_act_31} {NP_32}global transcriptional profiles{/NP_32} of {NP_B_33}laser-captured <B>PVN</B>{/NP_B_33} from {NP_34}ad libitum{/NP_34} {VP_act_35}fed{/VP_act_35} {NP_36}<s>mice</s>{/NP_36} versus {NP_37}48 h{/NP_37} {VP_act_38}fasted{/VP_act_38} {NP_39}<s>mice</s>{/NP_39} {VP_act_40}receiving{/VP_act_40} {NP_41}either sham or <p>leptin</p> treatment{/NP_41} {AV_42}intraperitoneally{/AV_42} .

{NP_P_43}Five hundred twenty-seven <p>PVN-expressed genes</p>{/NP_P_43} {VP_pass_44}were altered{/VP_pass_44} by {VP_act_45}fasting{/VP_act_45} in {NP_46}a manner{/NP_46} {NP_47}that{/NP_47} {VP_pass_48}was atleast partially reversible{/VP_pass_48} by {NP_P_49}<p>leptin</p>{/NP_P_49} .

{JP_50}Consistent{/JP_50} with {NP_51}previous reports{/NP_51} , {NP_C_52}<c>thyrotrophin</c>{/NP_C_52} {VP_act_53}releasing{/VP_act_53} {NP_54}<p>hormone mRNA</p> levels{/NP_54} {VP_pass_55}were decreased{/VP_pass_55} by {VP_act_56}fasting{/VP_act_56} but {VP_act_57}restored{/VP_act_57} to {NP_58}fed levels{/NP_58} with {NP_59}<p>leptin</p> treatment{/NP_59} .

{NP_60}mRNA levels{/NP_60} of {NP_P_61}<p>oxytocin</p> , <p>vasopressin</p> , and <p>somatostatin</p>{/NP_P_61} {VP_pass_62}were also reduced{/VP_pass_62} by {VP_act_63}fasting{/VP_act_63} and {VP_pass_64}restored{/VP_pass_64} by {NP_P_65}<p>leptin</p>{/NP_P_65} .

{JP_66}Given{/JP_66} {NP_67}the known effects{/NP_67} of {NP_P_68}<p>leptin</p>{/NP_P_68} on {NP_69}synaptic remodeling{/NP_69} , {NP_70}it{/NP_70} {VP_pass_neg_71}is notable{/VP_pass_neg_71} that , among {NP_P_72}the top 15 <Bppf>genes</Bppf>{/NP_P_72} {NP_73}that{/NP_73} {VP_pass_74}were positively regulated{/VP_pass_74} by {NP_P_75}<p>leptin</p>{/NP_P_75} , {CP_76}five{/CP_76} {VP_pass_77}have been implicated{/VP_pass_77} in {NP_78}synaptic function and/or plasticity{/NP_78} ( {NP_P_79}<p>basigin</p>{/NP_P_79} , {NP_P_80}<p>apolipoprotein E</p>{/NP_P_80} , {NP_P_81}<p>Gap43</p>{/NP_P_81} , {NP_P_82}<p>GABA(A) receptor -associated protein</p>{/NP_P_82} , and {JP_83}synuclein-gamma{/JP_83} ) .

{NP_84}Pathway analysis{/NP_84} {VP_act_85}identified{/VP_act_85} {NP_86}oxidative phosphorylation{/NP_86} , in {JP_87}particular{/JP_87} , {NP_P_88}<Bppf>genes</Bppf>{/NP_P_88} {VP_act_89}encoding{/VP_act_89} {NP_P_90}<Bppf>complex 1 proteins</Bppf>{/NP_P_90} {NP_91}that{/NP_91} {VP_act_92}play{/VP_act_92} {NP_93}a role{/NP_93} in {NP_94}<c>ubiquinone</c> biosynthesis{/NP_94} , {VP_pass_95}to be{/VP_pass_95} {NP_P_96}the predominant <Bppf>gene</Bppf>{/NP_P_96} {VP_act_97}set{/VP_act_97} {NP_98}that{/NP_98} {VP_pass_99}was significantly regulated{/VP_pass_99} in {NP_100}a <p>leptin</p> -dependent manner{/NP_100} .

{AV_101}Thus{/AV_101} , in {NP_102}addition{/NP_102} to {NP_103}its effects{/NP_103} on {NP_104}the expression{/NP_104} of {NP_105}a broad range{/NP_105} of {NP_PP_106}<Bppp>neuropeptides</Bppp>{/NP_PP_106} , {NP_P_107}<p>leptin</p>{/NP_P_107} {VP_act_108}may also exert{/VP_act_108} {NP_109}more general influences{/NP_109} on {NP_110}synaptic function{/NP_110} in , and {NP_111}the bioenergetic state{/NP_111} of , {NP_B_112}the <B>PVN</B>{/NP_B_112} .


{NP_1}PMID{/NP_1} - {CP_2}19020042{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Selective activation{/NP_4} of {NP_P_5}<p><p>p38 mitogen</p> -activated protein kinase</p>{/NP_P_5} in {NP_6}dopaminergic neurons{/NP_6} of {NP_7}substantia nigra{/NP_7} {VP_act_8}leads{/VP_act_8} to {NP_9}nuclear translocation{/NP_9} of {NP_P_10}<p>p53</p>{/NP_P_10} in {NP_11}<c>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated</c> <s>mice</s>{/NP_11} .

{NP_12}AB{/NP_12} - {NP_B_13}<B>Parkinson's disease ( PD )</B>{/NP_B_13} {VP_act_14}is{/VP_act_14} {NP_15}a progressive neurodegenerative disease{/NP_15} {VP_pass_16}characterized{/VP_pass_16} by {NP_17}the degeneration{/NP_17} of {NP_18}the dopaminergic neurons{/NP_18} in {NP_B_19}the <B>substantia nigra pars compacta ( SNpc )</B>{/NP_B_19} .

{NP_20}Activation{/NP_20} of {NP_P_21}the mixed <S>lineage</S> <Bppf>kinase</Bppf> and <p>c-Jun N-terminal kinase ( JNK )</p>{/NP_P_21} {VP_pass_22}has been reported{/VP_pass_22} in {NP_23}models{/NP_23} of {NP_B_24}<B>PD</B>{/NP_B_24} .

{NP_25}Our focus{/NP_25} {VP_pass_26}was{/VP_pass_26} {VP_act_27}to discern{/VP_act_27} whether {NP_28}distinct pathways{/NP_28} {VP_pass_29}were activated{/VP_pass_29} in {NP_30}<Bpcl>cell</Bpcl> -specific manner{/NP_30} within {NP_B_31}the <B>SNpc</B>{/NP_B_31} .

OUTPUT 0
PTM = ({NP_34};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>JNK</p>" in "{NP_37}<p>JNK</p> activation{/NP_37}" 	(Features:dist=0)
Substrate = ({NP_P_35}<p>p38 MAP kinase</p>{/NP_P_35};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_35}<p>p38 MAP kinase</p>{/NP_P_35}]
Site = (-;-;UNK)

{NP_32}We{/NP_32} {VP_act_33}now demonstrate{/VP_act_33} {NP_34}the selective phosphorylation{/NP_34} of {NP_P_35}<p>p38 MAP kinase</p>{/NP_P_35} within {NP_36}the dopaminergic neurons{/NP_36} , whereas {NP_37}<p>JNK</p> activation{/NP_37} {VP_act_38}occurs{/VP_act_38} {AV_39}predominantly{/AV_39} in {NP_40}the microglia{/NP_40} .

OUTPUT 1
PTM = ({NP_42};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>p38</p>" in "{NP_41}<p>p38</p> activation results{/NP_41}" 	(Features:dist=0|is-substrate_elsewhere|subject_main_modifier)
		Candidate="{NP_P_48}<p>Bax</p> and <p>Puma</p>{/NP_P_48}" 	(Features:dist=0|pparg)
		Candidate="<p>Bax</p>" in "{NP_P_48}<p>Bax</p> and <p>Puma</p>{/NP_P_48}" 	(Features:dist=0)
		Candidate="<p>Puma</p>" in "{NP_P_48}<p>Bax</p> and <p>Puma</p>{/NP_P_48}" 	(Features:dist=0)
Substrate = ({NP_P_43}<p>p53</p>{/NP_P_43};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_43}<p>p53</p>{/NP_P_43}]
Site = (-;-;UNK)

{NP_41}<p>p38</p> activation results{/NP_41} in {NP_42}downstream phosphorylation{/NP_42} of {NP_P_43}<p>p53</p>{/NP_P_43} and {VP_act_44}increased{/VP_act_44} {NP_P_45}<p>p53</p>{/NP_P_45} {VP_act_46}mediated{/VP_act_46} {NP_47}transcription{/NP_47} of {NP_P_48}<p>Bax</p> and <p>Puma</p>{/NP_P_48} in {NP_49}the ventral midbrain{/NP_49} .

OUTPUT 2
PTM = ({NP_61};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_51}<Bppf><p>p38</p> inhibitor</Bppf>{/NP_P_51}" 	(Features:dist=0|pparg)
Substrate = ({NP_P_62}<p>p53</p>{/NP_P_62};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_62}<p>p53</p>{/NP_P_62}]
Site = (-;-;UNK)

{NP_50}Treatment{/NP_50} with {NP_P_51}<Bppf><p>p38</p> inhibitor</Bppf>{/NP_P_51} , {NP_B_52}<B>SB239063</B>{/NP_B_52} {VP_act_53}protected{/VP_act_53} {NP_54}primary dopaminergic neurons{/NP_54} {VP_act_55}derived{/VP_act_55} from {NP_56}<s>human</s> <Bpcl>progenitor cells</Bpcl>{/NP_56} from {NP_B_57}<B>MPP(+)</B>{/NP_B_57} {VP_act_58}mediated{/VP_act_58} {NP_59}<Bpcl>cell</Bpcl> death{/NP_59} and {VP_act_60}prevented{/VP_act_60} {NP_61}the downstream phosphorylation{/NP_61} of {NP_P_62}<p>p53</p>{/NP_P_62} and {NP_63}its translocation{/NP_63} to {NP_64}the nucleus{/NP_64} in {NP_65}vivo{/NP_65} , in {NP_66}the ventral midbrain{/NP_66} .

OUTPUT 3
PTM = ({NP_P_68};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_68}<p>p38</p>{/NP_P_68};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_68}phosphorylated <p>p38</p>{/NP_P_68}14..16|<p>p38</p>]
Site = (-;-;UNK)

{NP_67}The increased staining{/NP_67} of {NP_P_68}phosphorylated <p>p38</p>{/NP_P_68} in {NP_69}the surviving neurons{/NP_69} of {NP_B_70}<B>SNpc</B>{/NP_B_70} in {NP_71}<s>human</s> brain sections{/NP_71} from {NP_72}patients{/NP_72} with {NP_B_73}<B>PD</B>{/NP_B_73} and in {NP_P_74}<p>MPTP</p>{/NP_P_74} {VP_act_75}treated{/VP_act_75} {NP_76}<s>mice</s>{/NP_76} but {AV_77}not{/AV_77} in {NP_78}the ventral tegmental area{/NP_78} {VP_act_79}provides{/VP_act_79} {NP_80}further evidence{/NP_80} {VP_act_81}suggesting{/VP_act_81} {NP_82}a role{/NP_82} for {NP_P_83}<p>p38</p>{/NP_P_83} in {NP_84}the degeneration{/NP_84} of {NP_85}dopaminergic neurons{/NP_85} of {NP_B_86}<B>SNpc</B>{/NP_B_86} .

{NP_87}We{/NP_87} {VP_act_88}thus demonstrate{/VP_act_88} {NP_89}the <Bpcl>cell</Bpcl> specific activation{/NP_89} of {NP_90}<p>MAP kinase</p> pathways{/NP_90} within {NP_B_91}the <B>SNpc</B>{/NP_B_91} after {NP_92}<p>MPTP</p> treatment{/NP_92} {VP_act_93}emphasizing{/VP_act_93} {NP_94}the role{/NP_94} of {NP_95}multiple signaling{/NP_95} {VP_act_96}cascades{/VP_act_96} in {NP_97}the pathogenesis and progression{/NP_97} of {NP_98}the disease{/NP_98} .

{NP_P_99}Selective <Bppf>inhibitors</Bppf>{/NP_P_99} of {NP_P_100}<p>p38</p>{/NP_P_100} {VP_act_101}may therefore{/VP_act_101} , {VP_act_102}help{/VP_act_102} {VP_act_103}preserve{/VP_act_103} {NP_104}the surviving neurons{/NP_104} in {NP_B_105}<B>PD</B>{/NP_B_105} and {JP_106}slow{/JP_106} down {NP_107}the disease progression{/NP_107} .


{NP_1}PMID{/NP_1} - {CP_2}19020050{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>MicroRNA-338</p>{/NP_P_4} {VP_act_5}regulates{/VP_act_5} {NP_6}local <p>cytochrome</p> c <p>oxidase IV mRNA</p> levels{/NP_6} and {NP_7}oxidative phosphorylation{/NP_7} in {NP_8}the axons{/NP_8} of {NP_9}sympathetic neurons{/NP_9} .

{NP_10}AB{/NP_10} - {NP_B_11}<B>MicroRNAs ( miRs )</B>{/NP_B_11} {VP_pass_12}are evolutionarily conserved{/VP_pass_12} , {VP_act_13}noncoding{/VP_act_13} {NP_P_14}<Bppf>RNA molecules</Bppf>{/NP_P_14} of {NP_15}approximately 21 nt{/NP_15} {NP_16}that{/NP_16} {VP_act_17}regulate{/VP_act_17} {NP_18}the expression{/NP_18} of {NP_P_19}<Bppf>genes</Bppf>{/NP_P_19} {NP_20}that{/NP_20} {VP_pass_21}are involved{/VP_pass_21} in {NP_22}various biological processes{/NP_22} , {JP_23}such{/JP_23} as {NP_24}<Bpcl>cell</Bpcl> proliferation and differentiation{/NP_24} .

{AV_25}Previously{/AV_25} , {NP_26}we{/NP_26} {VP_act_27}reported{/VP_act_27} {NP_28}the presence{/NP_28} of {NP_29}a heterogeneous population{/NP_29} of {NP_P_30}<p>mRNAs</p>{/NP_P_30} {JP_31}present{/JP_31} in {NP_PP_32}the axons and nerve <Bppp>terminals</Bppp>{/NP_PP_32} of {NP_33}primary sympathetic neurons{/NP_33} {VP_act_34}to include{/VP_act_34} {NP_35}the nuclear-encoded mitochondrial <p>mRNA</p> coding{/NP_35} for {NP_P_36}<p>COXIV</p>{/NP_P_36} .

{NP_37}<Bppp>Sequence</Bppp> analysis{/NP_37} of {NP_B_38}the <B>3'UTR</B>{/NP_B_38} of {NP_P_39}this <p>mRNA</p>{/NP_P_39} {VP_act_40}revealed{/VP_act_40} {NP_41}the presence{/NP_41} of {NP_PP_42}a putative <Bppp>binding site</Bppp>{/NP_PP_42} for {NP_P_43}<p>miR-338</p>{/NP_P_43} , {NP_B_44}a brain-specific <B>microRNA</B>{/NP_B_44} .

{NP_45}Transfection{/NP_45} of {NP_P_46}<p>precursor miR-338</p>{/NP_P_46} into {NP_47}the axons{/NP_47} of {NP_48}primary sympathetic neurons{/NP_48} {VP_act_49}decreases{/VP_act_49} {NP_50}<p>COXIV mRNA</p> and <Bppf>protein</Bppf> levels{/NP_50} and {NP_51}results{/NP_51} in a {VP_pass_52}decrease{/VP_pass_52} in {NP_53}mitochondrial activity{/NP_53} , as {JP_54}measured{/JP_54} by {NP_55}the reduction{/NP_55} of {NP_56}<p>ATP</p> levels{/NP_56} .

{AV_57}Conversely{/AV_57} , {NP_58}the transfection{/NP_58} of {NP_59}synthetic <p>anti-miR</p> oligonucleotides{/NP_59} {NP_60}that{/NP_60} {VP_act_61}inhibit{/VP_act_61} {NP_P_62}<p>miR-338</p>{/NP_P_62} {VP_act_63}increases{/VP_act_63} {NP_64}<p>COXIV</p> levels{/NP_64} , and {NP_65}results{/NP_65} in a {VP_pass_66}significant increase{/VP_pass_66} in {NP_67}oxidative phosphorylation{/NP_67} and {VP_act_68}also norepinephrine{/VP_act_68} {NP_69}uptake{/NP_69} in {NP_70}the axons{/NP_70} .

{NP_71}Our results{/NP_71} {VP_act_72}point{/VP_act_72} to {NP_73}a molecular mechanism{/NP_73} by {NP_74}which{/NP_74} {NP_B_75}this <B>microRNA</B>{/NP_B_75} {VP_act_76}participates{/VP_act_76} in {NP_77}the regulation{/NP_77} of {NP_78}axonal respiration and function{/NP_78} by {VP_act_79}modulating{/VP_act_79} {NP_80}the levels{/NP_80} of {NP_P_81}<p>COXIV</p>{/NP_P_81} , {NP_P_82}a <Bppf>protein</Bppf>{/NP_P_82} {NP_83}which{/NP_83} {VP_act_84}plays{/VP_act_84} {NP_85}a key role{/NP_85} in {NP_86}the assembly{/NP_86} of {NP_B_87}the mitochondrial <p>cytochrome</p> c <B>oxidase complex IV</B>{/NP_B_87} .


{NP_1}PMID{/NP_1} - {CP_2}19021062{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}<p>Lactate dehydrogenase 5</p> expression{/NP_4} in {NP_B_5}<B>non-Hodgkin B</B>{/NP_B_5} - {NP_6}<Bpcl>cell</Bpcl> lymphomas{/NP_6} {VP_pass_7}is associated{/VP_pass_7} with {NP_8}hypoxia{/NP_8} {VP_act_9}regulated{/VP_act_9} {NP_P_10}<Bppf>proteins</Bppf>{/NP_P_10} .

{NP_11}AB{/NP_11} - {NP_12}The expression{/NP_12} of {NP_P_13}<p>lactate dehydrogenase 5 ( LDH5 )</p>{/NP_P_13} , {NP_P_14}the major <p>LDH isoenzyme</p>{/NP_P_14} {VP_act_15}sustaining{/VP_act_15} {NP_16}the anaerobic transformation glycolysis{/NP_16} {VP_pass_17}was examined{/VP_pass_17} in {NP_18}<S>B-cell non-Hodgkin</S> lymphomas{/NP_18} .

{NP_19}Multi{/NP_19} - {NP_20}<Bpcl>tissue</Bpcl> slides{/NP_20} {VP_act_21}obtained{/VP_act_21} from {NP_22}patients{/NP_22} with {NP_23}diffuse large <S>B-cell</S> lymphomas{/NP_23} ( {NP_B_24}<B>DLBCL</B>{/NP_B_24} ; {NP_25}95 cases{/NP_25} ) , {NP_26}follicular lymphomas{/NP_26} ( {NP_C_27}<c>FL</c>{/NP_C_27} ; {NP_28}49 cases{/NP_28} ) and from {NP_29}non-neoplastic lymph nodes ( 48 cases ){/NP_29} {VP_pass_30}were used{/VP_pass_30} for {NP_31}<Bpcf>immuhistochemical</Bpcf> analysis{/NP_31} .

{NP_32}High <p>LDH5</p> expression (cytoplasmic and nuclear){/NP_32} {VP_pass_neg_33}was noted{/VP_pass_neg_33} in {NP_34}79/95 and 29/49 cases{/NP_34} of {NP_C_35}<c>DLBCL</c> and <c>FL</c>{/NP_C_35} , {AV_36}respectively{/AV_36} ( {NP_37}p{/NP_37} = {NP_38}0.002{/NP_38} ) .

{NP_39}No expression{/NP_39} {VP_pass_neg_40}was noted{/VP_pass_neg_40} in {NP_S_41}non-neoplastic <S>lymphocytes</S>{/NP_S_41} .

OUTPUT 0
PTM = ({VP_act_49};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

In {NP_B_42}<B>DLBCL</B>{/NP_B_42} , {NP_43}<p>LDH5</p> expression{/NP_43} {VP_pass_44}was significantly related{/VP_pass_44} {VP_act_45}to hypoxia{/VP_act_45} {NP_P_46}inducible factor <p>HIF1alpha</p>{/NP_P_46} , {NP_P_47}<p>HIF2alpha</p>{/NP_P_47} , {NP_P_48}<p>vascular endothelial growth factor ( VEGF )</p>{/NP_P_48} and {VP_act_49}phosphorylated{/VP_act_49} {NP_50}<p>vascular endothelial growth factor receptor 2 ( VEGFR2/KDR )</p> expression{/NP_50} .

In {NP_C_51}<c>FL</c>{/NP_C_51} , {AV_52}however{/AV_52} , {NP_53}a significant relation{/NP_53} {VP_pass_54}was confirmed{/VP_pass_54} with {NP_P_55}<p>pVEGFR2/KDR</p> and <p>HIF2alpha</p>{/NP_P_55} .

{NP_56}<c>FL</c> cases{/NP_56} with {NP_57}the highest microvessel density{/NP_57} {VP_pass_58}were{/VP_pass_58} those , which {VP_act_59}lacked{/VP_act_59} {NP_60}both <p>LDH5</p> and <p>VEGF</p> expression{/NP_60} .

{NP_61}It{/NP_61} {VP_pass_62}is concluded{/VP_pass_62} that {NP_P_63}<p>LDH5</p>{/NP_P_63} {VP_pass_64}is highly upregulated{/VP_pass_64} in {NP_65}<S>B-cell non-Hodgkin</S> lymphomas{/NP_65} and {VP_act_66}is{/VP_act_66} in {NP_67}direct relation{/NP_67} to {NP_68}<p>HIFs</p> expression{/NP_68} .

{NP_69}<p>LDH5</p> expression{/NP_69} {VP_pass_70}is linked{/VP_pass_70} with {NP_71}activated <p>VEGFR2/KDR</p> expression{/NP_71} in {NP_72}both lymphoid lesions{/NP_72} .


{NP_1}PMID{/NP_1} - {CP_2}19019317{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}The hereditary inclusion body myopathy enigma{/NP_4} and {NP_5}its future therapy{/NP_5} .

{NP_6}AB{/NP_6} - {NP_B_7}<B>Hereditary inclusion body myopathy ( HIBM )</B>{/NP_B_7} {VP_act_8}is{/VP_act_8} {NP_9}a genetic muscle disease{/NP_9} {JP_10}due{/JP_10} to {NP_11}mutations{/NP_11} in {NP_P_12}the <Bppf>gene</Bppf>{/NP_P_12} {VP_act_13}encoding{/VP_act_13} {NP_P_14}the <p>enzyme complex UDP-N-acetylglucosamine 2 epimerase-N-acetylmannosamine kinase (GNE)</p>{/NP_P_14} , {NP_15}which{/NP_15} {VP_act_16}catalyzes{/VP_act_16} {NP_17}the rate-limiting step{/NP_17} in {NP_18}<p>sialic acid</p> production{/NP_18} .

{NP_19}The review{/NP_19} {VP_act_20}describes{/VP_act_20} some of {NP_21}the disease features{/NP_21} {NP_22}that{/NP_22} {VP_act_23}may be relevant{/VP_act_23} for {NP_24}further understanding{/NP_24} of {NP_25}the metabolic impairment{/NP_25} of {NP_B_26}<B>HIBM</B>{/NP_B_26} and {NP_27}its future therapy{/NP_27} .

OUTPUT 0
PTM = ({NP_31};substrate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_28}It{/NP_28} {VP_act_29}also addresses{/VP_act_29} {NP_30}the <Bpcf>biochemical</Bpcf> basis{/NP_30} behind {NP_31}the substrate supplementation therapy{/NP_31} {VP_act_32}designed{/VP_act_32} for {NP_33}this condition{/NP_33} .


{NP_1}PMID{/NP_1} - {CP_2}19020711{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}<p>ILK</p> overexpression{/NP_4} in {NP_5}<s>human</s> hepatocellular carcinoma{/NP_5} and {NP_6}liver cirrhosis{/NP_6} {VP_act_7}correlates{/VP_act_7} with {NP_8}activation{/NP_8} of {NP_P_9}<p>Akt</p>{/NP_P_9} .

{NP_10}AB{/NP_10} - {NP_P_11}<p>Hepatocellular carcinoma ( HCC )</p>{/NP_P_11} {VP_act_12}is{/VP_act_12} {CP_13}one{/CP_13} of {NP_14}the most common life-threatening malignancies{/NP_14} in {NP_15}the world{/NP_15} .

{NP_16}The molecular mechanisms{/NP_16} {VP_act_17}leading{/VP_act_17} to {NP_18}the development{/NP_18} of {NP_P_19}<p>HCC</p>{/NP_P_19} {VP_pass_20}are{/VP_pass_20} {NP_21}<Bpf>complex</Bpf>{/NP_21} and {AV_22}only recently{/AV_22} {VP_act_23}have{/VP_act_23} {NP_24}they{/NP_24} {VP_pass_25}begun{/VP_pass_25} {VP_pass_26}to be clarified{/VP_pass_26} .

{NP_P_27}<p>Integrin linked-kinase ( ILK )</p>{/NP_P_27} , {NP_P_28}a multifunctional signaling and <Bppf>scaffold protein</Bppf>{/NP_P_28} of {NP_29}focal adhesion plaques{/NP_29} , {VP_pass_30}has been implicated{/VP_pass_30} in {NP_31}the pathogenesis{/NP_31} of {NP_32}several <s>human</s> malignancies{/NP_32} .

OUTPUT 0
PTM = ({NP_36};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_35}<p>ILK</p> , <p>beta-catenin</p> and <p>E-cadherin</p>{/NP_P_35}" 	(Features:dist=0|pparg)
		Candidate="<p>ILK</p>" in "{NP_P_35}<p>ILK</p> , <p>beta-catenin</p> and <p>E-cadherin</p>{/NP_P_35}" 	(Features:dist=0|in-title_elsewhere)
		Candidate="<p>E-cadherin</p>" in "{NP_P_35}<p>ILK</p> , <p>beta-catenin</p> and <p>E-cadherin</p>{/NP_P_35}" 	(Features:dist=0)
		Candidate="<p>beta-catenin</p>" in "{NP_P_35}<p>ILK</p> , <p>beta-catenin</p> and <p>E-cadherin</p>{/NP_P_35}" 	(Features:dist=0)
		Candidate="<p>HCCs</p>" in "{NP_P_40}69 <s>human</s> <p>HCCs</p>{/NP_P_40}" 	(Features:dist=0)
Substrate = ({NP_P_37}<p>Akt</p>{/NP_P_37};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_37}<p>Akt</p>{/NP_P_37}]
Site = (-;-;UNK)

In {NP_33}the current study{/NP_33} {NP_34}the expression{/NP_34} of {NP_P_35}<p>ILK</p> , <p>beta-catenin</p> and <p>E-cadherin</p>{/NP_P_35} and {NP_36}the phosphorylation{/NP_36} of {NP_P_37}<p>Akt</p>{/NP_P_37} {VP_pass_38}were studied{/VP_pass_38} by {NP_39}immunohistochemistry{/NP_39} in {NP_P_40}69 <s>human</s> <p>HCCs</p>{/NP_P_40} and {NP_41}adjacent normal and cirrhotic liver parenchyma{/NP_41} .

{NP_42}<p>ILK</p> and <p>phosphorylated-Akt ( p-Akt )</p> immunostaining{/NP_42} {VP_pass_43}was observed{/VP_pass_43} in {CP_44}100 and 79.7%{/CP_44} of {NP_P_45}<p>HCCs</p>{/NP_P_45} , {AV_46}respectively{/AV_46} , and {NP_47}their <Bppf>protein</Bppf> levels{/NP_47} {AV_48}correlated significantly{/AV_48} .

{NP_49}Activation{/NP_49} of {NP_P_50}<p>beta-catenin</p>{/NP_P_50} and {NP_51}downregulation{/NP_51} of {NP_P_52}<p>E-cadherin</p>{/NP_P_52} {VP_pass_53}were frequently observed{/VP_pass_53} in {NP_P_54}<p>HCC</p>{/NP_P_54} , but {NP_55}they{/NP_55} {VP_pass_neg_56}were not related{/VP_pass_neg_56} to {NP_57}<p>ILK</p> expression{/NP_57} .

OUTPUT 1
PTM = ({NP_60};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>ILK</p>" in "{NP_59}<p>ILK</p> expression{/NP_59}" 	(Features:dist=0|in-title_elsewhere)
Substrate = ({NP_P_61}<p>Akt</p>{/NP_P_61};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_61}<p>Akt</p>{/NP_P_61}]
Site = (-;-;UNK)

{NP_58}A strong correlation{/NP_58} between {NP_59}<p>ILK</p> expression{/NP_59} and {NP_60}phosphorylation{/NP_60} of {NP_P_61}<p>Akt</p>{/NP_P_61} {VP_pass_62}was also observed{/VP_pass_62} in {NP_63}cirrhotic liver{/NP_63} .

{AV_64}Moreover{/AV_64} , {NP_65}downregulation{/NP_65} of {NP_P_66}<p>E-cadherin</p>{/NP_P_66} and {NP_P_67}membranous <p>beta-catenin</p>{/NP_P_67} {VP_pass_68}were found{/VP_pass_68} in {NP_69}cirrhotic <Bpcl>tissue</Bpcl>{/NP_69} {VP_act_70}suggesting{/VP_act_70} {NP_71}their involvement{/NP_71} in {NP_72}the liver <Bpcl>tissue</Bpcl>{/NP_72} {VP_act_73}remodeling{/VP_act_73} {VP_pass_74}observed{/VP_pass_74} in {NP_75}cirrhosis{/NP_75} .

{NP_76}Our results{/NP_76} {VP_act_77}indicate{/VP_act_77} that {NP_78}<p>ILK</p> overexpression{/NP_78} during {NP_79}liver oncogenesis and cirrhosis{/NP_79} {VP_act_80}correlates{/VP_act_80} with {NP_81}activation{/NP_81} of {NP_P_82}<p>Akt</p>{/NP_P_82} but {AV_83}not{/AV_83} with {NP_P_84}other conventional <Bppf><p>ILK</p> targets</Bppf>{/NP_P_84} .


{NP_1}PMID{/NP_1} - {CP_2}19020728{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Glioma <Bpcl>cells</Bpcl>{/NP_4} {VP_act_5}enhance{/VP_act_5} {NP_6}endothelial <Bpcl>progenitor cell</Bpcl> angiogenesis{/NP_6} via {NP_P_7}<p>VEGFR-2</p>{/NP_P_7} , {NP_P_8}not <p>VEGFR-1</p>{/NP_P_8} .

{NP_9}AB{/NP_9} - Although {NP_10}potential contribution{/NP_10} of {NP_P_11}<p>endothelial progenitor cells ( EPCs )</p>{/NP_P_11} {VP_pass_12}to angiogenesis{/VP_pass_12} in {NP_13}glioma{/NP_13} {VP_pass_14}has been proposed{/VP_pass_14} , {NP_15}the molecular mechanisms{/NP_15} of {NP_16}<p>EPCs</p> recruitment{/NP_16} {VP_act_17}to vasculature{/VP_act_17} {VP_pass_neg_18}have not been fully elucidated{/VP_pass_neg_18} .

{AV_19}Here{/AV_19} , {NP_20}we{/NP_20} {VP_act_21}show{/VP_act_21} that the {JP_22}supernatant{/JP_22} from {NP_23}glioma <Bpcl>cells</Bpcl>{/NP_23} {VP_act_24}promotes{/VP_act_24} {NP_25}<p>EPCs</p> angiogenesis{/NP_25} via {NP_P_26}<p>VEGFR-2</p>{/NP_P_26} , {NP_P_27}not <p>VEGFR-1</p>{/NP_P_27} .

{AV_28}Moreover{/AV_28} , {NP_B_29}<B><p>VEGFR-2</p> siRNA</B>{/NP_B_29} {VP_act_30}inhibits{/VP_act_30} {NP_31}<p>VEGFR-2</p> expression{/NP_31} in {NP_P_32}<p>EPCs</p>{/NP_P_32} , {NP_33}tube formation{/NP_33} on {NP_34}matrigel{/NP_34} and {NP_35}<Bpcl>cell</Bpcl> migration{/NP_35} .

OUTPUT 0
PTM = ({NP_37};phosphorylations)
	HasAgentTheme="<p>Akt</p>|<p>ERK</p>" in "{NP_37}the <p>Akt</p> and <p>ERK</p> phosphorylations{/NP_37}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>MMP-9</p>" in "{NP_36}<p>MMP-9</p> activity and expression{/NP_36}" 	(Features:dist=0)
		Candidate="<p>VEGFR-2</p>" in "{NP_B_39}<B><p>VEGFR-2</p> siRNA</B>{/NP_B_39}" 	(Features:dist=0|in-title_elsewhere)
Substrate = ({NP_37}<p>Akt</p>{/NP_37};-)
({NP_37}<p>ERK</p>{/NP_37};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_37}the <p>Akt</p> and <p>ERK</p> phosphorylations{/NP_37}3..5|<p>Akt</p>9..11|<p>ERK</p>]
Site = (-;-;UNK)

{NP_36}<p>MMP-9</p> activity and expression{/NP_36} and {NP_37}the <p>Akt</p> and <p>ERK</p> phosphorylations{/NP_37} {VP_pass_38}are decreased{/VP_pass_38} by {NP_B_39}<B><p>VEGFR-2</p> siRNA</B>{/NP_B_39} .

{AV_40}Thus{/AV_40} , {NP_41}these results{/NP_41} {VP_act_42}indicate{/VP_act_42} that {NP_43}glioma <Bpcl>cells</Bpcl>{/NP_43} {VP_act_44}enhance{/VP_act_44} {NP_45}<p>EPC</p> angiogenesis{/NP_45} via {NP_P_46}<p>VEGFR-2</p>{/NP_P_46} , {NP_P_47}not <p>VEGFR-1</p>{/NP_P_47} , {VP_pass_48}mediated{/VP_pass_48} by {NP_49}the <p>MMP-9</p> , <p>Akt</p> and <p>ERK</p> signal pathways{/NP_49} .


{NP_1}PMID{/NP_1} - {CP_2}19020730{/CP_2}

{NP_3}TI{/NP_3} - {NP_C_4}<c>TAE226</c>{/NP_C_4} , {NP_P_5}a dual <Bppf>inhibitor</Bppf>{/NP_P_5} for {NP_P_6}<p>FAK</p> and <p>IGF-IR</p>{/NP_P_6} , {VP_act_7}has{/VP_act_7} {NP_8}inhibitory effects{/NP_8} on {NP_9}<p>mTOR</p> signaling{/NP_9} in {NP_10}esophageal <Bpcl>cancer cells</Bpcl>{/NP_10} .

{NP_11}AB{/NP_11} - {NP_12}Esophageal cancer{/NP_12} {VP_act_13}is{/VP_act_13} {CP_14}one{/CP_14} of {NP_15}the most aggressive cancers{/NP_15} in {NP_16}the world{/NP_16} .

{NP_17}Novel preventive and therapeutic strategies{/NP_17} {VP_act_18}tend{/VP_act_18} {VP_act_19}to target{/VP_act_19} {NP_P_20}the key <Bppf>molecules</Bppf>{/NP_P_20} {VP_pass_21}involved{/VP_pass_21} in {NP_22}the signaling transduction pathways{/NP_22} for {NP_23}<Bpcl>cell</Bpcl> growth{/NP_23} .

{NP_24}It{/NP_24} {VP_pass_25}is known{/VP_pass_25} that {NP_P_26}<p>FAK</p> and <p>mTOR</p>{/NP_P_26} {VP_pass_27}are{/VP_pass_27} {NP_28}important controllers{/NP_28} of {NP_29}<Bpcl>cell</Bpcl> growth{/NP_29} .

{NP_C_30}<c>TAE226</c>{/NP_C_30} , {NP_31}a novel small <Bpcf>molecule compound</Bpcf>{/NP_31} , {VP_act_32}is{/VP_act_32} {NP_P_33}a potent <Bppf>ATP competitive inhibitor</Bppf>{/NP_P_33} of {NP_P_34}<p>FAK</p> and <p>IGF-IR</p>{/NP_P_34} .

{NP_C_35}<c>TAE226</c>{/NP_C_35} {VP_act_36}can block{/VP_act_36} {NP_37}<p>FAK</p> and <p>IGF-IR</p> signaling pathways{/NP_37} .

{NP_38}The purpose{/NP_38} of {NP_39}this study{/NP_39} {VP_pass_40}was{/VP_pass_40} {VP_act_41}to explore{/VP_act_41} {NP_42}the inhibitory effects{/NP_42} on {NP_43}<p>mTOR</p> signaling{/NP_43} and {NP_44}the mechanism{/NP_44} of {NP_45}cell growth suppression{/NP_45} by {NP_C_46}<c>TAE226</c>{/NP_C_46} .

{NP_47}We{/NP_47} {VP_act_48}examined{/VP_act_48} {NP_49}the expression{/NP_49} of {NP_P_50}<p>mTOR</p> and <p>S6</p>{/NP_P_50} in {NP_B_51}esophageal <Bpcl>cancer cells</Bpcl> (SEG-1){/NP_B_51} and {NP_B_52}normal esophageal epithelial <Bpcl>cells</Bpcl> (KOB-13){/NP_B_52} and {NP_53}the efficacy{/NP_53} of {NP_C_54}<c>TAE226</c>{/NP_C_54} against {NP_S_55}<S>SEG-1 cells</S>{/NP_S_55} .

{NP_P_56}<p>mTOR</p> and <p>S6</p>{/NP_P_56} {VP_pass_57}were overexpressed{/VP_pass_57} in {NP_S_58}<S>SEG-1 cells</S>{/NP_S_58} {VP_act_59}compared{/VP_act_59} with {NP_S_60}<S>KOB-13 cells</S>{/NP_S_60} .

OUTPUT 0
PTM = ({NP_65};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}" 	(Features:dist=0)
		Candidate="S6|Ser240/244" in "{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}" 	(Features:dist=0)
		Candidate="<p>mTOR</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|in-title_elsewhere|is-substrate_elsewhere)
		Candidate="<p>S6</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0)
		Candidate="<p>Akt</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>p70S6K</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0|pparg)
		Candidate="<p>mTOR</p>" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0|in-title_elsewhere|is-substrate_elsewhere|pparg)
		Candidate="<pp>Ser2448</pp>" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0)
		Candidate="Ser2448" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0)
		Candidate="{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="<p>Akt</p>" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<pp>Ser473</pp>" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="Ser473" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
		Candidate="<p>p70S6K</p>" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<pp>Thr389</pp>" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
		Candidate="Thr389" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
Substrate = ({NP_P_B_67}<p>Akt</p>{/NP_P_B_67};-)
	Method=rule: (substrate) for phrase=[{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}0..3|<p>mTOR</p>]
	Method=rule: (substrate) for phrase=[{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}0..2|<p>Akt</p>]
	Method=rule: (substrate) for phrase=[{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}0..5|<p>p70S6K</p>]
Site = ({NP_PP_69}240{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_PP_69}244{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_PP_69}6{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_P_B_67}473{/NP_P_B_67};{NP_P_B_67}Ser{/NP_P_B_67};UNK)
	Method=rule: (site) for phrase=[{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}0..1|S6|Ser63..12|Ser240/244|Ser240,244]
	Method=rule: (site) for phrase=[{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}5..11|Ser2448|Ser2448]
	Method=rule: (site) for phrase=[{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}4..9|Ser473|Ser473]
	Method=rule: (site) for phrase=[{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}7..12|Thr389|Thr389]

OUTPUT 1
PTM = ({NP_65};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}" 	(Features:dist=0)
		Candidate="S6|Ser240/244" in "{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}" 	(Features:dist=0)
		Candidate="<p>mTOR</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|in-title_elsewhere|is-substrate_elsewhere)
		Candidate="<p>S6</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0)
		Candidate="<p>Akt</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>p70S6K</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0|pparg)
		Candidate="<p>mTOR</p>" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0|in-title_elsewhere|is-substrate_elsewhere|pparg)
		Candidate="<pp>Ser2448</pp>" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0)
		Candidate="Ser2448" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0)
		Candidate="{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="<p>Akt</p>" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<pp>Ser473</pp>" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="Ser473" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
		Candidate="<p>p70S6K</p>" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<pp>Thr389</pp>" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
		Candidate="Thr389" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
Substrate = ({NP_P_B_68}<p>p70S6K</p>{/NP_P_B_68};-)
	Method=rule: (substrate) for phrase=[{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}0..3|<p>mTOR</p>]
	Method=rule: (substrate) for phrase=[{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}0..2|<p>Akt</p>]
	Method=rule: (substrate) for phrase=[{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}0..5|<p>p70S6K</p>]
Site = ({NP_PP_69}240{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_PP_69}244{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_PP_69}6{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_P_B_68}389{/NP_P_B_68};{NP_P_B_68}Thr{/NP_P_B_68};UNK)
	Method=rule: (site) for phrase=[{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}0..1|S6|Ser63..12|Ser240/244|Ser240,244]
	Method=rule: (site) for phrase=[{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}5..11|Ser2448|Ser2448]
	Method=rule: (site) for phrase=[{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}4..9|Ser473|Ser473]
	Method=rule: (site) for phrase=[{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}7..12|Thr389|Thr389]

OUTPUT 2
PTM = ({NP_65};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}" 	(Features:dist=0)
		Candidate="S6|Ser240/244" in "{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}" 	(Features:dist=0)
		Candidate="<p>mTOR</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|in-title_elsewhere|is-substrate_elsewhere)
		Candidate="<p>S6</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0)
		Candidate="<p>Akt</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>p70S6K</p>" in "{NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0|pparg)
		Candidate="<p>mTOR</p>" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0|in-title_elsewhere|is-substrate_elsewhere|pparg)
		Candidate="<pp>Ser2448</pp>" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0)
		Candidate="Ser2448" in "{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}" 	(Features:dist=0)
		Candidate="{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="<p>Akt</p>" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<pp>Ser473</pp>" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="Ser473" in "{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}" 	(Features:dist=0)
		Candidate="{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
		Candidate="<p>p70S6K</p>" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<pp>Thr389</pp>" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
		Candidate="Thr389" in "{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}" 	(Features:dist=0)
Substrate = ({NP_P_B_66}<p>mTOR</p>{/NP_P_B_66};-)
	Method=rule: (substrate) for phrase=[{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}0..3|<p>mTOR</p>]
	Method=rule: (substrate) for phrase=[{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}0..2|<p>Akt</p>]
	Method=rule: (substrate) for phrase=[{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}0..5|<p>p70S6K</p>]
Site = ({NP_PP_69}240{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_PP_69}244{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_PP_69}6{/NP_PP_69};{NP_PP_69}Ser{/NP_PP_69};UNK)
({NP_P_B_66}2448{/NP_P_B_66};{NP_P_B_66}Ser{/NP_P_B_66};UNK)
	Method=rule: (site) for phrase=[{NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69}0..1|S6|Ser63..12|Ser240/244|Ser240,244]
	Method=rule: (site) for phrase=[{NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66}5..11|Ser2448|Ser2448]
	Method=rule: (site) for phrase=[{NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67}4..9|Ser473|Ser473]
	Method=rule: (site) for phrase=[{NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68}7..12|Thr389|Thr389]

{NP_C_61}<c>TAE226</c>{/NP_C_61} {VP_act_62}inhibited{/VP_act_62} {NP_63}the expression{/NP_63} of {NP_P_64}<p>mTOR</p> , <p>Akt</p> , <p>p70S6K</p> and <p>S6</p>{/NP_P_64} as well as {NP_65}the phosphorylation{/NP_65} of {NP_P_B_66}<p>mTOR</p> (<pp>Ser2448</pp>){/NP_P_B_66} , {NP_P_B_67}<p>Akt</p> (<pp>Ser473</pp>){/NP_P_B_67} , {NP_P_B_68}<p>p70S6K</p> (<pp>Thr389</pp>){/NP_P_B_68} and {NP_PP_69}<B>S6</B> ( <pp>Ser240/244</pp> ){/NP_PP_69} .

As {NP_70}a result{/NP_70} , {NP_C_71}<c>TAE226</c>{/NP_C_71} {VP_act_72}induced{/VP_act_72} {NP_73}a dose -dependent decrease{/NP_73} in {NP_74}<Bpcl>cell</Bpcl> growth ( number ){/NP_74} and {NP_75}damage{/NP_75} in {NP_76}the <Bpcl>cell</Bpcl> shape{/NP_76} .

{AV_77}Together{/AV_77} , {NP_78}these data{/NP_78} {VP_act_79}show{/VP_act_79} that {NP_C_80}<c>TAE226</c>{/NP_C_80} {VP_act_81}has{/VP_act_81} {NP_82}potent inhibitory effects{/NP_82} on {NP_83}<p>mTOR</p> signaling{/NP_83} and {NP_84}esophageal <Bpcl>cancer cell</Bpcl> growth{/NP_84} {VP_act_85}indicating{/VP_act_85} that {NP_C_86}<c>TAE226</c>{/NP_C_86} {VP_act_87}has{/VP_act_87} {NP_88}potential application{/NP_88} in {NP_89}esophageal cancer treatment{/NP_89} .


{NP_1}PMID{/NP_1} - {CP_2}19020741{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>AMPK</p>{/NP_P_4} {VP_act_5}mediates{/VP_act_5} {NP_6}curcumin-induced <Bpcl>cell</Bpcl> death{/NP_6} in {NP_7}<p>CaOV3</p> ovarian <Bpcl>cancer cells</Bpcl>{/NP_7} .

{NP_8}AB{/NP_8} - {NP_P_9}<p>AMP-activated protein kinase ( AMPK )</p>{/NP_P_9} , {NP_P_10}an <Bppf>evolutionarily conserved serine/threonine protein kinase</Bppf>{/NP_P_10} , {VP_act_11}serves{/VP_act_11} as {NP_12}an energy sensor{/NP_12} in {NP_13}all eukaryotic <Bpcl>cells</Bpcl>{/NP_13} .

{NP_14}Recent findings{/NP_14} {VP_act_15}suggest{/VP_act_15} that {NP_16}<p>AMPK</p> activation{/NP_16} {VP_act_17}strongly suppresses{/VP_act_17} {NP_18}<Bpcl>cell</Bpcl> proliferation{/NP_18} and {VP_act_19}induces{/VP_act_19} {NP_20}<Bpcl>cell</Bpcl> apoptosis{/NP_20} in {NP_21}a variety{/NP_21} of {NP_22}<Bpcl>cancer cells</Bpcl>{/NP_22} .

{NP_23}Our study{/NP_23} {VP_act_24}demonstrated{/VP_act_24} that {NP_B_25}chemopreventive agent <B>curcumin</B>{/NP_B_25} {VP_act_26}strongly activates{/VP_act_26} {NP_P_27}<p>AMPK</p>{/NP_P_27} in {NP_28}a <p>p38</p> -dependent manner{/NP_28} in {NP_29}<p>CaOV3</p> ovarian <Bpcl>cancer cells</Bpcl>{/NP_29} .

{NP_30}Pretreatment{/NP_30} of {NP_31}<Bpcl>cells</Bpcl>{/NP_31} with {NP_B_32}<c>compound C</c> (<p>AMPK</p> inhibitor){/NP_B_32} and {NP_B_33}<B>SB203580</B> ( <p>p38</p> inhibitor ){/NP_B_33} {VP_act_34}attenuates{/VP_act_34} {NP_35}curcumin-induced <Bpcl>cell</Bpcl> death{/NP_35} .

OUTPUT 0
PTM = ({NP_40};phosphorylation)
	HasAgentTheme="<p>p53</p>" in "{NP_40}<p>p53</p> phosphorylation ( <pp>Ser 15</pp> ){/NP_40}"
Inducer = ({NP_40}<p>p53</p>{/NP_40};-)
	Method=agent_or_theme_but_known_as_inducer (inducer) for phrase=[{NP_40}<p>p53</p> phosphorylation ( <pp>Ser 15</pp> ){/NP_40}0..2|<p>p53</p>]
Kinase = (-;-)
Substrate = (-;-)
Site = ({NP_40}15{/NP_40};{NP_40}Ser{/NP_40};UNK)
	Method=rule: (site) for phrase=[{NP_40}<p>p53</p> phosphorylation ( <pp>Ser 15</pp> ){/NP_40}19..23|Ser 15|Ser15]

OUTPUT 1
PTM = ({NP_43};phosphorylation)
	HasAgentTheme="<p>p53</p>" in "{NP_43}<p>p53</p> phosphorylation{/NP_43}"
Inducer = ({NP_40}<p>p53</p>{/NP_40};-)
	Method=rule: (inducer) for phrase=[{NP_40}<p>p53</p> phosphorylation ( <pp>Ser 15</pp> ){/NP_40}0..2|<p>p53</p>]
	Method=agent_or_theme_but_known_as_inducer (inducer) for phrase=[{NP_40}<p>p53</p> phosphorylation ( <pp>Ser 15</pp> ){/NP_40}0..2|<p>p53</p>{NP_43}<p>p53</p> phosphorylation{/NP_43}0..2|<p>p53</p>]
Kinase = (-;-)
	Method=closer (kinase) for phrase=[{NP_40}<p>p53</p> phosphorylation ( <pp>Ser 15</pp> ){/NP_40}0..2|<p>p53</p>]
		From: {NP_40}<p>p53</p> phosphorylation ( <pp>Ser 15</pp> ){/NP_40}0..2|<p>p53</p>{NP_43}<p>p53</p> phosphorylation{/NP_43}0..2|<p>p53</p>
Substrate = (-;-)
Site = (-;-;UNK)

{NP_36}We{/NP_36} {VP_act_37}also observed{/VP_act_37} that {NP_B_38}<B>curcumin</B>{/NP_B_38} {VP_act_39}induces{/VP_act_39} {NP_40}<p>p53</p> phosphorylation ( <pp>Ser 15</pp> ){/NP_40} and {NP_41}both <c>compound C</c> and <B>SB203580</B> pretreatment{/NP_41} {VP_act_42}inhibit{/VP_act_42} {NP_43}<p>p53</p> phosphorylation{/NP_43} .

{AV_44}Collectively{/AV_44} , {NP_45}our data{/NP_45} {VP_act_46}suggest{/VP_act_46} that {NP_P_47}<p>AMPK</p>{/NP_P_47} {VP_act_48}is{/VP_act_48} {NP_49}a new molecular target{/NP_49} of {NP_50}<B>curcumin</B> and <p>AMPK</p> activation{/NP_50} {VP_act_51}partially contributes{/VP_act_51} to {NP_52}the cytotoxic effect{/NP_52} of {NP_B_53}<B>curcumin</B>{/NP_B_53} in {NP_54}ovarian <Bpcl>cancer cells</Bpcl>{/NP_54} .


{NP_1}PMID{/NP_1} - {CP_2}19020661{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}The <p>marine-derived oligosaccharide sulfate ( MdOS )</p>{/NP_P_4} , {NP_P_5}a novel multiple <Bppf>tyrosine kinase inhibitor</Bppf>{/NP_P_5} , {NP_6}combats tumor{/NP_6} {VP_act_7}angiogenesis{/VP_act_7} {NP_8}both{/NP_8} in {NP_9}vitro and in vivo{/NP_9} .

{NP_10}AB{/NP_10} - Despite {NP_11}the emerging success{/NP_11} of {NP_P_12}multi-targeted protein <Bppf>tyrosine kinase ( <p>PTK</p> ) inhibitors</Bppf>{/NP_P_12} in {NP_13}cancer therapy{/NP_13} , {NP_14}significant side effects{/NP_14} and {NP_15}resistance concerns{/NP_15} {VP_act_16}seems{/VP_act_16} {VP_pass_17}to be avoided{/VP_pass_17} {JP_18}unlikely{/JP_18} .

{NP_19}The aim{/NP_19} of {NP_20}the present study{/NP_20} {VP_pass_21}was{/VP_pass_21} {VP_act_22}to identify{/VP_act_22} {NP_P_23}novel <Bppf>multi-targeting <p>PTK</p> inhibitors</Bppf>{/NP_P_23} .

{NP_24}The <Bppf>kinase</Bppf> enzymatic activities{/NP_24} {VP_pass_25}were measured{/VP_pass_25} by {NP_P_26}<p>enzyme-linked immunosorbent assay ( ELISA )</p>{/NP_P_26} .

{NP_27}The antiproliferative activities{/NP_27} in {NP_S_28}<S><s>human</s> microvascular endothelial cells ( HMECs )</S>{/NP_S_28} {VP_pass_29}were evaluated{/VP_pass_29} by {NP_30}<c>sulforhodamine ( SRB )</c> assay{/NP_30} .

OUTPUT 0
PTM = ({NP_31};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_31}The phosphorylation{/NP_31} of {NP_P_32}<Bppf>kinases</Bppf> and their downstream <Bppf>molecules</Bppf>{/NP_P_32} {VP_pass_33}was probed{/VP_pass_33} by {NP_34}western blot analysis{/NP_34} .

{NP_35}The binding mode{/NP_35} between {NP_P_36}<p>MdOS</p> and <p>PTKs</p>{/NP_P_36} {VP_pass_37}was profiled{/VP_pass_37} by {NP_38}<B>surface plasmon resonance ( SPR )</B> approach{/NP_38} and {NP_39}molecular simulation{/NP_39} .

{NP_40}Tube formation assay{/NP_40} , {NP_41}<s>rat</s> aortic ring method{/NP_41} and {NP_42}<s>chicken</s> chorioallantoic membrane assay{/NP_42} {VP_pass_43}were combined{/VP_pass_43} {VP_act_44}to illustrate{/VP_act_44} {NP_45}the in vitro and in vivo anti-angiogenic effects{/NP_45} .

{NP_46}Results{/NP_46} {VP_act_47}indicated{/VP_act_47} that {NP_P_48}<p>MdOS</p>{/NP_P_48} , {NP_C_49}a novel marine-derived <c>oligosaccharide sulfate</c>{/NP_C_49} , {VP_act_50}exhibited{/VP_act_50} {NP_51}a broad-spectrum <p>PTK</p> inhibitory action{/NP_51} .

At {NP_52}an enzymatic level{/NP_52} , {NP_P_53}<p>MdOS</p>{/NP_P_53} {VP_act_54}inhibited{/VP_act_54} {NP_P_55}<p>HER2</p> , <p>EGFR</p> , <p>VEGFR</p> , <p>PDGFR</p> , <p>c-Kit</p> , <p>FGFR1</p> and <p>c-Src</p>{/NP_P_55} , with {NP_56}little impact{/NP_56} on {NP_P_57}<p>FGFR2</p>{/NP_P_57} .

OUTPUT 1
PTM = ({NP_61};phosphorylation)
Inducer = ({NP_P_59}<p>MdOS</p>{/NP_P_59};-)
	Method=rule: (inducer) for phrase=[{NP_P_59}<p>MdOS</p>{/NP_P_59}]
Kinase = (-;-)
Substrate = ({NP_P_62}<p>PTKs</p>{/NP_P_62};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_62}<p>PTKs</p>{/NP_P_62}]
Site = (-;-;UNK)

In {NP_58}cellular settings{/NP_58} , {NP_P_59}<p>MdOS</p>{/NP_P_59} {VP_act_60}inhibited{/VP_act_60} {NP_61}phosphorylation{/NP_61} of {NP_P_62}<p>PTKs</p>{/NP_P_62} , {VP_pass_63}exemplified{/VP_pass_63} by {NP_P_64}<p>HER2</p> , <p>EGFR</p> and <p>VEGFR2</p>{/NP_P_64} , and {NP_P_65}downstream <Bppf>molecules</Bppf>{/NP_P_65} of {NP_P_66}<p>Erk1/2</p> and <p>AKT</p>{/NP_P_66} .

{VP_act_67}Further studies{/VP_act_67} {VP_act_68}demonstrated{/VP_act_68} that {NP_P_69}<p>MdOS</p>{/NP_P_69} {VP_act_70}acted{/VP_act_70} as {NP_P_71}an <Bppf>ATP-competitive inhibitor</Bppf>{/NP_P_71} via {VP_act_72}directly binding{/VP_act_72} to {NP_PP_73}the <Bppp>residues</Bppp>{/NP_PP_73} of {NP_74}entrance{/NP_74} {AV_75}rather{/AV_75} than those of {NP_76}the <p>ATP</p> -binding pocket{/NP_76} .

{AV_77}Furthermore{/AV_77} , {NP_P_78}<p>MdOS</p>{/NP_P_78} {VP_act_79}inhibited{/VP_act_79} {NP_80}proliferation{/NP_80} and {NP_81}tube formation{/NP_81} of {NP_S_82}<S>HMECs</S>{/NP_S_82} , {VP_act_83}arrested{/VP_act_83} {NP_84}microvessel outgrowth{/NP_84} of {NP_85}<s>rat</s> aortic rings{/NP_85} and {VP_act_86}hindered{/VP_act_86} {NP_87}the neovascularization{/NP_87} of {NP_88}<s>chick</s> allantoic membrane{/NP_88} .

{AV_89}Taken together{/AV_89} , {NP_90}results{/NP_90} {VP_act_91}presented{/VP_act_91} {VP_act_92}here indicated{/VP_act_92} that {NP_P_93}<p>MdOS</p>{/NP_P_93} {VP_act_94}exhibited{/VP_act_94} {NP_95}anti-angiogenic activity{/NP_95} in {NP_96}a <p>PTK</p> -dependent manner{/NP_96} and {VP_act_97}make{/VP_act_97} {NP_98}it{/NP_98} {NP_99}a promising agent{/NP_99} for {NP_100}further evaluation{/NP_100} in {NP_101}PTK-associated cancer therapy{/NP_101} .


{NP_1}PMID{/NP_1} - {CP_2}19020663{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Flow-cytometric <p>phosphoprotein</p> analysis{/NP_4} {VP_act_5}reveals{/VP_act_5} {NP_6}<Bpcf>agonist</Bpcf>{/NP_6} and {NP_7}temporal differences{/NP_7} in {NP_8}responses{/NP_8} of {NP_9}<s>murine</s> hematopoietic <Bpcl>stem/progenitor cells</Bpcl>{/NP_9} .

{NP_10}AB{/NP_10} - {NP_P_11}<p>Hematopoietic stem cells ( HSCs )</p>{/NP_P_11} {VP_pass_12}are probably{/VP_pass_12} {NP_13}the best-studied adult{/NP_13} <Bpcl>tissue</Bpcl> -restricted {NP_14}stem <Bpcl>cells</Bpcl>{/NP_14} .

OUTPUT 0
PTM = ({NP_P_17};phosphoproteins)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
	Method=rule:1.45.1.0.1 (substrate) for phrase=[{NP_P_17}<p>phosphoproteins</p>{/NP_P_17}]
	Filtered={NP_P_17}<p>phosphoproteins</p>{/NP_P_17}	(Category=generic)
	Method=rule:1.45.1.0.1 (substrate) for phrase=[{NP_P_17}<p>phosphoproteins</p>{/NP_P_17}]
Site = (-;-;UNK)

Although {NP_15}methods{/NP_15} for {NP_16}flow cytometric detection{/NP_16} of {NP_P_17}<p>phosphoproteins</p>{/NP_P_17} in {NP_18}hematopoeitic <Bpcl>progenitors</Bpcl> and <Bpcl>mature cells</Bpcl>{/NP_18} {VP_pass_19}are available{/VP_pass_19} , {NP_20}analogous protocols{/NP_20} for {NP_P_21}<p>HSC</p>{/NP_P_21} {VP_act_22}are lacking{/VP_act_22} .

{NP_23}We{/NP_23} {VP_act_24}present{/VP_act_24} {NP_25}a robust method{/NP_25} {VP_act_26}to study{/VP_act_26} {NP_27}intracellular signaling{/NP_27} in {NP_28}<c>immunophenotypically-defined</c> <s>murine</s> <S>HSC/progenitor cell ( HPC )</S>- enriched populations{/NP_28} .

{VP_act_29}Using{/VP_act_29} {NP_30}this method{/NP_30} , {NP_31}we{/NP_31} {VP_act_32}uncover{/VP_act_32} {NP_33}differences{/NP_33} in {NP_34}the response dynamics{/NP_34} of {NP_35}several <p>phosphoproteins</p> representative{/NP_35} of {NP_36}the <B>Ras/MAP-Kinase(K)</B> , <p>PI3K</p> , <p>mTOR</p> and <p>Jak/STAT</p> pathways{/NP_36} in {NP_P_37}<p>HSC/HPCs</p>{/NP_P_37} {VP_pass_38}stimulated{/VP_pass_38} by {NP_P_39}<p>Scf</p>{/NP_P_39} , {NP_P_40}<p>Thpo</p>{/NP_P_40} , as well as {NP_P_41}several other important <p>HSC/HPC agonists</p>{/NP_P_41} .


{NP_1}PMID{/NP_1} - {CP_2}19021699{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}<B>Angiotensin</B> inhibition{/NP_4} {VP_act_5}stimulates{/VP_act_5} {NP_P_6}<p>PPARgamma</p>{/NP_P_6} and {NP_7}the release{/NP_7} of {NP_P_8}<p>visfatin</p>{/NP_P_8} .

{NP_9}AB{/NP_9} - {NP_10}BACKGROUND{/NP_10} :

{NP_11}<p>Angiotensin converting enzyme inhibitors ( ACE-I )</p> and <p>angiotensin receptor blockers ( ARB )</p> exhibit beneficial antidiabetic effects{/NP_11} in {NP_12}patients{/NP_12} with {NP_13}type 2 diabetes{/NP_13} {JP_14}independent{/JP_14} of {NP_15}their blood pressure-lowering effects{/NP_15} .

{NP_16}Some antidiabetic properties{/NP_16} of {NP_P_17}<p>ARB</p> and <p>ACE-I</p>{/NP_P_17} {VP_pass_18}might{/VP_pass_18} by {JP_19}exerted{/JP_19} by {NP_20}activation{/NP_20} of {NP_P_21}<p>peroxisome proliferator-activated receptor gamma ( PPARgamma )</p>{/NP_P_21} .

{AV_22}However{/AV_22} , {NP_23}it{/NP_23} {VP_pass_neg_24}is not clear{/VP_pass_neg_24} whether {NP_25}this action{/NP_25} {VP_act_26}is{/VP_act_26} {NP_27}<Bpcf>drug</Bpcf>{/NP_27} {JP_28}specific{/JP_28} .

{NP_29}MATERIALS{/NP_29} AND {NP_30}METHODS{/NP_30} : {NP_31}The binding affinity{/NP_31} of {NP_32}telmisartan{/NP_32} , {NP_33}valsartan{/NP_33} , {NP_P_34}<c>lisinopril</c> , <c>rosiglitazone</c> and <p>angiotensin II</p>{/NP_P_34} to {NP_P_35}<p>PPARgamma</p>{/NP_P_35} {VP_pass_36}was assessed{/VP_pass_36} in {NP_37}a <Bpcl>cell</Bpcl> -free assay system{/NP_37} .

OUTPUT 0
PTM = ({NP_B_44};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_38}<p>PPARgamma</p>{/NP_P_38}" 	(Features:dist=0|in-title_elsewhere|studied|subject_main)
		Candidate="<p>PPARgamma</p>" in "{NP_P_38}<p>PPARgamma</p>{/NP_P_38}" 	(Features:dist=0|in-title_elsewhere|studied|subject_main|subject_main_modifier)
Substrate = ({NP_B_44}<p>protein kinase B ( pAKT )</p>{/NP_B_44};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_B_44}phosphorylated <p>protein kinase B ( pAKT )</p> and phosphorylated <B>insulin like growth factor-1 receptor ( pILGF-1R )</B>{/NP_B_44}14..33|<p>protein kinase B ( pAKT )</p>]
Site = (-;-;UNK)

{NP_P_38}<p>PPARgamma</p>{/NP_P_38} {VP_act_39}signalling{/VP_act_39} {VP_pass_40}was studied{/VP_pass_40} in {NP_41}isolated skeletal muscle <Bpcl>cells</Bpcl>{/NP_41} {VP_act_42}using{/VP_act_42} {NP_43}Western blot analysis{/NP_43} of {NP_B_44}phosphorylated <p>protein kinase B ( pAKT )</p> and phosphorylated <B>insulin like growth factor-1 receptor ( pILGF-1R )</B>{/NP_B_44} .

{AV_45}Further{/AV_45} , {NP_46}the ability{/NP_46} of {NP_47}the <Bpcf>drugs</Bpcf>{/NP_47} under {NP_48}study{/NP_48} {VP_act_49}to stimulate{/VP_act_49} {NP_50}the release{/NP_50} of {NP_P_51}the <p>adipocytokine visfatin</p>{/NP_P_51} {VP_pass_52}was investigated{/VP_pass_52} in {NP_S_53}isolated <s>human</s> <S>adipocytes</S>{/NP_S_53} , {NP_54}skeletal muscle <Bpcl>cells</Bpcl>{/NP_54} , and {NP_B_55}umbilical vein endothelial <Bpcl>cells</Bpcl> (HUVEC){/NP_B_55} .

{NP_56}RESULTS{/NP_56} : {NP_57}The binding affinity{/NP_57} to {NP_P_58}<p>PPARgamma</p>{/NP_P_58} {VP_pass_59}was highest{/VP_pass_59} for {NP_60}telmisartan{/NP_60} with {NP_61}a half-maximal effective concentration{/NP_61} of {NP_62}463 nM{/NP_62} , {VP_pass_63}followed{/VP_pass_63} by {NP_C_64}<c>lisinopril</c> ( 2.9 microM ){/NP_C_64} and {NP_65}valsartan ( 6.2 microM ){/NP_65} .

OUTPUT 1
PTM = ({NP_66};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

In {NP_66}skeletal muscle <Bpcl>cells</Bpcl> phosphorylation{/NP_66} of {NP_B_67}<B>ILGF-1R</B>{/NP_B_67} {VP_pass_68}was{/VP_pass_68} {NP_69}2-fold{/NP_69} {VP_act_70}increased{/VP_act_70} after {NP_71}incubation{/NP_71} with {NP_72}telmisartan{/NP_72} or {NP_73}valsartan{/NP_73} and {NP_74}1.7-fold{/NP_74} with {NP_C_75}<c>lisinopril</c>{/NP_C_75} .

{NP_76}<p>pAKT</p> expression{/NP_76} {VP_pass_77}was enhanced{/VP_pass_77} after {NP_78}incubation{/NP_78} with {NP_79}telmisartan{/NP_79} , {NP_80}valsartan{/NP_80} and with {NP_C_81}<c>lisinopril</c>{/NP_C_81} .

{NP_82}The release{/NP_82} of {NP_P_83}<p>visfatin</p>{/NP_P_83} from {NP_S_84}<S>adipocytes</S>{/NP_S_84} {VP_pass_85}was{/VP_pass_85} {NP_86}1.6-fold{/NP_86} {VP_act_87}increased{/VP_act_87} after {NP_88}treatment{/NP_88} with {NP_C_89}<c>lisinopril</c>{/NP_C_89} and about {NP_90}2.0-fold{/NP_90} {VP_act_91}increased{/VP_act_91} with {NP_92}telmisartan{/NP_92} and {NP_93}valsartan{/NP_93} .

{NP_94}Similar results{/NP_94} {VP_pass_95}were obtained{/VP_pass_95} in {NP_S_96}<S>skeletal muscle cells</S> and <S>HUVEC</S>{/NP_S_96} .

{NP_97}CONCLUSIONS{/NP_97} : {NP_98}Our data{/NP_98} {VP_act_99}confirm{/VP_act_99} {VP_act_100}agonism{/VP_act_100} of {NP_101}telmisartan{/NP_101} , {NP_102}valsartan{/NP_102} and {NP_C_103}<c>lisinopril</c>{/NP_C_103} on {NP_P_104}<p>PPARgamma</p>{/NP_P_104} .

{NP_105}Pharmacokinetic differences{/NP_105} {VP_act_106}may explain{/VP_act_106} {NP_107}different potencies{/NP_107} of {NP_108}<p>PPARgamma</p> stimulation{/NP_108} by {NP_109}<Bpcf>drugs</Bpcf>{/NP_109} {VP_act_110}acting{/VP_act_110} on {NP_111}the <B>renin-angiotensin</B> system{/NP_111} in {NP_112}clinical settings{/NP_112} .


{NP_1}PMID{/NP_1} - {CP_2}19021757{/CP_2}

{NP_3}TI{/NP_3} - {NP_PP_4}<pp>Tyr235</pp>{/NP_PP_4} of {NP_5}<s>human</s> cytosolic <p>phosphoenolpyruvate carboxykinase</p> influences{/NP_5} {VP_act_6}catalysis{/VP_act_6} through {NP_7}an anion-quadrupole interaction{/NP_7} with {NP_C_8}<c>phosphoenolpyruvate carboxylate</c>{/NP_C_8} .

{NP_9}AB{/NP_9} - {NP_PP_10}<pp>Tyr235</pp>{/NP_PP_10} of {NP_P_11}<p>GTP -dependent phosphoenolpyruvate ( PEP ) carboxykinase</p>{/NP_P_11} {VP_act_12}is{/VP_act_12} {NP_PP_13}a fully <Bppp>invariant residue</Bppp>{/NP_PP_13} .

{NP_14}The aromatic ring{/NP_14} of {NP_PP_15}this <Bppp>residue</Bppp>{/NP_PP_15} {VP_act_16}establishes{/VP_act_16} {NP_17}an energetically favorable weak anion-quadrupole interaction{/NP_17} with {NP_C_18}<c>PEP carboxylate</c>{/NP_C_18} .

{NP_19}The role{/NP_19} of {NP_PP_20}<pp>Tyr235</pp>{/NP_PP_20} in {NP_21}catalysis{/NP_21} {VP_pass_22}was investigated{/VP_pass_22} via {NP_23}kinetic analysis{/NP_23} of {NP_P_24}<Bppp>site</Bppp> -directed <Bppf>mutagenesis-derived variants</Bppf>{/NP_P_24} .

{NP_25}The <pp>Y235F</pp> change{/NP_25} {VP_act_26}lowered{/VP_act_26} {NP_B_27}the apparent <B>K(m)</B>{/NP_B_27} for {NP_C_28}<c>PEP</c>{/NP_C_28} by about {AV_29}six-fold{/AV_29} , {VP_act_30}raised{/VP_act_30} {NP_B_31}the apparent <B>K(m)</B>{/NP_B_31} for {NP_B_32}<B>Mn(2+)</B>{/NP_B_32} by about {NP_33}70-fold{/NP_33} , and {VP_act_34}decreased{/VP_act_34} {NP_C_35}<c>oxaloacetate ( OAA )</c>{/NP_C_35} {VP_act_36}-forming{/VP_act_36} {NP_37}activity{/NP_37} by about {NP_38}10-fold{/NP_38} .

{NP_39}These effects{/NP_39} {VP_pass_40}were due{/VP_pass_40} to {NP_41}an enhanced anion-quadrupole interaction{/NP_41} between {NP_PP_42}the aromatic side <Bppp>chain</Bppp>{/NP_PP_42} at {NP_PP_43}<pp>position 235</pp>{/NP_PP_43} , {NP_44}which{/NP_44} {VP_act_45}now lacked{/VP_act_45} {NP_C_46}a <c>hydroxyl group</c> , and <c>PEP</c>{/NP_C_46} {VP_act_47}carboxylate{/VP_act_47} , {NP_48}which{/NP_48} {VP_act_49}probably increased{/VP_act_49} {NP_50}the distance{/NP_50} between {NP_C_51}<c>PEP</c> and <c>Mn(2+)</c>{/NP_C_51} and {VP_act_52}consequently affected{/VP_act_52} {NP_53}the <c>phosphoryl</c> transfer step and overall catalysis{/NP_53} .

For {NP_54}the <pp>Y235A</pp> and <pp>Y235S</pp> changes{/NP_54} , {NP_55}an elimination{/NP_55} of {NP_56}the favorable edge-on interaction{/NP_56} {VP_act_57}increased{/VP_act_57} {NP_B_58}the apparent <B>K(m)</B>{/NP_B_58} for {NP_C_59}<c>PEP</c>{/NP_C_59} by {CP_60}four{/CP_60} - and {AV_61}six-fold{/AV_61} , {AV_62}respectively{/AV_62} , and {NP_B_63}the apparent <B>K(m)</B>{/NP_B_63} for {NP_B_64}<B>Mn(2+)</B>{/NP_B_64} by {CP_65}eight{/CP_65} - and {AV_66}six-fold{/AV_66} , {AV_67}respectively{/AV_67} .

{NP_68}The <p>pyruvate kinase</p> -like activity{/NP_68} , {VP_act_69}representing{/VP_act_69} {NP_70}the <c>PEP</c> dephosphorylation step{/NP_70} of {NP_71}the <B>OAA-forming</B> reaction{/NP_71} , {VP_pass_72}was affected{/VP_pass_72} by {NP_73}the substitutions{/NP_73} in {NP_74}a similar way{/NP_74} to {NP_75}the complete reaction{/NP_75} .

{NP_76}These observations{/NP_76} {VP_act_77}indicate{/VP_act_77} that {NP_78}the aromatic ring{/NP_78} of {NP_PP_79}<pp>Tyr235</pp>{/NP_PP_79} {VP_act_80}helps{/VP_act_80} {VP_act_81}to position{/VP_act_81} {NP_C_82}<c>PEP</c>{/NP_C_82} in {NP_PP_83}the active <Bppp>site</Bppp>{/NP_PP_83} and {NP_C_84}the <c>hydroxyl group</c>{/NP_C_84} {VP_act_85}allows{/VP_act_85} {NP_86}an optimal <B>PEP-Mn(2+)</B> distance{/NP_86} for {NP_87}efficient <c>phosphoryl</c> transfer{/NP_87} and {NP_88}overall catalysis{/NP_88} .

{NP_89}The <pp>Y235A</pp> and <pp>Y235S</pp> changes{/NP_89} {VP_act_90}drastically reduced{/VP_act_90} {NP_91}the <B>PEP-forming</B> and <p>OAA decarboxylase</p> activities{/NP_91} , {JP_92}probably due{/JP_92} to {NP_93}the elimination{/NP_93} of {NP_94}the stabilizing interaction{/NP_94} between {NP_PP_95}<pp>Tyr235</pp>{/NP_PP_95} and {NP_C_96}the respective <c>products</c> , <c>PEP</c> and <c>pyruvate</c>{/NP_C_96} .


{NP_1}PMID{/NP_1} - {CP_2}19021762{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}A novel <p>nucleoside kinase</p>{/NP_P_4} from {NP_5}<s>Burkholderia thailandensis</s>{/NP_5} : {NP_6}a <Bpf>member</Bpf>{/NP_6} of {NP_B_7}the <B>phosphofructokinase B-type family</B>{/NP_B_7} of {NP_P_8}<Bppf>enzymes</Bppf>{/NP_P_8} .

{NP_9}AB{/NP_9} - {NP_P_10}The <Bppf>genome</Bppf>{/NP_P_10} of {NP_11}the mesophilic <S>Gram-negative bacterium Burkholderia</S> thailandensis{/NP_11} {VP_act_12}contains{/VP_act_12} {NP_13}an open reading frame{/NP_13} ( {NP_14}i.e.{/NP_14} {NP_P_15}the <p>Bth I1158 gene</p>{/NP_P_15} ) {NP_16}that{/NP_16} {VP_pass_neg_17}has been annotated{/VP_pass_neg_17} as {NP_P_18}a putative <p>ribokinase</p> and <p>PFK-B family member</p>{/NP_P_18} .

{AV_19}Notably{/AV_19} , although {NP_PP_20}the deduced <Bppp>amino acid sequence</Bppp>{/NP_PP_20} of {NP_P_21}the <Bppf>gene</Bppf>{/NP_P_21} {VP_act_22}showed{/VP_act_22} {NP_23}only 29% similarity{/NP_23} to {NP_P_24}the recently identified <p>nucleoside kinase</p>{/NP_P_24} from {NP_25}hyperthermophilic archaea <c>Methanocaldococcus</c> jannaschii{/NP_25} , {CP_26}15{/CP_26} of {NP_PP_27}17 <Bppp>residues</Bppp>{/NP_PP_27} {VP_pass_28}reportedly involved{/VP_pass_28} in {NP_29}the catalytic activity{/NP_29} of {NP_P_30}<p>M.jannaschii nucleoside kinase</p>{/NP_P_30} {VP_pass_31}were conserved{/VP_pass_31} .

{NP_P_32}The <Bppf>gene</Bppf>{/NP_P_32} {VP_pass_33}was cloned{/VP_pass_33} and {VP_pass_34}functionally overexpressed{/VP_pass_34} in {NP_35}<s>Rhodococcus erythropolis</s>{/NP_35} , and {NP_P_36}the purified <Bppf>enzyme</Bppf>{/NP_P_36} {VP_pass_37}was characterized{/VP_pass_37} {AV_38}biochemically{/AV_38} .

OUTPUT 0
PTM = ({NP_39};substrate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_39}The <Bppf>substrate</Bppf> specificity{/NP_39} of {NP_P_40}the <Bppf>enzyme</Bppf>{/NP_P_40} {VP_pass_41}was unusually broad{/VP_pass_41} for {NP_P_42}a bacterial <p>PFK-B protein</p>{/NP_P_42} , and {NP_43}the specificity{/NP_43} {VP_act_44}extended{/VP_act_44} {AV_45}not only{/AV_45} to {NP_C_46}<c>purine</c> and <c>purine-analog nucleosides</c>{/NP_C_46} but {AV_47}also{/AV_47} to {NP_C_48}<c>uridine</c>{/NP_C_48} .

{NP_C_49}<c>Inosine</c>{/NP_C_49} {VP_pass_50}was{/VP_pass_50} {NP_51}the most effective <c>phosphoryl</c> acceptor{/NP_51} , with {NP_52}the highest k{/NP_52} ( {NP_53}<s>cat</s> <B>)/K(m)</B> value{/NP_53} ( 80 s {NP_54}( -1 ) .mm ( -1 ){/NP_54} ) {VP_pass_55}being achieved{/VP_pass_55} when {NP_P_56}<p>ATP</p>{/NP_P_56} {VP_act_57}served{/VP_act_57} as {NP_58}the <c>phosphoryl</c> donor{/NP_58} .

By {NP_59}contrast{/NP_59} , {NP_P_60}this <Bppf>enzyme</Bppf>{/NP_P_60} {VP_act_61}exhibited{/VP_act_61} {NP_62}no activity{/NP_62} toward {NP_63}ribose{/NP_63} , {VP_act_64}indicating{/VP_act_64} that {NP_P_65}the recombinant <Bppf>enzyme</Bppf>{/NP_P_65} {VP_pass_66}was{/VP_pass_66} {NP_P_67}a <p>nucleoside kinase</p>{/NP_P_67} {AV_68}rather{/AV_68} than {NP_P_69}a <p>ribokinase</p>{/NP_P_69} .

To {NP_70}our knowledge{/NP_70} , {NP_71}this{/NP_71} {VP_act_72}is{/VP_act_72} {NP_73}the first detailed analysis{/NP_73} of {NP_P_74}a bacterial <p>nucleoside kinase</p>{/NP_P_74} in {NP_B_75}the <B><p>PFK-B</p> family</B>{/NP_B_75} .


{NP_1}PMID{/NP_1} - {CP_2}19021767{/CP_2}

OUTPUT 0
PTM = ({NP_4};Phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_6}<p>Bud32p kinase</p>{/NP_P_6};-)
	Method=rule: (kinase) for phrase=[{NP_P_6}the <p>Bud32p kinase</p>{/NP_P_6}3..14|<p>Bud32p kinase</p>]
Substrate = ({NP_P_5}<p>Grx4p glutaredoxin</p>{/NP_P_5};-)
	Method=rule: (substrate) for phrase=[{NP_P_5}the <s>Saccharomyces cerevisiae</s> <p>Grx4p glutaredoxin</p>{/NP_P_5}26..42|<p>Grx4p glutaredoxin</p>]
Site = (-;-;UNK)

{NP_3}TI{/NP_3} - {NP_4}Phosphorylation{/NP_4} of {NP_P_5}the <s>Saccharomyces cerevisiae</s> <p>Grx4p glutaredoxin</p>{/NP_P_5} by {NP_P_6}the <p>Bud32p kinase</p>{/NP_P_6} {VP_act_7}unveils{/VP_act_7} {NP_8}a novel signaling pathway{/NP_8} {VP_act_9}involving{/VP_act_9} {NP_P_10}<p>Sch9p</p>{/NP_P_10} , {NP_11}a <s>yeast</s> <Bpf>member</Bpf>{/NP_11} of {NP_B_12}the Akt / <B>PKB subfamily</B>{/NP_B_12} .

{NP_13}AB{/NP_13} - {NP_P_14}The <s>Saccharomyces cerevisiae</s> atypical protein kinase <p>Bud32p</p>{/NP_P_14} {VP_act_15}is{/VP_act_15} {NP_16}a <Bpf>member</Bpf>{/NP_16} of {NP_17}the nuclear endopeptidase-like{/NP_17} , {NP_P_18}<Bppf>kinase</Bppf>{/NP_P_18} , {NP_P_19}<p>chromatin-associated/kinase</p>{/NP_P_19} , {NP_P_20}endopeptidase-like and other <Bppf>protein</Bppf>{/NP_P_20} of {NP_21}small size ( <B>EKC/KEOPS</B> ) <Bpf>complex</Bpf>{/NP_21} , {VP_act_22}known{/VP_act_22} {VP_pass_23}to be involved{/VP_pass_23} in {NP_24}the control{/NP_24} of {NP_25}transcription{/NP_25} and {NP_26}telomere homeostasis{/NP_26} .

{NP_P_27}<Bppf>Complex subunits</Bppf>{/NP_P_27} ( {NP_28}Pcc1p{/NP_28} , {NP_P_29}<p>Pcc2p</p>{/NP_P_29} , {NP_P_30}<p>Cgi121p</p>{/NP_P_30} , {NP_P_31}<p>Kae1p</p>{/NP_P_31} ) {VP_act_32}represent{/VP_act_32} , {AV_33}however{/AV_33} , {NP_34}a small subset{/NP_34} of {NP_P_35}the <Bppf>proteins</Bppf>{/NP_P_35} {JP_36}able{/JP_36} {VP_act_37}to interact{/VP_act_37} with {NP_P_38}<p>Bud32p</p>{/NP_P_38} , {VP_act_39}suggesting{/VP_act_39} that {NP_P_40}this <Bppf>protein</Bppf>{/NP_P_40} {VP_pass_41}may be endowed{/VP_pass_41} with {NP_42}additional roles{/NP_42} {JP_43}unrelated{/JP_43} to {NP_44}its participation{/NP_44} in {NP_B_45}the <B>EKC/KEOPS complex</B>{/NP_B_45} .

In {NP_46}this context{/NP_46} , {NP_47}we{/NP_47} {VP_act_48}investigated{/VP_act_48} {NP_49}the relationships{/NP_49} between {NP_P_50}<p>Bud32p</p>{/NP_P_50} and {NP_C_51}the nuclear <c>glutaredoxin <p>Grx4p</p></c>{/NP_C_51} , {VP_act_52}showing{/VP_act_52} that {NP_53}it{/NP_53} {VP_pass_54}is actually{/VP_pass_54} {NP_P_55}a physiological <Bppf>substrate</Bppf>{/NP_P_55} of {NP_P_56}the <Bppf>kinase</Bppf>{/NP_P_56} and that {NP_P_57}<p>Bud32p</p>{/NP_P_57} {VP_act_58}contributes{/VP_act_58} to {NP_59}the full functionality{/NP_59} of {NP_P_60}<p>Grx4p</p>{/NP_P_60} in {NP_61}vivo{/NP_61} .

OUTPUT 1
PTM = ({NP_66};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>Sch9p kinase</p>" in "{NP_71}the <p>Sch9p kinase</p> [<s>yeast</s> homolog{/NP_71}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="{NP_PP_68}<pp>Ser258</pp>{/NP_PP_68}" 	(Features:dist=0)
		Candidate="Ser258" in "{NP_PP_68}<pp>Ser258</pp>{/NP_PP_68}" 	(Features:dist=0)
		Candidate="<p>protein kinase B (Akt/PKB)</p>" in "{NP_P_72}mammalian <p>protein kinase B (Akt/PKB)</p>{/NP_P_72}" 	(Features:dist=0)
Substrate = ({NP_P_67}<p>Bud32p</p>{/NP_P_67};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_67}<p>Bud32p</p>{/NP_P_67}]
Site = ({NP_PP_68}258{/NP_PP_68};{NP_PP_68}Ser{/NP_PP_68};UNK)
	Method=rule: (site) for phrase=[{NP_PP_68}<pp>Ser258</pp>{/NP_PP_68}0..5|Ser258|Ser258]

{NP_62}We{/NP_62} {VP_act_63}also show{/VP_act_63} that {NP_64}this regulatory system{/NP_64} {VP_pass_65}is influenced{/VP_pass_65} by {NP_66}the phosphorylation{/NP_66} of {NP_P_67}<p>Bud32p</p>{/NP_P_67} at {NP_PP_68}<pp>Ser258</pp>{/NP_PP_68} , {NP_69}which{/NP_69} {VP_pass_70}is specifically mediated{/VP_pass_70} by {NP_71}the <p>Sch9p kinase</p> [<s>yeast</s> homolog{/NP_71} of {NP_P_72}mammalian <p>protein kinase B (Akt/PKB)</p>{/NP_P_72} ] .

OUTPUT 2
PTM = ({NP_74};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>Ser258</pp>" in "{NP_74}<pp>Ser258</pp> phosphorylation{/NP_74}" 	(Features:dist=0)
		Candidate="Ser258" in "{NP_74}<pp>Ser258</pp> phosphorylation{/NP_74}" 	(Features:dist=0)
		Candidate="{NP_P_78}the <Bppf>protein kinase</Bppf>{/NP_P_78}" 	(Features:dist=0|is-kinase_inherently)
Substrate = ({NP_P_75}<p>Bud32p</p>{/NP_P_75};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_75}<p>Bud32p</p>{/NP_P_75}]
Site = ({NP_74}258{/NP_74};{NP_74}Ser{/NP_74};UNK)
	Method=rule: (site) for phrase=[{NP_74}<pp>Ser258</pp> phosphorylation{/NP_74}0..5|Ser258|Ser258]

OUTPUT 3
PTM = ({VP_act_85};phosphorylate)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>Ser258</pp>" in "{NP_74}<pp>Ser258</pp> phosphorylation{/NP_74}" 	(Features:dist=0)
		Candidate="Ser258" in "{NP_74}<pp>Ser258</pp> phosphorylation{/NP_74}" 	(Features:dist=0)
		Candidate="{NP_P_78}the <Bppf>protein kinase</Bppf>{/NP_P_78}" 	(Features:dist=0|is-kinase_inherently)
Substrate = ({NP_P_75}<p>Bud32p</p>{/NP_P_75};-)
	Method=link (substrate) for phrase=[{NP_P_75}<p>Bud32p</p>{/NP_P_75}]
		From: {NP_86}it{/NP_86}
		Path: refer
Site = ({NP_74}258{/NP_74};{NP_74}Ser{/NP_74};UNK)
	Method=unclaimed_site_or_shared_substrate (site) for phrase=[{NP_74}<pp>Ser258</pp> phosphorylation{/NP_74}0..5|Ser258|Ser258]
	Candidates (Site):
		Candidate="{NP_74}<pp>Ser258</pp> phosphorylation{/NP_74}" 	(Features:is-aa|is-site)

{AV_73}Notably{/AV_73} , {NP_74}<pp>Ser258</pp> phosphorylation{/NP_74} of {NP_P_75}<p>Bud32p</p>{/NP_P_75} {VP_act_neg_76}does not alter{/VP_act_neg_76} {NP_77}the catalytic activity{/NP_77} of {NP_P_78}the <Bppf>protein kinase</Bppf>{/NP_P_78} per {NP_79}se{/NP_79} , but {VP_act_80}positively regulates{/VP_act_80} {NP_81}its ability{/NP_81} {VP_act_82}to interact{/VP_act_82} with {NP_P_83}<p>Grx4p</p>{/NP_P_83} and {AV_84}thus{/AV_84} {VP_act_85}to phosphorylate{/VP_act_85} {NP_86}it{/NP_86} .

{AV_87}Interestingly{/AV_87} , {NP_88}this novel signaling pathway{/NP_88} {VP_act_89}represents{/VP_act_89} {NP_90}a function{/NP_90} of {NP_P_91}<p>Bud32p</p>{/NP_P_91} {NP_92}that{/NP_92} {VP_pass_93}is independent{/VP_pass_93} from {NP_94}its role{/NP_94} in {NP_B_95}the <B>EKC/KEOPS complex</B>{/NP_B_95} , as {NP_96}the known functions{/NP_96} of {NP_97}the <Bpf>complex</Bpf>{/NP_97} in {NP_98}the regulation{/NP_98} of {NP_99}transcription{/NP_99} and {NP_100}telomere homeostasis{/NP_100} {VP_pass_101}are unaffected{/VP_pass_101} when {NP_102}the cascade{/NP_102} {VP_pass_103}is impaired{/VP_pass_103} .

{NP_104}A similar relationship{/NP_104} {VP_pass_105}has already been observed{/VP_pass_105} in {NP_106}<s>humans</s>{/NP_106} between {NP_P_107}<p>Akt/PKB</p> and <p>p53-related protein kinase ( Bud32p homolog )</p>{/NP_P_107} , and {VP_act_108}could indicate{/VP_act_108} that {NP_109}this pathway{/NP_109} {VP_pass_110}is conserved{/VP_pass_110} throughout {NP_111}evolution{/NP_111} .


{NP_1}PMID{/NP_1} - {CP_2}19021446{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Two-photon autofluorescence{/NP_4} and {NP_5}second-harmonic imaging{/NP_5} of {NP_6}adult stem <Bpcl>cells</Bpcl>{/NP_6} .

{NP_7}AB{/NP_7} - {NP_8}<s>Human</s> and animal stem <Bpcl>cells</Bpcl>{/NP_8} ( {NP_9}<s>rat</s> and <s>human</s> adult pancreatic stem <Bpcl>cells</Bpcl>{/NP_9} , {NP_10}salivary gland <Bpcl>stem cells</Bpcl> , and <s>human</s> dental pulp stem <Bpcl>cells</Bpcl>{/NP_10} ) {VP_pass_11}are investigated{/VP_pass_11} by {NP_12}femtosecond laser <B>5-D</B> two-photon microscopy{/NP_12} .

{NP_13}Autofluorescence{/NP_13} and {NP_B_14}<B>second-harmonic generation ( SHG )</B>{/NP_B_14} {VP_pass_15}are imaged{/VP_pass_15} with {NP_16}submicron spatial resolution{/NP_16} , {NP_17}270 ps temporal resolution{/NP_17} , and {NP_18}10 nm spectral resolution{/NP_18} .

OUTPUT 0
PTM = ({VP_act_21};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

In {JP_19}particular{/JP_19} , {NP_C_20}the reduced <c>coenzyme nicotinamide adenine</c>{/NP_C_20} ( {VP_act_21}phosphorylated{/VP_act_21} ) {NP_22}dinucleotide <p>[NAD(P) H]</p> and <p>flavoprotein</p> fluorescence{/NP_22} {VP_pass_23}is detected{/VP_pass_23} in {NP_24}stem <Bpcl>cell</Bpcl> monolayers{/NP_24} and {VP_act_25}stem{/VP_act_25} {NP_26}<Bpcl>cell</Bpcl> spheroids{/NP_26} .

{NP_27}Major emission peaks{/NP_27} at {NP_28}460 and 530 nm{/NP_28} with {NP_29}typical long fluorescence lifetimes ( tau2 ){/NP_29} of {NP_30}1.8{/NP_30} and {NP_31}2.0 ns{/NP_31} , {AV_32}respectively{/AV_32} , {VP_pass_33}are measured{/VP_pass_33} {VP_act_34}using{/VP_act_34} {NP_35}spectral imaging{/NP_35} and {NP_36}time-correlated single photon{/NP_36} {VP_act_37}counting{/VP_act_37} .

{NP_38}Differentiated stem <Bpcl>cells</Bpcl>{/NP_38} {VP_act_39}produce{/VP_act_39} {NP_40}the <p>extra cellular matrix ( ECM ) protein</p> collagen{/NP_40} , {VP_pass_41}detected{/VP_pass_41} by {NP_42}<B>SHG</B> signals{/NP_42} at {NP_43}435 nm{/NP_43} .

{NP_44}Multiphoton microscopes{/NP_44} {VP_act_45}may become{/VP_act_45} {NP_46}novel noninvasive tools{/NP_46} for {NP_47}marker-free optical stem <Bpcl>cell</Bpcl> characterization{/NP_47} and for {NP_48}on{/NP_48} - {NP_49}line monitoring{/NP_49} of {NP_50}differentiation{/NP_50} within {NP_51}a <B>3-D</B> microenvironment{/NP_51} .


{NP_1}PMID{/NP_1} - {CP_2}19023180{/CP_2}

OUTPUT 0
PTM = ({NP_4};phosphorylation)
	HasAgentTheme="<p>Cofilin</p>" in "{NP_4}<p>Cofilin</p> phosphorylation{/NP_4}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_9}<Bppf>growth factor</Bppf>{/NP_P_9}" 	(Features:dist=0|in-title|in-title_elsewhere)
Substrate = ({NP_4}<p>Cofilin</p>{/NP_4};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_4}<p>Cofilin</p> phosphorylation{/NP_4}0..6|<p>Cofilin</p>]
Site = (-;-;UNK)

{NP_3}TI{/NP_3} - {NP_4}<p>Cofilin</p> phosphorylation{/NP_4} {VP_act_5}mediates{/VP_act_5} {NP_6}proliferation{/NP_6} in {NP_7}response{/NP_7} {VP_act_8}to platelet-derived{/VP_act_8} {NP_P_9}<Bppf>growth factor</Bppf>{/NP_P_9} {JP_10}-BB{/JP_10} in {NP_11}<s>rat</s> aortic smooth muscle <Bpcl>cells</Bpcl>{/NP_11} .

{NP_12}AB{/NP_12} - {NP_P_13}<p>Cofilin</p>{/NP_P_13} , {NP_P_14}an <Bppf>actin-binding protein</Bppf>{/NP_P_14} , {VP_pass_15}is essential{/VP_pass_15} for {NP_16}a variety{/NP_16} of {NP_17}<Bpcl>cell</Bpcl> responses{/NP_17} .

OUTPUT 1
PTM = ({NP_22};phosphorylation)
	HasAgentTheme="<p>cofilin</p>" in "{NP_22}proliferation and <p>cofilin</p> phosphorylation{/NP_22}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_24}<p>platelet-derived growth factor ( PDGF )</p>{/NP_P_24}" 	(Features:dist=0)
		Candidate="{NP_S_25}<S><s>rat</s> aortic smooth muscle cells ( RASMCs )</S>{/NP_S_25}" 	(Features:dist=0)
Substrate = ({NP_22}<p>cofilin</p>{/NP_22};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_22}proliferation and <p>cofilin</p> phosphorylation{/NP_22}16..22|<p>cofilin</p>]
Site = (-;-;UNK)

In {NP_18}this study{/NP_18} , {NP_19}we{/NP_19} {VP_act_20}investigated{/VP_act_20} {NP_21}the correlation{/NP_21} between {NP_22}proliferation and <p>cofilin</p> phosphorylation{/NP_22} in {NP_23}response{/NP_23} to {NP_P_24}<p>platelet-derived growth factor ( PDGF )</p>{/NP_P_24} in {NP_S_25}<S><s>rat</s> aortic smooth muscle cells ( RASMCs )</S>{/NP_S_25} .

OUTPUT 2
PTM = ({NP_26};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_28}<p>mitogen-activated protein kinase ( MAPK )</p>{/NP_P_28};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_28}<p>mitogen-activated protein kinase ( MAPK )</p>{/NP_P_28}]
Site = (-;-;UNK)

{NP_26}The phosphorylation{/NP_26} of {NP_27}<p>cofilin</p> and activity{/NP_27} of {NP_P_28}<p>mitogen-activated protein kinase ( MAPK )</p>{/NP_P_28} {VP_pass_29}were measured{/VP_pass_29} by {NP_30}Western analyses and proliferation{/NP_30} in {NP_S_31}<S>RASMCs</S>{/NP_S_31} {VP_pass_32}was measured{/VP_pass_32} by {NP_33}BrdU incorporation assays{/NP_33} .

OUTPUT 3
PTM = ({NP_34};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_35}<p>cofilin</p>{/NP_P_35};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_35}<p>cofilin</p>{/NP_P_35}]
Site = (-;-;UNK)

{NP_34}The phosphorylation{/NP_34} of {NP_P_35}<p>cofilin</p>{/NP_P_35} in {NP_S_36}<S>RASMCs</S>{/NP_S_36} {VP_pass_37}was decreased{/VP_pass_37} by {NP_38}<c>PDGF-BB</c> treatment{/NP_38} at {NP_39}10 min{/NP_39} , but {VP_act_40}recovered{/VP_act_40} to {NP_41}the level{/NP_41} of {NP_42}the quiescent state{/NP_42} at {NP_43}60 min{/NP_43} .

{NP_44}<c>PDGF-BB</c> -induced dephosphorylation{/NP_44} of {NP_P_45}<p>cofilin</p>{/NP_P_45} {VP_pass_46}was inhibited{/VP_pass_46} by {NP_47}pretreatment{/NP_47} with {NP_48}piceatannol{/NP_48} ( {NP_P_49}a spleen <Bppf>tyrosine kinase [<p>Syk</p>] inhibitor</Bppf>{/NP_P_49} ) , {NP_P_50}<p>PP2</p>{/NP_P_50} ( {NP_P_51}a <Bppf><p>Src</p> inhibitor</Bppf>{/NP_P_51} ) , or {NP_B_52}<B>SP600125</B>{/NP_B_52} ( {NP_PP_53}a <pp>c-Jun N-terminal kinase [<p>JNK</p>] inhibitor</pp>{/NP_PP_53} ) , but {AV_54}not{/AV_54} by {NP_P_55}<p>PD98059</p>{/NP_P_55} , {NP_P_56}an <Bppf>inhibitor</Bppf>{/NP_P_56} of {NP_P_57}extracellular signal-regulated <p>kinase 1/2</p>{/NP_P_57} .

{NP_C_58}<c>PDGF-BB</c>{/NP_C_58} {VP_act_59}increased{/VP_act_59} {NP_60}<p>JNK</p> activity and proliferation{/NP_60} , and {NP_61}these responses{/NP_61} {VP_pass_62}were suppressed{/VP_pass_62} by {NP_B_63}<Bppf>kinase inhibitors</Bppf> and small interference <B>RNA-cofilin</B>{/NP_B_63} .

{NP_64}The results{/NP_64} {VP_act_65}suggest{/VP_act_65} that {NP_66}<c>PDGF-BB</c> -induced dephosphorylation{/NP_66} of {NP_P_67}<p>cofilin</p>{/NP_P_67} {VP_pass_68}can be promoted{/VP_pass_68} via {NP_69}the <p>JNK</p> pathway{/NP_69} , {NP_70}which{/NP_70} {VP_pass_71}is regulated{/VP_pass_71} by {NP_P_72}both <p>Syk</p> and <p>Src</p> <Bppf>kinases</Bppf>{/NP_P_72} and that {NP_73}<p>cofilin</p> dephosphorylation{/NP_73} {VP_pass_74}may be involved{/VP_pass_74} in {NP_75}<c>PDGF-BB</c> -induced <B>RASMC</B> proliferation{/NP_75} .

NORM=cofilin
SYNONYM=Cofilin
SYNONYM=cofilin


{NP_1}PMID{/NP_1} - {CP_2}19023807{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Apoptotic <Bpcl>cell</Bpcl> death{/NP_4} through {NP_5}inhibition{/NP_5} of {NP_6}<p>protein kinase CKII</p> activity{/NP_6} by {NP_C_7}<c>3,4-dihydroxybenzaldehyde</c>{/NP_C_7} {VP_act_8}purified{/VP_act_8} from {NP_9}<c>Xanthium</c> strumarium{/NP_9} .

{NP_10}AB{/NP_10} - {NP_11}The <p>CKII</p> inhibitory <Bpcf>compound</Bpcf>{/NP_11} {VP_pass_12}was purified{/VP_pass_12} from {NP_13}the fruit{/NP_13} of {NP_14}<c>Xanthium</c> strumarium{/NP_14} by {NP_15}organic solvent extraction{/NP_15} and {NP_16}silica gel chromatography{/NP_16} .

{NP_17}The inhibitory <Bpcf>compound</Bpcf>{/NP_17} {VP_pass_18}was identified{/VP_pass_18} as {NP_C_19}<c>3,4-dihydroxybenzaldehyde</c>{/NP_C_19} by {NP_20}analysis{/NP_20} with {NP_B_21}<B>FT-IR</B>{/NP_B_21} , {NP_P_22}<p>FAB-Mass</p>{/NP_P_22} , {NP_P_23}<p>EI-Mass</p>{/NP_P_23} , (1) {NP_B_24}<B>H-NMR</B>{/NP_B_24} and {NP_C_25}( 13 ) <c>C-NMR. 3,4-dihydroxybenzaldehyde</c>{/NP_C_25} {VP_act_26}inhibited{/VP_act_26} {NP_27}the <p>phosphotransferase</p> activity{/NP_27} of {NP_P_28}<p>CKII</p>{/NP_P_28} with {NP_B_29}<B>IC ( 50 )</B>{/NP_B_29} of about {NP_30}783 microM{/NP_30} .

OUTPUT 0
PTM = ({NP_P_37};substrate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_31}Steady-state studies{/NP_31} {VP_act_32}revealed{/VP_act_32} that {NP_P_33}the <Bppf>inhibitor</Bppf>{/NP_P_33} {VP_act_34}acts{/VP_act_34} as {NP_P_35}a competitive <Bppf>inhibitor</Bppf>{/NP_P_35} with {NP_36}respect{/NP_36} to {NP_P_37}the <Bppf>substrate</Bppf> <p>ATP</p>{/NP_P_37} .

{NP_38}A value{/NP_38} of {NP_39}138.6 microM{/NP_39} {VP_pass_40}was obtained{/VP_pass_40} for {NP_B_41}the apparent <B>K(i)</B>{/NP_B_41} .

{NP_42}Concentration{/NP_42} of {NP_43}300 microM 3,4-dihydroxybenzaldehyde{/NP_43} {VP_act_44}caused{/VP_act_44} {NP_45}50% growth inhibition{/NP_45} of {NP_46}<s>human</s> <c>cancer cell U937. 3,4-dihydroxybenzaldehyde</c> -induced <Bpcl>cell</Bpcl> death{/NP_46} {VP_pass_47}was characterised{/VP_pass_47} with {NP_48}the cleavage{/NP_48} of {NP_P_49}poly ( <B>ADP-ribose</B> ) <p>polymerase</p>{/NP_P_49} and {JP_50}procaspase-3{/JP_50} .

{AV_51}Furthermore{/AV_51} , {NP_P_52}the <Bppf>inhibitor</Bppf>{/NP_P_52} {VP_act_53}induced{/VP_act_53} {NP_54}the fragmentation{/NP_54} of {NP_55}DNA{/NP_55} into {NP_56}multiples{/NP_56} of {NP_57}180 bp{/NP_57} , {VP_act_58}indicating{/VP_act_58} that {NP_59}it{/NP_59} {VP_act_60}triggered{/VP_act_60} {NP_61}apoptosis{/NP_61} .

{NP_62}This induction{/NP_62} of {NP_63}apoptosis{/NP_63} by {NP_C_64}<c>3,4-dihydroxybenzaldehyde</c>{/NP_C_64} {VP_pass_65}was also confirmed{/VP_pass_65} by {VP_act_66}using{/VP_act_66} {NP_67}flow cytometry analysis{/NP_67} .

Since {NP_P_68}<p>CKII</p>{/NP_P_68} {VP_pass_69}is involved{/VP_pass_69} in {NP_70}<Bpcl>cell</Bpcl> proliferation and oncogenesis{/NP_70} , {NP_71}these results{/NP_71} {VP_act_72}suggest{/VP_act_72} that {NP_C_73}<c>3,4-dihydroxybenzaldehyde</c>{/NP_C_73} {VP_act_74}may function{/VP_act_74} by {VP_act_75}inhibiting{/VP_act_75} {NP_76}oncogenic disease{/NP_76} , {JP_77}atleast{/JP_77} in {NP_78}part{/NP_78} , through {NP_79}the inhibition{/NP_79} of {NP_80}<p>CKII</p> activity{/NP_80} .


{NP_1}PMID{/NP_1} - {CP_2}19024942{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}Milk{/NP_4} and {NP_5}dairy <Bpf>products</Bpf>{/NP_5} for {NP_6}<s>human</s> nutrition{/NP_6} : {NP_7}contribution{/NP_7} of {NP_8}technology{/NP_8} ] .

{NP_9}AB{/NP_9} - {NP_10}The <Bpf>complex</Bpf> composition{/NP_10} of {NP_11}milk{/NP_11} {VP_act_12}has led{/VP_act_12} to {NP_13}the development{/NP_13} of {NP_14}innovative technological processes{/NP_14} {JP_15}such{/JP_15} as {NP_16}membrane separation{/NP_16} .

{NP_17}The dairy industry{/NP_17} {VP_pass_18}is now able{/VP_pass_18} {VP_act_19}to offer{/VP_act_19} {NP_20}consumers safe <Bpf>classical products</Bpf>{/NP_20} ( {NP_21}liquid milk{/NP_21} , {NP_22}raw-milk cheeses{/NP_22} ) with {JP_23}little{/JP_23} or {NP_24}no heat treatment{/NP_24} .

{AV_25}Indeed{/AV_25} , {NP_26}heat treatment{/NP_26} {VP_act_27}undermines{/VP_act_27} {NP_28}the organoleptic qualities and bioactivity{/NP_28} of {NP_P_29}many <Bppf>molecules</Bppf>{/NP_P_29} {VP_pass_30}found{/VP_pass_30} in {NP_31}milk{/NP_31} .

{NP_32}New technologies{/NP_32} , and {NP_33}especially membrane microfiltration{/NP_33} , {VP_act_34}have{/VP_act_34} {NP_35}allowed researchers{/NP_35} {VP_act_36}to identify{/VP_act_36} {NP_37}two <Bpcf>groups</Bpcf>{/NP_37} of {NP_P_38}milk <Bppf>proteins</Bppf>{/NP_P_38} in {NP_39}terms{/NP_39} of {NP_40}their <s>human</s> absorption kinetics{/NP_40} : {NP_P_41}slow micellar <p>casein</p>{/NP_P_41} and {NP_P_42}fast whey <Bppf>proteins</Bppf>{/NP_P_42} .

{NP_43}The highly purified <Bpf>products</Bpf>{/NP_43} {VP_act_44}thus obtained{/VP_act_44} {VP_pass_45}are used{/VP_pass_45} for {NP_46}<s>infant</s> foods{/NP_46} and {VP_act_47}slimming{/VP_act_47} {NP_48}aids{/NP_48} , and as {NP_49}functional ingredients{/NP_49} .

{NP_50}The same technologies{/NP_50} {VP_pass_51}have been applied{/VP_pass_51} {VP_act_52}to colostrum{/VP_act_52} , {VP_act_53}yielding{/VP_act_53} {NP_54}a sterile &quot{/NP_54} ; {NP_55}serocolostrum&quot{/NP_55} ; {VP_act_56}containing{/VP_act_56} {NP_PP_57}biologically active <p>immunoglobulins</p> , <p>growth factors</p> , and <pp>polypeptides</pp>{/NP_PP_57} .

{JP_58}Combined{/JP_58} with {NP_59}other separation techniques{/NP_59} , {NP_60}membrane technologies{/NP_60} {VP_act_61}should soon allow{/VP_act_61} {NP_62}the separation and purification{/NP_62} of {NP_P_63}minor milk <Bppf>proteins</Bppf>{/NP_P_63} {VP_act_64}described{/VP_act_64} as {VP_act_65}having{/VP_act_65} {NP_66}essential roles{/NP_66} in {NP_67}<c>bone calcium</c> uptake and <B>vitamin</B> transport{/NP_67} , for {NP_68}example{/NP_68} .

OUTPUT 0
PTM = ({NP_PP_89};phosphopeptides)
Inducer = ({NP_PP_89}<p>casein</p>{/NP_PP_89};-)
	Method=rule: (inducer) for phrase=[{NP_PP_89}<p>fibrinogen</p> , <p>and--alpha(S)</p> and <pp>beta <p>casein</p> phosphopeptides</pp>{/NP_PP_89}31..36|<p>casein</p>]
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_89}<pp>beta <p>casein</p> phosphopeptides</pp>{/NP_PP_89})
	Method=rule: (siteother) for phrase=[{NP_PP_89}<p>fibrinogen</p> , <p>and--alpha(S)</p> and <pp>beta <p>casein</p> phosphopeptides</pp>{/NP_PP_89}27..51|<pp>beta <p>casein</p> phosphopeptides</pp>]

{NP_69}The use{/NP_69} of {NP_70}enzymatic membrane reactors{/NP_70} {VP_act_71}has led{/VP_act_71} to {NP_72}the identification{/NP_72} of {NP_PP_73}several bioactive <Bppp>peptides</Bppp>{/NP_PP_73} , {NP_PP_74}such <Bppp>as--kappa-caseinomacropeptide</Bppp>{/NP_PP_74} , {NP_75}which{/NP_75} {VP_act_76}induces{/VP_act_76} {NP_77}<p>CCK ( cholecystokinin )</p> secretion{/NP_77} and {VP_act_78}thus regulates{/VP_act_78} {NP_79}food intake{/NP_79} and {NP_80}<Bpcf>lipid</Bpcf> assimilation{/NP_80} , {NP_B_81}--alpha ( <pp>S1</pp> ) <B>CN</B> ( 91-100 ){/NP_B_81} , {NP_82}a <Bpcf>compound</Bpcf> with <c>benzodiazepine</c> activity{/NP_82} , - - {NP_P_83}<p>kappaCN</p> ( 106-116 ){/NP_P_83} , {NP_84}which{/NP_84} {VP_act_85}has{/VP_act_85} {NP_86}anti-thrombotic activity{/NP_86} by {VP_act_87}inhibiting{/VP_act_87} {NP_88}blood platelet binding{/NP_88} to {NP_PP_89}<p>fibrinogen</p> , <p>and--alpha(S)</p> and <pp>beta <p>casein</p> phosphopeptides</pp>{/NP_PP_89} , {NP_90}which{/NP_90} {VP_pass_91}are thought{/VP_pass_91} {VP_act_92}to increase{/VP_act_92} {NP_93}iron{/NP_93} and {NP_94}<c>calcium</c> absorption{/NP_94} .


{NP_1}PMID{/NP_1} - {CP_2}19026158{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Neuroprotective effect{/NP_4} of {NP_5}<c>sodium</c> ferulate{/NP_5} and {NP_6}signal transduction mechanisms{/NP_6} in {NP_7}the aged <s>rat</s>{/NP_7} {JP_8}hippocampus{/JP_8} .

{NP_9}AB{/NP_9} - {NP_10}AIM{/NP_10} :

{VP_act_11}To investigate{/VP_act_11} whether the {VP_pass_12}age-related increase{/VP_pass_12} in {NP_13}<p>interleukin-1beta ( IL-1beta )</p> and <p>c-Jun N-terminal kinases ( JNK )</p> pathway{/NP_13} {VP_pass_14}was coupled{/VP_pass_14} with a {VP_pass_15}decrease{/VP_pass_15} in {NP_16}<Bpcl>cell</Bpcl> survival signaling pathways{/NP_16} and whether {NP_17}<B>sodium ferulate ( SF )</B> treatment{/NP_17} {VP_pass_18}was effective{/VP_pass_18} in {VP_act_19}preventing{/VP_act_19} {NP_20}these age-associated changes{/NP_20} .

{NP_21}METHODS{/NP_21} : {NP_22}<Bpcf>Groups</Bpcf>{/NP_22} of {JP_23}young{/JP_23} and {NP_24}aged <s>rats</s>{/NP_24} {VP_pass_25}were fed{/VP_pass_25} for {NP_26}4 weeks{/NP_26} on {NP_27}a diet{/NP_27} {VP_pass_28}enriched{/VP_pass_28} in {NP_B_29}<B>SF</B>{/NP_B_29} ( {NP_30}100 mg/kg{/NP_30} and {NP_31}200 mg/kg{/NP_31} per {NP_32}day{/NP_32} ) .

OUTPUT 0
PTM = ({NP_C_43};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>MKK</p>" in "{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="{NP_P_42}<p>IL-1beta</p>{/NP_P_42}" 	(Features:dist=0|pparg)
		Candidate="{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>extracellular signal-regulated kinase ( ERK1/2 )</p>" in "{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-kinase_inherently|is-substrate_elsewhere)
		Candidate="<p>MEK</p>" in "{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Akt</p>" in "{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0)
		Candidate="<p>S6 protein kinase ( p70S6K )</p>" in "{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="<p>caspase-3</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
		Candidate="<p>caspase-7</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
Substrate = ({NP_P_44}<p>c-Jun</p>{/NP_P_44};-)
	Method=rule: (substrate) for phrase=[{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}8..12|<p>c-Jun</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_P_44};phospho-<p>c-Jun</p>)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="<p>MKK</p>" in "{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="{NP_P_42}<p>IL-1beta</p>{/NP_P_42}" 	(Features:dist=0|pparg)
		Candidate="{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>extracellular signal-regulated kinase ( ERK1/2 )</p>" in "{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-kinase_inherently|is-substrate_elsewhere)
		Candidate="{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>MEK</p>" in "{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Akt</p>" in "{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0)
		Candidate="<p>S6 protein kinase ( p70S6K )</p>" in "{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="<p>caspase-3</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
		Candidate="<p>caspase-7</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
Substrate = ({NP_P_44}<p>c-Jun</p>{/NP_P_44};-)
	Method=rule:1.45.2.1.2 (substrate) for phrase=[{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}8..12|<p>c-Jun</p>]
Site = (-;-;UNK)

OUTPUT 2
PTM = ({NP_P_45};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="<p>MKK</p>" in "{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="{NP_P_42}<p>IL-1beta</p>{/NP_P_42}" 	(Features:dist=0|pparg)
		Candidate="{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>c-Jun</p>" in "{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>extracellular signal-regulated kinase ( ERK1/2 )</p>" in "{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-kinase_inherently|is-substrate_elsewhere)
		Candidate="{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>MEK</p>" in "{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Akt</p>" in "{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0)
		Candidate="<p>S6 protein kinase ( p70S6K )</p>" in "{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="<p>caspase-3</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
		Candidate="<p>caspase-7</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
Substrate = ({NP_P_46}<p>MEK</p>{/NP_P_46};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}14..56|<p>extracellular signal-regulated kinase ( ERK1/2 )</p>]
	Method=rule: (substrate) for phrase=[{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}8..10|<p>MEK</p>]
Site = (-;-;UNK)

OUTPUT 3
PTM = ({NP_P_45};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="<p>MKK</p>" in "{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="{NP_P_42}<p>IL-1beta</p>{/NP_P_42}" 	(Features:dist=0|pparg)
		Candidate="{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>c-Jun</p>" in "{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>extracellular signal-regulated kinase ( ERK1/2 )</p>" in "{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-kinase_inherently|is-substrate_elsewhere)
		Candidate="{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>MEK</p>" in "{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Akt</p>" in "{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0)
		Candidate="<p>S6 protein kinase ( p70S6K )</p>" in "{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="<p>caspase-3</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
		Candidate="<p>caspase-7</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
Substrate = ({NP_P_45}<p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}14..56|<p>extracellular signal-regulated kinase ( ERK1/2 )</p>]
	Method=rule: (substrate) for phrase=[{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}8..10|<p>MEK</p>]
Site = (-;-;UNK)

OUTPUT 4
PTM = ({NP_P_46};phospho-<p>MEK</p>)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="<p>MKK</p>" in "{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="{NP_P_42}<p>IL-1beta</p>{/NP_P_42}" 	(Features:dist=0|pparg)
		Candidate="{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>c-Jun</p>" in "{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>extracellular signal-regulated kinase ( ERK1/2 )</p>" in "{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-kinase_inherently|is-substrate_elsewhere)
		Candidate="{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Akt</p>" in "{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0)
		Candidate="<p>S6 protein kinase ( p70S6K )</p>" in "{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="<p>caspase-3</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
		Candidate="<p>caspase-7</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
Substrate = ({NP_P_46}<p>MEK</p>{/NP_P_46};-)
	Method=rule:1.45.2.1.2 (substrate) for phrase=[{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}8..10|<p>MEK</p>]
Site = (-;-;UNK)

OUTPUT 5
PTM = ({NP_P_47};phospho-<p>Akt</p>)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="<p>MKK</p>" in "{NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43}" 	(Features:dist=0)
		Candidate="{NP_P_42}<p>IL-1beta</p>{/NP_P_42}" 	(Features:dist=0|pparg)
		Candidate="{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>c-Jun</p>" in "{NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>extracellular signal-regulated kinase ( ERK1/2 )</p>" in "{NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45}" 	(Features:dist=0|is-kinase_inherently|is-substrate_elsewhere)
		Candidate="{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>MEK</p>" in "{NP_P_46}phospho-<p>MEK</p>{/NP_P_46}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0)
		Candidate="<p>S6 protein kinase ( p70S6K )</p>" in "{NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="<p>caspase-3</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
		Candidate="<p>caspase-7</p>" in "{NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50}" 	(Features:dist=0)
Substrate = ({NP_P_47}<p>Akt</p>{/NP_P_47};-)
	Method=rule:1.45.2.1.2 (substrate) for phrase=[{NP_P_47}phospho-<p>Akt</p>{/NP_P_47}8..10|<p>Akt</p>]
Site = (-;-;UNK)

OUTPUT 6
PTM = ({NP_P_48};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

At {NP_33}the end{/NP_33} of {NP_34}the period{/NP_34} of {NP_35}dietary manipulation{/NP_35} , {NP_36}Western{/NP_36} {VP_act_37}blotting{/VP_act_37} {NP_38}analysis{/NP_38} {VP_pass_39}was used{/VP_pass_39} {VP_act_40}to determine{/VP_act_40} {NP_41}the expressions{/NP_41} of {NP_P_42}<p>IL-1beta</p>{/NP_P_42} , {NP_C_43}phosphorylated <c>mitogen-activated protein kinase kinase ( <p>MKK</p> ) 4 , phospho-JNK</c>{/NP_C_43} , {NP_P_44}phospho-<p>c-Jun</p>{/NP_P_44} , {NP_P_45}phosphorylated <p>extracellular signal-regulated kinase ( ERK1/2 )</p>{/NP_P_45} , {NP_P_46}phospho-<p>MEK</p>{/NP_P_46} , {NP_P_47}phospho-<p>Akt</p>{/NP_P_47} , {NP_P_48}phosphorylated ribosomal protein <p>S6 protein kinase ( p70S6K )</p>{/NP_P_48} , and {VP_act_49}activated{/VP_act_49} {NP_P_50}<p>caspase-3</p> and <p>caspase-7</p>{/NP_P_50} .

{NP_51}Nissl staining{/NP_51} {VP_pass_52}was used{/VP_pass_52} {VP_act_53}to observe{/VP_act_53} {NP_54}the morphological change{/NP_54} in {NP_PP_55}hippocampal <pp>CA1 regions</pp>{/NP_PP_55} .

{NP_56}<Bpcf>Immunohistochemical</Bpcf> techniques{/NP_56} for {NP_P_57}<p>glial fibrillary acidic protein ( GFAP )</p> and <p>integrin alphaM (OX-42)</p>{/NP_P_57} {VP_pass_58}were used{/VP_pass_58} {VP_act_59}to determine{/VP_act_59} {NP_60}the <S>astrocyte</S> and microglia activation{/NP_60} .

OUTPUT 7
PTM = ({NP_P_62};phospho-<p>MKK4</p>)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>IL-1beta protein</p>" in "{NP_P_62}<p>IL-1beta protein</p> levels , and phospho-<p>MKK4</p>{/NP_P_62}" 	(Features:dist=0)
		Candidate="<p>c-Jun</p>" in "{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>JNK1/2</p>" in "{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_62}<p>MKK4</p>{/NP_P_62};-)
	Method=rule:1.45.2.1.2 (substrate) for phrase=[{NP_P_62}<p>IL-1beta protein</p> levels , and phospho-<p>MKK4</p>{/NP_P_62}33..36|<p>MKK4</p>]
Site = (-;-;UNK)

OUTPUT 8
PTM = ({NP_P_63};phospho-<p>JNK1/2</p>)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>IL-1beta protein</p>" in "{NP_P_62}<p>IL-1beta protein</p> levels , and phospho-<p>MKK4</p>{/NP_P_62}" 	(Features:dist=0)
		Candidate="<p>MKK4</p>" in "{NP_P_62}<p>IL-1beta protein</p> levels , and phospho-<p>MKK4</p>{/NP_P_62}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>c-Jun</p>" in "{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>JNK1/2</p>" in "{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_63}<p>c-Jun</p>{/NP_P_63};-)
	Method=rule:1.45.2.1.5 (substrate) for phrase=[{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}26..30|<p>c-Jun</p>]
	Method=rule:1.45.2.1.2 (substrate) for phrase=[{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}8..13|<p>JNK1/2</p>]
Site = (-;-;UNK)

OUTPUT 9
PTM = ({NP_P_63};phospho-<p>JNK1/2</p>)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>IL-1beta protein</p>" in "{NP_P_62}<p>IL-1beta protein</p> levels , and phospho-<p>MKK4</p>{/NP_P_62}" 	(Features:dist=0)
		Candidate="<p>MKK4</p>" in "{NP_P_62}<p>IL-1beta protein</p> levels , and phospho-<p>MKK4</p>{/NP_P_62}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>c-Jun</p>" in "{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>JNK1/2</p>" in "{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_63}<p>JNK1/2</p>{/NP_P_63};-)
	Method=rule:1.45.2.1.5 (substrate) for phrase=[{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}26..30|<p>c-Jun</p>]
	Method=rule:1.45.2.1.2 (substrate) for phrase=[{NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63}8..13|<p>JNK1/2</p>]
Site = (-;-;UNK)

{NP_61}RESULTS{/NP_61} : {NP_P_62}<p>IL-1beta protein</p> levels , and phospho-<p>MKK4</p>{/NP_P_62} , {NP_P_63}phospho-<p>JNK1/2</p> , and phospho-<p>c-Jun</p>{/NP_P_63} {VP_pass_64}were significantly enhanced{/VP_pass_64} in {JP_65}hippocampus prepared{/JP_65} from {NP_66}age-matched control <s>rats</s>{/NP_66} .

{NP_67}Increased <p>IL-1beta</p> production and <p>JNK1/2</p> activation{/NP_67} {VP_pass_68}was accompanied{/VP_pass_68} by {NP_69}downregulation{/NP_69} of {NP_70}<p>MEK/ERK1/2</p> pathway and <p>Akt/p70S6K</p> pathway{/NP_70} , {VP_act_71}leading{/VP_act_71} to {NP_72}<Bpcl>cell</Bpcl> apoptosis{/NP_72} {VP_pass_73}assessed{/VP_pass_73} by {NP_74}activation{/NP_74} of {NP_P_75}<p>caspase-3</p>{/NP_P_75} .

{AV_76}Significantly{/AV_76} , {NP_77}treatment{/NP_77} of {NP_78}aged <s>rats</s>{/NP_78} with {NP_B_79}<B>SF</B>{/NP_B_79} ( {NP_80}100 mg/kg{/NP_80} and {NP_81}200 mg/kg{/NP_81} per {NP_82}day{/NP_82} ) for {NP_83}4 weeks{/NP_83} {VP_act_84}prevented{/VP_act_84} the {VP_pass_85}agerelated increase{/VP_pass_85} in {NP_86}<p>IL-1beta</p> and <p>IL-1beta</p> -induced <p>JNK</p> signaling pathway{/NP_86} and {AV_87}also{/AV_87} {NP_88}the age-related changes{/NP_88} in {NP_P_89}<p>ERK</p> and <p>Akt kinase</p>{/NP_P_89} .

{NP_90}CONCLUSION{/NP_90} : {NP_B_91}<B>SF</B>{/NP_B_91} {VP_act_92}plays{/VP_act_92} {NP_93}neuroprotective roles{/NP_93} through {NP_94}suppression{/NP_94} of {NP_95}<p>IL-1beta</p> and <p>IL-1beta</p> -induced <p>JNK</p> signaling{/NP_95} and {NP_96}upregulation{/NP_96} of {NP_97}<p>MEK/ERK1/2</p> and <p>Akt/p70S6K</p> survival pathways{/NP_97} .

NORM=c jun
SYNONYM=c-Jun


{NP_1}PMID{/NP_1} - {CP_2}19026161{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Hypoxia{/NP_4} {VP_act_5}confers{/VP_act_5} {NP_6}protection{/NP_6} against {NP_7}apoptosis{/NP_7} via {NP_8}the <p>PI3K/Akt</p> pathway{/NP_8} in {NP_9}endothelial <Bpcl>progenitor cells</Bpcl>{/NP_9} .

{NP_10}AB{/NP_10} - {NP_11}AIM{/NP_11} :

{NP_12}The recruitment{/NP_12} of {NP_S_13}<S>endothelial progenitor cells ( EPC )</S>{/NP_S_13} {VP_pass_14}to ischemia{/VP_pass_14} {VP_pass_15}has recently been suggested{/VP_pass_15} as {NP_16}an important mechanism{/NP_16} of {NP_17}<Bpcl>tissue</Bpcl> repair{/NP_17} .

Although {NP_18}<Bpcl>tissue</Bpcl> ischemia{/NP_18} {VP_act_19}can facilitate{/VP_act_19} {NP_20}<S>EPC</S> mobilization , recruitment , and retention{/NP_20} at {NP_PP_21}the hypoxic <Bppp>site</Bppp>{/NP_PP_21} , {NP_22}the effects{/NP_22} of {NP_23}hypoxia{/NP_23} on {NP_24}<S>EPC</S> survival{/NP_24} {VP_pass_neg_25}are not well known{/VP_pass_neg_25} .

In {NP_26}the present study{/NP_26} , {NP_27}we{/NP_27} {VP_act_28}examined{/VP_act_28} whether {NP_29}hypoxia ( 2% O2 ){/NP_29} {VP_act_30}would suppress{/VP_act_30} {NP_31}apoptosis{/NP_31} {VP_pass_32}induced{/VP_pass_32} by {NP_33}serum withdrawal{/NP_33} and whether {NP_34}survival signals{/NP_34} , {JP_35}such{/JP_35} as {NP_36}the <p>phosphatidylinositol 3-kinase ( PI3K )/Akt</p> and <p>extracellular signal-regulated protein kinase ( ERK )</p> pathways{/NP_36} , {VP_pass_37}were involved{/VP_pass_37} in {NP_38}this process{/NP_38} .

{NP_39}METHODS{/NP_39} : After {VP_pass_40}being serum-starved{/VP_pass_40} for {NP_41}24 h{/NP_41} , {NP_S_42}<S>EPC</S>{/NP_S_42} {VP_pass_43}were cultured{/VP_pass_43} under {NP_44}normoxic or hypoxic conditions ( 2% O2 ){/NP_44} for {NP_45}24 h{/NP_45} .

{NP_46}<Bpcl>Cell</Bpcl> survival{/NP_46} {VP_pass_47}was assessed{/VP_pass_47} by {NP_48}3-{/NP_48} ( {NP_49}4,5{/NP_49} - {NP_C_50}<c>dimethylthiazol-2-yl</c>{/NP_C_50} ) {NP_51}<c>-2,5-diphenyltetrazolium bromide</c> assay{/NP_51} , {NP_52}<B>annexin V-propidium</B> iodide dual-color flow cytometry{/NP_52} , and {NP_53}<B>terminal deoxynucleotidyl transferase-mediated digoxigenin-dUTP</B> nick-end labeling assay{/NP_53} .

{NP_54}The expressions{/NP_54} of {NP_P_55}signaling <Bppf>proteins</Bppf>{/NP_P_55} {VP_pass_56}were evaluated{/VP_pass_56} by {NP_57}Western blot analysis{/NP_57} .

{NP_58}RESULTS{/NP_58} : Under {NP_59}hypoxic conditions{/NP_59} , {NP_S_60}<S>EPC</S>{/NP_S_60} {VP_pass_61}were resistant{/VP_pass_61} {VP_act_62}to apoptosis{/VP_act_62} {VP_pass_63}induced{/VP_pass_63} by {NP_64}serum starvation{/NP_64} .

OUTPUT 0
PTM = ({NP_73};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_68}the <Bppf>LY294002 inhibitor</Bppf>{/NP_P_68}" 	(Features:dist=0)
Substrate = ({NP_P_74}<p>glycogen synthase kinase -3beta</p>{/NP_P_74};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_74}<p>glycogen synthase kinase -3beta</p>{/NP_P_74}]
Site = (-;-;UNK)

{NP_65}The inhibition{/NP_65} of {NP_66}the <p>PI3K/Akt</p> pathway{/NP_66} {VP_act_67}using{/VP_act_67} {NP_P_68}the <Bppf>LY294002 inhibitor</Bppf>{/NP_P_68} {VP_act_69}prevented{/VP_act_69} {NP_70}hypoxia-inhibited apoptosis{/NP_70} in {NP_S_71}<S>EPC</S>{/NP_S_71} and {VP_act_72}altered{/VP_act_72} {NP_73}the phosphorylation state{/NP_73} of {NP_P_74}<p>glycogen synthase kinase -3beta</p>{/NP_P_74} , {NP_P_75}an effector <Bppf>protein</Bppf>{/NP_P_75} {VP_pass_76}involved{/VP_pass_76} in {NP_77}regulation{/NP_77} of {NP_78}<S>EPC</S> apoptosis{/NP_78} .

{AV_79}However{/AV_79} , {NP_B_80}<B>ERK inhibitor PD98059</B>{/NP_B_80} {VP_act_81}had{/VP_act_81} {NP_82}no significant effect{/NP_82} on {NP_83}<Bpcl>cell</Bpcl> survival{/NP_83} .

{NP_84}CONCLUSION{/NP_84} : {NP_85}Our data{/NP_85} {VP_act_86}demonstrated{/VP_act_86} that {NP_87}hypoxia{/NP_87} {VP_act_88}inhibited{/VP_act_88} {NP_89}serum withdrawal-induced apoptosis{/NP_89} in {NP_S_90}<S>EPC</S>{/NP_S_90} , {NP_91}which{/NP_91} {VP_pass_92}might be associated{/VP_pass_92} with {NP_93}the activation{/NP_93} of {NP_94}the <p>PI3K/Akt</p> pathway{/NP_94} .


{NP_1}PMID{/NP_1} - {CP_2}19025518{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>mTORC2</p>{/NP_P_4} {VP_act_5}is{/VP_act_5} {NP_P_6}the hydrophobic <p>motif kinase</p>{/NP_P_6} for {NP_P_7}<p>SGK1</p>{/NP_P_7} .

{NP_8}AB{/NP_8} - {NP_9}The activation{/NP_9} of {NP_P_10}the <p>AGC ( protein kinase A/protein kinase G/protein kinase C )- family kinase SGK1 ( serum - and glucocorticoid-induced kinase 1 )</p>{/NP_P_10} by {NP_P_11}<p>insulin</p>{/NP_P_11} via {NP_P_12}<p>PI3K ( phosphoinositide 3-kinase )</p>{/NP_P_12} {VP_act_13}signalling{/VP_act_13} {VP_pass_14}has been appreciated{/VP_pass_14} for {NP_15}almost 10 years{/NP_15} .

OUTPUT 0
PTM = ({VP_act_19};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_16}<p>PDK1 ( phosphoinositide-dependent protein kinase 1 )</p>{/NP_P_16};-)
	Method=link (kinase) for phrase=[{NP_P_16}<p>PDK1 ( phosphoinositide-dependent protein kinase 1 )</p>{/NP_P_16}]
		From: {NP_18}that{/NP_18}
		Path: refer,identity
Substrate = ({NP_PP_20}<p>SGK1</p>{/NP_PP_20};-)
	Method=rule: (substrate) for phrase=[{NP_PP_20}the <pp><p>SGK1</p> catalytic domain</pp>{/NP_PP_20}3..6|<p>SGK1</p>]
Site = (-;-;{NP_PP_20}<pp><p>SGK1</p> catalytic domain</pp>{/NP_PP_20})
	Method=rule: (siteother) for phrase=[{NP_PP_20}the <pp><p>SGK1</p> catalytic domain</pp>{/NP_PP_20}3..21|<pp><p>SGK1</p> catalytic domain</pp>]

{NP_P_16}<p>PDK1 ( phosphoinositide-dependent protein kinase 1 )</p>{/NP_P_16} , {NP_P_17}a <Bppf>kinase</Bppf>{/NP_P_17} {NP_18}that{/NP_18} {VP_act_19}phosphorylates{/VP_act_19} {NP_PP_20}the <pp><p>SGK1</p> catalytic domain</pp>{/NP_PP_20} at {NP_PP_21}<pp>Thr(256)</pp>{/NP_PP_21} , {VP_pass_22}is known{/VP_pass_22} {VP_act_23}to play{/VP_act_23} {NP_24}a critical role{/NP_24} in {NP_25}<p>SGK1</p> activation{/NP_25} .

OUTPUT 1
PTM = ({NP_30};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>hydrophobic motif</pp>" in "{NP_B_34}the so-called <pp>hydrophobic motif</pp> , or <B>HM</B>{/NP_B_34}" 	(Features:dist=0)
		Candidate="{NP_PP_31}<pp>Ser(422)</pp>{/NP_PP_31}" 	(Features:dist=0)
		Candidate="Ser(422)" in "{NP_PP_31}<pp>Ser(422)</pp>{/NP_PP_31}" 	(Features:dist=0)
		Candidate="<Bppp>site</Bppp>" in "{NP_PP_32}a <Bppp>site</Bppp>{/NP_PP_32}" 	(Features:dist=0)
		Candidate="<Bppp>domain</Bppp>" in "{NP_PP_33}the catalytic <Bppp>domain</Bppp>{/NP_PP_33}" 	(Features:dist=0)
		Candidate="{NP_P_38}the <Bppf>kinase</Bppf>{/NP_P_38}" 	(Features:dist=0|is-kinase_inherently|pparg)
Substrate = ({NP_25}<p>SGK1</p>{/NP_25};-)
	Method=features_(other_sentence) (substrate) for phrase=[{NP_25}<p>SGK1</p> activation{/NP_25}0..3|<p>SGK1</p>]
	Candidates (Substrate):
		Candidate="<p>SGK1</p>" in "{NP_25}<p>SGK1</p> activation{/NP_25}" 	(Features:dist=-1|in-title_elsewhere|is-repeated|is-substrate_elsewhere|most-repeated)
		Candidate="<pp><p>SGK1</p> catalytic domain</pp>" in "{NP_PP_20}the <pp><p>SGK1</p> catalytic domain</pp>{/NP_PP_20}" 	(Features:dist=-1)
		Candidate="<p>SGK1</p>" in "{NP_PP_20}the <pp><p>SGK1</p> catalytic domain</pp>{/NP_PP_20}" 	(Features:dist=-1|in-title_elsewhere|is-repeated|is-substrate|most-repeated)
		Candidate="{NP_P_10}the <p>AGC ( protein kinase A/protein kinase G/protein kinase C )- family kinase SGK1 ( serum - and glucocorticoid-induced kinase 1 )</p>{/NP_P_10}" 	(Features:dist=-2|is-repeated|pparg)
		Candidate="<p>AGC ( protein kinase A/protein kinase G/protein kinase C )- family kinase SGK1 ( serum - and glucocorticoid-induced kinase 1 )</p>" in "{NP_P_10}the <p>AGC ( protein kinase A/protein kinase G/protein kinase C )- family kinase SGK1 ( serum - and glucocorticoid-induced kinase 1 )</p>{/NP_P_10}" 	(Features:dist=-2|is-repeated|pparg)
		Candidate="{NP_P_11}<p>insulin</p>{/NP_P_11}" 	(Features:dist=-2|is-repeated)
		Candidate="{NP_P_12}<p>PI3K ( phosphoinositide 3-kinase )</p>{/NP_P_12}" 	(Features:dist=-2|is-repeated)
		Candidate="{NP_P_16}<p>PDK1 ( phosphoinositide-dependent protein kinase 1 )</p>{/NP_P_16}" 	(Features:dist=-1|is-kinase|is-repeated|subject_main|subject_main_modifier)
		Candidate="{NP_P_17}a <Bppf>kinase</Bppf>{/NP_P_17}" 	(Features:dist=-1|is-kinase_inherently)
		Candidate="{NP_P_38}the <Bppf>kinase</Bppf>{/NP_P_38}" 	(Features:dist=0|is-kinase_inherently|pparg)
Site = ({NP_PP_31}422{/NP_PP_31};{NP_PP_31}Ser{/NP_PP_31};UNK)
	Method=rule: (site) for phrase=[{NP_PP_31}<pp>Ser(422)</pp>{/NP_PP_31}0..7|Ser(422)|Ser422]

{AV_26}However{/AV_26} , {NP_27}the identity{/NP_27} of {NP_28}the <Bppf>protein</Bppf> kinase(s){/NP_28} {JP_29}responsible{/JP_29} for {NP_30}phosphorylation{/NP_30} of {NP_PP_31}<pp>Ser(422)</pp>{/NP_PP_31} , {NP_PP_32}a <Bppp>site</Bppp>{/NP_PP_32} outside {NP_PP_33}the catalytic <Bppp>domain</Bppp>{/NP_PP_33} ( {NP_B_34}the so-called <pp>hydrophobic motif</pp> , or <B>HM</B>{/NP_B_34} ) {NP_35}that{/NP_35} {VP_act_36}promotes{/VP_act_36} {NP_37}activation{/NP_37} of {NP_P_38}the <Bppf>kinase</Bppf>{/NP_P_38} by {NP_P_39}<p>PDK1</p>{/NP_P_39} , {VP_pass_40}was unclear{/VP_pass_40} .

OUTPUT 2
PTM = ({NP_48};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = ({NP_48}422{/NP_48};{NP_48}Ser{/NP_48};UNK)
	Method=rule: (site) for phrase=[{NP_48}catalyses <pp>Ser(422)</pp> phosphorylation{/NP_48}9..16|Ser(422)|Ser422]

OUTPUT 3
PTM = ({VP_act_52};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_49}<p>mTORC2 ( mammalian target of rapamycin complex 2 )</p>{/NP_P_49};-)
	Method=link (kinase) for phrase=[{NP_P_49}<p>mTORC2 ( mammalian target of rapamycin complex 2 )</p>{/NP_P_49}]
		From: {NP_51}that{/NP_51}
		Path: refer,identity
	Method=link (kinase) for phrase=[{NP_P_50}a <p>multiprotein kinase</p>{/NP_P_50}]
		From: {NP_51}that{/NP_51}
		Path: refer
Substrate = ({NP_P_54}<p>PKB ( protein kinase B )</p>{/NP_P_54};-)
	Method=link (substrate) for phrase=[{NP_P_54}<p>PKB ( protein kinase B )</p>{/NP_P_54}]
		From: {NP_PP_53}a similar <Bppp>site</Bppp>{/NP_PP_53}
		Path: whole
Site = (-;-;{NP_PP_53}<Bppp>site</Bppp>{/NP_PP_53})
	Method=rule: (siteother) for phrase=[{NP_PP_53}a similar <Bppp>site</Bppp>{/NP_PP_53}8..11|<Bppp>site</Bppp>]

In {NP_41}work{/NP_41} {VP_pass_42}reported{/VP_pass_42} in {NP_43}this issue{/NP_43} of {NP_B_44}the <c>Biochemical Journal</c> , <B>Garcia-Martinez</B> and <B>Alessi</B>{/NP_B_44} {VP_act_45}have revealed{/VP_act_45} {NP_46}the identity{/NP_46} of {NP_P_47}a <p>'PDK2' kinase</p>{/NP_P_47} that {NP_48}catalyses <pp>Ser(422)</pp> phosphorylation{/NP_48} as {NP_P_49}<p>mTORC2 ( mammalian target of rapamycin complex 2 )</p>{/NP_P_49} , {NP_P_50}a <p>multiprotein kinase</p>{/NP_P_50} {NP_51}that{/NP_51} {VP_act_52}phosphorylates{/VP_act_52} {NP_PP_53}a similar <Bppp>site</Bppp>{/NP_PP_53} in {NP_P_54}<p>PKB ( protein kinase B )</p>{/NP_P_54} .

NORM=sgk 1
SYNONYM=SGK1


{NP_1}PMID{/NP_1} - {CP_2}19029977{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Diabetic state{/NP_4} , {NP_P_5}high <p>plasma insulin</p> and <p>angiotensin II</p>{/NP_P_5} {VP_act_6}combine{/VP_act_6} {VP_act_7}to augment{/VP_act_7} {NP_8}endothelin-1-induced vasoconstriction{/NP_8} via {NP_P_9}<p>ETA receptors</p> and <p>ERK</p>{/NP_P_9} .

{NP_10}AB{/NP_10} - {NP_11}BACKGROUND{/NP_11} AND {NP_12}PURPOSE{/NP_12} :

{NP_13}Mechanisms{/NP_13} {VP_act_14}associated{/VP_act_14} with {NP_15}the enhanced contractile response{/NP_15} {VP_pass_16}to <p>endothelin-1</p>{/VP_pass_16} in {NP_17}hyperinsulinaemic diabetes{/NP_17} {VP_pass_18}have been examined{/VP_pass_18} {VP_act_19}using{/VP_act_19} {NP_20}the <s>rat</s> aorta{/NP_20} .

{NP_21}Functions{/NP_21} for {NP_P_22}<p>angiotensin II</p>{/NP_P_22} , {NP_23}<p>endothelin-1</p> <Bppf>receptor</Bppf> expression and <p>extracellular signal-regulated kinase ( ERK )</p> have{/NP_23} {VP_pass_24}been investigated{/VP_pass_24} .

{NP_B_25}<B>EXPERIMENTAL APPROACH</B>{/NP_B_25} : {NP_26}Streptozotocin-induced diabetic <s>rats</s>{/NP_26} {VP_pass_27}were infused{/VP_pass_27} with {NP_P_28}<p>angiotensin II</p>{/NP_P_28} or , {VP_act_29}following{/VP_act_29} {NP_30}<p>insulin</p> treatment{/NP_30} , {VP_pass_31}were treated{/VP_pass_31} with {NP_32}losartan{/NP_32} , {NP_C_33}an <c><p>angiotensin II</p> receptor antagonist</c>{/NP_C_33} .

{NP_34}Contractions{/NP_34} of {NP_35}aortic strips{/NP_35} with or without {NP_36}endothelium{/NP_36} , in {NP_37}response{/NP_37} {VP_act_38}to <p>endothelin-1</p>{/VP_act_38} and {NP_P_39}<p>angiotensin II</p>{/NP_P_39} , {VP_pass_40}were examined{/VP_pass_40} in {NP_41}vitro{/NP_41} .

{NP_42}Aortic <p>ET(A) receptors</p> and <p>ERK/MEK</p> expression{/NP_42} {VP_pass_43}were measured{/VP_pass_43} by {VP_act_44}western blotting{/VP_act_44} .

{NP_B_45}<B>KEY RESULTS</B>{/NP_B_45} : {NP_46}Insulin-treated diabetic <s>rats</s>{/NP_46} {VP_act_47}exhibited{/VP_act_47} {VP_pass_48}increases{/VP_pass_48} in {NP_P_49}plasma <p>insulin</p>{/NP_P_49} , {NP_P_50}<p>angiotensin II</p>{/NP_P_50} and {JP_51}<p>endothelin-1</p>{/JP_51} .

{NP_52}The systolic blood pressure and endothelin-1-induced contractile responses{/NP_52} in {NP_53}aortae{/NP_53} in {NP_54}vitro{/NP_54} {VP_pass_55}were enhanced{/VP_pass_55} in {NP_56}insulin-treated diabetic <s>rats</s>{/NP_56} and {VP_pass_57}blunted{/VP_pass_57} by {NP_58}chronic losartan administration{/NP_58} .

{NP_B_59}<c>LY294002</c> <B>(phosphatidylinositol 3-kinase inhibitor)</B> and/or <B>PD98059 (MEK inhibitor)</B>{/NP_B_59} {VP_act_60}diminished{/VP_act_60} {NP_61}the enhanced contractile response{/NP_61} {VP_pass_62}to <p>endothelin-1</p>{/VP_pass_62} in {NP_63}aortae{/NP_63} from {NP_64}insulin-treated diabetic <s>rats</s>{/NP_64} .

OUTPUT 0
PTM = ({NP_66};phosphorylation)
	HasAgentTheme="<p>ERK</p>" in "{NP_66}endothelin-1-stimulated <p>ERK</p> phosphorylation{/NP_66}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>MEK-1/2 protein</p>" in "{NP_65}<c>ET(A)</c> and <p>ET(B) receptors</p> , <p>ERK-1/2</p> and <p>MEK-1/2 protein</p> expression{/NP_65}" 	(Features:dist=0)
		Candidate="<p>ET(B) receptors</p>" in "{NP_65}<c>ET(A)</c> and <p>ET(B) receptors</p> , <p>ERK-1/2</p> and <p>MEK-1/2 protein</p> expression{/NP_65}" 	(Features:dist=0)
Substrate = ({NP_66}<p>ERK</p>{/NP_66};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_66}endothelin-1-stimulated <p>ERK</p> phosphorylation{/NP_66}23..25|<p>ERK</p>]
Site = (-;-;UNK)

{NP_65}<c>ET(A)</c> and <p>ET(B) receptors</p> , <p>ERK-1/2</p> and <p>MEK-1/2 protein</p> expression{/NP_65} and {NP_66}endothelin-1-stimulated <p>ERK</p> phosphorylation{/NP_66} {VP_pass_67}were{/VP_pass_67} all {JP_68}increased{/JP_68} in {NP_69}aortae{/NP_69} from {NP_70}insulin-treated diabetic <s>rats</s>{/NP_70} .

{VP_act_71}Such increases{/VP_act_71} {VP_pass_72}were blunted{/VP_pass_72} by {NP_73}chronic losartan administration{/NP_73} .

OUTPUT 1
PTM = ({NP_79};phosphorylation)
	HasAgentTheme="<p>ERK</p>" in "{NP_79}<p>ERK</p> phosphorylation{/NP_79}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>endothelin receptors</p>" in "{NP_P_81}<p>endothelin receptors</p> and <p>ERK/MEK</p> <Bppf>proteins</Bppf>{/NP_P_81}" 	(Features:dist=0)
Substrate = ({NP_79}<p>ERK</p>{/NP_79};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_79}<p>ERK</p> phosphorylation{/NP_79}0..2|<p>ERK</p>]
Site = (-;-;UNK)

{NP_74}<p>Endothelin-1</p> -induced contraction{/NP_74} {VP_pass_75}was significantly higher{/VP_pass_75} in {NP_76}aortae{/NP_76} from {NP_B_77}<B>angiotensin II-infused diabetic rats.angiotensin II-infusion</B>{/NP_B_77} {VP_act_78}increased{/VP_act_78} {NP_79}<p>ERK</p> phosphorylation{/NP_79} , but {NP_80}the expression{/NP_80} of {NP_P_81}<p>endothelin receptors</p> and <p>ERK/MEK</p> <Bppf>proteins</Bppf>{/NP_P_81} {VP_act_82}remained{/VP_act_82} {JP_83}unchanged{/JP_83} .

{NP_84}CONCLUSIONS{/NP_84} AND {NP_B_85}<B>IMPLICATIONS</B>{/NP_B_85} : {NP_B_86}These <B>results</B>{/NP_B_86} {VP_act_87}suggest{/VP_act_87} that {NP_88}the combination{/NP_88} of {NP_P_89}high <p>plasma angiotensin II</p> and <p>insulin</p>{/NP_P_89} with {NP_90}a diabetic state{/NP_90} {VP_act_91}induced{/VP_act_91} {NP_92}enhancement{/NP_92} of {NP_93}endothelin-1-induced vasoconstriction , <p>ET(A) receptor</p> expression and <p>ERK</p> expression/activity{/NP_93} in {NP_94}the aorta{/NP_94} .

{NP_95}Losartan{/NP_95} {VP_act_96}improved{/VP_act_96} both {NP_97}the diabetes-related abnormalities{/NP_97} and {NP_98}the diabetic hypertension{/NP_98} .

NORM=erk
SYNONYM=ERK


{NP_1}PMID{/NP_1} - {CP_2}19001859{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>NFBD1/MDC1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_4} {VP_act_5}have{/VP_act_5} {NP_6}both redundant and unique roles{/NP_6} in {NP_7}the <p>ATM</p> pathway{/NP_7} .

{NP_8}AB{/NP_8} - {NP_P_9}<p>NFBD1/MDC1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_9} {VP_pass_10}are{/VP_pass_10} {NP_P_11}DNA damage checkpoint <Bppf>proteins</Bppf>{/NP_P_11} with {NP_PP_12}<pp><B>twin BRCT</B> domains</pp>{/NP_PP_12} .

In {NP_13}order{/NP_13} {VP_act_14}to determine{/VP_act_14} if {NP_15}they{/NP_15} {VP_act_16}have{/VP_act_16} {NP_17}redundant roles{/NP_17} in {NP_18}responses{/NP_18} to {VP_act_19}ionizing{/VP_act_19} {NP_20}radiation{/NP_20} , {NP_21}we{/NP_21} {VP_act_22}used{/VP_act_22} {NP_B_23}<B>siRNA</B> and <B>shRNA</B>{/NP_B_23} {VP_act_24}to deplete{/VP_act_24} {NP_P_25}<p>NFBD1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_25} in {JP_26}single{/JP_26} , {NP_27}double and triple combinations{/NP_27} .

{NP_28}These analyses{/NP_28} {VP_pass_29}were performed{/VP_pass_29} in {NP_S_30}early passage <s>human</s> <S>foreskin fibroblasts</S>{/NP_S_30} {AV_31}so{/AV_31} that {NP_32}checkpoint responses{/NP_32} {VP_pass_33}could be assessed{/VP_pass_33} in {NP_34}a normal genetic background{/NP_34} .

OUTPUT 0
PTM = ({NP_40};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>ATM</p>" in "{NP_44}ionizing radiation-induced <p>ATM</p> <pp>S1981</pp> autophosphorylation{/NP_44}" 	(Features:dist=0|in-title_elsewhere|is-autophosphorylated|is-autophosphorylated_elsewhere|is-kinase|is-kinase_elsewhere|is-substrate_elsewhere)
		Candidate="<pp>S1981</pp>" in "{NP_44}ionizing radiation-induced <p>ATM</p> <pp>S1981</pp> autophosphorylation{/NP_44}" 	(Features:dist=0|is-autophosphorylated_elsewhere)
		Candidate="S1981" in "{NP_44}ionizing radiation-induced <p>ATM</p> <pp>S1981</pp> autophosphorylation{/NP_44}" 	(Features:dist=0|is-autophosphorylated|is-autophosphorylated_elsewhere)
		Candidate="{NP_P_37}<p>NFBD1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_37}" 	(Features:dist=0|subject_subnc)
		Candidate="<p>NFBD1</p>" in "{NP_P_37}<p>NFBD1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_37}" 	(Features:dist=0)
		Candidate="<p>NFBD1</p>|<p>53BP1</p>|<p>BRCA1</p>" in "{NP_P_37}<p>NFBD1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_37}" 	(Features:dist=0|subject_subnc_modifier)
		Candidate="<p>BRCA1</p>" in "{NP_P_37}<p>NFBD1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_37}" 	(Features:dist=0)
		Candidate="<p>53BP1</p>" in "{NP_P_37}<p>NFBD1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_37}" 	(Features:dist=0)
		Candidate="<p>ATM-Chk2 pathway. 53BP1</p>" in "{NP_P_41}the <p>ATM-Chk2 pathway. 53BP1</p>{/NP_P_41}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_41}<p>ATM-Chk2 pathway. 53BP1</p>{/NP_P_41};-)
	Method=rule: (substrate) for phrase=[{NP_P_41}the <p>ATM-Chk2 pathway. 53BP1</p>{/NP_P_41}3..23|<p>ATM-Chk2 pathway. 53BP1</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_44};autophosphorylation)
Inducer = (-;-)
	Method=rule: (inducer) for phrase=[{NP_P_41}the <p>ATM-Chk2 pathway. 53BP1</p>{/NP_P_41}3..23|<p>ATM-Chk2 pathway. 53BP1</p>]
Kinase = ({NP_44}<p>ATM</p>{/NP_44};-)
	Method=autophos (kinase) for phrase=[{NP_44}ionizing radiation-induced <p>ATM</p> <pp>S1981</pp> autophosphorylation{/NP_44}25..27|<p>ATM</p>]
Substrate = ({NP_44}<p>ATM</p>{/NP_44};-)
	Method=link (substrate) for phrase=[{NP_44}ionizing radiation-induced <p>ATM</p> <pp>S1981</pp> autophosphorylation{/NP_44}25..27|<p>ATM</p>]
		From: {NP_44}ionizing radiation-induced <p>ATM</p> <pp>S1981</pp> autophosphorylation{/NP_44}28..32|<pp>S1981</pp>
		Path: whole
Site = ({NP_44}1981{/NP_44};{NP_44}Ser{/NP_44};UNK)
	Method=rule: (site) for phrase=[{NP_44}ionizing radiation-induced <p>ATM</p> <pp>S1981</pp> autophosphorylation{/NP_44}28..32|S1981|Ser1981]

{NP_35}We{/NP_35} {VP_act_36}report{/VP_act_36} that {NP_P_37}<p>NFBD1</p> , <p>53BP1</p> and <p>BRCA1</p>{/NP_P_37} {VP_act_38}have{/VP_act_38} {NP_39}both unique and redundant functions{/NP_39} in {NP_40}radiation-induced phosphorylation and localization events{/NP_40} in {NP_P_41}the <p>ATM-Chk2 pathway. 53BP1</p>{/NP_P_41} , but not {NP_P_42}<p>NFBD1</p> and <p>BRCA1</p>{/NP_P_42} , {VP_act_43}mediates{/VP_act_43} {NP_44}ionizing radiation-induced <p>ATM</p> <pp>S1981</pp> autophosphorylation{/NP_44} .

OUTPUT 2
PTM = ({NP_49};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>T68</pp>" in "{NP_49}<B>IR</B> -induced <p>Chk2</p> <pp>T68</pp> phosphorylation{/NP_49}" 	(Features:dist=0)
		Candidate="T68" in "{NP_49}<B>IR</B> -induced <p>Chk2</p> <pp>T68</pp> phosphorylation{/NP_49}" 	(Features:dist=0)
Substrate = ({NP_49}<p>Chk2</p>{/NP_49};-)
	Method=link (substrate) for phrase=[{NP_49}<B>IR</B> -induced <p>Chk2</p> <pp>T68</pp> phosphorylation{/NP_49}10..13|<p>Chk2</p>]
		From: {NP_49}<B>IR</B> -induced <p>Chk2</p> <pp>T68</pp> phosphorylation{/NP_49}14..16|<pp>T68</pp>
		Path: whole
Site = ({NP_49}68{/NP_49};{NP_49}Thr{/NP_49};UNK)
	Method=rule: (site) for phrase=[{NP_49}<B>IR</B> -induced <p>Chk2</p> <pp>T68</pp> phosphorylation{/NP_49}14..16|T68|Thr68]

In {NP_45}contrast{/NP_45} , {NP_46}all three mediators{/NP_46} {VP_act_47}collaborate{/VP_act_47} {VP_act_48}to promote{/VP_act_48} {NP_49}<B>IR</B> -induced <p>Chk2</p> <pp>T68</pp> phosphorylation{/NP_49} .

{NP_P_50}<p>NFBD1</p> and <p>53BP1</p>{/NP_P_50} , but not {NP_P_51}<p>BRCA1</p>{/NP_P_51} , {NP_52}work{/NP_52} {AV_53}together{/AV_53} {VP_act_54}to mediate{/VP_act_54} {NP_B_55}<B>pATMS1981</B> , <p>pChk2T68</p> and <B>NBS1 ionizing radiation induced foci ( IRIF )</B>{/NP_B_55} .

{AV_56}However{/AV_56} , {NP_57}the relative importance{/NP_57} of {NP_P_58}<p>NFBD1</p> and <p>53BP1</p>{/NP_P_58} in {NP_59}<B>IRIF</B> formation{/NP_59} {VP_act_60}differ{/VP_act_60} .

{NP_61}We{/NP_61} {VP_act_62}also determined{/VP_act_62} {NP_63}the interdependence{/NP_63} among {NP_64}mediators{/NP_64} in {NP_65}<B>IRIF</B> recruitment{/NP_65} .

{NP_66}We{/NP_66} {VP_act_67}extend{/VP_act_67} {NP_68}previous findings{/NP_68} in {NP_69}<Bpcl>cancer cells</Bpcl> and <Bpcl><s>mouse</s> cells</Bpcl>{/NP_69} that {NP_P_70}<p>NFBD1</p>{/NP_P_70} {VP_pass_71}is upstream{/VP_pass_71} of {NP_P_72}<p>53BP1</p> and <p>BRCA1</p>{/NP_P_72} to {NP_73}primary <s>human</s> <Bpcl>cells</Bpcl>{/NP_73} .

{AV_74}Furthermore{/AV_74} , {NP_P_75}<p>NFBD1</p>{/NP_P_75} {VP_act_76}promotes{/VP_act_76} {NP_B_77}<B><p>BRCA1</p> IRIF</B>{/NP_B_77} through {NP_78}both <p>53BP1</p> -dependent and <B>53BP1-independent</B> mechanisms{/NP_78} .


{NP_1}PMID{/NP_1} - {CP_2}19001871{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Identification{/NP_4} of {NP_P_5}<p>beta-catenin</p>{/NP_P_5} as {NP_P_6}a novel <Bppf>substrate</Bppf>{/NP_P_6} of {NP_P_7}<p>Polo-like kinase 1</p>{/NP_P_7} .

OUTPUT 0
PTM = ({NP_18};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_8}AB{/NP_8} - {NP_P_9}<p>Polo-like kinase 1 ( Plk1 )</p>{/NP_P_9} {VP_act_10}is{/VP_act_10} {NP_P_11}a <Bppf>serine/threonine kinase</Bppf>{/NP_P_11} {NP_12}that{/NP_12} {VP_act_13}plays{/VP_act_13} {NP_14}an important role{/NP_14} in {NP_15}<B>M phase</B> progression{/NP_15} by {VP_act_16}regulating{/VP_act_16} {NP_P_17}various downstream <Bppf>substrates</Bppf>{/NP_P_17} via {NP_18}phosphorylation{/NP_18} .

OUTPUT 1
PTM = ({NP_PP_28};phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_29}<p>Plk1</p>{/NP_P_29};-)
	Method=rule:1.40.1 (kinase) for phrase=[{NP_P_29}<p>Plk1</p>{/NP_P_29}]
Substrate = ({NP_P_35}<p>beta-catenin</p>{/NP_P_35};-)
	Method=link (substrate) for phrase=[{NP_P_35}<p>beta-catenin</p>{/NP_P_35}]
		From: {NP_PP_26}<pp>Ser-718</pp>{/NP_PP_26}0..6|Ser-718|Ser718
		Path: lexicalid,substrate|lexicalid,whole
Site = (-;-;{NP_PP_28}<Bppp>phosphorylation site</Bppp>{/NP_PP_28})
({NP_PP_26}718{/NP_PP_26};{NP_PP_26}Ser{/NP_PP_26};UNK)
	Method=link (site) for phrase=[{NP_PP_26}<pp>Ser-718</pp>{/NP_PP_26}0..6|Ser-718|Ser718]
		From: {NP_PP_28}a <Bppp>phosphorylation site</Bppp>{/NP_PP_28}
		Path: identity
	Method=rule: (siteother) for phrase=[{NP_PP_28}a <Bppp>phosphorylation site</Bppp>{/NP_PP_28}1..19|<Bppp>phosphorylation site</Bppp>]

OUTPUT 2
PTM = ({NP_P_31};phospho-<p>specific antibody</p>)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
	Method=rule:1.45.2.1.2 (substrate) for phrase=[{NP_P_31}a phospho-<p>specific antibody</p>{/NP_P_31}9..24|<p>specific antibody</p>]
Site = (-;-;UNK)

OUTPUT 3
PTM = ({NP_PP_33};phosphorylation)
Inducer = (-;-)
	Method=rule: (inducer) for phrase=[{NP_PP_33}<pp><p>Plk1</p> -dependent phosphorylation sites</pp>{/NP_PP_33}0..3|<p>Plk1</p>]
Kinase = ({NP_PP_33}<p>Plk1</p>{/NP_PP_33};-)
	Method=inducer_is_kinase (kinase) for phrase=[{NP_PP_33}<pp><p>Plk1</p> -dependent phosphorylation sites</pp>{/NP_PP_33}0..3|<p>Plk1</p>]
Substrate = (-;-)
Site = (-;-;{NP_PP_33}<pp><p>Plk1</p> -dependent phosphorylation sites</pp>{/NP_PP_33})
	Method=rule: (siteother) for phrase=[{NP_PP_33}<pp><p>Plk1</p> -dependent phosphorylation sites</pp>{/NP_PP_33}]

{AV_19}Here{/AV_19} , {NP_20}we{/NP_20} {VP_act_21}identified{/VP_act_21} {NP_P_22}<p>beta-catenin</p>{/NP_P_22} as {NP_P_23}a novel <Bppf>substrate</Bppf>{/NP_P_23} of {NP_P_24}<p>Plk1</p>{/NP_P_24} and {VP_act_25}determined{/VP_act_25} that {NP_PP_26}<pp>Ser-718</pp>{/NP_PP_26} {VP_act_27}is{/VP_act_27} {NP_PP_28}a <Bppp>phosphorylation site</Bppp>{/NP_PP_28} for {NP_P_29}<p>Plk1</p>{/NP_P_29} by {VP_act_30}using{/VP_act_30} {NP_P_31}a phospho-<p>specific antibody</p>{/NP_P_31} that {NP_32}cross-reacts{/NP_32} with {NP_PP_33}<pp><p>Plk1</p> -dependent phosphorylation sites</pp>{/NP_PP_33} .

OUTPUT 4
PTM = ({VP_pass_36};phosphorylated)
Inducer = (-;-)
Kinase = ({NP_P_37}<p>Plk1</p>{/NP_P_37};-)
	Method=rule: (kinase) for phrase=[{NP_P_37}recombinant <p>Plk1</p>{/NP_P_37}11..14|<p>Plk1</p>]
Substrate = ({NP_P_35}<p>beta-catenin</p>{/NP_P_35};-)
	Method=link (substrate) for phrase=[{NP_P_35}<p>beta-catenin</p>{/NP_P_35}]
		From: {NP_PP_34}<pp>Ser-718</pp>{/NP_PP_34}
		Path: whole
Site = ({NP_PP_34}718{/NP_PP_34};{NP_PP_34}Ser{/NP_PP_34};UNK)
	Method=rule: (site) for phrase=[{NP_PP_34}<pp>Ser-718</pp>{/NP_PP_34}0..6|Ser-718|Ser718]

OUTPUT 5
PTM = ({NP_39};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_PP_34}<pp>Ser-718</pp>{/NP_PP_34} of {NP_P_35}<p>beta-catenin</p>{/NP_P_35} {VP_pass_36}was directly phosphorylated{/VP_pass_36} by {NP_P_37}recombinant <p>Plk1</p>{/NP_P_37} in {NP_38}vitro{/NP_38} , with {NP_39}the phosphorylation signal{/NP_39} in {NP_40}<Bpcl>cells</Bpcl>{/NP_40} {VP_act_41}increasing{/VP_act_41} with {NP_42}overexpression{/NP_42} of {NP_P_43}<p>Plk1</p>{/NP_P_43} and {VP_act_44}decreasing{/VP_act_44} when {NP_P_45}endogenous <p>Plk1</p>{/NP_P_45} {VP_pass_46}was depleted{/VP_pass_46} by {VP_act_47}small interfering{/VP_act_47} {NP_48}RNA{/NP_48} .

OUTPUT 6
PTM = ({NP_49};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_PP_50}<pp>Ser-718</pp>{/NP_PP_50}" 	(Features:dist=0)
		Candidate="Ser-718" in "{NP_PP_50}<pp>Ser-718</pp>{/NP_PP_50}" 	(Features:dist=0)
		Candidate="{NP_P_53}<p>Plk1</p>{/NP_P_53}" 	(Features:dist=0|is-kinase_elsewhere|pparg)
Substrate = ({NP_P_35}<p>beta-catenin</p>{/NP_P_35};-)
	Method=link (substrate) for phrase=[{NP_P_35}<p>beta-catenin</p>{/NP_P_35}]
		From: {NP_PP_50}<pp>Ser-718</pp>{/NP_PP_50}0..6|Ser-718|Ser718
		Path: lexicalid,lexicalid,substrate|lexicalid,lexicalid,whole|lexicalid,substrate|lexicalid,whole
Site = ({NP_PP_50}718{/NP_PP_50};{NP_PP_50}Ser{/NP_PP_50};UNK)
	Method=rule: (site) for phrase=[{NP_PP_50}<pp>Ser-718</pp>{/NP_PP_50}0..6|Ser-718|Ser718]

{NP_49}The phosphorylation{/NP_49} at {NP_PP_50}<pp>Ser-718</pp>{/NP_PP_50} {VP_pass_51}was correlated{/VP_pass_51} with {NP_52}the cell cycle -dependent expression{/NP_52} of {NP_P_53}<p>Plk1</p>{/NP_P_53} {NP_54}which{/NP_54} {VP_act_55}reached{/VP_act_55} {NP_56}a maximum{/NP_56} in {NP_B_57}<B>M phase</B>{/NP_B_57} .

{NP_58}We{/NP_58} {VP_act_59}also confirmed{/VP_act_59} that there {VP_act_60}is{/VP_act_60} {NP_61}a physical interaction{/NP_61} between {NP_P_62}<p>beta-catenin</p> and <p>Plk1</p>{/NP_P_62} {VP_act_63}using{/VP_act_63} {NP_64}coimmunoprecipitation{/NP_64} and {NP_65}a <p>GST</p> pull-down assay{/NP_65} .

{NP_66}These results{/NP_66} {VP_act_67}demonstrate{/VP_act_67} that {NP_P_68}<p>beta-catenin</p>{/NP_P_68} {VP_act_69}is{/VP_act_69} {NP_P_70}a physiological <Bppf>substrate</Bppf>{/NP_P_70} of {NP_P_71}<p>Plk1</p>{/NP_P_71} in {NP_72}<Bpcl>cells</Bpcl>{/NP_72} , {NP_73}which{/NP_73} {VP_act_74}may provide{/VP_act_74} {NP_75}a novel insight{/NP_75} into {NP_76}the role{/NP_76} of {NP_P_77}<p>beta-catenin</p>{/NP_P_77} in {NP_B_78}<B>M phase</B>{/NP_B_78} .

NORM=plk 1
SYNONYM=Plk1


{NP_1}PMID{/NP_1} - {CP_2}19001874{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}DNA damage response activation{/NP_4} in {NP_S_5}<s>mouse</s> embryonic <S>fibroblasts</S>{/NP_S_5} {VP_act_6}undergoing{/VP_act_6} {NP_7}replicative senescence{/NP_7} and {VP_act_8}following{/VP_act_8} {NP_9}spontaneous immortalization{/NP_9} .

{NP_10}AB{/NP_10} - {NP_S_11}Primary <S><s>mouse</s> embryonic fibroblasts ( MEFs )</S>{/NP_S_11} {VP_pass_12}are{/VP_pass_12} {NP_13}a popular tool{/NP_13} for {NP_14}molecular and <Bpcl>cell</Bpcl> biology studies{/NP_14} .

{AV_15}However{/AV_15} , when {NP_S_16}<S>MEFs</S>{/NP_S_16} {VP_pass_17}are grown{/VP_pass_17} in {NP_18}vitro{/NP_18} under {NP_19}standard <Bpcl>tissue culture</Bpcl> conditions{/NP_19} , {NP_20}they{/NP_20} {VP_act_21}proliferate{/VP_act_21} {AV_22}only{/AV_22} for {NP_23}a limited number{/NP_23} of {NP_B_24}<B>population doublings ( PD )</B>{/NP_B_24} and {VP_act_25}eventually undergo{/VP_act_25} {NP_26}cellular senescence{/NP_26} .

{AV_27}Presently{/AV_27} , {NP_28}the molecular mechanisms{/NP_28} {VP_act_29}halting{/VP_act_29} {NP_30}cell cycle progression{/NP_30} and {VP_act_31}establishing{/VP_act_31} {NP_32}cellular senescence{/NP_32} under {NP_33}these conditions{/NP_33} {VP_pass_34}are unclear{/VP_pass_34} .

{AV_35}Here{/AV_35} , {NP_36}we{/NP_36} {VP_act_37}show{/VP_act_37} that {NP_B_38}a robust <B>DNA damage response ( DDR )</B>{/NP_B_38} {VP_pass_39}is activated{/VP_pass_39} when {NP_S_40}<S>MEFs</S>{/NP_S_40} {VP_act_41}undergo{/VP_act_41} {NP_42}replicative cellular senescence{/NP_42} .

OUTPUT 0
PTM = ({NP_P_49};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>substrates</p>" in "{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}" 	(Features:dist=0)
		Candidate="<p>gammaH2AX</p>" in "{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_49}<p>gammaH2AX</p>{/NP_P_49};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}17..26|<p>substrates</p>]
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}30..38|<p>gammaH2AX</p>]
	Filtered={NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}17..26|<p>substrates</p>	(Category=generic)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}17..26|<p>substrates</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_P_49};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>substrates</p>" in "{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}" 	(Features:dist=0)
		Candidate="<p>gammaH2AX</p>" in "{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = (-;-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}17..26|<p>substrates</p>]
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}30..38|<p>gammaH2AX</p>]
	Filtered={NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}17..26|<p>substrates</p>	(Category=generic)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49}17..26|<p>substrates</p>]
Site = (-;-;UNK)

{NP_43}Senescent <Bpcl>cells</Bpcl>{/NP_43} {VP_act_44}accumulate{/VP_act_44} {NP_B_45}<B>senescence-associated DDR foci ( SDFs )</B>{/NP_B_45} {VP_act_46}containing{/VP_act_46} {NP_47}the activated form{/NP_47} of {NP_P_48}<p>ATM</p>{/NP_P_48} , {NP_P_49}its phosphorylated <p>substrates</p> and <p>gammaH2AX</p>{/NP_P_49} .

In {NP_S_50}senescent <S>MEFs</S>{/NP_S_50} , {NP_51}<B>DDR</B> markers{/NP_51} {VP_pass_neg_52}do not preferentially accumulate{/VP_pass_neg_52} at {NP_53}telomeres{/NP_53} , {NP_54}the end{/NP_54} of {NP_P_55}linear <Bppf>chromosomes</Bppf>{/NP_P_55} .

{NP_56}It{/NP_56} {VP_pass_57}has been observed{/VP_pass_57} that {NP_58}proliferation{/NP_58} of {NP_S_59}<S>MEFs</S>{/NP_S_59} {VP_pass_60}is extended{/VP_pass_60} if {NP_61}they{/NP_61} {VP_pass_62}are cultured{/VP_pass_62} at {NP_63}low <c>oxygen</c> tension ( 3% <B>O(2)</B> ){/NP_63} .

{NP_64}We{/NP_64} {VP_act_65}observed{/VP_act_65} that under {NP_66}these conditions{/NP_66} , {NP_B_67}<B>DDR</B>{/NP_B_67} {VP_pass_neg_68}is not observed{/VP_pass_neg_68} and {NP_69}senescence{/NP_69} {VP_pass_neg_70}is not established{/VP_pass_neg_70} .

{AV_71}Importantly{/AV_71} , {NP_72}inactivation{/NP_72} of {NP_P_73}<p>ATM</p>{/NP_P_73} in {NP_S_74}senescent <S>MEFs</S>{/NP_S_74} {VP_act_75}allows{/VP_act_75} {VP_act_76}escape{/VP_act_76} from {NP_77}senescence and progression{/NP_77} through {NP_78}the S-phase{/NP_78} .

{AV_79}Therefore{/AV_79} , {NP_S_80}<S>MEFs</S>{/NP_S_80} {VP_act_81}undergoing{/VP_act_81} {NP_82}cellular senescence{/NP_82} {VP_act_83}arrest{/VP_act_83} {NP_84}their proliferation{/NP_84} {JP_85}due{/JP_85} to {NP_86}the activation{/NP_86} of {NP_87}a DNA damage checkpoint{/NP_87} {VP_pass_88}mediated{/VP_pass_88} by {NP_P_89}<p>ATM kinase</p>{/NP_P_89} .

{AV_90}Finally{/AV_90} , {NP_91}we{/NP_91} {VP_act_92}observed{/VP_act_92} that {NP_S_93}spontaneously immortalized proliferating <S>MEFs</S>{/NP_S_93} {VP_act_94}display{/VP_act_94} {NP_95}markers{/NP_95} of {NP_B_96}an activated <B>DDR</B>{/NP_B_96} , {VP_act_97}indicating{/VP_act_97} {NP_98}the presence{/NP_98} of {NP_99}chromosomal DNA damage{/NP_99} in {NP_100}these established <Bpcl>cell lines</Bpcl>{/NP_100} .


{NP_1}PMID{/NP_1} - {CP_2}19001025{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Novel cardiac apoptotic pathway{/NP_4} : {NP_5}the dephosphorylation{/NP_5} of {NP_P_6}<Bppf>apoptosis repressor</Bppf>{/NP_P_6} with {NP_PP_7}<pp><p>caspase</p> recruitment domain</pp>{/NP_PP_7} by {NP_P_8}<p>calcineurin</p>{/NP_P_8} .

{NP_9}AB{/NP_9} - {NP_10}BACKGROUND{/NP_10} :

{NP_P_11}<p>Apoptosis repressor with caspase recruitment domain ( ARC )</p>{/NP_P_11} {VP_pass_12}is abundantly expressed{/VP_pass_12} in {NP_S_13}<S>cardiomyocytes</S>{/NP_S_13} .

OUTPUT 0
PTM = ({VP_act_15};phosphorylate)
Inducer = (-;-)
Kinase = ({NP_P_14}<p>Protein kinase CK2</p>{/NP_P_14};-)
	Method=rule:1.11.1.1.1 (kinase) for phrase=[{NP_P_14}<p>Protein kinase CK2</p>{/NP_P_14}]
Substrate = ({NP_P_16}<p>ARC</p>{/NP_P_16};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_16}<p>ARC</p>{/NP_P_16}]
Site = ({NP_PP_17}149{/NP_PP_17};{NP_PP_17}Thr{/NP_PP_17};UNK)
	Method=rule: (site) for phrase=[{NP_PP_17}<pp>threonine-149</pp>{/NP_PP_17}0..12|threonine-149|Thr149]

{NP_P_14}<p>Protein kinase CK2</p>{/NP_P_14} {VP_act_15}can phosphorylate{/VP_act_15} {NP_P_16}<p>ARC</p>{/NP_P_16} at {NP_PP_17}<pp>threonine-149</pp>{/NP_PP_17} , {VP_act_18}thereby enabling{/VP_act_18} {NP_P_19}<p>ARC</p>{/NP_P_19} {VP_act_20}to antagonize{/VP_act_20} {NP_21}apoptosis{/NP_21} .

OUTPUT 1
PTM = ({NP_22};phosphorylation)
	HasAgentTheme="<p>ARC</p>" in "{NP_22}<p>ARC</p> phosphorylation{/NP_22}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_22}<p>ARC</p>{/NP_22};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_22}<p>ARC</p> phosphorylation{/NP_22}0..2|<p>ARC</p>]
Site = (-;-;UNK)

{NP_22}<p>ARC</p> phosphorylation{/NP_22} {VP_act_23}occurs{/VP_act_23} in {NP_24}a constitutive manner{/NP_24} .

{AV_25}Nevertheless{/AV_25} , {NP_S_26}<S>cardiomyocytes</S>{/NP_S_26} {VP_act_27}still undergo{/VP_act_27} {VP_act_28}apoptosis{/VP_act_28} {NP_29}that{/NP_29} {VP_pass_30}is related{/VP_pass_30} to {NP_31}cardiac diseases{/NP_31} {JP_32}such{/JP_32} as {NP_33}myocardial infarction and heart failure{/NP_33} .

Whether {NP_34}the occurrence{/NP_34} of {NP_35}apoptosis{/NP_35} {VP_pass_36}is related{/VP_pass_36} to {NP_37}the loss{/NP_37} of {NP_38}protection{/NP_38} by {NP_P_39}<p>ARC</p>{/NP_P_39} under {NP_40}pathological conditions{/NP_40} {VP_act_41}remains{/VP_act_41} {JP_42}unknown{/JP_42} .

OUTPUT 2
PTM = ({NP_45};phosphorylation)
	HasAgentTheme="<p>ARC</p>" in "{NP_45}<p>ARC</p> phosphorylation levels{/NP_45}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_45}<p>ARC</p>{/NP_45};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_45}<p>ARC</p> phosphorylation levels{/NP_45}0..2|<p>ARC</p>]
Site = (-;-;UNK)

{NP_43}METHODS{/NP_43} AND {NP_44}RESULTS{/NP_44} : {NP_45}<p>ARC</p> phosphorylation levels{/NP_45} {VP_pass_46}are decreased{/VP_pass_46} in {NP_S_47}<S>cardiomyocytes</S>{/NP_S_47} {VP_act_48}treated{/VP_act_48} with {NP_49}isoproterenol{/NP_49} or {NP_C_50}<c>aldosterone</c>{/NP_C_50} .

OUTPUT 3
PTM = ({NP_55};phosphorylation)
	HasAgentTheme="<p>ARC</p>" in "{NP_55}<p>ARC</p> phosphorylation levels{/NP_55}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_55}<p>ARC</p>{/NP_55};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_55}<p>ARC</p> phosphorylation levels{/NP_55}0..2|<p>ARC</p>]
Site = (-;-;UNK)

{NP_51}We{/NP_51} {VP_act_52}explored{/VP_act_52} {NP_53}the molecular mechanism{/NP_53} by {NP_54}which{/NP_54} {NP_55}<p>ARC</p> phosphorylation levels{/NP_55} {VP_pass_56}are decreased{/VP_pass_56} .

OUTPUT 4
PTM = ({NP_63};phosphorylation)
	HasAgentTheme="<p>ARC</p>" in "{NP_63}<p>ARC</p> phosphorylation levels{/NP_63}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_60}<p>calcineurin</p>{/NP_P_60}" 	(Features:dist=0|in-title_elsewhere|pparg)
Substrate = ({NP_63}<p>ARC</p>{/NP_63};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_63}<p>ARC</p> phosphorylation levels{/NP_63}0..2|<p>ARC</p>]
Site = (-;-;UNK)

{NP_57}Our results{/NP_57} {VP_act_58}reveal{/VP_act_58} that {NP_59}either direct incubation or coexpression{/NP_59} with {NP_P_60}<p>calcineurin</p>{/NP_P_60} {VP_act_61}leads{/VP_act_61} to a {VP_pass_62}decrease{/VP_pass_62} in {NP_63}<p>ARC</p> phosphorylation levels{/NP_63} .

OUTPUT 5
PTM = ({NP_68};phosphorylation)
	HasAgentTheme="<p>ARC</p>" in "{NP_68}<p>ARC</p> phosphorylation levels{/NP_68}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_65}<p>calcineurin</p>{/NP_P_65}" 	(Features:dist=0|in-title_elsewhere|pparg)
Substrate = ({NP_68}<p>ARC</p>{/NP_68};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_68}<p>ARC</p> phosphorylation levels{/NP_68}0..2|<p>ARC</p>]
Site = (-;-;UNK)

{NP_64}Inhibition{/NP_64} of {NP_P_65}<p>calcineurin</p>{/NP_P_65} {VP_act_66}can attenuate{/VP_act_66} {NP_67}the reduction{/NP_67} in {NP_68}<p>ARC</p> phosphorylation levels{/NP_68} on {NP_69}treatment{/NP_69} with {NP_70}isoproterenol{/NP_70} or {NP_C_71}<c>aldosterone</c>{/NP_C_71} .

OUTPUT 6
PTM = ({NP_75};phosphorylation)
	HasAgentTheme="<p>ARC</p>" in "{NP_75}<p>ARC</p> phosphorylation levels{/NP_75}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_78}<p>calcineurin</p>{/NP_P_78}" 	(Features:dist=0|in-title_elsewhere|pparg)
Substrate = ({NP_75}<p>ARC</p>{/NP_75};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_75}<p>ARC</p> phosphorylation levels{/NP_75}0..2|<p>ARC</p>]
Site = (-;-;UNK)

{NP_72}These data{/NP_72} {VP_act_73}indicate{/VP_act_73} that {NP_74}the reduction{/NP_74} in {NP_75}<p>ARC</p> phosphorylation levels{/NP_75} {VP_pass_76}is related{/VP_pass_76} to {NP_77}its dephosphorylation{/NP_77} by {NP_P_78}<p>calcineurin</p>{/NP_P_78} .

OUTPUT 7
PTM = ({NP_87};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_81}<p>ARC</p>{/NP_P_81};-)
	Method=link (substrate) for phrase=[{NP_P_81}<p>ARC</p>{/NP_P_81}]
		From: {NP_87}its phosphorylation status{/NP_87}0..2|its
		Path: refer
Site = (-;-;UNK)

{NP_79}Our results{/NP_79} {VP_act_80}further reveal{/VP_act_80} that {NP_P_81}<p>ARC</p>{/NP_P_81} {VP_act_82}can prevent{/VP_act_82} {NP_83}isoproterenol{/NP_83} - and {NP_84}aldosterone-induced apoptosis{/NP_84} , but {NP_85}this function{/NP_85} {VP_act_86}depends{/VP_act_86} on {NP_87}its phosphorylation status{/NP_87} .

{NP_88}Isoproterenol{/NP_88} and {NP_P_89}<p>aldosterone upregulate Fas ligand</p> expression , and <p>Fas ligand</p> and <p>caspase-8</p>{/NP_P_89} {VP_pass_90}are required{/VP_pass_90} for {NP_91}isoproterenol{/NP_91} and {NP_C_92}<c>aldosterone</c>{/NP_C_92} {VP_act_93}to induce{/VP_act_93} {NP_94}apoptosis{/NP_94} .

{AV_95}However{/AV_95} , {JP_96}phosphorylated{/JP_96} but not {NP_P_97}dephosphorylated <p>ARC</p>{/NP_P_97} {VP_pass_98}is able{/VP_pass_98} {VP_act_99}to inhibit{/VP_act_99} {NP_100}caspase-8-mediated apoptosis{/NP_100} .

OUTPUT 8
PTM = ({NP_P_101};Phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<Bppp>death domain</Bppp>" in "{NP_PP_110}<Bppp>death domain</Bppp>{/NP_PP_110}" 	(Features:dist=0)
		Candidate="{NP_P_109}<p>Fas-associated protein</p>{/NP_P_109}" 	(Features:dist=0|pparg)
Substrate = ({NP_P_101}<p>ARC</p>{/NP_P_101};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_101}Phosphorylated <p>ARC</p>{/NP_P_101}14..16|<p>ARC</p>]
Site = (-;-;{NP_PP_110}<Bppp>death domain</Bppp>{/NP_PP_110})

{NP_P_101}Phosphorylated <p>ARC</p>{/NP_P_101} {VP_act_102}exerts{/VP_act_102} {NP_103}its effects{/NP_103} against {NP_P_104}<p>caspase-8</p>{/NP_P_104} by {VP_act_105}directly associating{/VP_act_105} with {JP_106}procaspase-8{/JP_106} and {VP_act_107}inhibiting{/VP_act_107} {NP_108}its interaction{/NP_108} with {NP_P_109}<p>Fas-associated protein</p>{/NP_P_109} with {NP_PP_110}<Bppp>death domain</Bppp>{/NP_PP_110} .

{NP_111}CONCLUSIONS{/NP_111} : {NP_112}Our study{/NP_112} {VP_act_113}identifies{/VP_act_113} {NP_114}a novel cardiac apoptotic pathway{/NP_114} in {NP_115}which{/NP_115} {NP_P_116}<p>ARC</p>{/NP_P_116} {VP_pass_117}is dephosphorylated{/VP_pass_117} by {NP_P_118}<p>calcineurin</p>{/NP_P_118} .

{NP_119}This pathway{/NP_119} {VP_act_120}could be{/VP_act_120} {NP_121}a component{/NP_121} in {NP_122}the cardiac apoptotic machinery{/NP_122} .

NORM=arc
SYNONYM=ARC


{NP_1}PMID{/NP_1} - {CP_2}19029645{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Non-neuronal cholinergic system{/NP_4} and {NP_5}signal transduction pathways{/NP_5} {VP_pass_6}mediated{/VP_pass_6} by {NP_7}band 3{/NP_7} in {NP_8}red blood <Bpcl>cells</Bpcl>{/NP_8} .

{NP_9}AB{/NP_9} - {NP_10}BACKGROUND{/NP_10} :

{NP_P_11}<S>Non-neuronal acetylcholine ( ACh )</S> and <p>acetylcholinesterase ( AChE )</p>{/NP_P_11} {VP_pass_12}have been recognized{/VP_pass_12} in {NP_13}the past{/NP_13} .

{NP_S_14}Vascular <S>ACh</S>{/NP_S_14} {VP_pass_15}has been associated{/VP_pass_15} by {NP_16}us{/NP_16} with {NP_17}the regulation{/NP_17} of {NP_18}microcirculatory flow{/NP_18} by {VP_act_19}modulating{/VP_act_19} {NP_20}<c>nitric oxide ( NO )</c> intracellular mobilization{/NP_20} , {NP_21}metabolism ( <B>NOx</B> ){/NP_21} and {NP_22}release{/NP_22} from {NP_S_23}<S>erythrocytes</S>{/NP_S_23} , as well as {NP_24}the <c>glycolytic</c> flux{/NP_24} .

{NP_C_25}<c>Velnacrine maleate</c>{/NP_C_25} {VP_act_26}is{/VP_act_26} {NP_P_27}a well-known <Bppf>AChE inhibitor</Bppf>{/NP_P_27} {NP_28}which{/NP_28} {VP_act_29}plays{/VP_act_29} {NP_30}a competitive role{/NP_30} by {VP_act_31}decreasing{/VP_act_31} {NP_32}<c>NO</c> -mediated <S>erythrocyte</S> responses{/NP_32} .

OUTPUT 0
PTM = ({VP_act_40};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)
	Method=rule: (site) for phrase=[{NP_P_42}band 3 <Bppf>protein</Bppf>{/NP_P_42}4..4| 3|3]

OUTPUT 1
PTM = ({NP_P_48};phosphotyrosine)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)
	Method=rule: (site) for phrase=[{NP_P_48}<p>phosphotyrosine-phosphatases ( PTP )</p>{/NP_P_48}7..14|tyrosine|Tyr]

{NP_33}A plausible hypothesis{/NP_33} {VP_act_34}to explain{/VP_act_34} {NP_35}the mechanisms{/NP_35} {VP_act_36}underlying{/VP_act_36} {NP_37}those events hinges{/NP_37} on {NP_38}the NO translocation{/NP_38} among {NP_P_39}nitrosylated <Bppf>molecules</Bppf>{/NP_P_39} and {VP_act_40}phosphorylated/dephosphorylated{/VP_act_40} {NP_41}states{/NP_41} of {NP_P_42}band 3 <Bppf>protein</Bppf>{/NP_P_42} , {VP_pass_43}processed{/VP_pass_43} by {NP_44}major tyrosine{/NP_44} - {NP_P_45}<Bppf>kinases</Bppf>{/NP_P_45} ( {NP_P_46}<p>PTK</p>{/NP_P_46} : {NP_P_47}<p>p72syk</p> , <p>p53/56lyn</p> and <p>p59/61hck</p>{/NP_P_47} ) and {NP_P_48}<p>phosphotyrosine-phosphatases ( PTP )</p>{/NP_P_48} .

OUTPUT 2
PTM = ({NP_61};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_49}METHODS{/NP_49} : To {VP_act_50}assess{/VP_act_50} {NP_51}this hypothesis{/NP_51} under {NP_52}the influence{/NP_52} of {NP_C_53}<c>AChE effectors ( acetylcholine/velnacrine )</c>{/NP_C_53} , {NP_54}blood samples{/NP_54} from {NP_55}healthy donors{/NP_55} {VP_pass_56}were harvested{/VP_pass_56} and {NP_57}Western blot analysis{/NP_57} {VP_pass_58}was subsequently used{/VP_pass_58} {VP_act_59}to determine{/VP_act_59} {NP_60}the degree{/NP_60} of {NP_61}band 3 phosphorylation{/NP_61} , in {NP_62}the presence and absence{/NP_62} of {NP_P_63}<Bppf>PTK/PTP inhibitors</Bppf>{/NP_P_63} .

NO and {NP_C_64}<c>nitrites/nitrates</c>{/NP_C_64} {VP_pass_65}were quantified{/VP_pass_65} {VP_act_66}using{/VP_act_66} {NP_67}an amperometric method{/NP_67} and {NP_B_68}the <B>Griess Reaction</B>{/NP_B_68} , {AV_69}respectively{/AV_69} , in {NP_70}<S>erythrocyte</S> suspensions{/NP_70} .

{NP_71}Measurements{/NP_71} of {NP_B_72}<B>erythrocyte metabolites</B>{/NP_B_72} ( {NP_C_73}<c>2,3-bisphosphoglycerate</c>{/NP_C_73} ; {NP_P_74}<p>glyceraldehyde 3-phosphate dehydrogenase</p>{/NP_P_74} ; {NP_P_75}<p>glucose-6-phosphodehydrogenase</p>{/NP_P_75} ; {NP_C_76}<c>lactate</c>{/NP_C_76} ) , {NP_77}<p>hemoglobin</p> and cyclic nucleotides{/NP_77} {VP_pass_78}were conducted{/VP_pass_78} {AV_79}afterwards{/AV_79} .

{NP_80}RESULTS{/NP_80} : {VP_act_81}Increased{/VP_act_81} {NP_82}levels{/NP_82} of {NP_83}phosphorylated-band 3{/NP_83} {VP_act_84}obtained{/VP_act_84} upon {NP_85}<p>p72syk</p> inhibition{/NP_85} {VP_act_86}suggest{/VP_act_86} {NP_P_87}<p>p59/61hck</p> and <p>p53/56lyn</p>{/NP_P_87} as {NP_P_88}secondary involved <Bppf>kinases</Bppf>{/NP_P_88} .

As to {NP_89}<B>NO/NOx</B> quantification{/NP_89} , in {NP_90}the presence{/NP_90} of {NP_B_91}<B>PTKi</B>{/NP_B_91} {NP_92}we{/NP_92} {VP_act_93}reported{/VP_act_93} {NP_94}higher levels{/NP_94} with {NP_C_95}<c>velnacrine-AChE</c>{/NP_C_95} , as {JP_96}opposed{/JP_96} to {NP_C_97}<c>acetylcholine-AChE</c>{/NP_C_97} .

OUTPUT 3
PTM = ({NP_101};3-phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_C_98}<c>Calpeptin</c>{/NP_C_98} , {NP_P_99}a <Bppf>PTP inhibitor</Bppf>{/NP_P_99} {NP_100}which{/NP_100} {NP_101}triggers full band 3-phosphorylation{/NP_101} , {VP_act_102}led{/VP_act_102} to {NP_PP_103}the <Bppp>opposite</Bppp>{/NP_PP_103} {NP_104}NO mobilization{/NP_104} , {VP_pass_105}being reinforced{/VP_pass_105} by {NP_S_106}<S>ACh</S>{/NP_S_106} .

{NP_P_107}<p>Oxy-hemoglobin</p> , <p>glyceraldehyde 3-phosphate dehydrogenase</p> and <p>glucose-6-phosphodehydrogenase</p>{/NP_P_107} {VP_pass_108}were found{/VP_pass_108} {VP_act_109}to decrease{/VP_act_109} with {NP_S_110}<S>ACh</S>{/NP_S_110} , whereas {NP_PP_111}<pp>P50</pp>{/NP_PP_111} , {NP_C_112}<c>lactate</c>{/NP_C_112} and {NP_P_113}both <p>cGMP/cAMP</p>{/NP_P_113} {VP_act_114}happened{/VP_act_114} {VP_act_115}to increase{/VP_act_115} .

OUTPUT 4
PTM = ({NP_126};3-phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_116}CONCLUSION{/NP_116} : {NP_117}Changes{/NP_117} on {NP_118}<s>human</s> <B>erythrocyte NOx</B> mobilization{/NP_118} and {NP_119}metabolic fluxes{/NP_119} {VP_act_120}occur{/VP_act_120} under {NP_121}influence{/NP_121} of {NP_P_122}non-neuronal <p>ACh/AChE</p>{/NP_P_122} , {AV_123}in turn{/AV_123} {JP_124}dependent{/JP_124} on {NP_125}the degree{/NP_125} of {NP_126}band 3-phosphorylation{/NP_126} .

Since {NP_127}these vascular events{/NP_127} {VP_act_128}may potentially change{/VP_act_128} under {NP_129}pathological conditions{/NP_129} , {NP_130}coadjuvant <Bpcf>drugs</Bpcf>{/NP_130} {VP_pass_131}could become accessible{/VP_pass_131} in {NP_132}the setting{/NP_132} of {NP_133}microcirculation disease{/NP_133} .


{NP_1}PMID{/NP_1} - {CP_2}19029686{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Mystery{/NP_4} of {NP_5}DNA repair{/NP_5} : {NP_6}the role{/NP_6} of {NP_P_7}the <p>MRN complex</p> and <p>ATM kinase</p>{/NP_P_7} in {NP_8}DNA damage repair{/NP_8} .

{NP_9}AB{/NP_9} - {NP_P_10}<Bppf>Genomes</Bppf>{/NP_P_10} {VP_pass_11}are{/VP_pass_11} {NP_12}subject{/NP_12} to {NP_13}a number{/NP_13} of {NP_14}exogenous or endogenous <B>DNA-damaging</B> agents{/NP_14} {NP_15}that{/NP_15} {VP_act_16}cause{/VP_act_16} {NP_PP_17}<pp>DNA double-strand breaks ( DSBs )</pp>{/NP_PP_17} .

{NP_18}These critical DNA lesions{/NP_18} {VP_act_19}can result{/VP_act_19} in {NP_20}<Bpcl>cell</Bpcl> death{/NP_20} or {NP_21}a wide variety{/NP_21} of {NP_22}genetic alterations{/NP_22} , {VP_act_23}including{/VP_act_23} {NP_24}deletions{/NP_24} , {NP_25}translocations{/NP_25} , {NP_26}loss{/NP_26} of {NP_27}heterozygosity{/NP_27} , {NP_28}<Bppf>chromosome</Bppf> loss{/NP_28} , or {NP_29}<Bppf>chromosome</Bppf> fusions{/NP_29} , {NP_30}which{/NP_30} {VP_act_31}enhance{/VP_act_31} {NP_32}<Bppf>genome</Bppf> instability{/NP_32} and {VP_act_33}can trigger{/VP_act_33} {NP_34}carcinogenesis{/NP_34} .

{NP_35}The <Bpcl>cells</Bpcl>{/NP_35} {VP_act_36}have developed{/VP_act_36} {NP_37}an efficient mechanism{/NP_37} {VP_act_38}to cope{/VP_act_38} with {NP_39}DNA damages{/NP_39} by {VP_act_40}evolving{/VP_act_40} {NP_41}the DNA repair machinery{/NP_41} .

There {VP_pass_42}are{/VP_pass_42} {NP_43}2 major <B>DSB</B> repair mechanisms{/NP_43} : {NP_B_44}<B>nonhomologous end joining ( NHEJ )</B> and <B>homologous recombination ( HR )</B>{/NP_B_44} .

{NP_P_45}One <Bppf>element</Bppf>{/NP_P_45} of {NP_46}the repair machinery{/NP_46} {VP_act_47}is{/VP_act_47} {NP_P_48}the <p>MRN complex</p>{/NP_P_48} , {VP_act_49}consisting{/VP_act_49} of {NP_P_50}<p>MRE11</p> , <p>RAD50</p> and <p>NBN</p>{/NP_P_50} ( {VP_act_51}previously described{/VP_act_51} as {NP_P_52}<p>NBS1</p>{/NP_P_52} ) , which {VP_pass_53}is involved{/VP_pass_53} in {NP_54}DNA replication{/NP_54} , {NP_55}DNA repair{/NP_55} , and {VP_act_56}signaling{/VP_act_56} to {NP_57}the <Bpcl>cell</Bpcl> cycle checkpoints{/NP_57} .

{NP_58}A number{/NP_58} of {NP_P_59}<Bppf>kinases</Bppf>{/NP_P_59} , like {NP_P_60}<p>ATM ( ataxia-telangiectasia mutated )</p> , <p>ATR ( ataxia-telangiectasia and Rad-3-related )</p> , and <p>DNA PKcs ( DNA protein kinase catalytic subunit )</p>{/NP_P_60} , {VP_act_61}phosphorylate{/VP_act_61} {NP_62}various <Bppf>protein</Bppf> targets{/NP_62} in {NP_63}order{/NP_63} {VP_act_64}to repair{/VP_act_64} {NP_65}the damage{/NP_65} .

If {NP_66}the damage{/NP_66} {VP_pass_neg_67}cannot be repaired{/VP_pass_neg_67} , {NP_68}they{/NP_68} {VP_act_69}direct{/VP_act_69} {NP_70}the <Bpcl>cell</Bpcl>{/NP_70} {VP_act_71}to apoptosis{/VP_act_71} .

{NP_P_72}The <p>MRN complex</p>{/NP_P_72} as well as {NP_P_73}repair <Bppf>kinases</Bppf>{/NP_P_73} {VP_pass_74}are also involved{/VP_pass_74} in {NP_75}telomere maintenance{/NP_75} and {NP_76}<Bppf>genome</Bppf> stability{/NP_76} .

{NP_77}The dysfunction{/NP_77} of {NP_P_78}particular <Bppf>elements</Bppf>{/NP_P_78} {VP_pass_79}involved{/VP_pass_79} in {NP_80}the repair mechanisms{/NP_80} {VP_act_81}leads{/VP_act_81} to {NP_82}genome instability disorders{/NP_82} , like {NP_P_83}<B>ataxia telangiectasia ( A-T )</B> , <B>A-T-like disorder ( ATLD )</B> and <p>Nijmegen breakage syndrome ( NBS )</p>{/NP_P_83} .

{NP_P_84}The mutated <Bppf>genes</Bppf>{/NP_P_84} {JP_85}responsible{/JP_85} for {NP_86}these disorders code{/NP_86} for {NP_P_87}<Bppf>proteins</Bppf>{/NP_P_87} {NP_88}that{/NP_88} {VP_act_89}play{/VP_act_89} {NP_90}key roles{/NP_90} in {NP_91}the process{/NP_91} of {NP_92}DNA repair{/NP_92} .

{AV_93}Here{/AV_93} {NP_94}we{/NP_94} {VP_act_95}present{/VP_act_95} {NP_96}a detailed review{/NP_96} of {NP_97}current knowledge{/NP_97} on {NP_P_98}the <p>MRN complex</p>{/NP_P_98} , {NP_P_99}<Bppf>kinases</Bppf>{/NP_P_99} {VP_pass_100}engaged{/VP_pass_100} in {NP_101}DNA repair{/NP_101} , and {NP_102}genome instability disorders{/NP_102} .


{NP_1}PMID{/NP_1} - {CP_2}19029084{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Time -dependent activation{/NP_4} of {NP_P_5}<p>ERK1/2</p>{/NP_P_5} in {NP_PP_6}nerve <Bppp>terminals</Bppp>{/NP_PP_6} of {NP_7}the dentin-pulp <p>complex following bradykinin</p> treatment{/NP_7} .

OUTPUT 0
PTM = ({VP_act_19};phosphorylating)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_9}The <p>extracellular signal-regulated kinases 1 and 2 ( ERK1/2 )</p> have{/NP_9}" 	(Features:dist=0)
		Candidate="<p>extracellular signal-regulated kinases 1 and 2 ( ERK1/2 )</p>" in "{NP_9}The <p>extracellular signal-regulated kinases 1 and 2 ( ERK1/2 )</p> have{/NP_9}" 	(Features:dist=0|subject_main_modifier)
		Candidate="{NP_P_13}the inflammatory mediator <p>bradykinin ( BK )</p>{/NP_P_13}" 	(Features:dist=0)
		Candidate="<p>bradykinin ( BK )</p>" in "{NP_P_13}the inflammatory mediator <p>bradykinin ( BK )</p>{/NP_P_13}" 	(Features:dist=0)
		Candidate="<p>receptors</p>" in "{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>ion channels</p>" in "{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}" 	(Features:dist=0)
Substrate = (-;-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}0..8|<p>receptors</p>]
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}12..22|<p>ion channels</p>]
	Filtered={NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}0..8|<p>receptors</p>	(Category=generic)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}0..8|<p>receptors</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({VP_act_19};phosphorylating)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_9}The <p>extracellular signal-regulated kinases 1 and 2 ( ERK1/2 )</p> have{/NP_9}" 	(Features:dist=0)
		Candidate="<p>extracellular signal-regulated kinases 1 and 2 ( ERK1/2 )</p>" in "{NP_9}The <p>extracellular signal-regulated kinases 1 and 2 ( ERK1/2 )</p> have{/NP_9}" 	(Features:dist=0|subject_main_modifier)
		Candidate="{NP_P_13}the inflammatory mediator <p>bradykinin ( BK )</p>{/NP_P_13}" 	(Features:dist=0)
		Candidate="<p>bradykinin ( BK )</p>" in "{NP_P_13}the inflammatory mediator <p>bradykinin ( BK )</p>{/NP_P_13}" 	(Features:dist=0)
		Candidate="<p>receptors</p>" in "{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>ion channels</p>" in "{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}" 	(Features:dist=0)
Substrate = ({NP_P_20}<p>ion channels</p>{/NP_P_20};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}0..8|<p>receptors</p>]
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}12..22|<p>ion channels</p>]
	Filtered={NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}0..8|<p>receptors</p>	(Category=generic)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20}0..8|<p>receptors</p>]
Site = (-;-;UNK)

{NP_8}AB{/NP_8} - {NP_9}The <p>extracellular signal-regulated kinases 1 and 2 ( ERK1/2 )</p> have{/NP_9} {VP_pass_10}been implicated{/VP_pass_10} in {NP_11}the inflammation -dependent sensitization{/NP_11} of {NP_12}nociceptors{/NP_12} , and {NP_P_13}the inflammatory mediator <p>bradykinin ( BK )</p>{/NP_P_13} {VP_act_14}led{/VP_act_14} to {NP_15}a reduced threshold{/NP_15} in {NP_PP_16}the nociceptor <Bppp>terminals</Bppp>{/NP_PP_16} , {VP_act_17}activating{/VP_act_17} {NP_18}intracellular signaling{/NP_18} by {VP_act_19}phosphorylating{/VP_act_19} {NP_P_20}<p>receptors</p> and <p>ion channels</p>{/NP_P_20} .

{NP_21}The effects{/NP_21} of {NP_P_22}<p>BK</p>{/NP_P_22} on {NP_23}the non-transcriptional modulation{/NP_23} of {NP_P_24}the <p>ERK1/2</p>{/NP_P_24} in {NP_PP_25}the peripheral nociceptor <Bppp>terminals</Bppp>{/NP_PP_25} , {VP_act_26}including{/VP_act_26} in {NP_27}nerve endings{/NP_27} of {NP_28}the dentin-pulp <Bpf>complex</Bpf>{/NP_28} , {VP_pass_29}are unknown{/VP_pass_29} .

OUTPUT 2
PTM = ({NP_33};phosphorylation)
	HasAgentTheme="<p>ERK1/2</p>" in "{NP_33}the <p>ERK1/2</p> phosphorylation{/NP_33}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_31}<p>BK</p>{/NP_P_31}" 	(Features:dist=0|subject_main_modifier)
		Candidate="<p>BK</p>" in "{NP_P_31}<p>BK</p>{/NP_P_31}" 	(Features:dist=0|studied|subject_main_modifier)
Substrate = ({NP_33}<p>ERK1/2</p>{/NP_33};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_33}the <p>ERK1/2</p> phosphorylation{/NP_33}3..8|<p>ERK1/2</p>]
Site = (-;-;{NP_PP_34}<Bppp>terminals</Bppp>{/NP_PP_34})
	Method=rule: (siteother) for phrase=[{NP_PP_34}nerve <Bppp>terminals</Bppp>{/NP_PP_34}5..13|<Bppp>terminals</Bppp>]

{NP_30}The time -dependent effects{/NP_30} of {NP_P_31}<p>BK</p>{/NP_P_31} ( {NP_B_32}10 ( -7 ) <B>M</B>{/NP_B_32} ) on {NP_33}the <p>ERK1/2</p> phosphorylation{/NP_33} in {NP_PP_34}nerve <Bppp>terminals</Bppp>{/NP_PP_34} of {NP_35}the dentin-pulp <Bpf>complex</Bpf>{/NP_35} {VP_pass_36}were investigated{/VP_pass_36} by {NP_37}quantitative and double immunolabeling{/NP_37} with {NP_38}<Bpcl>organ</Bpcl> bath experiments{/NP_38} .

In {NP_PP_39}nerve <Bppp>terminals</Bppp>{/NP_PP_39} , {NP_40}total{/NP_40} and {NP_P_41}<p>p-ERK1/2</p>{/NP_P_41} {VP_pass_42}were detected{/VP_pass_42} .

In {NP_43}comparison{/NP_43} with {NP_44}the controls{/NP_44} , {NP_45}the numbers{/NP_45} of {NP_46}<p>p-ERK1/2-positive</p> nerve endings{/NP_46} {VP_act_47}increased{/VP_act_47} after {NP_48}1 and 3 min{/NP_48} and {VP_act_49}decreased{/VP_act_49} after {NP_50}10 min{/NP_50} of {NP_51}<p>BK</p> treatment{/NP_51} .

OUTPUT 3
PTM = ({NP_57};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_55}<p>BK</p>{/NP_P_55}" 	(Features:dist=0|subject_subnc)
		Candidate="<p>BK</p>" in "{NP_P_55}<p>BK</p>{/NP_P_55}" 	(Features:dist=0|subject_subnc|subject_subnc_modifier)
Substrate = ({NP_P_58}<p>ERK1/2</p>{/NP_P_58};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_58}<p>ERK1/2</p>{/NP_P_58}]
Site = (-;-;{NP_PP_59}<Bppp>terminals</Bppp>{/NP_PP_59})
	Method=rule: (siteother) for phrase=[{NP_PP_59}nerve <Bppp>terminals</Bppp>{/NP_PP_59}5..13|<Bppp>terminals</Bppp>]

{NP_52}Analysis{/NP_52} of {NP_53}the data{/NP_53} {VP_act_54}indicates{/VP_act_54} that {NP_P_55}<p>BK</p>{/NP_P_55} {VP_act_56}induces{/VP_act_56} {NP_57}phosphorylation-mediated local activation{/NP_57} of {NP_P_58}<p>ERK1/2</p>{/NP_P_58} in {NP_PP_59}nerve <Bppp>terminals</Bppp>{/NP_PP_59} {VP_act_60}modulating{/VP_act_60} {NP_61}nociception{/NP_61} in {NP_62}the dentin-pulp <Bpf>complex</Bpf>{/NP_62} .

NORM=erk 1/2
SYNONYM=ERK1/2


{NP_1}PMID{/NP_1} - {CP_2}19026876{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}A <p>dentin sialophosphoprotein</p> mutation{/NP_4} {NP_5}that{/NP_5} {VP_act_6}partially disrupts{/VP_act_6} {NP_7}a splice acceptor <B>site causes type II dentin</B> dysplasia{/NP_7} .

OUTPUT 0
PTM = ({NP_P_9};sialophosphoprotein)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_8}AB{/NP_8} - {NP_P_9}The <p>dentin sialophosphoprotein ( DSPP ) gene</p>{/NP_P_9} on {NP_P_10}<p>chromosome 4q21.3</p>{/NP_P_10} {VP_act_11}encodes{/VP_act_11} {NP_P_12}the major noncollagenous <Bppf>protein</Bppf>{/NP_P_12} in {NP_B_13}tooth <B>dentin</B>{/NP_B_13} .

{NP_14}<p>DSPP</p> mutations{/NP_14} {VP_pass_15}are{/VP_pass_15} {NP_16}the principal cause{/NP_16} of <B>dentin</B> dysplasia type II , {NP_17}dentinogenesis imperfecta type II , and dentinogenesis imperfecta type III{/NP_17} .

{NP_18}We{/NP_18} {VP_act_19}have identified{/VP_act_19} {NP_B_20}a <p>DSPP</p> splice junction mutation <B>(IVS2-6T &gt; G)</B>{/NP_B_20} in {NP_21}a <Bpf>family</Bpf>{/NP_21} with <B>dentin</B> dysplasia type II .

{NP_22}The primary dentition{/NP_22} {VP_pass_23}is discolored{/VP_pass_23} {JP_24}brown{/JP_24} with {NP_25}severe attrition{/NP_25} .

{NP_26}The mildly discolored permanent dentition{/NP_26} {VP_act_27}has{/VP_act_27} {NP_28}thistle-shaped pulp chambers{/NP_28} , {NP_29}pulp stones{/NP_29} , and {NP_30}eventual pulp obliteration{/NP_30} .

{NP_31}The mutation{/NP_31} {VP_act_32}is{/VP_act_32} in {NP_33}the sixth nucleotide{/NP_33} from {NP_34}the end{/NP_34} of {NP_35}intron 2{/NP_35} , {VP_act_36}perfectly segregates{/VP_act_36} with {NP_37}the disease phenotype{/NP_37} , and {VP_pass_38}is absent{/VP_pass_38} in {NP_P_39}200 normal control <Bppf>chromosomes</Bppf>{/NP_P_39} .

{NP_40}An{/NP_40} in {NP_41}vitro{/NP_41} {VP_act_42}splicing{/VP_act_42} {NP_43}assay{/NP_43} {VP_act_44}shows{/VP_act_44} that {NP_B_45}<B>pre-mRNA</B>{/NP_B_45} {VP_act_46}splicing{/VP_act_46} of {NP_P_47}the <Bppf>mutant allele</Bppf>{/NP_P_47} {VP_act_48}generates{/VP_act_48} {NP_49}<Bppf>wild-type</Bppf> <p>mRNA</p> and mRNA{/NP_49} {VP_act_50}lacking{/VP_act_50} {NP_51}exon 3{/NP_51} in {NP_52}approximately equal amounts{/NP_52} .

{VP_act_53}Skipping{/VP_act_53} {NP_54}exon 3{/NP_54} {VP_act_55}might interfere{/VP_act_55} with {NP_56}<Bppp>signal peptide</Bppp> cleavage{/NP_56} , {VP_act_57}causing{/VP_act_57} {NP_58}endoplasmic reticulum stress{/NP_58} , and {VP_act_59}also reduce{/VP_act_59} {NP_60}<p>DSPP</p> secretion{/NP_60} , {VP_act_61}leading{/VP_act_61} {VP_act_62}to haploinsufficiency{/VP_act_62} .


{NP_1}PMID{/NP_1} - {CP_2}19001138{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}B <Bpcl>cells</Bpcl>{/NP_4} {VP_act_5}drive{/VP_act_5} {NP_6}<S>lymphocyte</S> activation and expansion{/NP_6} in {NP_7}<s>mice</s>{/NP_7} with {NP_8}the <p>CD45</p> wedge mutation and <p>Fas</p> deficiency{/NP_8} .

OUTPUT 0
PTM = ({NP_12};phosphorylation)
Inducer = ({NP_P_10}<p>CD45</p>{/NP_P_10};-)
({NP_P_10}<p>Fas</p>{/NP_P_10};-)
	Method=rule: (inducer) for phrase=[{NP_P_10}<p>CD45</p> and <p>Fas</p>{/NP_P_10}0..3|<p>CD45</p>7..9|<p>Fas</p>]
Kinase = (-;-)
Substrate = (-;-)
Site = (-;{NP_12}Tyr{/NP_12};UNK)
	Method=rule: (site) for phrase=[{NP_12}<pp>tyrosine</pp> phosphorylation and apoptotic signaling pathways{/NP_12}0..7|tyrosine|Tyr]

{NP_9}AB{/NP_9} - {NP_P_10}<p>CD45</p> and <p>Fas</p>{/NP_P_10} {VP_act_11}regulate{/VP_act_11} {NP_12}<pp>tyrosine</pp> phosphorylation and apoptotic signaling pathways{/NP_12} , {AV_13}respectively{/AV_13} .

{NP_14}Mutation{/NP_14} of {NP_PP_15}an inhibitory wedge <Bppp>motif</Bppp>{/NP_PP_15} in {NP_16}<p>CD45 (E613R)</p> results{/NP_16} in {NP_S_17}hyperresponsive <S>thymocytes</S> and <S>B cells</S>{/NP_S_17} on {NP_18}the <B>C57BL/6</B> background{/NP_18} , but {NP_19}no overt autoimmunity{/NP_19} , whereas {NP_20}<p>Fas</p> deletion results{/NP_20} in {NP_21}a mild autoimmune disease{/NP_21} on {NP_22}the same genetic background{/NP_22} .

In {NP_23}this study{/NP_23} , {NP_24}we{/NP_24} {VP_act_25}show{/VP_act_25} that {NP_26}these two mutations{/NP_26} {VP_pass_27}cooperate{/VP_pass_27} in {NP_28}<s>mice</s>{/NP_28} , {VP_act_29}causing{/VP_act_29} {NP_30}early lethality{/NP_30} , {NP_31}<Bppf>autoantibody</Bppf> production{/NP_31} , and {NP_32}substantial lymphoproliferation{/NP_32} .

In {NP_33}<Bppf>double-mutant</Bppf> <s>mice</s>{/NP_33} , {NP_34}this phenotype{/NP_34} {VP_pass_35}was dependent{/VP_pass_35} on {NP_S_36}both <S>T</S> and <S>B cells</S>{/NP_S_36} .

{NP_37}T <Bpcl>cell</Bpcl> activation{/NP_37} {VP_act_38}required{/VP_act_38} {NP_39}signaling{/NP_39} in {NP_40}response{/NP_40} to {NP_41}endogenous or commensal <Bpf>antigens</Bpf>{/NP_41} , {VP_pass_42}demonstrated{/VP_pass_42} by {NP_43}the introduction{/NP_43} of {NP_P_44}a transgenic <p>T cell receptor</p>{/NP_P_44} .

{NP_45}Genetic deletion{/NP_45} of {NP_S_46}<S>B cells</S>{/NP_S_46} {VP_act_47}also prevented{/VP_act_47} {NP_48}<S>T cell</S> activation{/NP_48} .

{AV_49}Similarly{/AV_49} , {NP_S_50}<S>T cells</S>{/NP_S_50} {VP_pass_51}were necessary{/VP_pass_51} for {NP_52}<p>B cell autoantibody</p> production{/NP_52} .

{AV_53}However{/AV_53} , {NP_S_54}<S>B cells</S>{/NP_S_54} {VP_act_55}appeared{/VP_act_55} {VP_pass_56}to be intrinsically activated{/VP_pass_56} {AV_57}even{/AV_57} in {NP_58}the absence{/NP_58} of {NP_S_59}<S>T cells</S>{/NP_S_59} , {VP_act_60}suggesting{/VP_act_60} that {NP_61}they{/NP_61} {VP_act_62}may drive{/VP_act_62} {NP_63}the phenotype{/NP_63} of {NP_64}these <s>mice</s>{/NP_64} .

{NP_65}These results{/NP_65} {VP_act_66}reveal{/VP_act_66} {NP_67}a requirement{/NP_67} for {NP_68}careful control{/NP_68} of {NP_69}<S>B cell</S> signaling{/NP_69} and {NP_70}<Bpcl>cell</Bpcl> death{/NP_70} in {VP_act_71}preventing{/VP_act_71} {NP_72}inappropriate <S>lymphocyte</S> activation and autoimmunity{/NP_72} .


{NP_1}PMID{/NP_1} - {CP_2}19015309{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>VE-PTP</p>{/NP_P_4} {VP_act_5}maintains{/VP_act_5} {NP_6}the endothelial barrier{/NP_6} via {NP_P_7}<p>plakoglobin</p>{/NP_P_7} and {VP_pass_8}becomes dissociated{/VP_pass_8} from {NP_P_9}<p>VE-cadherin</p>{/NP_P_9} by {NP_S_10}<S>leukocytes</S>{/NP_S_10} and by {NP_P_11}<p>VEGF</p>{/NP_P_11} .

{NP_12}AB{/NP_12} - {NP_13}We{/NP_13} {VP_act_14}have shown{/VP_act_14} {AV_15}recently{/AV_15} that {NP_P_16}<p>vascular endothelial protein tyrosine phosphatase ( VE-PTP )</p>{/NP_P_16} , {NP_P_17}an endothelial-specific <Bppf>membrane protein</Bppf>{/NP_P_17} , {VP_act_18}associates{/VP_act_18} with {NP_P_19}<p>vascular endothelial ( VE )- cadherin</p>{/NP_P_19} and {VP_act_20}enhances{/VP_act_20} {NP_21}<p>VE-cadherin</p> function{/NP_21} in {NP_22}transfected <Bpcl>cells</Bpcl>{/NP_22} ( {NP_23}Nawroth{/NP_23} , {NP_B_24}<B>R.</B>{/NP_B_24} , {NP_B_25}<B>G. Poell</B>{/NP_B_25} , {NP_B_26}<B>A. Ranft</B>{/NP_B_26} , {NP_B_27}<B>U. Samulowitz</B>{/NP_B_27} , {NP_B_28}<B>G. Fachinger</B>{/NP_B_28} , {NP_B_29}<B>M. Golding</B>{/NP_B_29} , {NP_B_30}<B>D.T</B>{/NP_B_30} .

{NP_B_31}Shima , <B>U. Deutsch</B> , and <B>D. Vestweber. 2002</B>{/NP_B_31} .

{NP_B_32}<B>EMBO J. 21</B>{/NP_B_32} : {CP_33}4885-4895{/CP_33} ) .

{NP_34}We{/NP_34} {VP_act_35}show{/VP_act_35} that {NP_P_36}<p>VE-PTP</p>{/NP_P_36} {VP_pass_37}is indeed required{/VP_pass_37} for {NP_38}endothelial <Bpcl>cell</Bpcl> contact integrity{/NP_38} , because {NP_39}down-regulation{/NP_39} of {NP_40}its expression{/NP_40} {VP_act_41}enhanced{/VP_act_41} {NP_42}endothelial <Bpcl>cell</Bpcl> permeability{/NP_42} , {VP_act_43}augmented{/VP_act_43} {NP_44}<S>leukocyte</S> transmigration{/NP_44} , and {VP_act_45}inhibited{/VP_act_45} {NP_46}<p>VE-cadherin</p> -mediated adhesion{/NP_46} .

{NP_47}Binding{/NP_47} of {NP_S_48}<S>neutrophils</S>{/NP_S_48} as well as {NP_S_49}<S>lymphocytes</S>{/NP_S_49} to {NP_50}endothelial <Bpcl>cells</Bpcl>{/NP_50} {VP_act_51}triggered{/VP_act_51} {NP_52}rapid ( 5 min ) dissociation{/NP_52} of {NP_P_53}<p>VE-PTP</p>{/NP_P_53} from {NP_P_54}<p>VE-cadherin</p>{/NP_P_54} .

{NP_55}This dissociation{/NP_55} {VP_pass_56}was only seen{/VP_pass_56} with {NP_P_57}tumor <Bppf>necrosis factor alpha-activated</Bppf>{/NP_P_57} , but not {VP_act_neg_58}resting{/VP_act_neg_58} , {NP_59}endothelial <Bpcl>cells</Bpcl>{/NP_59} .

Besides {NP_S_60}<S>leukocytes</S>{/NP_S_60} , {NP_P_61}vascular endothelial <Bppf>growth factor</Bppf>{/NP_P_61} {VP_act_62}also rapidly dissociated{/VP_act_62} {NP_P_63}<p>VE-PTP</p>{/NP_P_63} from {NP_P_64}<p>VE-cadherin</p>{/NP_P_64} , {JP_65}indicative{/JP_65} of {NP_66}a more general role{/NP_66} of {NP_P_67}<p>VE-PTP</p>{/NP_P_67} in {NP_68}the regulation{/NP_68} of {NP_69}endothelial <Bpcl>cell</Bpcl> contacts{/NP_69} .

{NP_70}Dissociation{/NP_70} of {NP_P_71}<p>VE-PTP</p> and <p>VE-cadherin</p>{/NP_P_71} in {NP_72}endothelial <Bpcl>cells</Bpcl>{/NP_72} {VP_pass_73}was accompanied{/VP_pass_73} by {NP_74}<pp>tyrosine</pp> phoshorylation{/NP_74} of {NP_P_75}<p>VE-cadherin</p> , <p>beta-catenin</p> , and <p>plakoglobin</p>{/NP_P_75} .

{AV_76}Surprisingly{/AV_76} , {NP_P_77}only <p>plakoglobin</p>{/NP_P_77} but not {NP_P_78}<p>beta-catenin</p>{/NP_P_78} {VP_pass_79}was necessary{/VP_pass_79} for {NP_P_80}<p>VE-PTP</p>{/NP_P_80} {VP_act_81}to support{/VP_act_81} {NP_82}<p>VE-cadherin</p> adhesion{/NP_82} in {NP_83}endothelial <Bpcl>cells</Bpcl>{/NP_83} .

OUTPUT 0
PTM = ({NP_89};phosphorylation)
Inducer = ({NP_P_87}<p>VE-PTP</p>{/NP_P_87};-)
	Method=rule: (inducer) for phrase=[{NP_P_87}<p>VE-PTP</p>{/NP_P_87}]
Kinase = (-;-)
Substrate = ({NP_P_90}<p>plakoglobin</p>{/NP_P_90};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_90}<p>plakoglobin</p>{/NP_P_90}]
Site = (-;{NP_89}Tyr{/NP_89};UNK)
	Method=rule: (site) for phrase=[{NP_89}<pp>tyrosine</pp> phosphorylation{/NP_89}0..7|tyrosine|Tyr]

In {NP_84}addition{/NP_84} , {VP_act_85}inhibiting{/VP_act_85} {NP_86}the expression{/NP_86} of {NP_P_87}<p>VE-PTP</p>{/NP_P_87} {VP_act_88}preferentially increased{/VP_act_88} {NP_89}<pp>tyrosine</pp> phosphorylation{/NP_89} of {NP_P_90}<p>plakoglobin</p>{/NP_P_90} but not {NP_P_91}<p>beta-catenin</p>{/NP_P_91} .

In {NP_92}conclusion{/NP_92} , {NP_S_93}<S>leukocytes</S>{/NP_S_93} {VP_act_94}interacting{/VP_act_94} with {NP_95}endothelial <Bpcl>cells</Bpcl>{/NP_95} {VP_act_96}rapidly dissociate{/VP_act_96} {NP_P_97}<p>VE-PTP</p>{/NP_P_97} from {NP_P_98}<p>VE-cadherin</p>{/NP_P_98} , {VP_act_99}weakening{/VP_act_99} {NP_100}endothelial <Bpcl>cell</Bpcl> contacts{/NP_100} via {NP_101}a mechanism{/NP_101} {NP_102}that{/NP_102} {VP_act_103}requires{/VP_act_103} {NP_P_104}<p>plakoglobin</p>{/NP_P_104} but not {NP_P_105}<p>beta-catenin</p>{/NP_P_105} .


{NP_1}PMID{/NP_1} - {CP_2}19026814{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}Inhibitory <p>kappa B kinase -beta</p>{/NP_P_4} {VP_act_5}is{/VP_act_5} {NP_6}a target{/NP_6} for {NP_P_7}specific <Bppf>nuclear factor kappa</Bppf>{/NP_P_7} {VP_act_8}B-mediated delayed{/VP_act_8} {NP_9}cardioprotection{/NP_9} .

{NP_10}AB{/NP_10} - {NP_11}OBJECTIVE{/NP_11} :

{NP_12}Myocardial ischemia/reperfusion injury{/NP_12} {VP_act_13}remains{/VP_act_13} {NP_14}a vexing problem{/NP_14} .

{VP_act_15}Translating{/VP_act_15} {NP_16}experimental strategies{/NP_16} {NP_17}that{/NP_17} {VP_act_18}deliver{/VP_act_18} {NP_19}protective agents{/NP_19} before {NP_20}the ischemic insult limits clinical applicability{/NP_20} .

{NP_21}We{/NP_21} {VP_act_22}targeted{/VP_act_22} {NP_P_23}2 <Bppf>proteins</Bppf>{/NP_P_23} in {NP_B_24}the <p>nuclear factor-kappaB</p> pathway , <p>inhibitory kappa B kinase -beta</p> , and <B>26S</B>{/NP_B_24} {JP_25}cardiac proteasome{/JP_25} {VP_act_26}to determine{/VP_act_26} {NP_27}their cardioprotective effects{/NP_27} when {VP_act_28}delivered{/VP_act_28} during {NP_29}reperfusion{/NP_29} .

{NP_30}METHODS{/NP_30} : {NP_31}<B>C57BL/6</B> <s>mice</s>{/NP_31} {VP_act_32}underwent{/VP_act_32} {VP_act_33}left{/VP_act_33} {VP_act_34}anterior descending{/VP_act_34} {NP_35}artery occlusion{/NP_35} for {NP_36}30 minutes{/NP_36} .

{NP_P_37}An inhibitory <p>kappa B kinase -beta inhibitor (Compound A)</p>{/NP_P_37} , {NP_P_38}a proteasome <Bppf>inhibitor</Bppf> (PS-519){/NP_P_38} , or {NP_39}vehicle{/NP_39} {VP_pass_40}was administered{/VP_pass_40} at {VP_act_41}left anterior descending{/VP_act_41} {NP_42}artery release{/NP_42} or {NP_43}2 hours{/NP_43} {AV_44}afterward{/AV_44} .

{NP_45}Infarct size{/NP_45} {VP_pass_46}was analyzed{/VP_pass_46} {NP_47}24 hours{/NP_47} {AV_48}later{/AV_48} .

{NP_49}Pressure-volume loops{/NP_49} {VP_pass_50}were performed{/VP_pass_50} at {NP_51}72 hours{/NP_51} .

{NP_52}Serum{/NP_52} and {VP_act_53}left{/VP_act_53} {NP_54}ventricular <Bpcl>tissue</Bpcl>{/NP_54} {VP_pass_55}were collected{/VP_pass_55} {NP_56}1 hour{/NP_56} after {NP_57}injury{/NP_57} {VP_act_58}to examine{/VP_act_58} {NP_59}<Bppf>protein</Bppf> expression{/NP_59} by {NP_60}<Bppf>enzyme</Bppf> -linked immunosorbent assay and Western blot{/NP_60} .

{NP_61}RESULTS{/NP_61} : {NP_62}<p>Inhibitory kappa B kinase -beta</p> and proteasome inhibition{/NP_62} {VP_act_63}significantly attenuated{/VP_act_63} {NP_64}infarct size{/NP_64} and {VP_act_65}preserved{/VP_act_65} {NP_66}ejection fraction{/NP_66} {VP_act_67}compared{/VP_act_67} with {NP_68}the vehicle <Bpcf>groups</Bpcf>{/NP_68} .

When {VP_act_69}delivered{/VP_act_69} {NP_70}even 2 hours{/NP_70} after {NP_71}reperfusion{/NP_71} , {NP_B_72}<B>Compound A</B>{/NP_B_72} , but {NP_PP_73}not <pp>PS-519</pp>{/NP_PP_73} , {VP_act_74}still decreased{/VP_act_74} {NP_75}infarct size{/NP_75} in {NP_76}<s>mice</s>{/NP_76} .

{AV_77}Finally{/AV_77} , when {VP_pass_78}delivered{/VP_pass_78} at {NP_79}reperfusion{/NP_79} , {NP_80}successful inhibition{/NP_80} of {JP_81}phosphorylated-p65{/JP_81} and {VP_act_82}decreased{/VP_act_82} {NP_83}<p>interleukin-6</p> and <p>tumor necrosis factor -alpha</p> levels{/NP_83} {VP_pass_84}occurred{/VP_pass_84} in {NP_85}<s>mice</s>{/NP_85} {VP_act_86}given{/VP_act_86} {NP_P_87}the inhibitory <p>kappa B kinase -beta inhibitor</p>{/NP_P_87} , but {AV_88}not{/AV_88} in {NP_89}<s>mice</s>{/NP_89} with {NP_90}proteasome inhibition{/NP_90} .

{NP_91}CONCLUSION{/NP_91} : Although {NP_92}<p>inhibitory kappa B kinase -beta</p> and proteasome inhibition{/NP_92} at {NP_93}reperfusion{/NP_93} {VP_act_94}attenuated{/VP_act_94} {NP_95}infarct size{/NP_95} after {NP_96}acute ischemia/reperfusion{/NP_96} , {NP_97}only inhibitory <p>kappa B kinase -beta</p> inhibition{/NP_97} {VP_act_98}provided{/VP_act_98} {NP_99}cardioprotection{/NP_99} through {NP_100}specific suppression{/NP_100} of {NP_101}<p>nuclear factor-kappaB</p> signaling{/NP_101} .

{NP_102}This feature{/NP_102} of {NP_103}highly targeted <p>nuclear factor-kappaB</p> inhibition{/NP_103} {VP_act_104}might account{/VP_act_104} for {NP_105}its delayed protective effects{/NP_105} , {VP_act_106}providing{/VP_act_106} {NP_107}a clinically relevant option{/NP_107} for {VP_act_108}treating{/VP_act_108} {NP_109}myocardial ischemia/reperfusion{/NP_109} {VP_act_110}associated{/VP_act_110} with {NP_111}unknown periods{/NP_111} of {NP_112}ischemia and reperfusion{/NP_112} as {JP_113}seen{/JP_113} in {NP_114}cardiac surgery{/NP_114} and {NP_115}acute coronary syndromes{/NP_115} .


{NP_1}PMID{/NP_1} - {CP_2}19026779{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}The <Bpf>structure</Bpf>{/NP_4} of {NP_P_5}<p>Fcp1</p>{/NP_P_5} , {NP_P_6}an essential <p>RNA polymerase II CTD phosphatase</p>{/NP_P_6} .

OUTPUT 0
PTM = ({VP_act_11};phosphorylating)
Inducer = (-;-)
	Method=rule: (inducer) for phrase=[{NP_P_8}<p>Kinases</p> and <p>phosphatases</p>{/NP_P_8}0..6|<p>Kinases</p>10..21|<p>phosphatases</p>]
Kinase = (-;-)
	Filtered={NP_P_8}<p>Kinases</p> and <p>phosphatases</p>{/NP_P_8}0..6|<p>Kinases</p>10..21|<p>phosphatases</p>	(Category=generic)
Substrate = ({NP_P_14}<p>RNA polymerase II</p>{/NP_P_14};-)
	Method=link (substrate) for phrase=[{NP_P_14}<p>RNA polymerase II</p>{/NP_P_14}]
		From: {NP_PP_12}the <pp>C-terminal domain ( CTD )</pp>{/NP_PP_12}
		Path: whole,whole
Site = (-;-;{NP_PP_12}<pp>C-terminal domain ( CTD )</pp>{/NP_PP_12})
	Method=rule: (siteother) for phrase=[{NP_PP_12}the <pp>C-terminal domain ( CTD )</pp>{/NP_PP_12}3..23|<pp>C-terminal domain ( CTD )</pp>]

{NP_7}AB{/NP_7} - {NP_P_8}<p>Kinases</p> and <p>phosphatases</p>{/NP_P_8} {VP_act_9}regulate{/VP_act_9} {NP_10}mRNA synthesis and processing{/NP_10} by {VP_act_11}phosphorylating and dephosphorylating{/VP_act_11} {NP_PP_12}the <pp>C-terminal domain ( CTD )</pp>{/NP_PP_12} of {NP_P_13}the largest <Bppf>subunit</Bppf>{/NP_P_13} of {NP_P_14}<p>RNA polymerase II</p>{/NP_P_14} .

{NP_P_15}<p>Fcp1</p>{/NP_P_15} {VP_act_16}is{/VP_act_16} {NP_P_17}an essential <p>CTD phosphatase</p>{/NP_P_17} {NP_18}that{/NP_18} {VP_act_19}preferentially hydrolyzes{/VP_act_19} {NP_PP_20}<pp><pp>Ser2</pp>-PO(4)</pp>{/NP_PP_20} of {NP_21}the tandem <pp><B>YSPTSPS</B> CTD</pp> heptad array{/NP_21} .

{NP_B_22}<B><p>Fcp1</p> crystal structures</B>{/NP_B_22} {VP_pass_23}were captured{/VP_pass_23} at {NP_24}two stages{/NP_24} of {NP_25}the reaction pathway{/NP_25} : {NP_B_26}a <B>Mg-BeF(3) complex</B>{/NP_B_26} {NP_27}that{/NP_27} {VP_act_28}mimics{/VP_act_28} {NP_G_29}the <c>aspartylphosphate</c>{/NP_G_29} {JP_30}intermediate{/JP_30} and {NP_B_31}a <B>Mg-AlF(4) (-) complex</B>{/NP_B_31} {NP_32}that{/NP_32} {VP_act_33}mimics{/VP_act_33} {NP_34}the transition state{/NP_34} of {NP_35}the hydrolysis step{/NP_35} .

{NP_P_36}<p>Fcp1</p>{/NP_P_36} {VP_act_37}is{/VP_act_37} {NP_P_38}a <p>Y-shaped protein</p>{/NP_P_38} {VP_act_39}composed{/VP_act_39} of {NP_PP_40}an <pp>acylphosphatase domain</pp>{/NP_PP_40} {VP_pass_41}located{/VP_pass_41} at {NP_42}the base{/NP_42} of {NP_43}a deep canyon{/NP_43} {VP_pass_44}formed{/VP_pass_44} by {VP_act_45}flanking{/VP_act_45} {NP_46}modules{/NP_46} {NP_47}that{/NP_47} {VP_act_48}are missing{/VP_act_48} from {NP_49}the <p>small CTD phosphatase ( SCP )</p> clade{/NP_49} : {NP_PP_50}an <pp><B>Fcp1-specific</B> helical domain</pp>{/NP_PP_50} and {NP_PP_51}a <pp>C-terminal BRCA1 C-terminal ( BRCT ) domain</pp>{/NP_PP_51} .

{NP_52}The <Bpf>structure</Bpf> and mutational analysis{/NP_52} {VP_act_53}reveals{/VP_act_53} that {NP_P_54}<p>Fcp1</p> and <p>Scp1</p>{/NP_P_54} ( {NP_P_55}a <p><pp>Ser5</pp>-selective phosphatase</p>{/NP_P_55} ) {VP_act_56}adopt{/VP_act_56} {NP_57}different <pp>CTD</pp> -binding modes{/NP_57} ; {NP_58}we{/NP_58} {VP_act_59}surmise{/VP_act_59} {NP_60}the <pp>CTD</pp> threads{/NP_60} through {NP_61}the <p>Fcp1</p> canyon{/NP_61} {VP_act_62}to access{/VP_act_62} {NP_PP_63}the active <Bppp>site</Bppp>{/NP_PP_63} .


{NP_1}PMID{/NP_1} - {CP_2}19005492{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}<B>GammaH2AX</B> and cancer{/NP_4} .

OUTPUT 0
PTM = ({NP_6};phosphorylation)
	HasAgentTheme="<p>H2AX</p>" in "{NP_6}Histone <p>H2AX</p> phosphorylation{/NP_6}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_PP_13}<pp>DNA double-strand breaks ( DSBs )</pp>{/NP_PP_13}" 	(Features:dist=0)
		Candidate="{NP_PP_7}a <pp>serine four residues</pp>{/NP_PP_7}" 	(Features:dist=0)
		Candidate="serine" in "{NP_PP_7}a <pp>serine four residues</pp>{/NP_PP_7}" 	(Features:dist=0)
Substrate = ({NP_6}<p>H2AX</p>{/NP_6};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_6}Histone <p>H2AX</p> phosphorylation{/NP_6}7..10|<p>H2AX</p>]
Site = (-;{NP_PP_7}Ser{/NP_PP_7};UNK)
	Method=rule: (site) for phrase=[{NP_PP_7}a <pp>serine four residues</pp>{/NP_PP_7}1..6|serine|Ser]

{NP_5}AB{/NP_5} - {NP_6}Histone <p>H2AX</p> phosphorylation{/NP_6} on {NP_PP_7}a <pp>serine four residues</pp>{/NP_PP_7} from {NP_PP_8}the <pp>carboxyl terminus</pp>{/NP_PP_8} ( {VP_act_9}producing{/VP_act_9} {NP_P_10}<p>gammaH2AX</p>{/NP_P_10} ) {VP_act_11}is{/VP_act_11} {NP_12}a sensitive marker{/NP_12} for {NP_PP_13}<pp>DNA double-strand breaks ( DSBs )</pp>{/NP_PP_13} .

{NP_PP_14}<pp>DSBs</pp>{/NP_PP_14} {VP_act_15}may lead{/VP_act_15} to {NP_16}cancer{/NP_16} but , {AV_17}paradoxically{/AV_17} , {VP_pass_18}are also used{/VP_pass_18} {VP_act_19}to kill{/VP_act_19} {NP_20}<Bpcl>cancer cells</Bpcl>{/NP_20} .

{VP_act_21}Using{/VP_act_21} {NP_22}<p>gammaH2AX</p> detection{/NP_22} {VP_act_23}to determine{/VP_act_23} {NP_24}the extent{/NP_24} of {NP_25}<B>DSB</B> induction{/NP_25} {VP_act_26}may help{/VP_act_26} {VP_act_27}to detect{/VP_act_27} {NP_28}precancerous <Bpcl>cells</Bpcl>{/NP_28} , {VP_act_29}to stage{/VP_act_29} {NP_30}cancers{/NP_30} , {VP_act_31}to monitor{/VP_act_31} {NP_32}the effectiveness{/NP_32} of {NP_33}cancer therapies{/NP_33} and {VP_act_34}to develop{/VP_act_34} {NP_35}novel <Bpcf>anticancer drugs</Bpcf>{/NP_35} .


{NP_1}PMID{/NP_1} - {CP_2}19030108{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Differential roles{/NP_4} of {NP_P_5}the <Bppf><p>PKC</p> novel isoforms</Bppf> , <p>PKCdelta</p> and <p>PKCepsilon</p>{/NP_P_5} , in {NP_6}<s>mouse</s> and <s>human</s> platelets{/NP_6} .

{NP_7}AB{/NP_7} - {NP_8}BACKGROUND{/NP_8} :

{VP_act_9}Increasing{/VP_act_9} {NP_10}evidence{/NP_10} {VP_act_11}suggests{/VP_act_11} that {NP_P_12}individual <Bppf>isoforms</Bppf>{/NP_P_12} of {NP_P_13}<p>protein kinase C ( PKC )</p>{/NP_P_13} {VP_act_14}play{/VP_act_14} {NP_15}distinct roles{/NP_15} in {VP_act_16}regulating{/VP_act_16} {NP_17}platelet activation{/NP_17} .

{NP_B_18}<B>METHODOLOGY/PRINCIPAL FINDINGS</B>{/NP_B_18} : In {NP_19}this study{/NP_19} , {NP_20}we{/NP_20} {VP_pass_21}focus{/VP_pass_21} on {NP_22}the role{/NP_22} of {NP_P_23}two novel <p>PKC isoforms</p>{/NP_P_23} , {NP_P_24}<p>PKCdelta</p> and <p>PKCepsilon</p>{/NP_P_24} , in {NP_25}both <s>mouse</s> and <s>human</s> platelets{/NP_25} .

OUTPUT 0
PTM = ({NP_30};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)
	Method=rule: (site) for phrase=[{NP_30}transient <pp>tyrosine</pp> phosphorylation{/NP_30}9..16|tyrosine|Tyr]

{NP_P_26}<p>PKCdelta</p>{/NP_P_26} {VP_pass_27}is robustly expressed{/VP_pass_27} in {NP_28}<s>human</s> platelets{/NP_28} and {VP_act_29}undergoes{/VP_act_29} {NP_30}transient <pp>tyrosine</pp> phosphorylation{/NP_30} upon {NP_31}stimulation{/NP_31} by {NP_P_32}<p>thrombin</p>{/NP_P_32} or {NP_P_33}the collagen <Bppf>receptor</Bppf>{/NP_P_33} , {NP_P_34}<p>GPVI</p>{/NP_P_34} , {NP_35}which{/NP_35} {VP_pass_36}becomes sustained{/VP_pass_36} in {NP_37}the presence{/NP_37} of {NP_P_38}the <Bppf>pan-PKC inhibitor</Bppf>{/NP_P_38} , {NP_P_39}<p>Ro 31-8220</p>{/NP_P_39} .

OUTPUT 1
PTM = ({NP_44};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>tyrosine</pp>" in "{NP_44}sustained <pp>tyrosine</pp> phosphorylation{/NP_44}" 	(Features:dist=0)
		Candidate="tyrosine" in "{NP_44}sustained <pp>tyrosine</pp> phosphorylation{/NP_44}" 	(Features:dist=0)
Substrate = ({NP_P_42}<p>PKCdelta</p>{/NP_P_42};-)
	Method=rule:2.501.1 (substrate) for phrase=[{NP_P_42}<p>PKCdelta</p>{/NP_P_42}]
Site = (-;{NP_44}Tyr{/NP_44};UNK)
	Method=rule: (site) for phrase=[{NP_44}sustained <pp>tyrosine</pp> phosphorylation{/NP_44}9..16|tyrosine|Tyr]

In {NP_40}<s>mouse</s> platelets{/NP_40} , {AV_41}however{/AV_41} , {NP_P_42}<p>PKCdelta</p>{/NP_P_42} {VP_act_43}undergoes{/VP_act_43} {NP_44}sustained <pp>tyrosine</pp> phosphorylation{/NP_44} upon {NP_45}activation{/NP_45} .

In {NP_46}contrast{/NP_46} {NP_P_47}the related <Bppf>isoform</Bppf>{/NP_P_47} , {NP_P_48}<p>PKCepsilon</p>{/NP_P_48} , {VP_pass_49}is expressed{/VP_pass_49} at {NP_50}high levels{/NP_50} in {NP_51}<s>mouse</s>{/NP_51} but not {NP_52}<s>human</s> platelets{/NP_52} .

There {VP_act_53}is{/VP_act_53} {NP_54}a marked inhibition{/NP_54} in {NP_55}aggregation{/NP_55} and {NP_56}dense granule secretion{/NP_56} to {NP_57}low concentrations{/NP_57} of {NP_P_58}<p>GPVI agonists</p>{/NP_P_58} in {NP_59}<s>mouse</s> platelets{/NP_59} {VP_act_60}lacking{/VP_act_60} {NP_P_61}<p>PKCepsilon</p>{/NP_P_61} in {NP_62}contrast{/NP_62} to {NP_63}a minor inhibition{/NP_63} in {NP_64}response{/NP_64} to {NP_C_65}<c>G protein -coupled receptor agonists</c>{/NP_C_65} .

OUTPUT 2
PTM = ({NP_69};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)
	Method=rule: (site) for phrase=[{NP_69}<pp>tyrosine</pp> phosphorylation{/NP_69}0..7|tyrosine|Tyr]
	Method=rule: (siteother) for phrase=[{NP_PP_70}the <pp>FcRgamma-chain</pp>{/NP_PP_70}3..16|<pp>FcRgamma-chain</pp>]

{NP_66}This reduction{/NP_66} {VP_pass_67}is mediated{/VP_pass_67} by {NP_68}inhibition{/NP_68} of {NP_69}<pp>tyrosine</pp> phosphorylation{/NP_69} of {NP_PP_70}the <pp>FcRgamma-chain</pp>{/NP_PP_70} and {VP_act_71}downstream proteins{/VP_act_71} , {NP_72}an effect{/NP_72} {VP_pass_73}also observed{/VP_pass_73} in {NP_74}wild-type <s>mouse</s> platelets{/NP_74} in {NP_75}the presence{/NP_75} of {NP_P_76}a <Bppf><p>PKC</p> inhibitor</Bppf>{/NP_P_76} .

{NP_77}CONCLUSIONS{/NP_77} : {NP_78}These results{/NP_78} {VP_act_79}demonstrate{/VP_act_79} {NP_80}a reciprocal relationship{/NP_80} in {NP_81}levels{/NP_81} of {NP_82}the novel <p>PKC isoforms delta</p> and epsilon{/NP_82} in {NP_83}<s>human</s> and <s>mouse</s> platelets{/NP_83} and {NP_84}a selective role{/NP_84} for {NP_P_85}<p>PKCepsilon</p>{/NP_P_85} in {VP_act_86}signalling{/VP_act_86} through {NP_P_87}<p>GPVI</p>{/NP_P_87} .


{NP_1}PMID{/NP_1} - {CP_2}19025429{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Effect{/NP_4} of {NP_C_5}<c>atorvastatin</c>{/NP_C_5} on {NP_6}the pharmacokinetics and pharmacodynamics{/NP_6} of {NP_7}prasugrel{/NP_7} and {NP_8}clopidogrel{/NP_8} in {NP_9}healthy subjects{/NP_9} .

{NP_10}AB{/NP_10} - {NP_11}STUDY OBJECTIVE{/NP_11} :

{VP_act_12}To investigate{/VP_act_12} {NP_13}the potential effect{/NP_13} of {NP_14}<c>atorvastatin 80</c> mg/day{/NP_14} on {NP_15}the pharmacokinetics and pharmacodynamics{/NP_15} of {NP_C_16}the <c>thienopyridines</c>{/NP_C_16} {VP_act_17}prasugrel{/VP_act_17} and {NP_18}clopidogrel{/NP_18} .

{NP_19}DESIGN{/NP_19} : {NP_20}Open-label{/NP_20} , {VP_act_21}randomized{/VP_act_21} , {NP_22}crossover{/NP_22} , {JP_23}two-arm{/JP_23} , {NP_24}parallel{/NP_24} - {NP_25}<Bpcf>group</Bpcf> study{/NP_25} .

{VP_act_26}SETTING{/VP_act_26} : {NP_27}Single clinical research center{/NP_27} in {NP_B_28}the <B>United Kingdom</B>{/NP_B_28} .

{NP_C_29}<c>PARTICIPANTS</c>{/NP_C_29} : {NP_30}Sixty-nine healthy <s>men</s>{/NP_30} {VP_act_31}aged{/VP_act_31} {NP_32}18-60 years{/NP_32} .

{NP_33}Intervention{/NP_33} .

{NP_34}Subjects{/NP_34} {VP_act_35}received{/VP_act_35} either {NP_36}a loading dose{/NP_36} of {NP_37}prasugrel 60 mg{/NP_37} {VP_pass_38}followed{/VP_pass_38} by {NP_39}a maintenance dose{/NP_39} of {NP_40}10 mg/day{/NP_40} or {NP_41}a loading dose{/NP_41} of {NP_42}clopidogrel 300 mg{/NP_42} {VP_pass_43}followed{/VP_pass_43} by {NP_44}75 mg/day{/NP_44} .

{NP_45}The <Bpcf>drug</Bpcf>{/NP_45} {VP_pass_46}was given{/VP_pass_46} as {NP_47}monotherapy{/NP_47} for {NP_48}10 days{/NP_48} , and after {NP_49}a <B>6-day run-in</B> period{/NP_49} with {NP_50}<c>atorvastatin 80</c> mg/day{/NP_50} , {NP_51}the same dosage{/NP_51} of {NP_C_52}<c>atorvastatin</c>{/NP_C_52} {VP_pass_53}was continued{/VP_pass_53} with {NP_C_54}the respective <c>thienopyridine</c>{/NP_C_54} for {NP_55}10 days{/NP_55} .

{NP_56}A <B>14-day</B> washout period{/NP_56} {VP_act_57}separated{/VP_act_57} {NP_58}the treatment regimens{/NP_58} .

OUTPUT 0
PTM = ({NP_P_72};diphosphate)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate=" 5| 20" in "{NP_P_72}<c>adenosine 5'-diphosphate 20 microM</c> and <p>vasodilator-stimulated phosphoprotein ( VASP )</p>{/NP_P_72}" 	(Features:dist=0)
Substrate = ({NP_P_72}<p>vasodilator-stimulated phosphoprotein ( VASP )</p>{/NP_P_72};-)
Site = (-;-;UNK)
	Method=rule: (site) for phrase=[{NP_P_72}<c>adenosine 5'-diphosphate 20 microM</c> and <p>vasodilator-stimulated phosphoprotein ( VASP )</p>{/NP_P_72}9..9| 5|523..24| 20|20]

{NP_C_59}<c>MEASUREMENTS</c>{/NP_C_59} AND {NP_B_60}<B>MAIN RESULTS</B>{/NP_B_60} : {NP_61}Blood samples{/NP_61} {VP_pass_62}were collected{/VP_pass_62} before and at {NP_63}various time points{/NP_63} after {VP_act_64}dosing{/VP_act_64} on {NP_65}days 1 and 11{/NP_65} for {NP_66}determination{/NP_66} of {NP_67}plasma concentrations{/NP_67} of {NP_68}<Bpf>metabolites</Bpf>{/NP_68} and for {NP_69}measurement{/NP_69} of {NP_70}platelet aggregation{/NP_70} {VP_pass_71}induced{/VP_pass_71} by {NP_P_72}<c>adenosine 5'-diphosphate 20 microM</c> and <p>vasodilator-stimulated phosphoprotein ( VASP )</p>{/NP_P_72} .

{NP_73}Coadministration{/NP_73} of {NP_C_74}<c>atorvastatin</c>{/NP_C_74} {VP_act_neg_75}did not alter{/VP_act_neg_75} {NP_76}exposure{/NP_76} to {NP_77}active <Bpf>metabolites</Bpf>{/NP_77} of {NP_78}prasugrel{/NP_78} or {NP_79}clopidogrel{/NP_79} after {NP_80}the loading dose{/NP_80} and {VP_act_neg_81}thus did not alter{/VP_act_neg_81} {NP_82}inhibition{/NP_82} of {NP_83}platelet aggregation ( IPA ){/NP_83} .

During {NP_84}maintenance{/NP_84} {VP_act_85}dosing{/VP_act_85} , {NP_86}<c>atorvastatin</c> administration{/NP_86} {VP_pass_87}resulted{/VP_pass_87} in {NP_88}17%{/NP_88} and {NP_89}28%{/NP_89} {VP_pass_90}increases{/VP_pass_90} in {NP_91}the area{/NP_91} under {NP_92}the plasma concentration-time curve ( <B>AUC</B> ) values{/NP_92} of {NP_93}prasugrel's{/NP_93} and {VP_act_94}clopidogrel's{/VP_act_94} {NP_95}active <Bpf>metabolites</Bpf>{/NP_95} , {AV_96}respectively{/AV_96} .

{NP_97}These small changes{/NP_97} in {NP_B_98}<B>AUC</B>{/NP_B_98} {VP_pass_neg_99}did not result{/VP_pass_neg_99} in {NP_100}a significant change{/NP_100} in {NP_101}<B>IPA</B> response{/NP_101} {VP_act_102}to prasugrel{/VP_act_102} but {VP_act_103}did{/VP_act_103} {NP_104}result{/NP_104} in a {VP_pass_105}significant increase{/VP_pass_105} in {NP_B_106}<B>IPA</B>{/NP_B_106} during {NP_107}clopidogrel maintenance{/NP_107} {VP_act_108}dosing{/VP_act_108} at some , but {AV_109}not{/AV_109} all , of {NP_110}the time points{/NP_110} on {NP_111}day 11{/NP_111} .

OUTPUT 1
PTM = ({NP_117};phosphorylation)
	HasAgentTheme="<p>VASP</p>" in "{NP_117}<p>VASP</p> phosphorylation{/NP_117}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_117}<p>VASP</p>{/NP_117};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_117}<p>VASP</p> phosphorylation{/NP_117}0..3|<p>VASP</p>]
Site = (-;-;UNK)

{NP_112}Coadministration{/NP_112} of {NP_C_113}<c>atorvastatin</c>{/NP_C_113} with {NP_114}either prasugrel or clopidogrel{/NP_114} {VP_act_115}had{/VP_act_115} {NP_116}no effect{/NP_116} on {NP_117}<p>VASP</p> phosphorylation{/NP_117} {JP_118}relative{/JP_118} to {NP_C_119}the <c>thienopyridine</c>{/NP_C_119} {AV_120}alone{/AV_120} after {NP_121}the loading dose{/NP_121} .

{NP_122}CONCLUSION{/NP_122} : {NP_123}Coadministration{/NP_123} of {NP_124}<c>atorvastatin 80</c> mg/day{/NP_124} with {NP_125}prasugrel{/NP_125} or {NP_126}clopidogrel{/NP_126} {VP_act_neg_127}did not negatively affect{/VP_act_neg_127} {NP_128}the antiplatelet response{/NP_128} to {NP_129}either <Bpcf>drug</Bpcf>{/NP_129} after {NP_130}a loading dose{/NP_130} or during {NP_131}maintenance{/NP_131} {VP_act_132}dosing{/VP_act_132} .

{NP_133}The lack{/NP_133} of {NP_134}a clinically meaningful effect{/NP_134} of {NP_C_135}high-dose <c>atorvastatin</c>{/NP_C_135} on {NP_136}the pharmacodynamic response{/NP_136} {VP_act_137}to prasugrel{/VP_act_137} after {NP_138}the loading or maintenance dose{/NP_138} {VP_act_139}indicates{/VP_act_139} that {NP_140}no dosage adjustment{/NP_140} {VP_pass_141}should be necessary{/VP_pass_141} in {NP_142}patients{/NP_142} {VP_act_143}receiving{/VP_act_143} {NP_144}these <Bpcf>drugs</Bpcf>{/NP_144} {AV_145}concomitantly{/AV_145} .


{NP_1}PMID{/NP_1} - {CP_2}19007950{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Abscisic acid -induced modulation{/NP_4} of {JP_5}metabolic{/JP_5} and {NP_6}redox control pathways{/NP_6} in {NP_7}<s>Arabidopsis thaliana</s>{/NP_7} .

{NP_8}AB{/NP_8} - {NP_P_9}<p>Abscisic acid ( ABA )</p>{/NP_P_9} {VP_pass_10}has been implicated{/VP_pass_10} as {NP_11}a mediator{/NP_11} in {NP_12}plant responses{/NP_12} to {NP_13}various environmental stresses{/NP_13} .

{VP_act_14}To evaluate{/VP_act_14} {NP_15}the transcriptional and metabolic events{/NP_15} {AV_16}downstream{/AV_16} of {NP_17}<p>ABA</p> perception{/NP_17} , {NP_18}<s>Arabidopsis thaliana</s> seedlings{/NP_18} {VP_pass_19}were analyzed{/VP_pass_19} by {NP_20}<Bppf>transcript</Bppf> and <Bpf>metabolite</Bpf>{/NP_20} {VP_act_21}profiling{/VP_act_21} , and {NP_22}results{/NP_22} {VP_pass_23}were integrated{/VP_pass_23} , {VP_act_24}using{/VP_act_24} {NP_25}the recently developed <B>BioPathAt</B> tool{/NP_25} , in {NP_26}the context{/NP_26} of {NP_27}the <Bpcf>biochemical</Bpcf> pathways{/NP_27} {VP_pass_28}affected{/VP_pass_28} by {NP_29}this treatment{/NP_29} .

Besides {NP_30}the up-regulation{/NP_30} of {NP_31}pathways{/NP_31} {VP_act_32}related{/VP_act_32} to {NP_33}the biosynthesis{/NP_33} of {NP_34}compatible solutes{/NP_34} ( {NP_C_35}raffinose <B>family</B> <c>oligosaccharides</c>{/NP_C_35} and {NP_PP_36}certain <Bppp>amino acids</Bppp>{/NP_PP_36} ) as {NP_37}a response{/NP_37} to {NP_38}<p>ABA</p> treatment{/NP_38} , {NP_39}we{/NP_39} {VP_act_40}also observed{/VP_act_40} {NP_41}a down-regulation{/NP_41} of {NP_P_42}numerous <Bppf>genes</Bppf>{/NP_P_42} {JP_43}putatively localized{/JP_43} to and {VP_pass_44}possibly involved{/VP_pass_44} in {NP_45}the reorganization{/NP_45} of {NP_46}<Bpcl>cell</Bpcl> walls{/NP_46} , {NP_47}an association{/NP_47} {NP_48}that{/NP_48} {VP_pass_neg_49}had not been recognized{/VP_pass_neg_49} {AV_50}previously{/AV_50} .

{NP_51}<Bpf>Metabolite</Bpf>{/NP_51} {VP_act_52}profiling{/VP_act_52} {VP_act_53}indicated{/VP_act_53} that {NP_54}specific antioxidants{/NP_54} , {NP_P_55}particularly <c>alpha-tocopherol</c> and <p>L-ascorbic acid</p>{/NP_P_55} , {VP_pass_56}were accumulated{/VP_pass_56} at {NP_57}higher levels{/NP_57} in {NP_58}<B>ABA-treated</B> seedlings{/NP_58} {VP_act_59}compared{/VP_act_59} {VP_act_60}to appropriate{/VP_act_60} {NP_61}controls{/NP_61} .

{NP_62}The transcription{/NP_62} of {NP_P_63}<Bppf>genes</Bppf>{/NP_P_63} {VP_pass_64}involved{/VP_pass_64} in {NP_65}<c>alpha-tocopherol</c> biosynthesis{/NP_65} {VP_pass_66}were coordinately up-regulated and appeared{/VP_pass_66} {VP_pass_67}to be integrated{/VP_pass_67} into {NP_68}a network{/NP_68} of {NP_69}reactions{/NP_69} {VP_act_70}controlling{/VP_act_70} {NP_71}the levels{/NP_71} of {NP_72}reactive <c>oxygen</c> species{/NP_72} .

{JP_73}Based{/JP_73} upon {NP_74}the observed <Bppf>gene</Bppf> expression patterns{/NP_74} , {NP_75}these redox control mechanisms{/NP_75} {VP_act_76}might involve{/VP_act_76} {NP_77}an <p>ABA</p> -mediated transition{/NP_77} of {NP_78}mitochondrial respiration{/NP_78} to {NP_79}the alternative{/NP_79} , {NP_80}non-phosphorylating respiratory <Bppp>chain</Bppp> mode{/NP_80} .

{NP_81}The presented data{/NP_81} {VP_act_82}herein provide{/VP_act_82} {NP_83}indirect evidence{/NP_83} for {NP_84}crosstalk{/NP_84} between {NP_85}metabolic pathways and pathways{/NP_85} {VP_act_86}regulating{/VP_act_86} {NP_87}redox homeostasis{/NP_87} as {NP_88}a response{/NP_88} to {NP_89}<p>ABA</p> treatment{/NP_89} , and {VP_act_90}allowed{/VP_act_90} {NP_91}us{/NP_91} {VP_act_92}to identify{/VP_act_92} {NP_P_93}candidate <Bppf>genes</Bppf>{/NP_P_93} for {NP_94}follow-up studies{/NP_94} {VP_act_95}to dissect{/VP_act_95} {NP_96}this interaction{/NP_96} at {NP_97}the <Bpcf>biochemical</Bpcf> and molecular level{/NP_97} .

{NP_98}Our results{/NP_98} {VP_act_99}also indicate{/VP_act_99} {NP_100}an intricate relationship{/NP_100} , at the {JP_101}transcriptional{/JP_101} and {NP_102}possibly post-transcriptional levels{/NP_102} , between {NP_103}<p>ABA</p> biosynthesis , the xanthophyll cycle , and <p>ascorbic acid</p> recycling{/NP_103} .


{NP_1}PMID{/NP_1} - {CP_2}19026018{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Exercise{/NP_4} , {NP_5}vascular wall{/NP_5} and {NP_6}cardiovascular diseases{/NP_6} : {NP_P_7}an update ( <p>Part 1</p> ){/NP_P_7} .

{NP_8}AB{/NP_8} - {NP_B_9}<B>Cardiovascular disease ( CVD )</B>{/NP_B_9} {VP_act_10}remains{/VP_act_10} {NP_11}the leading cause{/NP_11} of {NP_12}morbidity{/NP_12} and {NP_13}premature mortality{/NP_13} in {NP_14}both <s>women</s> and <s>men</s>{/NP_14} in {NP_15}most industrialized countries{/NP_15} , and {VP_act_16}has{/VP_act_16} for {NP_17}some time{/NP_17} {VP_act_18}also established{/VP_act_18} {NP_19}a prominent role{/NP_19} in {VP_act_20}developing{/VP_act_20} {NP_21}nations{/NP_21} .

In {NP_22}fact{/NP_22} , {NP_23}obesity{/NP_23} , {NP_24}diabetes mellitus{/NP_24} and {NP_25}hypertension{/NP_25} {VP_pass_26}are now commonplace even{/VP_pass_26} in {NP_27}<s>children</s>{/NP_27} and {NP_28}youths{/NP_28} .

{NP_29}Regular exercise{/NP_29} {VP_act_30}is rapidly gaining{/VP_act_30} {NP_31}widespread advocacy{/NP_31} as {NP_32}a preventative measure{/NP_32} in {NP_33}schools{/NP_33} , {NP_34}medical circles{/NP_34} and in {NP_35}the popular media{/NP_35} .

There {VP_act_36}is{/VP_act_36} {NP_37}overwhelming evidence{/NP_37} {VP_act_38}garnered{/VP_act_38} from {NP_39}a number{/NP_39} of {NP_40}sources{/NP_40} , {VP_act_41}including{/VP_act_41} {JP_42}epidemiological{/JP_42} , {NP_43}prospective cohort{/NP_43} and {NP_44}intervention studies{/NP_44} , {VP_act_45}suggesting{/VP_act_45} that {NP_B_46}<B>CVD</B>{/NP_B_46} {VP_pass_47}is largely{/VP_pass_47} {NP_48}a disease{/NP_48} {VP_act_49}associated{/VP_act_49} with {NP_50}physical inactivity{/NP_50} .

{NP_51}A rapidly advancing body{/NP_51} of {NP_52}<s>human</s> and animal data{/NP_52} {VP_act_53}confirms{/VP_act_53} {NP_54}an important beneficial role{/NP_54} for {NP_55}exercise{/NP_55} in {NP_56}the prevention and treatment{/NP_56} of {NP_B_57}<B>CVD</B>{/NP_B_57} .

OUTPUT 0
PTM = ({NP_81};phosphorylation)
	HasAgentTheme="<p>eNOS</p>" in "{NP_81}<p>vascular endothelial nitric oxide synthase ( eNOS )</p> , expression and <p>eNOS</p> <pp>Ser-1177</pp> phosphorylation{/NP_81}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>Ser-1177</pp>" in "{NP_81}<p>vascular endothelial nitric oxide synthase ( eNOS )</p> , expression and <p>eNOS</p> <pp>Ser-1177</pp> phosphorylation{/NP_81}" 	(Features:dist=0)
		Candidate="Ser-1177" in "{NP_81}<p>vascular endothelial nitric oxide synthase ( eNOS )</p> , expression and <p>eNOS</p> <pp>Ser-1177</pp> phosphorylation{/NP_81}" 	(Features:dist=0)
		Candidate="{NP_P_58}<p>Part 1</p>{/NP_P_58}" 	(Features:dist=0|in-prefix)
		Candidate="{NP_P_71}endothelial <Bppf>genes</Bppf>{/NP_P_71}" 	(Features:dist=0|pparg)
		Candidate="{NP_P_77}<p>p67phox</p>{/NP_P_77}" 	(Features:dist=0|pparg)
Substrate = ({NP_81}<p>eNOS</p>{/NP_81};-)
	Method=agent|theme_but_kinase_is_known (substrate) for phrase=[{NP_81}<p>vascular endothelial nitric oxide synthase ( eNOS )</p> , expression and <p>eNOS</p> <pp>Ser-1177</pp> phosphorylation{/NP_81}58..61|<p>eNOS</p>]
	Method=link (substrate) for phrase=[{NP_81}<p>vascular endothelial nitric oxide synthase ( eNOS )</p> , expression and <p>eNOS</p> <pp>Ser-1177</pp> phosphorylation{/NP_81}58..61|<p>eNOS</p>]
		From: {NP_81}<p>vascular endothelial nitric oxide synthase ( eNOS )</p> , expression and <p>eNOS</p> <pp>Ser-1177</pp> phosphorylation{/NP_81}62..69|<pp>Ser-1177</pp>
		Path: whole
Site = ({NP_81}1177{/NP_81};{NP_81}Ser{/NP_81};UNK)
	Method=rule: (site) for phrase=[{NP_81}<p>vascular endothelial nitric oxide synthase ( eNOS )</p> , expression and <p>eNOS</p> <pp>Ser-1177</pp> phosphorylation{/NP_81}62..69|Ser-1177|Ser1177]

In {NP_P_58}<p>Part 1</p>{/NP_P_58} of {NP_59}this review{/NP_59} {NP_60}we{/NP_60} {VP_act_61}discuss{/VP_act_61} {NP_62}the impact{/NP_62} of {NP_63}exercise{/NP_63} on {NP_B_64}<B>CVD</B>{/NP_B_64} , and {NP_65}we{/NP_65} {VP_act_66}highlight{/VP_act_66} {NP_67}the effects{/NP_67} of {NP_68}exercise{/NP_68} on (i) {NP_69}endothelial function{/NP_69} by {NP_70}regulation{/NP_70} of {NP_P_71}endothelial <Bppf>genes</Bppf>{/NP_P_71} {VP_act_72}mediating{/VP_act_72} {NP_73}oxidative metabolism , inflammation , apoptosis , cellular growth and proliferation{/NP_73} , {VP_act_74}increased{/VP_act_74} {NP_P_75}<p>superoxide dismutase ( SOD ) -1</p>{/NP_P_75} , {NP_76}down-regulation{/NP_76} of {NP_P_77}<p>p67phox</p>{/NP_P_77} , {VP_act_78}changes{/VP_act_78} in {NP_79}intracellular <c>calcium</c> level{/NP_79} , {VP_act_80}increased{/VP_act_80} {NP_81}<p>vascular endothelial nitric oxide synthase ( eNOS )</p> , expression and <p>eNOS</p> <pp>Ser-1177</pp> phosphorylation{/NP_81} ;

{NP_82}( ii ) vascular smooth muscle function{/NP_82} by either {NP_83}an increased affinity{/NP_83} of {NP_84}the Ca2+ extrusion mechanism{/NP_84} or {NP_B_85}an augmented <B>Ca2+</B>{/NP_B_85} {VP_act_86}buffering{/VP_act_86} {NP_87}system{/NP_87} by {NP_88}the superficial sarcoplasmic reticulum{/NP_88} {VP_act_89}to increase{/VP_act_89} {NP_90}<B>Ca2+</B> sequestration{/NP_90} , {VP_pass_91}increase{/VP_pass_91} in {NP_92}<p>K+ channel</p> activity and/or expression{/NP_92} , and {VP_pass_93}increase{/VP_pass_93} in {NP_94}<B>L-type Ca2+</B> current density{/NP_94} ;

{NP_95}( iii ) antioxidant systems{/NP_95} by {NP_96}elevation{/NP_96} of {NP_P_97}<p>Mn-SOD</p> , <p>Cu/Zn-SOD</p> and <p>catalase</p>{/NP_P_97} , {VP_act_98}increases{/VP_act_98} in {NP_99}<p>glutathione peroxidase</p> activity and activation{/NP_99} of {NP_G_100}vascular <c>nicotinamide adenine dinucleotide phosphate</c>{/NP_G_100} [ ( {NP_101}<p>NAD(P) H] oxidase</p> and <p>p22phox</p> expression{/NP_101} ;

{NP_102}( iv ) <p>heat shock protein ( HSP )</p> expression{/NP_102} by {VP_act_103}stimulating{/VP_act_103} {NP_104}<p>HSP70</p> expression{/NP_104} in {NP_105}myocardium{/NP_105} , {NP_106}skeletal muscle{/NP_106} and {AV_107}even{/AV_107} in {NP_S_108}<s>human</s> <S>leucocytes</S>{/NP_S_108} , {AV_109}probably{/AV_109} through {NP_110}heat shock <Bppf>transcription factor 1</Bppf> activity{/NP_110} ;

(v) {NP_111}inflammation{/NP_111} by {VP_act_112}reducing{/VP_act_112} {NP_P_113}serum inflammatory <p>cytokines</p>{/NP_P_113} {JP_114}such{/JP_114} as {NP_P_115}<p>high-sensitivity C-reactive protein ( hCRP )</p>{/NP_P_115} , {NP_P_116}<p>interleukin ( IL ) -6</p>{/NP_P_116} , {NP_P_117}<p>IL-18</p> and <p>tumour necrosis factor -alpha</p>{/NP_P_117} and by {VP_act_118}regulating{/VP_act_118} {NP_119}<p>Toll-like receptor 4</p> pathway{/NP_119} .

{NP_120}Exercise{/NP_120} {VP_act_121}also alters{/VP_act_121} {NP_122}vascular remodelling{/NP_122} , {NP_123}which{/NP_123} {VP_act_124}involves{/VP_act_124} {NP_125}two forms{/NP_125} of {NP_126}vessel growth{/NP_126} {VP_act_127}including{/VP_act_127} {NP_128}angiogenesis and arteriogenesis{/NP_128} .

{NP_129}Angiogenesis{/NP_129} {VP_act_130}refers{/VP_act_130} to {NP_131}the formation{/NP_131} of {NP_132}new capillary networks{/NP_132} .

{NP_133}Arteriogenesis{/NP_133} {VP_act_134}refers{/VP_act_134} to {NP_135}the growth{/NP_135} of {NP_136}pre-existent collateral arterioles{/NP_136} {VP_act_137}leading{/VP_act_137} to {NP_138}formation{/NP_138} of {NP_139}large conductance arteries{/NP_139} {NP_140}that{/NP_140} {VP_pass_141}are well capable{/VP_pass_141} {VP_act_142}to compensate{/VP_act_142} for {NP_143}the loss{/NP_143} of {NP_144}function{/NP_144} of {NP_145}occluded arteries{/NP_145} .

{NP_146}Another aim{/NP_146} of {NP_147}this review{/NP_147} {VP_act_148}is{/VP_act_148} {VP_pass_149}to focus{/VP_pass_149} on {NP_150}exercise-related cardiovascular protection{/NP_150} against {NP_B_151}<B>CVD</B>{/NP_B_151} and {VP_act_152}associated{/VP_act_152} {NP_P_153}risk <Bppf>factors</Bppf>{/NP_P_153} {JP_154}such{/JP_154} as {VP_act_155}aging{/VP_act_155} , {NP_156}coronary heart disease{/NP_156} , {NP_157}hypertension{/NP_157} , {NP_158}heart failure{/NP_158} , {NP_159}diabetes mellitus{/NP_159} and {NP_160}peripheral arterial diseases{/NP_160} {VP_pass_161}mediated{/VP_pass_161} by {NP_162}vascular remodelling{/NP_162} .

{AV_163}Lastly{/AV_163} , {NP_164}this review{/NP_164} {VP_act_165}examines{/VP_act_165} {NP_166}the benefits{/NP_166} of {NP_167}exercise{/NP_167} in {VP_act_168}mitigating{/VP_act_168} {JP_169}pre-eclampsia{/JP_169} during {NP_170}pregnancy{/NP_170} by {NP_171}mechanisms{/NP_171} {NP_172}that{/NP_172} {VP_act_173}include{/VP_act_173} {NP_174}improved blood flow{/NP_174} , {VP_act_175}reduced{/VP_act_175} {NP_176}blood pressure{/NP_176} , {VP_act_177}enhanced{/VP_act_177} {NP_178}placental growth and vascularity{/NP_178} , {VP_act_179}increased{/VP_act_179} {NP_180}activity{/NP_180} of {NP_P_181}<Bppf>antioxidant enzymes</Bppf>{/NP_P_181} , {VP_act_182}reduced{/VP_act_182} {NP_183}oxidative stress{/NP_183} and {VP_act_184}restored{/VP_act_184} {NP_185}vascular endothelial dysfunction{/NP_185} .


{NP_1}PMID{/NP_1} - {CP_2}19031691{/CP_2}

OUTPUT 0
PTM = ({NP_P_5};phosphoprotein)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_3}TI{/NP_3} - [ {NP_4}Characterization{/NP_4} of {NP_P_5}rabies <p>virus phosphoprotein</p>{/NP_P_5} in {NP_6}high prevalence provinces{/NP_6} of {NP_B_7}<B>China</B>{/NP_B_7} ] .

{NP_8}AB{/NP_8} - {NP_9}OBJECTIVE{/NP_9} :

OUTPUT 1
PTM = ({NP_P_11};phosphoprotein)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

OUTPUT 2
PTM = ({NP_P_14};phosphoproteins)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_15}<Bppp>regions</Bppp>{/NP_PP_15})
	Method=rule: (siteother) for phrase=[{NP_PP_15}high-incidence <Bppp>regions</Bppp>{/NP_PP_15}14..20|<Bppp>regions</Bppp>]

{NP_10}Characterization{/NP_10} of {NP_P_11}rabies <p>virus phosphoprotein</p>{/NP_P_11} through {NP_12}analyzation{/NP_12} of {NP_13}genetic variations{/NP_13} about {NP_P_14}rabies <p>virus phosphoproteins</p>{/NP_P_14} in {NP_PP_15}high-incidence <Bppp>regions</Bppp>{/NP_PP_15} in {NP_B_16}<B>China</B>{/NP_B_16} .

{NP_17}METHODS{/NP_17} : {NP_PP_18}The nucleotide <Bppp>sequence</Bppp>{/NP_PP_18} of {NP_B_19}the <B>P gene</B>{/NP_B_19} of {NP_20}<c>Guangxi</c> , <B>Guizhou</B> and <B>Hunan</B> provinces positive sample's{/NP_20} {VP_pass_21}were sequenced{/VP_pass_21} , and {NP_22}the <B>P</B> region's similarity and phylogenetic analyses{/NP_22} {VP_pass_23}were completed{/VP_pass_23} by {VP_act_24}using{/VP_act_24} {NP_25}softer wares{/NP_25} .

{NP_26}RESULTS{/NP_26} : {NP_27}The similarity{/NP_27} of {NP_PP_28}<pp><B>P region's</B> nucleotide sequence</pp>{/NP_PP_28} {VP_act_29}is{/VP_act_29} {NP_30}82.1%-100%{/NP_30} , while , {NP_31}the similarity{/NP_31} of {NP_PP_32}<Bppp>amino acid sequence</Bppp>{/NP_PP_32} {VP_act_33}is{/VP_act_33} {NP_34}87.5%-100%{/NP_34} .

OUTPUT 3
PTM = ({NP_P_36};phosphoprotein)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
	Method=rule:1.45.1.0.1 (substrate) for phrase=[{NP_P_36}<p>phosphoprotein</p>{/NP_P_36}]
	Filtered={NP_P_36}<p>phosphoprotein</p>{/NP_P_36}	(Category=generic)
	Method=rule:1.45.1.0.1 (substrate) for phrase=[{NP_P_36}<p>phosphoprotein</p>{/NP_P_36}]
Site = (-;-;UNK)

{NP_35}A little variation{/NP_35} in {NP_P_36}<p>phosphoprotein</p>{/NP_P_36} {VP_act_neg_37}cannot influence{/VP_act_neg_37} {NP_38}its biological functions{/NP_38} .

{NP_39}CONCLUSION{/NP_39} : {NP_40}All rabies viruses{/NP_40} {VP_pass_41}isolated{/VP_pass_41} from {NP_42}<c>Guangxi</c> , <B>Guizhou</B> and <B>Hunan</B> provinces{/NP_42} {VP_pass_43}belong{/VP_pass_43} to {VP_act_neg_44}genotype{/VP_act_neg_44} {CP_45}1{/CP_45} and {NP_46}share same phylogenesis{/NP_46} and {NP_P_47}same <Bppf>genome</Bppf>{/NP_P_47} {JP_48}characteristic{/JP_48} ; {NP_49}<B>Virus</B> distribution{/NP_49} {VP_act_50}presents{/VP_act_50} {NP_51}unique Characterization{/NP_51} ; {NP_B_52}Some <B>virus</B>{/NP_B_52} {VP_act_53}isolates{/VP_act_53} from {NP_54}<B>Hunan</B> province{/NP_54} and {NP_B_55}<B>Thailand</B>{/NP_B_55} {VP_act_56}may come{/VP_act_56} from {NP_B_57}the same <B>virus</B>{/NP_B_57} .


{NP_1}PMID{/NP_1} - {CP_2}19031740{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}Influence{/NP_4} of {NP_5}<p>nm23-H1 gene</p> silence{/NP_5} in {NP_S_6}<S>K562 cell</S>{/NP_S_6} on {NP_7}its differentiation{/NP_7} toward {NP_S_8}<S>megakaryocyte</S>{/NP_S_8} ] .

{NP_9}AB{/NP_9} - {NP_10}OBJECTIVE{/NP_10} :

{VP_act_11}To construct{/VP_act_11} {NP_12}a stable <S>nm23-H1-knock-down cell</S> model{/NP_12} with {NP_S_13}<S>K562 cell line</S>{/NP_S_13} and {VP_act_14}study{/VP_act_14} {NP_15}its differentiation{/NP_15} toward {NP_S_16}<S>megakaryocyte</S>{/NP_S_16} .

{NP_17}METHODS{/NP_17} : {NP_B_18}Eukaryotic expression vector <B>pSilencer 4.1-CMV-sinm23</B>{/NP_B_18} {VP_act_19}expressing{/VP_act_19} {NP_P_20}<p>siRNA</p>{/NP_P_20} {VP_act_21}targeting{/VP_act_21} {NP_P_22}<p>nm23-H1</p>{/NP_P_22} {VP_pass_23}was transfected{/VP_pass_23} into {NP_S_24}<S>K562 cells</S>{/NP_S_24} with {NP_25}lipofectamine2000{/NP_25} .

{NP_26}<Bpcl>Cells</Bpcl>{/NP_26} with {NP_27}stably <p>nm23-H1</p> silence{/NP_27} {VP_pass_28}were screened{/VP_pass_28} out by {NP_PP_29}<pp>G418</pp>{/NP_PP_29} .

{NP_30}Real-time quantitative PCR{/NP_30} , {NP_31}immunocytochemistry{/NP_31} , {NP_32}western blot{/NP_32} {VP_pass_33}were used{/VP_pass_33} {VP_act_34}to confirm{/VP_act_34} {NP_35}the <p>nm23-H1-knock-down K562</p> model{/NP_35} .

{NP_36}Cell differentiation capacity{/NP_36} {VP_pass_37}was detected{/VP_pass_37} by {NP_38}NBT reduction assay{/NP_38} .

{NP_B_39}Surface <B>antigen Gp IIb-IIIa (CD41)</B>{/NP_B_39} of {NP_40}knock-down <Bpcl>cells</Bpcl>{/NP_40} {VP_pass_41}treated{/VP_pass_41} with {NP_C_42}<c>phorbol 12-myristate 13-acetate</c>{/NP_C_42} {VP_pass_43}was analyzed{/VP_pass_43} by {NP_44}flow cytometry{/NP_44} .

{NP_45}Western blot{/NP_45} {VP_pass_46}was used{/VP_pass_46} {VP_act_47}to detect{/VP_act_47} {NP_48}the <p>ERK1/2</p> signal pathway{/NP_48} after {NP_49}the stimulation{/NP_49} of {NP_C_50}<c>phorbol 12-myristate 13-acetate</c>{/NP_C_50} .

{NP_51}RESULTS{/NP_51} : {NP_P_52}Endogenous <p>nm23-H1</p>{/NP_P_52} {VP_pass_53}was silenced{/VP_pass_53} by {NP_B_54}<B>pSilencer 4.1-CMV-sinm23</B>{/NP_B_54} and {NP_55}the silence efficiency{/NP_55} {VP_pass_56}was{/VP_pass_56} up to {NP_57}75%{/NP_57} and {NP_58}70%{/NP_58} in {NP_59}mRNA and <Bppf>protein</Bppf> levels{/NP_59} {VP_act_60}respectively compared{/VP_act_60} with {NP_61}the mock <Bpcl>cells</Bpcl>{/NP_61} .

Under {NP_62}<c>phorbol 12-myristate 13-acetate</c> treatment{/NP_62} , {NP_63}the knock-down <Bpcl>cells</Bpcl>{/NP_63} {VP_act_64}displayed{/VP_act_64} {NP_65}a significantly increased differentiation ability{/NP_65} toward {NP_S_66}<S>megakaryocyte</S>{/NP_S_66} {VP_act_67}compared{/VP_act_67} with {NP_68}control{/NP_68} .

{NP_69}The <B>NBT</B> reduction values{/NP_69} {VP_pass_70}were{/VP_pass_70} {NP_71}( 0.31 +/- 0.07 ){/NP_71} and {NP_72}( 0.23 +/- 0.05 ){/NP_72} {AV_73}respectively{/AV_73} .

OUTPUT 0
PTM = ({NP_81};phosphorylation)
	HasAgentTheme="<p>ERK1/2</p>" in "{NP_81}the increased <p>ERK1/2</p> phosphorylation{/NP_81}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_76}<p>nm23-H1 gene</p>{/NP_P_76}" 	(Features:dist=0|in-title_elsewhere|subject_subnc)
		Candidate="<p>nm23-H1 gene</p>" in "{NP_P_76}<p>nm23-H1 gene</p>{/NP_P_76}" 	(Features:dist=0|in-title_elsewhere|subject_subnc|subject_subnc_modifier)
Substrate = ({NP_81}<p>ERK1/2</p>{/NP_81};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_81}the increased <p>ERK1/2</p> phosphorylation{/NP_81}12..17|<p>ERK1/2</p>]
Site = (-;-;UNK)

{VP_act_74}Further results{/VP_act_74} {VP_act_75}revealed{/VP_act_75} that {NP_P_76}<p>nm23-H1 gene</p>{/NP_P_76} {VP_act_77}regulating{/VP_act_77} {NP_78}the megakaryocytic differentiation{/NP_78} {VP_pass_79}was due{/VP_pass_79} in {NP_80}part{/NP_80} to {NP_81}the increased <p>ERK1/2</p> phosphorylation{/NP_81} .

{NP_82}CONCLUSIONS{/NP_82} : {NP_83}A stable <S><p>nm23-H1-knock-down K562</p> cell</S> model{/NP_83} {VP_act_84}is successfully constructed.<p>nm23-H1</p>{/VP_act_84} {VP_act_85}involves{/VP_act_85} in {VP_act_86}regulating{/VP_act_86} {NP_87}the megakaryocytic differentiation{/NP_87} of {NP_S_88}<S>K562 cell line</S>{/NP_S_88} .


{NP_1}PMID{/NP_1} - {CP_2}19031822{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}Effect{/NP_4} of {NP_C_5}<s>Escherichia coli</s> <c>lipopolysaccharide</c>{/NP_C_5} on {NP_6}mineralized matrix formation in vitro differentiation <s>human</s> dental pulp <Bpcl>cell</Bpcl>{/NP_6} ] .

{NP_7}AB{/NP_7} - {NP_8}OBJECTIVE{/NP_8} :

{VP_act_9}To investigated{/VP_act_9} {NP_10}the effect{/NP_10} of {NP_P_11}<p>Escherichia coli ( Ec ) LPS</p>{/NP_P_11} on {NP_12}<p>alkaline phosphatase ( ALP )</p> activity and expression{/NP_12} of {NP_13}<p>dentin sialophosphoprotein ( DSPP )</p> and <p>osteocalcin ( OCN ) genes</p> in vitro differentiation <s>human</s> <Bpcl>dental pulp cell</Bpcl>{/NP_13} .

{NP_14}METHODS{/NP_14} : {NP_15}Odontoblast-like <Bpcl>cells</Bpcl>{/NP_15} {VP_pass_16}were cultured{/VP_pass_16} , {NP_17}<Bpcl>cells</Bpcl>{/NP_17} {VP_act_18}exposed{/VP_act_18} to {NP_P_19}<p>Ec LPS</p>{/NP_P_19} for {NP_20}12 h{/NP_20} , {NP_21}total RNA{/NP_21} {VP_pass_22}was isolated{/VP_pass_22} and {NP_P_23}<p>DSPP</p>{/NP_P_23} , {NP_P_24}<p>OCN transcripts</p>{/NP_P_24} {VP_pass_25}were examined{/VP_pass_25} by {NP_B_26}real-time <B>RT-PCR</B>{/NP_B_26} .

{NP_27}<p>ALP</p> kit{/NP_27} {VP_pass_28}were used{/VP_pass_28} to {NP_29}assessed the changes{/NP_29} of {NP_30}<p>ALP</p> activity{/NP_30} .

{NP_31}RESULTS{/NP_31} : {NP_32}Real-time <B>RT-PCR</B> analysis{/NP_32} {VP_act_33}indicated{/VP_act_33} that {NP_P_34}<p>Ec LPS</p>{/NP_P_34} {VP_act_35}induced{/VP_act_35} about {NP_36}a 3.6-fold{/NP_36} {VP_act_37}decrease{/VP_act_37} for {NP_P_38}<p>DSPP gene</p>{/NP_P_38} and {NP_39}a 1.6-fold{/NP_39} {VP_act_40}decrease{/VP_act_40} for {NP_P_41}<p>OCN gene</p>{/NP_P_41} in {NP_42}odontoblast-like <Bpcl>cells</Bpcl>{/NP_42} as {JP_43}compared{/JP_43} with {NP_44}controls{/NP_44} .

At {NP_45}the same time{/NP_45} , {NP_46}<Bpcl>cells</Bpcl>{/NP_46} {VP_pass_47}treated{/VP_pass_47} with {NP_P_48}<p>LPS</p>{/NP_P_48} {VP_act_49}could depress{/VP_act_49} {NP_50}<p>ALP</p> activity{/NP_50} from {NP_51}( 1156.10 +/- 100.60 ) pmol x h ( -1 ) x ng{/NP_51} {AV_52}( -1 ) down{/AV_52} to {NP_53}( 884.80 +/- 26.72 ) pmol x h ( -1 ) x ng ( -1 ){/NP_53} .

{NP_54}CONCLUSIONS{/NP_54} : {NP_55}These results{/NP_55} {VP_act_56}indicate{/VP_act_56} that {NP_57}exposure{/NP_57} of {NP_58}odontoblast-like <Bpcl>cells</Bpcl>{/NP_58} to {NP_P_59}<p>LPS</p>{/NP_P_59} {VP_act_60}can alter{/VP_act_60} {NP_61}<Bpcl>cells</Bpcl>{/NP_61} {VP_pass_62}function{/VP_pass_62} by {VP_act_63}downregulating{/VP_act_63} {NP_64}<Bpcl>cell</Bpcl> markers{/NP_64} of {NP_65}odontoblastic activity{/NP_65} .


{NP_1}PMID{/NP_1} - {CP_2}19031942{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}Activated <p>p38-MAPK</p>{/NP_P_4} and {NP_5}gemcitabine sensitivity{/NP_5} in {NP_6}recurrent ovarian cancer{/NP_6} .

{NP_7}AB{/NP_7} - {NP_8}BACKGROUND{/NP_8} :

{NP_9}Our study{/NP_9} {VP_act_10}aimed{/VP_act_10} {VP_act_11}to investigate{/VP_act_11} if {NP_P_12}<p>p38-MAPK</p>{/NP_P_12} {VP_pass_13}determined{/VP_pass_13} in {NP_14}primary ovarian cancer{/NP_14} {VP_act_15}can serve{/VP_act_15} as {NP_16}a predictive marker{/NP_16} for {NP_17}sensitivity{/NP_17} {VP_act_18}to gemcitabine{/VP_act_18} {NP_19}treatment{/NP_19} in {NP_20}recurrent disease{/NP_20} .

OUTPUT 0
PTM = ({NP_P_23};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_23}<p>p38-MAPK</p>{/NP_P_23};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_23}Activated ( phosphorylated ) <p>p38-MAPK</p>{/NP_P_23}25..32|<p>p38-MAPK</p>]
Site = (-;-;UNK)

{NP_21}MATERIALS{/NP_21} AND {NP_22}METHODS{/NP_22} : {NP_P_23}Activated ( phosphorylated ) <p>p38-MAPK</p>{/NP_P_23} {VP_pass_24}was immunohistochemically assessed{/VP_pass_24} in {NP_25}paraffin-embedded tumors{/NP_25} {VP_pass_26}obtained{/VP_pass_26} at {NP_27}primary debulking surgery{/NP_27} from {NP_28}45 patients{/NP_28} {VP_act_29}treated{/VP_act_29} with {NP_30}gemcitabine{/NP_30} for {NP_31}platinum-resistant recurrence{/NP_31} .

{NP_32}The value{/NP_32} of {NP_P_33}activated <p>p38-MAPK</p>{/NP_P_33} in {VP_act_34}predicting{/VP_act_34} {NP_35}sensitivity{/NP_35} {VP_act_36}to gemcitabine{/VP_act_36} {NP_37}treatment{/NP_37} {VP_pass_38}was statistically evaluated{/VP_pass_38} .

{NP_39}RESULTS{/NP_39} : {NP_P_40}Activated <p>p38-MAPK</p>{/NP_P_40} {VP_pass_41}was demonstrated{/VP_pass_41} in {NP_42}all healthy ovaries{/NP_42} and {NP_43}all ovarian carcinomas{/NP_43} {VP_act_44}examined{/VP_act_44} .

In {NP_45}controls{/NP_45} , {NP_B_46}the median <B>histological score ( H-score )</B>{/NP_B_46} for {NP_47}activated <p>p38-MAPK</p> staining{/NP_47} {VP_pass_48}was{/VP_pass_48} {CP_49}200{/CP_49} , while in {NP_50}ovarian cancer{/NP_50} {NP_B_51}the median <B>H-score</B>{/NP_B_51} {VP_pass_52}was{/VP_pass_52} {CP_53}100{/CP_53} .

{NP_54}Activity{/NP_54} of {NP_P_55}<p>p38-MAPK</p>{/NP_P_55} in {NP_56}ovarian <Bpcl>cancer tissue</Bpcl>{/NP_56} {VP_pass_neg_57}was not associated{/VP_pass_neg_57} with {NP_58}overall response or survival{/NP_58} after {NP_59}gemcitabine chemotherapy{/NP_59} .

{NP_60}CONCLUSION{/NP_60} : {NP_61}<p>P38-MAPK</p> activity{/NP_61} , {VP_pass_62}determined{/VP_pass_62} by {NP_63}immunohistochemistry{/NP_63} in {NP_64}ovarian cancer specimens{/NP_64} {VP_pass_65}obtained{/VP_pass_65} at {NP_66}primary diagnosis{/NP_66} , {VP_act_neg_67}cannot serve{/VP_act_neg_67} as {NP_68}a predictive marker{/NP_68} for {NP_69}sensitivity{/NP_69} {VP_act_70}to gemcitabine{/VP_act_70} {NP_71}treatment{/NP_71} in {NP_72}platinum-resistant disease{/NP_72} .


{NP_1}PMID{/NP_1} - {CP_2}19032687{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Variations{/NP_4} in {NP_5}creatine <Bppf>kinase</Bppf> activity{/NP_5} and {NP_6}reactive <c>oxygen</c> species levels{/NP_6} {VP_pass_7}are involved{/VP_pass_7} in {NP_8}capacitation{/NP_8} of {NP_9}<s>bovine</s> spermatozoa{/NP_9} .

OUTPUT 0
PTM = ({NP_16};substrate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_10}AB{/NP_10} - {NP_11}The generation{/NP_11} of {NP_C_12}<c>reactive oxygen species ( ROS )</c>{/NP_C_12} {VP_pass_13}is associated{/VP_pass_13} with {NP_P_14}some <Bppf>factors</Bppf>{/NP_P_14} {JP_15}such{/JP_15} as {NP_16}oxidative <Bppf>substrate</Bppf> sources{/NP_16} , {NP_17}mitochondrial function and <p>NAD(P) H oxidase</p> activity{/NP_17} .

In {NP_18}<s>bovine</s> spermatozoa{/NP_18} , {NP_19}<B>heparin</B> capacitation{/NP_19} {VP_act_20}produces{/VP_act_20} {NP_21}a respiratory burst{/NP_21} {JP_22}sensitive{/JP_22} to {NP_C_23}<c>diphenyleneiodonium ( DPI )</c>{/NP_C_23} .

{NP_P_24}<p>Creatine kinase ( CK )</p>{/NP_P_24} {VP_pass_25}is related{/VP_pass_25} to {NP_26}extramitochondrial <p>ATP</p> disponibility{/NP_26} .

{NP_27}Our purpose{/NP_27} {VP_pass_28}was{/VP_pass_28} {VP_act_29}to determine{/VP_act_29} {NP_30}the variation{/NP_30} in {NP_31}<c>ROS</c> level{/NP_31} and {NP_32}its relation{/NP_32} with {NP_P_33}<p>NAD(P) H oxidase</p>{/NP_P_33} {JP_34}sensitive{/JP_34} to {NP_35}<c>DPI</c> and <p>CK</p> participation{/NP_35} , as {NP_P_36}<Bppf>factors</Bppf>{/NP_P_36} {VP_pass_37}involved{/VP_pass_37} in {NP_38}redox state{/NP_38} and {NP_39}energy generation{/NP_39} in {NP_40}capacitation{/NP_40} .

{NP_41}The <c>chlortetracycline</c> technique{/NP_41} {VP_pass_42}was used{/VP_pass_42} {VP_act_43}to evaluate{/VP_act_43} {NP_44}capacitation{/NP_44} .

{NP_45}<p>CK</p> activity and <c>ROS</c> level{/NP_45} {VP_pass_46}were measured{/VP_pass_46} by {NP_47}spectrophotometry{/NP_47} and {NP_C_48}<c>spectrofluorometry</c>{/NP_C_48} {AV_49}respectively{/AV_49} .

{NP_50}The capacitation percentage{/NP_50} {VP_pass_51}was increased{/VP_pass_51} by {NP_52}<B>heparin</B> or <B>quercetin</B> treatment{/NP_52} ( {NP_53}P &lt{/NP_53} ; {NP_54}0.05{/NP_54} ) and {NP_55}no significant differences{/NP_55} in {NP_56}sperm viability{/NP_56} {VP_pass_57}were observed{/VP_pass_57} .

{NP_58}Samples{/NP_58} {VP_pass_59}treated{/VP_pass_59} with {NP_B_60}<B>heparin</B> or <B>quercetin</B>{/NP_B_60} {VP_act_61}maintained{/VP_act_61} {NP_62}the same <c>ROS</c> level{/NP_62} as {NP_63}control{/NP_63} ( {NP_64}238.62 +/- 23.47 arbitrary <Bpcf>units</Bpcf>{/NP_64} per {NP_65}<B>10(8)</B> spermatozoa{/NP_65} ) {NP_66}( P &gt; 0.05 ){/NP_66} .

{NP_67}<p>CK</p> activity{/NP_67} {VP_pass_68}decreased{/VP_pass_68} by {NP_69}50%{/NP_69} with {NP_B_70}<B>heparin</B> or <B>quercetin</B>{/NP_B_70} ( {NP_71}P &lt{/NP_71} ; {NP_72}0.05{/NP_72} ) .

In {NP_73}<c>DPI</c> presence{/NP_73} , {NP_74}capacitation{/NP_74} {VP_pass_75}was inhibited{/VP_pass_75} and {NP_76}differential <p>CK</p> activities and ROS level variations{/NP_76} {VP_pass_77}were observed{/VP_pass_77} in {NP_78}<B>heparin</B> - or quercetin-treated samples{/NP_78} ( {NP_79}P &lt{/NP_79} ; {NP_80}0.05{/NP_80} ) .

In {NP_81}cryopreserved <s>bovine</s> spermatozoa{/NP_81} , {NP_82}capacitation{/NP_82} {VP_act_83}requires{/VP_act_83} {NP_84}equilibrium{/NP_84} between {NP_85}oxidative damage susceptibility and <c>ROS</c> levels{/NP_85} .

{NP_86}<p>CK</p> activity{/NP_86} {VP_pass_87}is associated{/VP_pass_87} with {NP_88}redox state variation{/NP_88} and {NP_89}energy sources{/NP_89} .

In {NP_90}conclusion{/NP_90} , {NP_91}capacitation induction{/NP_91} {VP_act_92}depends{/VP_act_92} on {NP_P_93}<p>NADPH oxidase</p>{/NP_P_93} and {NP_G_94}the shuttle creatine-creatine <c>phosphate</c>{/NP_G_94} , both {JP_95}sensitive{/JP_95} to {NP_C_96}<c>DPI</c>{/NP_C_96} .


{NP_1}PMID{/NP_1} - {CP_2}19034100{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Signaling pathways{/NP_4} {VP_pass_5}involved{/VP_pass_5} in {NP_6}desflurane-induced postconditioning{/NP_6} in {NP_7}<s>human</s> atrial myocardium{/NP_7} in {NP_8}vitro{/NP_8} .

{NP_9}AB{/NP_9} - {NP_10}BACKGROUND{/NP_10} :

{NP_11}Isoflurane{/NP_11} and {NP_12}sevoflurane{/NP_12} {VP_pass_13}have been shown{/VP_pass_13} {VP_act_14}to elicit{/VP_act_14} {NP_15}myocardial postconditioning{/NP_15} , but {NP_16}the effect{/NP_16} of {NP_17}desflurane{/NP_17} {VP_act_18}remain{/VP_act_18} {JP_19}unknown{/JP_19} .

{NP_20}The authors{/NP_20} {VP_act_21}studied{/VP_act_21} {NP_22}the mechanisms{/NP_22} {VP_pass_23}involved{/VP_pass_23} in {NP_24}desflurane-induced myocardial postconditioning{/NP_24} .

{NP_25}METHODS{/NP_25} : {VP_act_26}Contracting{/VP_act_26} {NP_27}isolated <s>human</s> right atrial trabeculae{/NP_27} ( {NP_28}34 degrees C{/NP_28} , {NP_B_29}stimulation frequency 1 <B>Hz</B>{/NP_B_29} ) {VP_pass_30}were exposed{/VP_pass_30} to {NP_31}<B>30-min</B> hypoxia{/NP_31} {VP_pass_32}followed{/VP_pass_32} by {NP_33}<B>60-min</B> reoxygenation{/NP_33} .

{NP_34}Desflurane{/NP_34} at {NP_35}3%{/NP_35} , {NP_36}6%{/NP_36} , and {CP_37}9%{/CP_37} {VP_pass_38}was administered{/VP_pass_38} during {NP_B_39}the first <B>5-min</B>{/NP_B_39} of {NP_40}reoxygenation{/NP_40} .

{VP_act_41}Postconditioning{/VP_act_41} with {NP_42}6% desflurane{/NP_42} {VP_pass_43}was studied{/VP_pass_43} in {NP_44}the presence{/NP_44} of {NP_45}1 microM calphostin C{/NP_45} , {NP_P_46}a <Bppf><p>protein kinase C</p> inhibitor</Bppf>{/NP_P_46} ; {NP_C_47}800 mm <c>5-hydroxydecanoate</c>{/NP_C_47} , {NP_P_48}a mitochondrial <p>adenosine triphosphate-sensitive potassium channels antagonist</p>{/NP_P_48} ; {NP_49}1 microM <p>Akt</p> inhibitor{/NP_49} ; {NP_50}20 microM PD89058{/NP_50} , {NP_P_51}an <Bppf>extracellular-regulated <p>kinase 1/2</p> inhibitor</Bppf>{/NP_P_51} ; and {NP_52}1 microM SB 202190{/NP_52} , {NP_P_53}a <p><p>p38 mitogen</p> -activated protein kinase inhibitor</p>{/NP_P_53} .

{NP_54}The force{/NP_54} of {NP_55}contraction{/NP_55} at {NP_56}the end{/NP_56} of {NP_57}the <B>60-min</B> reoxygenation period{/NP_57} {VP_pass_58}was compared{/VP_pass_58} ( {VP_act_59}mean{/VP_act_59} {NP_B_60}+/- <B>SD</B>{/NP_B_60} ) .

OUTPUT 0
PTM = ({NP_61};phosphorylation)
	HasAgentTheme="<Bppf>protein kinase</Bppf>" in "{NP_61}The <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_61}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_61}The <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_61}23..35|<Bppf>protein kinase</Bppf>]
	Filtered={NP_61}The <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_61}23..35|<Bppf>protein kinase</Bppf>	(Category=generic)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_61}The <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_61}23..35|<Bppf>protein kinase</Bppf>]
Site = (-;-;UNK)

{NP_61}The <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_61} {VP_pass_62}was studied{/VP_pass_62} {VP_act_63}using{/VP_act_63} {NP_64}Western{/NP_64} {VP_act_65}blotting{/VP_act_65} .

{NP_66}RESULTS{/NP_66} : {NP_67}Desflurane{/NP_67} at {NP_68}3%{/NP_68} ( {NP_69}77 +/- 10%{/NP_69} of {NP_70}baseline{/NP_70} ) , {NP_71}6%{/NP_71} ( {NP_72}90 +/- 14%{/NP_72} of {NP_73}baseline{/NP_73} ) , and {CP_74}9%{/CP_74} ( {NP_75}86 +/- 11%{/NP_75} of {NP_76}baseline{/NP_76} ) {VP_act_77}enhanced{/VP_act_77} {NP_78}the recovery{/NP_78} of {NP_79}force{/NP_79} after {NP_80}60 min{/NP_80} of {NP_81}reoxygenation{/NP_81} as {JP_82}compared{/JP_82} with {NP_83}the control <Bpcf>group</Bpcf>{/NP_83} ( {NP_84}51 +/- 9%{/NP_84} of {NP_85}baseline{/NP_85} ; {NP_86}<B>P</B> &lt{/NP_86} ; {NP_87}0.001{/NP_87} ) .

{NP_C_88}<c>Calphostin C</c>{/NP_C_88} ( {NP_89}55 +/- 3%{/NP_89} of {NP_90}baseline{/NP_90} ) , {NP_C_91}<c>5-hydroxydecanoate</c>{/NP_C_91} ( {NP_92}53 +/- 3%{/NP_92} of {NP_93}baseline{/NP_93} ) , {NP_P_94}<Bppf><p>Akt</p> inhibitor</Bppf>{/NP_P_94} ( {NP_95}57 +/- 8%{/NP_95} of {NP_96}baseline{/NP_96} ) , {NP_B_97}<B>PD89058</B>{/NP_B_97} ( {NP_98}64 +/- 6%{/NP_98} of {NP_99}baseline{/NP_99} ) , and {NP_B_100}<B>SB 202190</B>{/NP_B_100} ( {NP_101}61 +/- 3%{/NP_101} of {NP_102}baseline{/NP_102} ) {VP_act_103}abolished{/VP_act_103} {NP_104}desflurane-induced postconditioning{/NP_104} .

OUTPUT 1
PTM = ({NP_109};phosphorylation)
	HasAgentTheme="<Bppf>protein kinase</Bppf>" in "{NP_109}<p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_109}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_109}<p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_109}20..32|<Bppf>protein kinase</Bppf>]
	Filtered={NP_109}<p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_109}20..32|<Bppf>protein kinase</Bppf>	(Category=generic)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_109}<p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_109}20..32|<Bppf>protein kinase</Bppf>]
Site = (-;-;UNK)

{NP_105}Western blot analysis{/NP_105} {VP_act_106}showed{/VP_act_106} that {NP_107}6% desflurane{/NP_107} {VP_act_108}increased{/VP_act_108} {NP_109}<p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_109} .

OUTPUT 2
PTM = ({NP_119};phosphorylation)
	HasAgentTheme="<Bppf>protein kinase</Bppf>" in "{NP_119}extracellular-regulated <p>kinase 1/2</p> activation , and <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_119}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>kinase 1/2</p>" in "{NP_119}extracellular-regulated <p>kinase 1/2</p> activation , and <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_119}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="{NP_P_117}mitochondrial <p>adenosine triphosphate-sensitive potassium channels</p>{/NP_P_117}" 	(Features:dist=0|pparg)
		Candidate="<p>adenosine triphosphate-sensitive potassium channels</p>" in "{NP_P_117}mitochondrial <p>adenosine triphosphate-sensitive potassium channels</p>{/NP_P_117}" 	(Features:dist=0|pparg)
Substrate = (-;-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_119}extracellular-regulated <p>kinase 1/2</p> activation , and <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_119}66..78|<Bppf>protein kinase</Bppf>]
	Filtered={NP_119}extracellular-regulated <p>kinase 1/2</p> activation , and <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_119}66..78|<Bppf>protein kinase</Bppf>	(Category=generic)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_119}extracellular-regulated <p>kinase 1/2</p> activation , and <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_119}66..78|<Bppf>protein kinase</Bppf>]
Site = (-;-;UNK)

{NP_110}CONCLUSIONS{/NP_110} : {NP_111}In vitro{/NP_111} , {NP_112}desflurane{/NP_112} {VP_act_113}postconditioned{/VP_act_113} {NP_114}<s>human</s> atrial myocardium{/NP_114} through {NP_115}<p>protein kinase C</p> activation{/NP_115} , {NP_116}opening{/NP_116} of {NP_P_117}mitochondrial <p>adenosine triphosphate-sensitive potassium channels</p>{/NP_P_117} , {NP_P_118}<p>Akt</p>{/NP_P_118} and {NP_119}extracellular-regulated <p>kinase 1/2</p> activation , and <p>p38 mitogen</p> -activated <Bppf>protein kinase</Bppf> phosphorylation{/NP_119} .


{NP_1}PMID{/NP_1} - {CP_2}19034104{/CP_2}

{NP_3}TI{/NP_3} - {NP_C_4}<c>Gabapentin</c>{/NP_C_4} {VP_act_5}acts{/VP_act_5} within {NP_PP_6}the <Bppp>locus</Bppp>{/NP_PP_6} {JP_7}coeruleus{/JP_7} {VP_act_8}to alleviate{/VP_act_8} {NP_9}neuropathic pain{/NP_9} .

{NP_10}AB{/NP_10} - {NP_11}BACKGROUND{/NP_11} :

{NP_12}<c>Gabapentin</c> recruits{/NP_12} {VP_act_13}descending{/VP_act_13} {NP_14}inhibition{/NP_14} {VP_act_15}to produce{/VP_act_15} {NP_16}analgesia{/NP_16} after {NP_17}nerve injury{/NP_17} , but whether {NP_18}this{/NP_18} {VP_act_19}is{/VP_act_19} {NP_20}a local action{/NP_20} in {NP_21}the brainstem{/NP_21} {VP_pass_22}is unknown{/VP_pass_22} .

{NP_23}The authors{/NP_23} {VP_act_24}hypothesized{/VP_act_24} that {NP_B_25}<B>gabapentin</B>{/NP_B_25} {VP_act_26}activates{/VP_act_26} {NP_27}noradrenergic neurons{/NP_27} in {NP_PP_28}the <pp>locus coeruleus ( LC )</pp>{/NP_PP_28} by {NP_29}a local action{/NP_29} .

{NP_30}METHODS{/NP_30} : {NP_31}Male <s>rats</s>{/NP_31} {VP_act_32}underwent{/VP_act_32} {NP_B_33}<B>L5-L6 spinal nerve ligation ( SNL )</B>{/NP_B_33} and {VP_act_34}received{/VP_act_34} {NP_35}<Bpcf>drugs</Bpcf>{/NP_35} by {NP_B_36}<B>intra-LC</B>{/NP_B_36} or {NP_37}systemic routes{/NP_37} for {NP_38}behavior testing{/NP_38} , {NP_39}immunohistochemistry{/NP_39} in {NP_40}the <pp>LC</pp> , and microdialysis{/NP_40} in {NP_41}the spinal dorsal horn{/NP_41} .

In {NP_42}other studies{/NP_42} , {NP_43}brainstem slices{/NP_43} from {NP_44}normal and <B>SNL</B> animals{/NP_44} {VP_pass_45}were used{/VP_pass_45} for {NP_46}immunohistochemistry{/NP_46} .

{NP_47}RESULTS{/NP_47} : {NP_B_48}<B>SNL</B>{/NP_B_48} {VP_act_49}increased{/VP_act_49} {NP_B_50}<B>LONGTOKEN</B>{/NP_B_50} {VP_act_51}-expressing{/VP_act_51} {NP_52}nuclei{/NP_52} {AV_53}bilaterally{/AV_53} in {NP_PP_54}the <pp>LC</pp>{/NP_PP_54} , and {VP_act_55}increased{/VP_act_55} {NP_56}noradrenaline release{/NP_56} in {NP_57}the spinal dorsal horn{/NP_57} .

{NP_C_58}<c>Gabapentin</c>{/NP_C_58} , whether in {NP_59}isolated brainstem slices{/NP_59} or in {NP_60}conscious or anesthetized animals{/NP_60} , {VP_act_61}increased{/VP_act_61} {NP_62}<B>pCREB-expressing</B> nuclei{/NP_62} in {NP_PP_63}the <pp>LC</pp>{/NP_PP_63} .

The {VP_pass_64}net increase{/VP_pass_64} in {NP_65}<p>pCREB</p> expression{/NP_65} by {NP_B_66}<B>gabapentin</B>{/NP_B_66} {VP_act_neg_67}did not differ{/VP_act_neg_67} between {NP_68}normal and <B>SNL</B> conditions{/NP_68} .

{NP_69}This gabapentin-induced <p>pCREB</p> activation{/NP_69} in {NP_70}<pp>LC</pp> neurons{/NP_70} {VP_pass_71}was abolished{/VP_pass_71} by {NP_C_72}an <c>AMPA receptor antagonist</c>{/NP_C_72} , {NP_C_73}<c>6-cyano-7-nitroquinoxaline-2,3-dione</c> (CNQX){/NP_C_73} .

{NP_C_74}<c>Intra-LC-injected gabapentin</c>{/NP_C_74} {VP_act_75}reduced{/VP_act_75} {NP_76}hypersensitivity{/NP_76} in {NP_77}<B>SNL</B> <s>rats</s>{/NP_77} in {NP_78}a dose -dependent manner{/NP_78} .

{NP_79}Both <B>intra-LC</B> coadministration{/NP_79} of {NP_B_80}<B>CNQX</B>{/NP_B_80} and {NP_81}intrathecal administration{/NP_81} of {NP_C_82}the alpha2-adrenoceptor <c>antagonist idazoxan</c>{/NP_C_82} {VP_act_83}blocked{/VP_act_83} {NP_84}antihypersensitivity{/NP_84} by {NP_B_85}<B>intra-LC gabapentin</B>{/NP_B_85} .

{NP_B_86}Intravenous <B>gabapentin</B>{/NP_B_86} {VP_act_87}induced{/VP_act_87} {NP_88}noradrenaline release{/NP_88} in {NP_89}the spinal dorsal horn{/NP_89} .

{NP_90}The net amount{/NP_90} of {NP_91}noradrenaline release{/NP_91} by {NP_B_92}<B>gabapentin</B>{/NP_B_92} {VP_pass_93}is larger{/VP_pass_93} in {NP_94}<B>SNL</B> <s>rats</s>{/NP_94} {VP_act_95}compared{/VP_act_95} with {NP_96}the normal condition{/NP_96} , although {NP_97}the percentage{/NP_97} {VP_act_98}increases{/VP_act_98} from {NP_99}the baseline{/NP_99} {VP_pass_100}were{/VP_pass_100} the {JP_101}same{/JP_101} .

{NP_102}CONCLUSIONS{/NP_102} : {NP_103}These results{/NP_103} {VP_act_104}suggest{/VP_act_104} that {NP_B_105}<B>gabapentin</B>{/NP_B_105} {VP_act_106}acts{/VP_act_106} {AV_107}directly{/AV_107} in {NP_108}the brainstem{/NP_108} via {NP_109}a glutamate -dependent mechanism{/NP_109} {VP_act_110}to stimulate{/VP_act_110} {NP_111}descending inhibition{/NP_111} {VP_act_112}to produce{/VP_act_112} {NP_113}antihypersensitivity{/NP_113} after {NP_114}peripheral nerve injury{/NP_114} .


{NP_1}PMID{/NP_1} - {CP_2}19000314{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Displacement affinity chromatography{/NP_4} of {NP_B_5}<B><p>protein phosphatase</p> one ( <p>PP1</p> ) complexes</B>{/NP_B_5} .

{NP_6}AB{/NP_6} - {NP_7}BACKGROUND{/NP_7} :

{NP_P_8}<p>Protein phosphatase one ( PP1 )</p>{/NP_P_8} {VP_act_9}is{/VP_act_9} a {JP_10}ubiquitously expressed{/JP_10} , {VP_act_11}highly conserved{/VP_act_11} {NP_P_12}<p>protein phosphatase</p>{/NP_P_12} {NP_13}that{/NP_13} {VP_act_14}dephosphorylates{/VP_act_14} {NP_PP_15}<p>target protein</p> <pp>serine</pp> and <pp>threonine residues</pp>{/NP_PP_15} .

{NP_P_16}<p>PP1</p>{/NP_P_16} {VP_pass_17}is localized{/VP_pass_17} to {NP_PP_18}its <Bppp>site</Bppp>{/NP_PP_18} of {NP_19}action{/NP_19} by {VP_act_20}interacting{/VP_act_20} with {VP_act_21}targeting{/VP_act_21} or {NP_P_22}regulatory <Bppf>proteins</Bppf>{/NP_P_22} , {NP_23}a majority{/NP_23} of {NP_24}which{/NP_24} {VP_act_25}contains{/VP_act_25} {NP_PP_26}a primary <Bppp>docking site</Bppp>{/NP_PP_26} {VP_act_27}referred{/VP_act_27} to as {NP_PP_28}the <pp>RVXF/W motif</pp>{/NP_PP_28} .

{NP_29}RESULTS{/NP_29} : {NP_30}We{/NP_30} {VP_act_31}demonstrate{/VP_act_31} that {NP_PP_32}a <Bppp>peptide</Bppp>{/NP_PP_32} {VP_pass_33}based{/VP_pass_33} on {NP_PP_34}the <pp>RVXF/W motif</pp>{/NP_PP_34} {VP_act_35}can effectively displace{/VP_act_35} {NP_P_36}<p>PP1</p>{/NP_P_36} {VP_act_37}bound{/VP_act_37} {NP_P_38}<Bppf>proteins</Bppf>{/NP_P_38} from {NP_P_39}<p>PP1</p>{/NP_P_39} {VP_pass_40}retained{/VP_pass_40} on {NP_B_41}the <p>phosphatase</p> affinity matrix <B>microcystin-Sepharose</B>{/NP_B_41} .

{NP_42}Subsequent co-immunoprecipitation experiments{/NP_42} {VP_act_43}confirmed{/VP_act_43} that {NP_P_44}each identified <Bppf>binding protein</Bppf>{/NP_P_44} {VP_pass_45}was{/VP_pass_45} either {NP_46}a direct <p>PP1</p> interactor{/NP_46} or {VP_pass_47}was{/VP_pass_47} in {NP_48}a <Bpf>complex</Bpf>{/NP_48} {NP_49}that{/NP_49} {VP_act_50}contains{/VP_act_50} {NP_P_51}<p>PP1</p>{/NP_P_51} .

{NP_52}Our results{/NP_52} {VP_act_53}have linked{/VP_act_53} {NP_P_54}<p>PP1</p>{/NP_P_54} to {NP_P_55}numerous new nuclear functions and <Bppf>proteins</Bppf>{/NP_P_55} , {VP_act_56}including{/VP_act_56} {NP_P_57}<p>Ki-67</p>{/NP_P_57} , {NP_P_58}<p>Rif-1</p>{/NP_P_58} , {NP_B_59}<p>topoisomerase</p> IIalpha{/NP_B_59} , {NP_60}several nuclear helicases{/NP_60} , {NP_P_61}<p>NUP153</p>{/NP_P_61} and {NP_P_62}the <p>TRRAP complex</p>{/NP_P_62} .

{NP_63}CONCLUSION{/NP_63} : {NP_64}This modification{/NP_64} of {NP_65}the <B>microcystin-Sepharose</B> technique{/NP_65} {VP_act_66}offers{/VP_act_66} {NP_67}an effective means{/NP_67} of {VP_act_68}purifying{/VP_act_68} {NP_P_69}novel <p>PP1</p> regulatory <Bppf>subunits</Bppf>{/NP_P_69} and {VP_act_70}associated{/VP_act_70} {NP_P_71}<Bppf>proteins</Bppf>{/NP_P_71} and {VP_act_72}provides{/VP_act_72} {NP_73}a simple method{/NP_73} {VP_act_74}to uncover{/VP_act_74} {NP_75}a link{/NP_75} between {NP_P_76}<p>PP1</p>{/NP_P_76} and {NP_77}additional cellular processes{/NP_77} .


{NP_1}PMID{/NP_1} - {CP_2}19002174{/CP_2}

{NP_3}TI{/NP_3} - <p>Isothiocyanate NB7M</p> causes {NP_4}selective cytotoxicity{/NP_4} , {VP_act_5}pro-apoptotic signalling{/VP_act_5} and {NP_6}cell -cycle regression{/NP_6} in {NP_7}ovarian <Bpcl>cancer cells</Bpcl>{/NP_7} .

{NP_8}AB{/NP_8} - {NP_9}The present report{/NP_9} {VP_act_10}identifies{/VP_act_10} {NP_P_11}<p>indole-3-ethyl isothiocyanate NB7M</p>{/NP_P_11} as {NP_12}a potent cytotoxic agent{/NP_12} with {NP_13}selective activity{/NP_13} against {NP_14}<Bpcl>cell lines</Bpcl>{/NP_14} {VP_act_15}derived{/VP_act_15} from {NP_16}various tumour types{/NP_16} .

{NP_17}Ovarian <Bpcl>cancer cell lines</Bpcl>{/NP_17} {VP_act_18}showed{/VP_act_18} {NP_19}sensitivity{/NP_19} to {NP_P_20}<p>NB7M</p>{/NP_P_20} ( {NP_21}60-70% cytotoxicity{/NP_21} at {NP_22}2.5 microM{/NP_22} ) , in {NP_23}contrast{/NP_23} {VP_act_24}to control{/VP_act_24} {NP_25}<Bpcl>cells</Bpcl>{/NP_25} ( {NP_P_26}<p>TCL-1</p> and <p>HTR-8</p>{/NP_P_26} ; {NP_27}<B>IC ( 50 )</B> approximately 15 microM{/NP_27} ) .

In {NP_28}a screen{/NP_28} {VP_pass_29}performed{/VP_pass_29} by {NP_B_30}the <B>National Cancer Institute ( NCI )</B>{/NP_B_30} ( {NP_31}<B>NCI ( 60 )</B> <Bpcl>cancer cell</Bpcl>{/NP_31} - {NP_32}line assay{/NP_32} ) {NP_P_33}<p>NB7M (NSC746077)</p>{/NP_P_33} {VP_act_34}reduced{/VP_act_34} {NP_35}growth{/NP_35} up to {NP_36}100%{/NP_36} with {NP_B_37}an <B>IC ( 50 )</B>{/NP_B_37} between {NP_38}0.1{/NP_38} and {NP_39}10 microM{/NP_39} {VP_act_40}depending{/VP_act_40} on {NP_41}the <Bpcl>cell line</Bpcl>{/NP_41} {VP_act_42}studied{/VP_act_42} .

{VP_act_43}Using{/VP_act_43} {NP_44}<B>SKOV-3</B> ovarian <Bpcl>cancer cells</Bpcl>{/NP_44} as {NP_45}a model{/NP_45} , {NP_46}mechanisms{/NP_46} of {NP_47}cytotoxicity{/NP_47} {VP_pass_48}were analysed{/VP_pass_48} .

{NP_P_49}<p>NB7M</p>{/NP_P_49} {VP_act_50}caused{/VP_act_50} {NP_51}hallmarks{/NP_51} of {NP_52}apoptosis{/NP_52} {JP_53}such{/JP_53} as {NP_54}<p>PARP-1</p> deactivation{/NP_54} , {NP_55}<p>chromatin</p> condensation{/NP_55} , {NP_56}DNA nicks{/NP_56} , {NP_57}activation{/NP_57} of {NP_P_58}<p>caspases-9</p>{/NP_P_58} , {NP_59}-8{/NP_59} , {NP_60}-3{/NP_60} , {NP_61}loss{/NP_61} of {NP_62}mitochondrial transmembrane depolarisation potential{/NP_62} and {NP_63}upregulation{/NP_63} of {NP_P_64}pro-apoptotic <p>mitogen activated protein kinases</p>{/NP_P_64} ( {NP_P_65}<p>p38</p>{/NP_P_65} , {NP_P_66}<p>SAP/JNK</p>{/NP_P_66} ) .

OUTPUT 0
PTM = ({NP_69};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_67}<p>NB7M</p>{/NP_P_67}" 	(Features:dist=0|subject_main)
		Candidate="<p>NB7M</p>" in "{NP_P_67}<p>NB7M</p>{/NP_P_67}" 	(Features:dist=0|subject_main|subject_main_modifier)
		Candidate="{NP_P_72}<p>AKT</p>{/NP_P_72}" 	(Features:dist=0|is-kinase_inherently)
		Candidate="{NP_P_76}<p>DNA-Pk</p> and <p>AXL receptor tyrosine kinase</p>{/NP_P_76}" 	(Features:dist=0|is-kinase_inherently|pparg)
		Candidate="<p>DNA-Pk</p>" in "{NP_P_76}<p>DNA-Pk</p> and <p>AXL receptor tyrosine kinase</p>{/NP_P_76}" 	(Features:dist=0)
		Candidate="<p>AXL receptor tyrosine kinase</p>" in "{NP_P_76}<p>DNA-Pk</p> and <p>AXL receptor tyrosine kinase</p>{/NP_P_76}" 	(Features:dist=0)
Substrate = ({NP_P_70}<p>prosurvival kinases</p>{/NP_P_70};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_70}<p>prosurvival kinases</p>{/NP_P_70}]
Site = (-;-;UNK)

{NP_P_67}<p>NB7M</p>{/NP_P_67} {VP_act_68}downregulated{/VP_act_68} {NP_69}phosphorylation{/NP_69} of {NP_P_70}<p>prosurvival kinases</p>{/NP_P_70} ( {NP_P_71}<p>PI-3K</p>{/NP_P_71} , {NP_P_72}<p>AKT</p>{/NP_P_72} , {NP_P_73}<p>IKK alpha</p>{/NP_P_73} ) , {NP_P_74}<p>transcription factor NF-kappaB</p>{/NP_P_74} , and {NP_75}expression{/NP_75} of {NP_P_76}<p>DNA-Pk</p> and <p>AXL receptor tyrosine kinase</p>{/NP_P_76} .

{NP_77}Subcytotoxic doses{/NP_77} of {NP_P_78}<p>NB7M</p>{/NP_P_78} {VP_act_79}inhibited{/VP_act_79} {NP_80}DNA synthesis{/NP_80} , {VP_act_81}caused{/VP_act_81} {NP_82}G1-phase cell -cycle arrest{/NP_82} and {VP_act_83}upregulated{/VP_act_83} {NP_84}<p>p27</p> expression{/NP_84} .

{NP_85}The present report{/NP_85} {VP_act_86}suggests{/VP_act_86} that {NP_P_87}<p>NB7M</p>{/NP_P_87} {VP_act_88}is{/VP_act_88} {NP_89}a selective cytotoxic agent{/NP_89} in {NP_90}vitro{/NP_90} for {NP_91}<Bpcl>cell lines</Bpcl>{/NP_91} {VP_act_92}derived{/VP_act_92} from {NP_93}ovarian and certain other tumours{/NP_93} .

In {NP_94}addition{/NP_94} , {NP_P_95}<p>NB7M</p>{/NP_P_95} {VP_act_96}acts{/VP_act_96} as {NP_97}a growth/cell-cycle-suppressing agent{/NP_97} and {VP_pass_98}may be developed{/VP_pass_98} as {NP_99}a potential therapeutic <Bpcf>drug</Bpcf>{/NP_99} {VP_act_100}to treat{/VP_act_100} {NP_101}ovarian cancer{/NP_101} .


{NP_1}PMID{/NP_1} - {CP_2}19018258{/CP_2}

OUTPUT 0
PTM = ({NP_P_4};Phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_4}<p>c-Src</p>{/NP_P_4};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_4}Phosphorylated <p>c-Src</p>{/NP_P_4}14..18|<p>c-Src</p>]
Site = (-;-;UNK)

{NP_3}TI{/NP_3} - {NP_P_4}Phosphorylated <p>c-Src</p>{/NP_P_4} in {NP_5}the nucleus{/NP_5} {VP_pass_6}is associated{/VP_pass_6} with {NP_7}improved <s>patient</s> outcome{/NP_7} in {NP_8}<B>ER-positive</B> breast cancer{/NP_8} .

{NP_9}AB{/NP_9} - {NP_10}Elevated <p>c-Src protein</p> expression{/NP_10} {VP_pass_11}has been shown{/VP_pass_11} in {NP_12}breast cancer{/NP_12} and {NP_13}in vitro evidence{/NP_13} {VP_act_14}suggests{/VP_act_14} {NP_15}a role{/NP_15} in {NP_16}endocrine resistance{/NP_16} .

{VP_act_17}To investigate{/VP_act_17} whether {NP_P_18}<p>c-Src</p>{/NP_P_18} {VP_pass_19}is involved{/VP_pass_19} in {NP_20}endocrine resistance{/NP_20} , {NP_21}we{/NP_21} {VP_act_22}examined{/VP_act_22} {NP_23}the expression{/NP_23} of both {JP_24}total{/JP_24} and {VP_act_25}activated{/VP_act_25} {NP_P_26}<p>c-Src</p>{/NP_P_26} in {NP_27}<s>human</s> breast cancer specimens{/NP_27} from {NP_28}a cohort{/NP_28} of {NP_29}<p>oestrogen receptor (ER)</p>- positive tamoxifen-treated breast cancer patients{/NP_29} .

{NP_30}<Bpcl>Tissue</Bpcl> microarray technology{/NP_30} {VP_pass_31}was employed{/VP_pass_31} {VP_act_32}to analyse{/VP_act_32} {NP_33}262 tumour specimens{/NP_33} {VP_act_34}taken{/VP_act_34} before {NP_35}tamoxifen treatment{/NP_35} .

{NP_36}Immunohistochemistry{/NP_36} {VP_act_37}using{/VP_act_37} {NP_P_38}total <p>c-Src</p>{/NP_P_38} and {NP_P_39}activated <p>c-Src antibodies</p>{/NP_P_39} {VP_pass_40}was performed{/VP_pass_40} .

{NP_41}<c>Kaplan-Meier</c> survival curves{/NP_41} {VP_pass_42}were constructed{/VP_pass_42} and {NP_43}log-rank test{/NP_43} {VP_pass_44}were performed{/VP_pass_44} .

{NP_45}High level{/NP_45} of {NP_P_46}nuclear activated <p>Src</p>{/NP_P_46} {VP_pass_47}was significantly associated{/VP_pass_47} with {NP_48}improved overall survival{/NP_48} ( {NP_49}P{/NP_49} = {NP_50}0.047{/NP_50} ) and {NP_51}lower recurrence rates{/NP_51} on {JP_52}tamoxifen{/JP_52} ( {NP_53}P{/NP_53} = {NP_54}0.02{/NP_54} ) .

{NP_55}Improved <s>patient</s> outcome{/NP_55} {VP_pass_56}was only seen{/VP_pass_56} with {NP_P_57}activated <p>Src</p>{/NP_P_57} in {NP_58}the nucleus{/NP_58} .

{NP_59}Nuclear activated <p>Src</p> expression{/NP_59} {VP_pass_60}was significantly associated{/VP_pass_60} with {NP_61}node-negative disease{/NP_61} and {NP_P_62}a lower <p>NPI</p>{/NP_P_62} ( {NP_63}P&lt{/NP_63} ; {NP_64}0.05{/NP_64} ) .

On {NP_65}<Bpcf>subgroup</Bpcf> analysis{/NP_65} , {NP_66}only <p>ER-positive/progesterone receptor ( PgR )</p>- positive tumours{/NP_66} {VP_pass_67}were associated{/VP_pass_67} with {NP_68}improved survival{/NP_68} ( {NP_69}P{/NP_69} = {NP_70}0.004{/NP_70} ) .

{NP_71}This{/NP_71} {VP_act_72}shows{/VP_act_72} that {NP_73}<p>c-Src</p> activity{/NP_73} {VP_pass_74}is increased{/VP_pass_74} in {NP_75}breast cancer{/NP_75} and that {NP_P_76}activated <p>Src</p>{/NP_P_76} within {NP_77}the nucleus{/NP_77} of {NP_78}<B>ER-positive</B> tumours{/NP_78} {VP_act_79}predicts{/VP_act_79} {NP_80}an improved outcome{/NP_80} .

In {NP_81}<B>ER/PgR-positive</B> disease{/NP_81} , {VP_act_82}activated{/VP_act_82} {NP_P_83}<p>Src kinase</p>{/NP_P_83} {VP_act_neg_84}does not appear{/VP_act_neg_84} {VP_pass_85}to be involved{/VP_pass_85} in {NP_86}de novo endocrine resistance{/NP_86} .

{NP_87}Further study{/NP_87} {VP_pass_88}is required{/VP_pass_88} in {NP_89}<B>ER-negative</B> breast cancer{/NP_89} as {NP_90}this{/NP_90} {VP_act_91}may represent{/VP_act_91} {NP_92}a cohort{/NP_92} in {NP_93}which{/NP_93} {NP_94}it{/NP_94} {VP_pass_95}is associated{/VP_pass_95} with {NP_96}poor outcome{/NP_96} .


{NP_1}PMID{/NP_1} - {CP_2}19034280{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Antiproliferative activity{/NP_4} of {NP_C_5}<c>PEP005</c>{/NP_C_5} , {NP_6}a novel ingenol angelate{/NP_6} {NP_7}that{/NP_7} {VP_act_8}modulates{/VP_act_8} {NP_9}<p>PKC</p> functions{/NP_9} , {AV_10}alone{/AV_10} and in {NP_11}combination{/NP_11} with {NP_12}cytotoxic agents{/NP_12} in {NP_13}<s>human</s> colon <Bpcl>cancer cells</Bpcl>{/NP_13} .

{NP_14}AB{/NP_14} - {NP_C_15}<c>PEP005</c>{/NP_C_15} {VP_act_16}is{/VP_act_16} {NP_17}a novel ingenol angelate{/NP_17} {NP_18}that{/NP_18} {VP_act_19}modulates{/VP_act_19} {NP_20}<p>protein kinases C ( PKC )</p> functions{/NP_20} by {VP_act_21}activating{/VP_act_21} {NP_P_22}<p>PKC delta</p>{/NP_P_22} and {VP_act_23}inhibiting{/VP_act_23} {NP_P_24}<p>PKC alpha</p>{/NP_P_24} .

{NP_25}This study{/NP_25} {VP_act_26}assessed{/VP_act_26} {NP_27}the antiproliferative effects{/NP_27} of {NP_C_28}<c>PEP005</c>{/NP_C_28} {AV_29}alone{/AV_29} and in {NP_30}combination{/NP_30} with {NP_31}several other anticancer agents{/NP_31} in {NP_32}a panel{/NP_32} of {NP_33}10 <s>human</s> <Bpcl>cancer cell lines</Bpcl>{/NP_33} {VP_act_34}characterised{/VP_act_34} for {NP_35}expression{/NP_35} of {NP_P_36}several <p>PKC isoforms</p>{/NP_P_36} .

{NP_C_37}<c>PEP005</c>{/NP_C_37} {VP_act_38}displayed{/VP_act_38} {NP_39}antiproliferative effects{/NP_39} at {NP_40}clinically relevant concentrations{/NP_40} with {NP_41}a unique cytotoxicity profile{/NP_41} {NP_42}that{/NP_42} {VP_act_43}differs{/VP_act_43} from that of {NP_44}most other investigated cytotoxic agents{/NP_44} , {VP_act_45}including{/VP_act_45} {NP_C_46}<c>staurosporine</c>{/NP_C_46} .

In {NP_47}a subset{/NP_47} of {NP_48}colon <Bpcl>cancer cells</Bpcl>{/NP_48} , {NP_B_49}the <B>IC ( 50 )</B>{/NP_B_49} of {NP_C_50}<c>PEP005</c>{/NP_C_50} {VP_act_51}ranged{/VP_act_51} from {NP_52}0.01-140 microM{/NP_52} .

{NP_53}The antiproliferative effects{/NP_53} of {NP_C_54}<c>PEP005</c>{/NP_C_54} {VP_pass_55}were shown{/VP_pass_55} {VP_pass_56}to be{/VP_pass_56} {NP_57}concentration{/NP_57} - and {NP_58}time{/NP_58} {JP_59}-dependent{/JP_59} .

In {NP_S_60}<S>Colo205 cells</S>{/NP_S_60} , {NP_61}apoptosis induction{/NP_61} {VP_pass_62}was observed{/VP_pass_62} at {NP_63}concentrations{/NP_63} {VP_act_64}ranging{/VP_act_64} from {NP_65}0.03{/NP_65} to {NP_66}3 microM{/NP_66} .

{NP_67}Exposure{/NP_67} to {NP_C_68}<c>PEP005</c>{/NP_C_68} {VP_act_69}also induced{/VP_act_69} {NP_70}accumulation{/NP_70} of {NP_71}<Bpcl>cells</Bpcl>{/NP_71} in {NP_72}the <B>G1</B> phase{/NP_72} of {NP_73}the <Bpcl>cell</Bpcl> cycle{/NP_73} .

OUTPUT 0
PTM = ({NP_77};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_78}<p>PKC delta</p>{/NP_P_78};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_78}<p>PKC delta</p> and <p>p38</p>{/NP_P_78}0..7|<p>PKC delta</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_78}<p>PKC delta</p> and <p>p38</p>{/NP_P_78}11..13|<p>p38</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_77};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_78}<p>p38</p>{/NP_P_78};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_78}<p>PKC delta</p> and <p>p38</p>{/NP_P_78}0..7|<p>PKC delta</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_78}<p>PKC delta</p> and <p>p38</p>{/NP_P_78}11..13|<p>p38</p>]
Site = (-;-;UNK)

In {NP_74}addition{/NP_74} , {NP_C_75}<c>PEP005</c>{/NP_C_75} {VP_act_76}increased{/VP_act_76} {NP_77}the phosphorylation{/NP_77} of {NP_P_78}<p>PKC delta</p> and <p>p38</p>{/NP_P_78} .

In {NP_S_79}<S>Colo205 cells</S>{/NP_S_79} , {NP_80}combinations{/NP_80} of {NP_C_81}<c>PEP005</c>{/NP_C_81} with {NP_82}several cytotoxic agents{/NP_82} {VP_act_83}including{/VP_act_83} {NP_B_84}<B>oxaliplatin</B>{/NP_B_84} , {NP_P_85}<p>SN38</p>{/NP_P_85} , {NP_B_86}<B>5FU</B>{/NP_B_86} , {NP_87}gemcitabine{/NP_87} , {NP_C_88}<c>doxorubicin</c>{/NP_C_88} , {NP_89}vinorelbine{/NP_89} , and {NP_C_90}<c>docetaxel</c>{/NP_C_90} {VP_act_91}yielded{/VP_act_91} {NP_92}<Bppp>sequence</Bppp> -dependent antiproliferative effects{/NP_92} .

{NP_93}<Bpcl>Cell</Bpcl> cycle blockage{/NP_93} {VP_pass_94}induced{/VP_pass_94} by {NP_C_95}<c>PEP005</c>{/NP_C_95} in {NP_B_96}late <B>G1</B>{/NP_B_96} {VP_act_97}lasted{/VP_act_97} for up to {NP_98}24 h{/NP_98} and {AV_99}therefore{/AV_99} {NP_100}a 24 h{/NP_100} {JP_101}lag-time{/JP_101} between {NP_C_102}<c>PEP005</c>{/NP_C_102} and {NP_103}subsequent exposure{/NP_103} to {NP_104}cytotoxics{/NP_104} {VP_pass_105}was required{/VP_pass_105} {VP_act_106}to optimise{/VP_act_106} {NP_107}<c>PEP005</c> combinations{/NP_107} with {NP_108}several anticancer agents{/NP_108} .

{NP_109}These data{/NP_109} {VP_act_110}support{/VP_act_110} {NP_111}further evaluation{/NP_111} of {NP_C_112}<c>PEP005</c>{/NP_C_112} as {NP_113}an anticancer agent{/NP_113} and {VP_act_114}may help{/VP_act_114} {VP_act_115}to optimise{/VP_act_115} {NP_116}clinical trials{/NP_116} with {NP_117}<B>PEP005-based</B> combinations{/NP_117} in {NP_118}patients{/NP_118} with {NP_119}solid tumours{/NP_119} .


{NP_1}PMID{/NP_1} - {CP_2}19033821{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Inhibitory effect{/NP_4} of {NP_C_5}<c>dehydrozingerone</c>{/NP_C_5} on {NP_6}vascular smooth muscle <Bpcl>cell</Bpcl> function{/NP_6} .

{NP_7}AB{/NP_7} - {NP_B_8}<B>BACKGROUND/AIMS</B>{/NP_B_8} :

{NP_P_9}<Bppf>Growth factor</Bppf>{/NP_P_9} and {NP_10}oxidative stress-mediated migration and proliferation{/NP_10} of {NP_S_11}<S>vascular smooth muscle cells ( VSMCs )</S>{/NP_S_11} {VP_act_12}play{/VP_act_12} {NP_13}a key role{/NP_13} in {NP_14}the pathogenesis{/NP_14} of {NP_15}atherosclerosis{/NP_15} .

{NP_16}The objective{/NP_16} of {NP_17}this study{/NP_17} {VP_pass_18}was{/VP_pass_18} {VP_act_19}to assess{/VP_act_19} {NP_20}the ability{/NP_20} of {NP_C_21}<c>dehydrozingerone</c>{/NP_C_21} , {NP_22}a structural <Bpf>analog</Bpf>{/NP_22} of {NP_B_23}<B>curcumin</B>{/NP_B_23} , {VP_act_24}to inhibit{/VP_act_24} {NP_25}<B>PDGF</B> -stimulated vascular functions{/NP_25} in {NP_S_26}<S>VSMCs</S>{/NP_S_26} .

{NP_27}METHODS{/NP_27} : {NP_S_28}<S>VSMCs</S>{/NP_S_28} {VP_pass_29}isolated{/VP_pass_29} from {NP_30}adult <s>rats</s>{/NP_30} {VP_pass_31}were treated{/VP_pass_31} with {NP_C_32}<c>dehydrozingerone</c> ( 0 to 50 microM ){/NP_C_32} before {NP_33}challenge{/NP_33} with {NP_B_34}<B>PDGF (10 ng/mL)</B>{/NP_B_34} and {NP_35}migration , proliferation , and collagen synthesis{/NP_35} {VP_pass_36}were assayed{/VP_pass_36} by {JP_37}transwell-migration{/JP_37} , {NP_C_38}<c>thymidine-</c>{/NP_C_38} , and {NP_39}L-proline -incorporation assays{/NP_39} , {AV_40}respectively{/AV_40} .

OUTPUT 0
PTM = ({NP_41};Phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>PDGF-receptor ( PDGFR )</p>" in "{NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Akt</p>" in "{NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_42}<p>Akt</p>{/NP_P_42};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42}0..19|<p>PDGF-receptor ( PDGFR )</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42}23..25|<p>Akt</p>]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_41};Phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>PDGF-receptor ( PDGFR )</p>" in "{NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Akt</p>" in "{NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_42}<p>PDGF-receptor ( PDGFR )</p>{/NP_P_42};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42}0..19|<p>PDGF-receptor ( PDGFR )</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42}23..25|<p>Akt</p>]
Site = (-;-;UNK)

{NP_41}Phosphorylation{/NP_41} of {NP_P_42}<p>PDGF-receptor ( PDGFR )</p> and <p>Akt</p>{/NP_P_42} {VP_pass_43}were assessed{/VP_pass_43} by {NP_44}Western{/NP_44} {VP_act_45}blotting{/VP_act_45} .

{NP_46}Cellular protein <p>tyrosine phosphatase ( PTP )</p> activity{/NP_46} {VP_pass_47}was determined{/VP_pass_47} by {NP_48}the extent{/NP_48} of {NP_49}<c>p-nitro-phenyl phosphate</c> hydrolysis{/NP_49} .

OUTPUT 2
PTM = ({NP_54};phosphorylation)
Inducer = ({NP_54}<p>PDGF/H2O2</p>{/NP_54};-)
	Method=rule: (inducer) for phrase=[{NP_54}<B>PDGF</B> -stimulated <B>VSMC</B> migration , proliferation , collagen synthesis , and <p>PDGF/H2O2</p> -stimulated phosphorylation{/NP_54}64..72|<p>PDGF/H2O2</p>]
Kinase = (-;-)
Substrate = ({NP_P_55}<p>PDGFR-beta</p>{/NP_P_55};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_55}<p>PDGFR-beta</p>{/NP_P_55}]
	Method=rule: (substrate) for phrase=[{NP_P_56}downstream <p>Akt</p>{/NP_P_56}10..12|<p>Akt</p>]
Site = (-;-;UNK)

OUTPUT 3
PTM = ({NP_54};phosphorylation)
Inducer = ({NP_54}<p>PDGF/H2O2</p>{/NP_54};-)
	Method=rule: (inducer) for phrase=[{NP_54}<B>PDGF</B> -stimulated <B>VSMC</B> migration , proliferation , collagen synthesis , and <p>PDGF/H2O2</p> -stimulated phosphorylation{/NP_54}64..72|<p>PDGF/H2O2</p>]
Kinase = (-;-)
Substrate = ({NP_P_56}<p>Akt</p>{/NP_P_56};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_55}<p>PDGFR-beta</p>{/NP_P_55}]
	Method=rule: (substrate) for phrase=[{NP_P_56}downstream <p>Akt</p>{/NP_P_56}10..12|<p>Akt</p>]
Site = (-;-;UNK)

{NP_50}RESULTS{/NP_50} : {NP_C_51}<c>Dehydrozingerone</c>{/NP_C_51} {VP_act_52}elicited{/VP_act_52} {NP_53}a concentration -dependent inhibition{/NP_53} of {NP_54}<B>PDGF</B> -stimulated <B>VSMC</B> migration , proliferation , collagen synthesis , and <p>PDGF/H2O2</p> -stimulated phosphorylation{/NP_54} of {NP_P_55}<p>PDGFR-beta</p>{/NP_P_55} and {NP_P_56}downstream <p>Akt</p>{/NP_P_56} .

{NP_C_57}<c>Dehydrozingerone</c>{/NP_C_57} {VP_act_58}also inhibited{/VP_act_58} {NP_59}<p>H2O2</p> -mediated oxidation{/NP_59} of {NP_B_60}<B>PTP</B>{/NP_B_60} .

{NP_61}CONCLUSIONS{/NP_61} : {NP_C_62}<c>Dehydrozingerone</c>{/NP_C_62} {VP_act_63}is{/VP_act_63} {NP_P_64}a potent <Bppf>inhibitor</Bppf>{/NP_P_64} of {NP_65}growth factor/ <p>H2O2</p> -stimulated <B>VSMC</B> functions{/NP_65} and {VP_act_66}may play{/VP_act_66} {NP_67}a critical role{/NP_67} in {VP_act_68}regulating{/VP_act_68} {NP_69}these events{/NP_69} after {NP_70}vascular injury{/NP_70} .

{NP_71}Inhibition{/NP_71} of {NP_72}oxidation{/NP_72} of {NP_P_73}cellular <p>phosphatases</p>{/NP_P_73} {VP_act_74}may represent{/VP_act_74} {CP_75}one{/CP_75} of {NP_76}the mechanisms{/NP_76} by {NP_77}which{/NP_77} {NP_C_78}<c>dehydrozingerone</c>{/NP_C_78} {VP_act_79}inhibits{/VP_act_79} {NP_80}these <B>VSMC</B> functions{/NP_80} .

{NP_81}Inability{/NP_81} of {NP_82}the structural <Bpf>analog</Bpf> isoeugenol{/NP_82} {VP_act_83}to inhibit{/VP_act_83} {NP_84}<B>PDGF</B> -signaling{/NP_84} {VP_act_85}suggests{/VP_act_85} that {NP_PP_86}the <pp><c>carbonyl</c> side chain</pp>{/NP_PP_86} {VP_act_87}may be necessary{/VP_act_87} for {NP_88}activity{/NP_88} .

NORM=akt
SYNONYM=Akt


{NP_1}PMID{/NP_1} - {CP_2}19033822{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Cardioprotection{/NP_4} by {VP_act_5}postconditioning{/VP_act_5} {VP_pass_6}is lost{/VP_pass_6} in {NP_7}<B>WOKW</B> <s>rats</s>{/NP_7} with {NP_8}metabolic syndrome{/NP_8} : {NP_9}role{/NP_9} of {NP_P_10}<p>glycogen synthase kinase 3beta</p>{/NP_P_10} .

{NP_11}AB{/NP_11} - {NP_12}BACKGROUND{/NP_12} AND {NP_13}OBJECTIVE{/NP_13} :

{VP_act_14}Postconditioning{/VP_act_14} by {NP_15}repetitive <B>I/R</B> cycles{/NP_15} {AV_16}immediately{/AV_16} after {NP_17}onset{/NP_17} of {NP_18}reperfusion{/NP_18} {VP_act_19}protects{/VP_act_19} {NP_20}the heart{/NP_20} .

{NP_21}Metabolic disorders{/NP_21} {VP_act_22}undermine{/VP_act_22} {NP_23}the protection{/NP_23} of {VP_act_24}preconditioning{/VP_act_24} .

{NP_25}The present study{/NP_25} {VP_act_26}tested{/VP_act_26} whether {VP_act_27}postconditioning{/VP_act_27} {VP_act_28}protects{/VP_act_28} {NP_29}hearts{/NP_29} from {NP_30}<s>rats</s>{/NP_30} with {NP_31}established metabolic syndrome [Wistar-Ottawa-Karlsburg W <s>rats</s> ( <B>WOKW</B> )]{/NP_31} .

{NP_32}METHODS{/NP_32} AND {NP_33}RESULTS{/NP_33} : After {NP_34}28 weeks{/NP_34} of {NP_35}age{/NP_35} , {NP_36}<B>WOKW</B> <s>rats</s>{/NP_36} {VP_pass_37}were much heavier{/VP_pass_37} than {NP_38}<B>DA ( Dark Agouti )</B> and <B>Wistar</B> control <s>rats</s>{/NP_38} and {VP_act_39}showed{/VP_act_39} {NP_40}the pattern{/NP_40} of {NP_41}the metabolic syndrome{/NP_41} .

{VP_act_42}Postconditioning{/VP_act_42} {VP_pass_43}was performed{/VP_pass_43} by {NP_44}3 <B>30-second</B> cycles{/NP_44} of {NP_45}reperfusion/ischemia{/NP_45} {AV_46}immediately{/AV_46} after {NP_47}the regional ischemia ( 30 minutes ){/NP_47} .

{NP_48}Infarct size{/NP_48} {VP_pass_49}was comparable{/VP_pass_49} in {NP_50}all control hearts{/NP_50} from {NP_51}<B>DA</B> , <B>Wistar</B> , and <B>WOKW</B> <s>rats</s>{/NP_51} ( {NP_52}58 +/- 2%{/NP_52} , {NP_53}49 +/- 3%{/NP_53} ; {NP_54}49 +/- 2%{/NP_54} , {AV_55}respectively{/AV_55} ) .

{VP_act_56}Postconditioning{/VP_act_56} {NP_57}significantly reduced the infarct size{/NP_57} in {NP_58}<B>DA</B> <s>rats</s> ( 39 +/- 5% ){/NP_58} and {NP_59}<B>Wistar</B> rats ( 29 +/- 3% ){/NP_59} .

In {NP_60}<B>WOKW</B> <s>rats</s>{/NP_60} , {NP_61}the infarct{/NP_61} {VP_act_62}sparing{/VP_act_62} {NP_63}effect{/NP_63} of {VP_act_64}postconditioning{/VP_act_64} {VP_pass_65}was lost{/VP_pass_65} {NP_P_66}( 43 +/- 4% ) .<p>GSK-3beta</p>{/NP_P_66} and {NP_P_67}<p>Erk</p>{/NP_P_67} {VP_pass_68}are involved{/VP_pass_68} in {NP_69}the signaling{/NP_69} of {VP_act_70}postconditioning{/VP_act_70} .

OUTPUT 0
PTM = ({NP_72};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_73}these <Bppf>proteins</Bppf>{/NP_P_73}" 	(Features:dist=0|pparg)
Substrate = ({NP_P_66}<p>GSK-3beta</p>{/NP_P_66};-)
	Method=link (substrate) for phrase=[{NP_P_66}( 43 +/- 4% ) .<p>GSK-3beta</p>{/NP_P_66}10..18|<p>GSK-3beta</p>{NP_P_67}<p>Erk</p>{/NP_P_67}]
		From: {NP_P_73}these <Bppf>proteins</Bppf>{/NP_P_73}
		Path: refer
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_72};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_73}these <Bppf>proteins</Bppf>{/NP_P_73}" 	(Features:dist=0|pparg)
Substrate = ({NP_P_67}<p>Erk</p>{/NP_P_67};-)
	Method=link (substrate) for phrase=[{NP_P_66}( 43 +/- 4% ) .<p>GSK-3beta</p>{/NP_P_66}10..18|<p>GSK-3beta</p>{NP_P_67}<p>Erk</p>{/NP_P_67}]
		From: {NP_P_73}these <Bppf>proteins</Bppf>{/NP_P_73}
		Path: refer
Site = (-;-;UNK)

{AV_71}Therefore{/AV_71} , {NP_72}the phosphorylation{/NP_72} of {NP_P_73}these <Bppf>proteins</Bppf>{/NP_P_73} {VP_pass_74}was determined{/VP_pass_74} by {NP_75}Western blot analysis{/NP_75} .

OUTPUT 2
PTM = ({NP_77};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_78}<p>GSK-3beta</p>{/NP_P_78};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_78}<p>GSK-3beta</p>{/NP_P_78}]
Site = (-;-;UNK)

{VP_act_76}Postconditioning{/VP_act_76} {NP_77}significantly increased the phosphorylation{/NP_77} of {NP_P_78}<p>GSK-3beta</p>{/NP_P_78} in {NP_79}<B>DA</B> and <B>Wistar</B> rats{/NP_79} ( {NP_80}1.6-fold{/NP_80} in {NP_81}<B>DA</B> <s>rats</s>{/NP_81} , {NP_82}2.3-fold{/NP_82} in {NP_83}<B>Wistar</B> rats{/NP_83} , {NP_84}<B>P</B> &lt{/NP_84} ; {NP_85}0.05{/NP_85} ) but {VP_act_86}failed{/VP_act_86} {VP_pass_87}to do so{/VP_pass_87} in {NP_88}<B>WOKW</B> <s>rats</s>{/NP_88} .

OUTPUT 3
PTM = ({NP_91};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_92}<p>Erk</p>{/NP_P_92};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_92}<p>Erk</p>{/NP_P_92}]
Site = (-;-;UNK)

{AV_89}Similarly{/AV_89} , {NP_90}a trend{/NP_90} for {NP_91}an increased phosphorylation{/NP_91} of {NP_P_92}<p>Erk</p>{/NP_P_92} {VP_pass_93}was found{/VP_pass_93} in {NP_94}<B>DA</B> <s>rats</s>{/NP_94} but {AV_95}not{/AV_95} in {NP_96}<B>WOKW</B> <s>rats</s>{/NP_96} .

OUTPUT 4
PTM = ({NP_106};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>GSK-3beta</p>" in "{NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Erk</p>" in "{NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_107}<p>GSK-3beta</p>{/NP_P_107};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107}0..8|<p>GSK-3beta</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107}12..14|<p>Erk</p>]
Site = (-;-;UNK)

OUTPUT 5
PTM = ({NP_106};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>GSK-3beta</p>" in "{NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107}" 	(Features:dist=0|is-substrate_elsewhere)
		Candidate="<p>Erk</p>" in "{NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107}" 	(Features:dist=0|is-substrate_elsewhere)
Substrate = ({NP_P_107}<p>Erk</p>{/NP_P_107};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107}0..8|<p>GSK-3beta</p>]
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107}12..14|<p>Erk</p>]
Site = (-;-;UNK)

{AV_97}Thus{/AV_97} {NP_98}the inefficacy{/NP_98} of {VP_act_99}postconditioning{/VP_act_99} in {VP_act_100}reducing{/VP_act_100} {NP_101}infarct size{/NP_101} in {NP_102}<s>rats</s>{/NP_102} with {NP_103}metabolic syndrome{/NP_103} {VP_pass_104}is paralleled{/VP_pass_104} by {NP_105}a lack{/NP_105} of {NP_106}phosphorylation{/NP_106} of {NP_P_107}<p>GSK-3beta</p> and <p>Erk</p>{/NP_P_107} .

{NP_108}CONCLUSION{/NP_108} : {NP_109}The metabolic syndrome{/NP_109} , as {JP_110}shown{/JP_110} in {NP_111}this animal model{/NP_111} , {VP_act_112}completely abrogates{/VP_act_112} {NP_113}the postconditioning{/NP_113} .

OUTPUT 6
PTM = ({NP_116};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_117}<p>GSK-3beta</p>{/NP_P_117};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_117}<p>GSK-3beta</p>{/NP_P_117}]
Site = (-;-;UNK)

{NP_114}This blockade{/NP_114} {VP_act_115}involves{/VP_act_115} {NP_116}the phosphorylation{/NP_116} of {NP_P_117}<p>GSK-3beta</p>{/NP_P_117} .

{NP_118}Further studies{/NP_118} {VP_act_119}have{/VP_act_119} {VP_act_120}to evaluate{/VP_act_120} whether {NP_121}this block{/NP_121} of {VP_act_122}postconditioning{/VP_act_122} {VP_act_123}makes{/VP_act_123} {NP_124}patients{/NP_124} with {NP_125}a metabolic syndrome{/NP_125} {JP_126}more susceptible{/JP_126} to {NP_127}myocardial damage{/NP_127} after {NP_128}infarction{/NP_128} .

NORM=erk
SYNONYM=Erk

NORM=gsk 3beta
SYNONYM=GSK-3beta


{NP_1}PMID{/NP_1} - {CP_2}19033652{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Tumor metabolism{/NP_4} : {NP_5}<Bpcl>cancer cells</Bpcl>{/NP_5} {VP_act_6}give{/VP_act_6} and {VP_act_7}take{/VP_act_7} {NP_C_8}<c>lactate</c>{/NP_C_8} .

{NP_PP_9}<c>AB - Tumors contain well-oxygenated ( aerobic )</c> and <pp>poorly oxygenated ( hypoxic ) regions</pp>{/NP_PP_9} , {NP_10}which{/NP_10} {VP_pass_11}were thought{/VP_pass_11} {VP_act_12}to utilize{/VP_act_12} {NP_C_13}<c>glucose</c>{/NP_C_13} for {JP_14}oxidative{/JP_14} and {NP_15}<c>glycolytic</c> metabolism{/NP_15} , {AV_16}respectively{/AV_16} .

In {NP_17}this issue{/NP_17} of {NP_B_18}the <B>JCI</B>{/NP_B_18} , {NP_19}Sonveaux et al.show{/NP_19} that {NP_20}<s>human</s> <Bpcl>cancer cells</Bpcl>{/NP_20} {JP_21}cultured{/JP_21} under {NP_22}hypoxic conditions{/NP_22} {VP_act_23}convert{/VP_act_23} {NP_C_24}<c>glucose</c>{/NP_C_24} to {NP_C_25}<c>lactate</c>{/NP_C_25} and {VP_act_26}extrude{/VP_act_26} {NP_27}it{/NP_27} , whereas {NP_28}aerobic <Bpcl>cancer cells</Bpcl>{/NP_28} {VP_act_29}take{/VP_act_29} up {NP_C_30}<c>lactate</c>{/NP_C_30} via {NP_P_31}<p>monocarboxylate transporter 1 ( MCT1 )</p>{/NP_P_31} and {VP_act_32}utilize{/VP_act_32} {NP_33}it{/NP_33} for {NP_34}oxidative phosphorylation{/NP_34} ( {VP_act_35}see{/VP_act_35} {NP_36}the related article{/NP_36} {VP_act_37}beginning{/VP_act_37} on {NP_38}page 3930{/NP_38} ) .

When {NP_P_39}<p>MCT1</p>{/NP_P_39} {VP_pass_40}is inhibited{/VP_pass_40} , {NP_41}aerobic <Bpcl>cancer cells</Bpcl>{/NP_41} {VP_act_42}take{/VP_act_42} up {NP_C_43}<c>glucose</c>{/NP_C_43} {AV_44}rather{/AV_44} than {NP_C_45}<c>lactate</c>{/NP_C_45} , and {NP_S_46}<S>hypoxic cancer cells</S>{/NP_S_46} {VP_act_47}die{/VP_act_47} {JP_48}due{/JP_48} to {NP_49}<c>glucose</c> deprivation{/NP_49} .

{NP_50}Treatment{/NP_50} of {NP_51}tumor-bearing <s>mice</s>{/NP_51} with {NP_P_52}an <Bppf>inhibitor</Bppf>{/NP_P_52} of {NP_53}<p>MCT1</p> retarded tumor growth{/NP_53} .

{NP_54}<p>MCT1</p> expression{/NP_54} {VP_pass_55}was detected{/VP_pass_55} {AV_56}exclusively{/AV_56} in {NP_PP_57}nonhypoxic <Bppp>regions</Bppp>{/NP_PP_57} of {NP_58}<s>human</s> cancer biopsy samples{/NP_58} , and in {NP_59}combination{/NP_59} , {NP_60}these data{/NP_60} {VP_act_61}suggest{/VP_act_61} that {NP_62}<p>MCT1</p> inhibition{/NP_62} {VP_act_63}holds{/VP_act_63} {JP_64}potential{/JP_64} as {NP_65}a novel cancer therapy{/NP_65} .


{NP_1}PMID{/NP_1} - {CP_2}19033656{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}<p>KIS</p>{/NP_P_4} {VP_act_5}protects{/VP_act_5} against {NP_6}adverse vascular remodeling{/NP_6} by {VP_act_7}opposing{/VP_act_7} {NP_8}stathmin-mediated <B>VSMC</B> migration{/NP_8} in {NP_9}<s>mice</s>{/NP_9} .

{NP_10}AB{/NP_10} - {NP_11}Vascular proliferative diseases{/NP_11} {VP_pass_12}are characterized{/VP_pass_12} by {NP_13}<B>VSMC</B> proliferation and migration{/NP_13} .

{NP_14}<p>Kinase interacting with stathmin ( KIS )</p> targets 2 key <Bpf>regulators</Bpf>{/NP_14} of {NP_15}<Bpcl>cell</Bpcl> proliferation and migration{/NP_15} , {NP_P_16}the <p>cyclin -dependent kinase inhibitor p27Kip1</p>{/NP_P_16} and {NP_P_17}the <p>microtubule-destabilizing protein stathmin</p>{/NP_P_17} .

OUTPUT 0
PTM = ({NP_18};Phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_20}<p>KIS</p>{/NP_P_20};-)
	Method=rule:1.12.1.1.0.2 (kinase) for phrase=[{NP_P_20}<p>KIS</p>{/NP_P_20}]
Substrate = ({NP_P_19}<p>p27Kip1</p>{/NP_P_19};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_19}<p>p27Kip1</p>{/NP_P_19}]
Site = (-;-;UNK)

OUTPUT 1
PTM = ({NP_27};phosphorylation)
	HasAgentTheme="<p>stathmin</p>" in "{NP_27}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_27}"
Inducer = (-;-)
	Method=rule: (inducer) for phrase=[{NP_27}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_27}0..2|<p>KIS</p>]
Kinase = ({NP_27}<p>KIS</p>{/NP_27};-)
	Method=inducer_is_kinase (kinase) for phrase=[{NP_27}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_27}0..2|<p>KIS</p>]
Substrate = ({NP_27}<p>stathmin</p>{/NP_27};-)
	Method=agent|theme_but_kinase_is_known (substrate) for phrase=[{NP_27}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_27}12..19|<p>stathmin</p>]
	Method=rule:1.2.51.1.3 (substrate) for phrase=[{NP_27}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_27}12..19|<p>stathmin</p>]
Site = (-;-;UNK)

{NP_18}Phosphorylation{/NP_18} of {NP_P_19}<p>p27Kip1</p>{/NP_P_19} by {NP_P_20}<p>KIS</p>{/NP_P_20} {VP_act_21}leads{/VP_act_21} to {NP_22}<Bpcl>cell</Bpcl>{/NP_22} {VP_act_23}-cycle{/VP_act_23} {NP_24}progression{/NP_24} , whereas {NP_PP_25}the target <Bppp>sequence</Bppp>{/NP_PP_25} and {NP_26}the physiological relevance{/NP_26} of {NP_27}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_27} in {NP_B_28}<B>VSMCs</B>{/NP_B_28} {VP_pass_29}are unknown{/VP_pass_29} .

{AV_30}Here{/AV_30} {NP_31}we{/NP_31} {VP_act_32}demonstrated{/VP_act_32} that {NP_33}vascular wound repair{/NP_33} in {NP_34}<B>KIS-/-</B> <s>mice</s>{/NP_34} {VP_pass_35}resulted{/VP_pass_35} in {NP_36}accelerated formation{/NP_36} of {NP_37}neointima{/NP_37} , {NP_38}which{/NP_38} {VP_pass_39}is composed{/VP_pass_39} {AV_40}predominantly{/AV_40} of {NP_B_41}<B>VSMCs</B>{/NP_B_41} .

{NP_42}Deletion{/NP_42} of {NP_P_43}<p>KIS</p>{/NP_P_43} {VP_act_44}increased{/VP_act_44} {NP_P_45}<B>VSMC</B> migratory activity and <p>cytoplasmic tubulin</p>{/NP_P_45} {VP_act_46}destabilizing{/VP_act_46} {NP_47}activity{/NP_47} , but {VP_act_48}abolished{/VP_act_48} {NP_49}<B>VSMC</B> proliferation{/NP_49} through {NP_50}the delayed nuclear export and degradation{/NP_50} of {NP_P_51}<p>p27Kip1</p>{/NP_P_51} .

OUTPUT 2
PTM = ({NP_57};phosphorylation)
	HasAgentTheme="<p>stathmin</p>" in "{NP_57}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_57}"
Inducer = (-;-)
	Method=rule: (inducer) for phrase=[{NP_57}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_57}0..2|<p>KIS</p>]
Kinase = ({NP_57}<p>KIS</p>{/NP_57};-)
	Method=inducer_is_kinase (kinase) for phrase=[{NP_57}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_57}0..2|<p>KIS</p>]
Substrate = ({NP_57}<p>stathmin</p>{/NP_57};-)
	Method=agent|theme_but_kinase_is_known (substrate) for phrase=[{NP_57}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_57}12..19|<p>stathmin</p>]
	Method=rule:1.2.51.1.3 (substrate) for phrase=[{NP_57}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_57}12..19|<p>stathmin</p>]
Site = ({NP_PP_58}38{/NP_PP_58};{NP_PP_58}Ser{/NP_PP_58};UNK)
	Method=rule: (site) for phrase=[{NP_PP_58}<pp>serine 38</pp>{/NP_PP_58}0..7|serine 38|Ser38]

{NP_52}This promigratory phenotype{/NP_52} {VP_act_53}resulted{/VP_act_53} from {NP_54}increased <p>stathmin protein</p> levels{/NP_54} , {VP_pass_55}caused{/VP_pass_55} by {NP_56}a lack{/NP_56} of {NP_57}<p>KIS</p> -mediated <p>stathmin</p> phosphorylation{/NP_57} at {NP_PP_58}<pp>serine 38</pp>{/NP_PP_58} and {VP_act_59}diminished{/VP_act_59} {NP_60}<p>stathmin protein</p> degradation{/NP_60} .

{NP_61}Downregulation{/NP_61} of {NP_P_62}<p>stathmin</p>{/NP_P_62} in {NP_B_63}<B>KIS-/- VSMCs</B>{/NP_B_63} {VP_act_64}fully restored{/VP_act_64} {NP_65}the phenotype{/NP_65} , and {NP_66}stathmin-deficient <s>mice</s>{/NP_66} {VP_act_67}demonstrated{/VP_act_67} {NP_68}reduced lesion formation{/NP_68} in {NP_69}response{/NP_69} to {NP_70}vascular injury{/NP_70} .

{NP_71}These data{/NP_71} {VP_act_72}suggest{/VP_act_72} that {NP_P_73}<p>KIS</p>{/NP_P_73} {VP_act_74}protects{/VP_act_74} against {NP_75}excessive neointima formation{/NP_75} by {VP_act_76}opposing{/VP_act_76} {NP_77}stathmin-mediated <B>VSMC</B> migration{/NP_77} and that {NP_78}<B>VSMC</B> migration{/NP_78} {VP_act_79}represents{/VP_act_79} {NP_80}a major mechanism{/NP_80} of {NP_81}vascular wound repair{/NP_81} , {VP_act_82}constituting{/VP_act_82} {NP_83}a relevant target and mechanism{/NP_83} for {NP_84}therapeutic interventions{/NP_84} .

NORM=kis
SYNONYM=KIS


{NP_1}PMID{/NP_1} - {CP_2}19034877{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Effect{/NP_4} of {NP_5}<p>Jak2 kinase</p> inhibition{/NP_5} on {NP_6}<p>Stat1</p> and <p>Stat3</p> activation and apoptosis{/NP_6} of {NP_7}tubular epithelial <Bpcl>cells</Bpcl>{/NP_7} {VP_pass_8}induced{/VP_pass_8} by {NP_9}<c>ATP</c> depletion/recovery{/NP_9} .

{NP_10}AB{/NP_10} - {NP_11}BACKGROUND{/NP_11} :

{NP_12}Apoptosis{/NP_12} {VP_pass_13}is involved{/VP_pass_13} in {NP_B_14}<B>acute renal failure ( ARF )</B>{/NP_B_14} .

{NP_15}Its exact mechanism{/NP_15} {VP_act_16}still remains{/VP_act_16} {VP_pass_17}to be explored{/VP_pass_17} .

{NP_18}The <p>Jak-Stat</p> pathway{/NP_18} {VP_act_19}participates{/VP_act_19} in {NP_20}inflammation , apoptosis and tumorigenesis{/NP_20} .

In {NP_21}an in vitro model{/NP_21} of {NP_B_22}renal <B>ischemia/reperfusion injury ( IRI )</B>{/NP_B_22} , {NP_23}we{/NP_23} {VP_act_24}investigated{/VP_act_24} {NP_25}the role{/NP_25} of {NP_26}<p>Jak2 kinase</p> inhibition{/NP_26} on {NP_27}<p>signal transducer and activator of transcription 1 ( Stat1 )</p> and <p>Stat3</p> activations{/NP_27} as well as {NP_28}apoptosis{/NP_28} of {NP_S_29}<S><s>human</s> proximal tubular epithelial cells ( HKCs )</S>{/NP_S_29} {VP_pass_30}induced{/VP_pass_30} by {NP_31}<c>adenosine triphosphate ( ATP )</c> depletion/recovery{/NP_31} .

{NP_32}METHODS{/NP_32} : {NP_33}<c>ATP</c> depletion{/NP_33} of {NP_S_34}<S>HKCs</S>{/NP_S_34} {VP_pass_35}is induced{/VP_pass_35} by {NP_C_36}<c>antimycin A</c>{/NP_C_36} .

OUTPUT 0
PTM = ({NP_40};phosphorylations)
	HasAgentTheme="<p>Stat1</p>|<p>Stat3</p>" in "{NP_40}<p>Stat1</p> and <p>Stat3</p> phosphorylations{/NP_40}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_40}<p>Stat1</p>{/NP_40};-)
({NP_40}<p>Stat3</p>{/NP_40};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_40}<p>Stat1</p> and <p>Stat3</p> phosphorylations{/NP_40}0..4|<p>Stat1</p>8..12|<p>Stat3</p>]
Site = (-;-;UNK)

{NP_37}RESULTS{/NP_37} : {NP_B_38}The <B>Jak2-specific inhibitor AG490</B>{/NP_B_38} {VP_act_39}decreased{/VP_act_39} {NP_40}<p>Stat1</p> and <p>Stat3</p> phosphorylations{/NP_40} and {VP_act_41}promoted{/VP_act_41} {NP_42}<B>HKC</B> apoptosis{/NP_42} {VP_pass_43}induced{/VP_pass_43} by {NP_44}<c>ATP</c> depletion/recovery{/NP_44} .

{NP_45}CONCLUSIONS{/NP_45} : {NP_46}Our results{/NP_46} {VP_act_47}have demonstrated{/VP_act_47} that {NP_48}<p>Jak2</p> inhibition{/NP_48} {VP_pass_49}participated{/VP_pass_49} in {NP_50}the <c>ATP</c> depletion-induced apoptosis{/NP_50} of {NP_S_51}<S>HKCs</S>{/NP_S_51} , {NP_52}which{/NP_52} {VP_act_53}might be{/VP_act_53} {NP_54}a potential target{/NP_54} for {NP_55}prevention and treatment{/NP_55} of {NP_B_56}<B>ARF</B>{/NP_B_56} .


{NP_1}PMID{/NP_1} - {CP_2}19011095{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Ablation{/NP_4} of {NP_PP_5}smooth muscle <pp><p>myosin</p> heavy chain <p>SM2</p></pp>{/NP_PP_5} {VP_act_6}increases{/VP_act_6} {NP_7}smooth muscle contraction{/NP_7} and {NP_8}results{/NP_8} in {NP_9}postnatal death{/NP_9} in {NP_10}<s>mice</s>{/NP_10} .

{NP_11}AB{/NP_11} - {NP_12}The physiological relevance{/NP_12} of {NP_P_13}<p>smooth muscle myosin isoforms SM1</p> and <p>SM2</p>{/NP_P_13} {VP_pass_neg_14}has not been understood{/VP_pass_neg_14} .

In {NP_15}this study{/NP_15} {NP_16}we{/NP_16} {VP_act_17}generated{/VP_act_17} {NP_18}a <s>mouse</s> model{/NP_18} {JP_19}specifically deficient{/JP_19} in {NP_P_20}<p>SM2 myosin isoform</p>{/NP_P_20} but {VP_act_21}expressing{/VP_act_21} {NP_P_22}<p>SM1</p>{/NP_P_22} , {VP_act_23}using{/VP_act_23} {NP_P_24}an exon-specific <Bppf>gene</Bppf>{/NP_P_24} {VP_act_25}targeting{/VP_act_25} {NP_26}strategy{/NP_26} .

{NP_27}The <p>SM2</p> homozygous knockout ( <B><p>SM2</p>(-/-)</B> ) <s>mice</s>{/NP_27} {VP_pass_28}died{/VP_pass_28} within {NP_29}30 days{/NP_29} after {NP_30}birth{/NP_30} , {VP_act_31}showing{/VP_act_31} {NP_32}pathologies{/NP_32} {VP_act_33}including{/VP_act_33} {NP_34}segmental distention{/NP_34} of {NP_35}alimentary tract{/NP_35} , {NP_36}retention{/NP_36} of {NP_37}urine{/NP_37} in {NP_38}renal pelvis{/NP_38} , {NP_39}distension{/NP_39} of {NP_40}bladder{/NP_40} , and {NP_41}the development{/NP_41} of {NP_42}end-stage hydronephrosis{/NP_42} .

In {NP_43}contrast{/NP_43} , {NP_44}the heterozygous ( <B><p>SM2</p>(+/-)</B> ) <s>mice</s>{/NP_44} {VP_act_45}appeared{/VP_act_45} {JP_46}normal{/JP_46} and {VP_act_47}reproduced{/VP_act_47} {AV_48}well{/AV_48} .

In {NP_49}<B><p>SM2</p>(-/-)</B> bladder smooth muscle{/NP_49} {NP_50}the loss{/NP_50} of {NP_P_51}<p>SM2 myosin</p>{/NP_P_51} {VP_pass_52}was accompanied{/VP_pass_52} by {NP_53}a concomitant down-regulation{/NP_53} of {NP_P_54}<p>SM1</p>{/NP_P_54} and {NP_55}a reduced number{/NP_55} of {NP_P_56}thick <Bppf>filaments</Bppf>{/NP_P_56} .

{AV_57}However{/AV_57} , {NP_58}muscle strips{/NP_58} from {NP_59}<B><p>SM2</p>(-/-)</B> bladder{/NP_59} {VP_act_60}showed{/VP_act_60} {NP_61}increased contraction{/NP_61} to {NP_62}<B>K(+)</B> depolarization{/NP_62} or in {NP_63}response{/NP_63} to {NP_B_64}<B>M3 receptor agonist Carbachol</B>{/NP_B_64} .

An {VP_act_65}increase{/VP_act_65} of {NP_66}contraction{/NP_66} {VP_pass_67}was also observed{/VP_pass_67} in {NP_68}<B><p>SM2</p>(-/-)</B> aorta{/NP_68} .

OUTPUT 0
PTM = ({NP_72};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>SM2</p>" in "{NP_70}the <B><p>SM2</p>(-/-)</B> bladder{/NP_70}" 	(Features:dist=0|in-title_elsewhere|subject_main_modifier)
Substrate = ({NP_72}<p>myosin</p>{/NP_72};-)
	Method=link (substrate) for phrase=[{NP_72}unaltered regulatory <pp><p>myosin</p> light chain ( MLC20 )</pp> phosphorylation{/NP_72}19..24|<p>myosin</p>]
		From: {NP_72}unaltered regulatory <pp><p>myosin</p> light chain ( MLC20 )</pp> phosphorylation{/NP_72}19..41|<pp><p>myosin</p> light chain ( MLC20 )</pp>
		Path: whole
Site = (-;-;{NP_72}<pp><p>myosin</p> light chain ( MLC20 )</pp>{/NP_72})
	Method=rule: (siteother) for phrase=[{NP_72}unaltered regulatory <pp><p>myosin</p> light chain ( MLC20 )</pp> phosphorylation{/NP_72}19..41|<pp><p>myosin</p> light chain ( MLC20 )</pp>]

{AV_69}However{/AV_69} , {NP_70}the <B><p>SM2</p>(-/-)</B> bladder{/NP_70} {VP_pass_71}was associated{/VP_pass_71} with {NP_72}unaltered regulatory <pp><p>myosin</p> light chain ( MLC20 )</pp> phosphorylation{/NP_72} .

{AV_73}Moreover{/AV_73} , {NP_P_74}other contractile <Bppf>proteins</Bppf>{/NP_P_74} , {JP_75}such{/JP_75} as {NP_P_76}<p>alpha-actin</p> and <p>tropomyosin</p>{/NP_P_76} , {VP_pass_neg_77}were not altered{/VP_pass_neg_77} in {NP_78}<B><p>SM2</p>(-/-)</B> bladder{/NP_78} .

{AV_79}Therefore{/AV_79} , {NP_80}the loss{/NP_80} of {NP_P_81}<p>SM2 myosin</p>{/NP_P_81} {AV_82}alone{/AV_82} {VP_act_83}could have{/VP_act_83} {NP_84}induced hypercontractility{/NP_84} in {NP_85}smooth muscle{/NP_85} , {VP_act_86}suggesting{/VP_act_86} that {AV_87}distinctly{/AV_87} from {NP_P_88}<p>SM1</p>{/NP_P_88} , {NP_P_89}<p>SM2</p>{/NP_P_89} {VP_act_90}may negatively modulate{/VP_act_90} {NP_91}force development{/NP_91} during {NP_92}smooth muscle contraction{/NP_92} .

{AV_93}Also{/AV_93} , because {NP_94}<B><p>SM2</p>(-/-)</B> <s>mice</s>{/NP_94} {VP_act_95}develop{/VP_act_95} {NP_96}lethal <Bpcl>multiorgan</Bpcl> dysfunctions{/NP_96} , {NP_97}we{/NP_97} {VP_act_98}propose{/VP_act_98} {NP_99}this regulatory property{/NP_99} of {NP_P_100}<p>SM2</p>{/NP_P_100} {VP_pass_101}is essential{/VP_pass_101} for {NP_102}normal contractile activity{/NP_102} in {NP_103}postnatal smooth muscle physiology{/NP_103} .


{NP_1}PMID{/NP_1} - {CP_2}19011111{/CP_2}

OUTPUT 0
PTM = ({NP_4};Phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_6}<p>protein kinase D</p>{/NP_P_6};-)
	Method=rule:1.12.1.1.0.2 (kinase) for phrase=[{NP_P_6}<p>protein kinase D</p>{/NP_P_6}]
Substrate = ({NP_P_5}<p>Par-1 polarity kinase</p>{/NP_P_5};-)
	Method=rule: (substrate) for phrase=[{NP_P_5}the <p>Par-1 polarity kinase</p>{/NP_P_5}3..21|<p>Par-1 polarity kinase</p>]
Site = (-;-;UNK)

{NP_3}TI{/NP_3} - {NP_4}Phosphorylation{/NP_4} of {NP_P_5}the <p>Par-1 polarity kinase</p>{/NP_P_5} by {NP_P_6}<p>protein kinase D</p>{/NP_P_6} {VP_act_7}regulates{/VP_act_7} {NP_8}<p>14-3-3</p> binding and membrane association{/NP_8} .

{NP_9}AB{/NP_9} - {NP_P_10}The <p>Par-1 protein kinases</p>{/NP_P_10} {VP_pass_11}are conserved{/VP_pass_11} from {NP_12}<s>yeast</s>{/NP_12} to {NP_13}<s>humans</s>{/NP_13} , {NP_14}where{/NP_14} {NP_15}they{/NP_15} {VP_act_16}function{/VP_act_16} as {NP_17}key polarity determinants{/NP_17} .

{NP_P_18}The mammalian <p>Par-1 family</p>{/NP_P_18} {VP_pass_19}is comprised{/VP_pass_19} of {NP_20}4 <Bpf>members</Bpf>{/NP_20} ( {NP_21}Par-1a{/NP_21} , {NP_22}-b{/NP_22} , {NP_23}-c{/NP_23} , and {NP_24}-d{/NP_24} ) .

OUTPUT 1
PTM = ({VP_act_29};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_28}<p>protein kinase C ( aPKC )</p>{/NP_P_28};-)
	Method=rule: (kinase) for phrase=[{NP_P_28}atypical <p>protein kinase C ( aPKC )</p>{/NP_P_28}8..27|<p>protein kinase C ( aPKC )</p>]
Substrate = ({NP_P_30}<p>Par-1 kinases</p>{/NP_P_30};-)
	Method=link (substrate) for phrase=[{NP_P_30}the <p>Par-1 kinases</p>{/NP_P_30}3..14|<p>Par-1 kinases</p>]
		From: {NP_PP_31}a conserved <pp>threonine residue (T595)</pp>{/NP_PP_31}
		Path: whole
	Method=rule: (substrate) for phrase=[{NP_P_30}the <p>Par-1 kinases</p>{/NP_P_30}3..14|<p>Par-1 kinases</p>]
Site = (-;{NP_PP_31}Thr{/NP_PP_31};UNK)
({NP_PP_31}595{/NP_PP_31};{NP_PP_31}Thr{/NP_PP_31};UNK)
	Method=rule: (site) for phrase=[{NP_PP_31}a conserved <pp>threonine residue (T595)</pp>{/NP_PP_31}10..18|threonine|Thr27..30|T595|Thr595]

{AV_25}Previously{/AV_25} , {NP_26}we{/NP_26} {VP_act_27}demonstrated{/VP_act_27} that {NP_P_28}atypical <p>protein kinase C ( aPKC )</p>{/NP_P_28} {VP_act_29}phosphorylates{/VP_act_29} {NP_P_30}the <p>Par-1 kinases</p>{/NP_P_30} on {NP_PP_31}a conserved <pp>threonine residue (T595)</pp>{/NP_PP_31} {VP_act_32}to regulate{/VP_act_32} {NP_33}localization and <Bppf>kinase</Bppf> activity{/NP_33} .

{AV_34}Here{/AV_34} , {NP_35}we{/NP_35} {VP_act_36}demonstrate{/VP_act_36} that {NP_P_37}<p>Par-1b</p>{/NP_P_37} {VP_pass_38}is also regulated{/VP_pass_38} by {NP_39}another arm{/NP_39} of {NP_40}the <p>PKC</p> pathway{/NP_40} , {CP_41}one{/CP_41} {NP_42}that{/NP_42} {VP_act_43}involves{/VP_act_43} {NP_P_44}<p>novel PKCs ( nPKC )</p> and <p>protein kinase D</p>{/NP_P_44} .

OUTPUT 2
PTM = ({NP_49};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_C_47}the <p>PKC activator</p> <c>phorbol-12-myristate-13-acetate ( PMA )</c>{/NP_C_47}" 	(Features:dist=0)
		Candidate="<p>PKC activator</p>" in "{NP_C_47}the <p>PKC activator</p> <c>phorbol-12-myristate-13-acetate ( PMA )</c>{/NP_C_47}" 	(Features:dist=0)
		Candidate="{NP_PP_51}<pp><pp>serine 400</pp> ( S400 )</pp>{/NP_PP_51}" 	(Features:dist=0)
		Candidate="serine 400|S400" in "{NP_PP_51}<pp><pp>serine 400</pp> ( S400 )</pp>{/NP_PP_51}" 	(Features:dist=0)
		Candidate="{NP_P_55}all 4 mammalian <p>Par-1 kinases</p>{/NP_P_55}" 	(Features:dist=0|is-kinase_inherently|is-substrate_elsewhere)
		Candidate="<p>Par-1 kinases</p>" in "{NP_P_55}all 4 mammalian <p>Par-1 kinases</p>{/NP_P_55}" 	(Features:dist=0|is-kinase_inherently|is-substrate_elsewhere)
Substrate = ({NP_P_50}<p>Par-1b</p>{/NP_P_50};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_50}<p>Par-1b</p>{/NP_P_50}]
Site = ({NP_PP_51}400{/NP_PP_51};{NP_PP_51}Ser{/NP_PP_51};UNK)
	Method=rule: (site) for phrase=[{NP_PP_51}<pp><pp>serine 400</pp> ( S400 )</pp>{/NP_PP_51}0..8|serine 400|Ser40010..13|S400|Ser400]

{NP_45}Treatment{/NP_45} of {NP_46}<Bpcl>cells</Bpcl>{/NP_46} with {NP_C_47}the <p>PKC activator</p> <c>phorbol-12-myristate-13-acetate ( PMA )</c>{/NP_C_47} {VP_act_48}potently stimulated{/VP_act_48} {NP_49}phosphorylation{/NP_49} of {NP_P_50}<p>Par-1b</p>{/NP_P_50} on {NP_PP_51}<pp><pp>serine 400</pp> ( S400 )</pp>{/NP_PP_51} , {NP_PP_52}a <Bppp>residue</Bppp>{/NP_PP_52} {NP_53}that{/NP_53} {VP_pass_54}is conserved{/VP_pass_54} in {NP_P_55}all 4 mammalian <p>Par-1 kinases</p>{/NP_P_55} as well as {NP_56}the fly ortholog{/NP_56} .

OUTPUT 3
PTM = ({VP_act_66};phosphorylates)
Inducer = (-;-)
Kinase = ({NP_P_63}<p>PKD</p>{/NP_P_63};-)
	Method=link (kinase) for phrase=[{NP_P_63}<p>PKD</p>{/NP_P_63}]
		From: {NP_64}which{/NP_64}
		Path: refer
Substrate = ({NP_P_67}<p>Par-1b</p>{/NP_P_67};-)
	Method=rule:1.1.1.1 (substrate) for phrase=[{NP_P_67}<p>Par-1b</p>{/NP_P_67}]
Site = ({NP_PP_68}400{/NP_PP_68};{NP_PP_68}Ser{/NP_PP_68};UNK)
	Method=rule: (site) for phrase=[{NP_PP_68}<pp>S400</pp>{/NP_PP_68}0..3|S400|Ser400]

{NP_57}We{/NP_57} {VP_act_58}demonstrate{/VP_act_58} that {NP_C_59}<c>PMA</c>{/NP_C_59} {VP_act_60}stimulates{/VP_act_60} {NP_P_61}<p>nPKC</p>{/NP_P_61} {VP_act_62}to activate{/VP_act_62} {NP_P_63}<p>PKD</p>{/NP_P_63} , {NP_64}which{/NP_64} {AV_65}in turn{/AV_65} {VP_act_66}directly phosphorylates{/VP_act_66} {NP_P_67}<p>Par-1b</p>{/NP_P_67} on {NP_PP_68}<pp>S400</pp>{/NP_PP_68} {VP_act_69}to positively regulate{/VP_act_69} {NP_70}<p>14-3-3</p> binding{/NP_70} and {VP_act_71}to negatively regulate{/VP_act_71} {NP_72}membrane association{/NP_72} .

{AV_73}Thus{/AV_73} , {NP_74}2 arms{/NP_74} of {NP_75}the <p>PKC</p> pathway{/NP_75} {VP_act_76}regulate{/VP_act_76} {NP_77}interactions{/NP_77} between {NP_P_78}<p>Par-1b</p> and <p>14-3-3</p> <Bppf>proteins</Bppf>{/NP_P_78} : {NP_P_79}one involving <p>aPKC</p>{/NP_P_79} and {NP_P_80}the other <p>nPKC/PKD</p>{/NP_P_80} .


{NP_1}PMID{/NP_1} - {CP_2}19015526{/CP_2}

OUTPUT 0
PTM = ({NP_4};phosphorylation)
Inducer = (-;-)
	Method=rule: (inducer) for phrase=[{NP_4}<p>ATM</p> -mediated <pp>serine 72</pp> phosphorylation{/NP_4}0..2|<p>ATM</p>]
Kinase = ({NP_4}<p>ATM</p>{/NP_4};-)
	Method=inducer_is_kinase (kinase) for phrase=[{NP_4}<p>ATM</p> -mediated <pp>serine 72</pp> phosphorylation{/NP_4}0..2|<p>ATM</p>]
Substrate = (-;-)
Site = ({NP_4}72{/NP_4};{NP_4}Ser{/NP_4};UNK)
	Method=rule: (site) for phrase=[{NP_4}<p>ATM</p> -mediated <pp>serine 72</pp> phosphorylation{/NP_4}12..19|serine 72|Ser72]

{NP_3}TI{/NP_3} - {NP_4}<p>ATM</p> -mediated <pp>serine 72</pp> phosphorylation{/NP_4} {VP_act_5}stabilizes{/VP_act_5} {NP_P_6}ribonucleotide <p>reductase</p> small <p>subunit p53R2 protein</p>{/NP_P_6} against {NP_P_7}<p>MDM2</p>{/NP_P_7} to {NP_8}DNA damage{/NP_8} .

{NP_9}AB{/NP_9} - {NP_P_10}Ribonucleotide <p>reductase</p> small <p>subunit p53R2</p>{/NP_P_10} {VP_pass_11}was identified{/VP_pass_11} as {NP_P_12}a <p>p53</p> target <Bppf>gene</Bppf>{/NP_P_12} {NP_13}that{/NP_13} {VP_act_14}provides{/VP_act_14} {NP_P_15}<p>dNTP</p>{/NP_P_15} for {NP_16}DNA damage repair{/NP_16} .

{AV_17}However{/AV_17} , {NP_18}the slow transcriptional induction{/NP_18} of {NP_P_19}<p>p53R2</p>{/NP_P_19} in {NP_20}RNA{/NP_20} {VP_act_neg_21}may not be rapid enough{/VP_act_neg_21} for {VP_act_22}prompt{/VP_act_22} {NP_23}DNA damage repair{/NP_23} , {NP_24}which{/NP_24} {VP_act_25}has{/VP_act_25} {VP_pass_26}to occur{/VP_pass_26} within {NP_27}a few hours{/NP_27} of {NP_28}damage{/NP_28} .

OUTPUT 1
PTM = ({VP_pass_33};phosphorylated)
Inducer = (-;-)
Kinase = ({NP_P_35}<p>ataxia telangiectasia mutated ( ATM )</p>{/NP_P_35};-)
	Method=rule:1.13.1.1 (kinase) for phrase=[{NP_P_35}<p>ataxia telangiectasia mutated ( ATM )</p>{/NP_P_35}]
Substrate = ({NP_P_32}<p>p53R2</p>{/NP_P_32};-)
	Method=rule:1.3.1.1.0.1 (substrate) for phrase=[{NP_P_32}<p>p53R2</p>{/NP_P_32}]
Site = ({NP_PP_34}72{/NP_PP_34};{NP_PP_34}Ser{/NP_PP_34};UNK)
	Method=rule: (site) for phrase=[{NP_PP_34}<pp>Ser(72)</pp>{/NP_PP_34}0..6|Ser(72)|Ser72]

{AV_29}Here{/AV_29} , {NP_30}we{/NP_30} {VP_act_31}demonstrate{/VP_act_31} that {NP_P_32}<p>p53R2</p>{/NP_P_32} {VP_pass_33}becomes rapidly phosphorylated{/VP_pass_33} at {NP_PP_34}<pp>Ser(72)</pp>{/NP_PP_34} by {NP_P_35}<p>ataxia telangiectasia mutated ( ATM )</p>{/NP_P_35} within {NP_36}30 min{/NP_36} after {NP_37}genotoxic stress{/NP_37} .

{NP_P_38}<p>p53R2</p>{/NP_P_38} , as well as {NP_P_39}its heterodimeric partner <p>RRM1</p>{/NP_P_39} , {VP_pass_40}are associated{/VP_pass_40} with {NP_P_41}<p>ATM</p>{/NP_P_41} in {NP_42}vivo{/NP_42} .

OUTPUT 2
PTM = ({NP_45};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>Ser(72)</pp>" in "{NP_45}<p>ATM</p> -mediated <pp>Ser(72)</pp> phosphorylation{/NP_45}" 	(Features:dist=0)
		Candidate="Ser(72)" in "{NP_45}<p>ATM</p> -mediated <pp>Ser(72)</pp> phosphorylation{/NP_45}" 	(Features:dist=0)
Substrate = ({NP_P_32}<p>p53R2</p>{/NP_P_32};-)
	Method=link (substrate) for phrase=[{NP_P_32}<p>p53R2</p>{/NP_P_32}]
		From: {NP_45}<p>ATM</p> -mediated <pp>Ser(72)</pp> phosphorylation{/NP_45}12..18|Ser(72)|Ser72
		Path: lexicalid,substrate|lexicalid,whole
	Method=link (substrate) for phrase=[{NP_P_54}<p>p53R2</p>{/NP_P_54}]
		From: {NP_45}<p>ATM</p> -mediated <pp>Ser(72)</pp> phosphorylation{/NP_45}12..18|Ser(72)|Ser72
		Path: lexicalid,lexicalid,whole|lexicalid,whole
Site = ({NP_45}72{/NP_45};{NP_45}Ser{/NP_45};UNK)
	Method=rule: (site) for phrase=[{NP_45}<p>ATM</p> -mediated <pp>Ser(72)</pp> phosphorylation{/NP_45}12..18|Ser(72)|Ser72]

{NP_43}Mutational studies{/NP_43} {VP_act_44}further indicate{/VP_act_44} that {NP_45}<p>ATM</p> -mediated <pp>Ser(72)</pp> phosphorylation{/NP_45} {VP_pass_46}is essential{/VP_pass_46} for {VP_act_47}maintaining{/VP_act_47} {NP_48}<p>p53R2 protein</p> stability{/NP_48} and {VP_act_49}conferring{/VP_act_49} {NP_50}resistance{/NP_50} to {NP_51}DNA damage{/NP_51} .

{NP_52}The mutation{/NP_52} of {NP_PP_53}<pp>Ser(72)</pp>{/NP_PP_53} on {NP_P_54}<p>p53R2</p>{/NP_P_54} to {NP_55}<pp>alanine</pp> results{/NP_55} in {NP_56}the hyperubiquitination{/NP_56} of {NP_P_57}<p>p53R2</p>{/NP_P_57} and {VP_act_58}reduces{/VP_act_58} {NP_59}<p>p53R2</p> stability{/NP_59} .

{NP_P_60}<p>MDM2</p>{/NP_P_60} , {NP_P_61}a <p>ubiquitin ligase</p>{/NP_P_61} for {NP_P_62}<p>p53</p>{/NP_P_62} , {VP_act_63}interacts and facilitates{/VP_act_63} {NP_64}ubiquitination{/NP_64} of {NP_P_65}the <Bppf>S72A-p53R2 mutant</Bppf>{/NP_P_65} {AV_66}more efficiently{/AV_66} than {NP_B_67}<B>WT-p53R2</B>{/NP_B_67} after {NP_68}DNA damage{/NP_68} in {NP_69}vivo{/NP_69} .

OUTPUT 3
PTM = ({NP_75};phosphorylation)
Inducer = (-;-)
	Method=rule: (inducer) for phrase=[{NP_75}<p>ATM</p> -mediated phosphorylation{/NP_75}0..2|<p>ATM</p>]
Kinase = ({NP_75}<p>ATM</p>{/NP_75};-)
	Method=inducer_is_kinase (kinase) for phrase=[{NP_75}<p>ATM</p> -mediated phosphorylation{/NP_75}0..2|<p>ATM</p>]
Substrate = ({NP_P_77}<p>p53R2</p>{/NP_P_77};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_77}<p>p53R2</p>{/NP_P_77}]
Site = ({NP_76}72{/NP_76};{NP_76}Ser{/NP_76};UNK)
	Method=unclaimed_site_or_shared_substrate (site) for phrase=[{NP_76}<pp>Ser(72)</pp> and <p>MDM2</p> -dependent turnover{/NP_76}0..6|Ser(72)|Ser72]
	Candidates (Site):
		Candidate="{NP_76}<pp>Ser(72)</pp> and <p>MDM2</p> -dependent turnover{/NP_76}" 	(Features:is-aa)

{NP_70}Our results{/NP_70} {VP_act_71}strongly suggest{/VP_act_71} {NP_72}a novel mechanism{/NP_72} for {NP_73}the regulation{/NP_73} of {NP_74}<p>p53R2</p> activity{/NP_74} via {NP_75}<p>ATM</p> -mediated phosphorylation{/NP_75} at {NP_76}<pp>Ser(72)</pp> and <p>MDM2</p> -dependent turnover{/NP_76} of {NP_P_77}<p>p53R2</p>{/NP_P_77} {VP_pass_78}dephosphorylated{/VP_pass_78} at {NP_PP_79}the same <Bppp>residue</Bppp>{/NP_PP_79} .

NORM=atm
SYNONYM=ATM
SYNONYM=ataxia telangiectasia mutated ( ATM )


{NP_1}PMID{/NP_1} - {CP_2}19017804{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Striatal dysregulation{/NP_4} of {NP_P_5}<p>Cdk5</p>{/NP_P_5} {VP_act_6}alters{/VP_act_6} {NP_7}locomotor responses{/NP_7} to {NP_C_8}<c>cocaine</c>{/NP_C_8} , {NP_9}motor{/NP_9} {VP_act_10}learning{/VP_act_10} , and {NP_11}dendritic morphology{/NP_11} .

{NP_12}AB{/NP_12} - {NP_13}Motor{/NP_13} {VP_act_14}learning{/VP_act_14} and {NP_15}neuro-adaptations{/NP_15} to {NP_16}<Bpcf>drugs</Bpcf>{/NP_16} of {NP_17}abuse{/NP_17} {VP_act_18}rely{/VP_act_18} upon {NP_19}neuronal signaling{/NP_19} in {NP_20}the striatum{/NP_20} .

{NP_P_21}<p>Cyclin-dependent kinase 5 ( Cdk5 )</p>{/NP_P_21} {VP_act_22}regulates{/VP_act_22} {NP_23}striatal dopamine neurotransmission{/NP_23} and {NP_24}behavioral responses{/NP_24} to {NP_C_25}<c>cocaine</c>{/NP_C_25} .

Although {NP_26}the role{/NP_26} for {NP_P_27}<p>Cdk5</p>{/NP_P_27} in {NP_28}neurodegeneration{/NP_28} in {NP_29}the cortex{/NP_29} and {JP_30}hippocampus{/JP_30} and in {NP_31}hippocampal -dependent learning{/NP_31} {VP_pass_32}has been demonstrated{/VP_pass_32} , {NP_33}its dysregulation{/NP_33} in {NP_34}the striatum{/NP_34} {VP_pass_neg_35}has not been examined{/VP_pass_neg_35} .

{AV_36}Here{/AV_36} {NP_37}we{/NP_37} {VP_act_38}show{/VP_act_38} that {NP_39}strong activation{/NP_39} of {NP_P_40}striatal <p>NMDA receptors</p>{/NP_P_40} {VP_act_41}produced{/VP_act_41} {NP_P_42}<p>p25</p>{/NP_P_42} , {NP_43}the truncated form{/NP_43} of {NP_P_44}the <p>Cdk5 co-activator p35</p>{/NP_P_44} .

{AV_45}Furthermore{/AV_45} , {NP_46}inducible overexpression{/NP_46} of {NP_P_47}<p>p25</p>{/NP_P_47} in {NP_48}the striatum{/NP_48} {VP_act_49}prevented{/VP_act_49} {NP_50}locomotor sensitization{/NP_50} to {NP_C_51}<c>cocaine</c>{/NP_C_51} and {VP_act_52}attenuated{/VP_act_52} {NP_53}motor coordination{/NP_53} and {VP_act_54}learning{/VP_act_54} .

OUTPUT 0
PTM = ({NP_P_65};substrates)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_55}This{/NP_55} {VP_act_56}corresponded{/VP_act_56} with {NP_57}reduced dendritic spine density{/NP_57} , {VP_act_58}increased{/VP_act_58} {NP_59}neuro-inflammation{/NP_59} , {VP_act_60}altered{/VP_act_60} {NP_61}dopamine signaling{/NP_61} , and {VP_act_62}shifted{/VP_act_62} {NP_63}<p>Cdk5</p> specificity{/NP_63} with {NP_64}regard{/NP_64} to {NP_P_65}physiological and aberrant <Bppf>substrates</Bppf>{/NP_P_65} , but {NP_66}no apparent loss{/NP_66} of {NP_67}striatal neurons{/NP_67} .

{AV_68}Thus{/AV_68} , {NP_69}dysregulation{/NP_69} of {NP_P_70}<p>Cdk5</p>{/NP_P_70} {VP_act_71}dramatically affects{/VP_act_71} {NP_72}striatal -dependent brain function{/NP_72} and {VP_act_73}may be relevant{/VP_act_73} {VP_act_74}to non-neurodegenerative{/VP_act_74} {NP_75}disorders{/NP_75} {VP_act_76}involving{/VP_act_76} {NP_77}dopamine neurotransmission{/NP_77} .


{NP_1}PMID{/NP_1} - {CP_2}19020080{/CP_2}

{NP_3}TI{/NP_3} - {NP_P_4}A bifunctional <p>kinase -phosphatase</p>{/NP_P_4} in {NP_5}bacterial chemotaxis{/NP_5} .

OUTPUT 0
PTM = ({NP_7};Phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_6}AB{/NP_6} - {NP_7}Phosphorylation-based signaling pathways{/NP_7} {VP_act_8}employ{/VP_act_8} {NP_9}dephosphorylation mechanisms{/NP_9} for {NP_10}signal termination{/NP_10} .

{NP_PP_11}<pp>Histidine</pp>{/NP_PP_11} {VP_act_12}to aspartate{/VP_act_12} {VP_act_13}phosphosignaling{/VP_act_13} in {NP_14}the two-component system{/NP_14} that {NP_15}controls bacterial chemotaxis{/NP_15} {VP_pass_16}has been studied{/VP_pass_16} {AV_17}extensively{/AV_17} .

{NP_18}<s>Rhodobacter sphaeroides</s>{/NP_18} {VP_act_19}has{/VP_act_19} {NP_20}a <Bpf>complex</Bpf> chemosensory pathway{/NP_20} with {NP_21}multiple homologues{/NP_21} of {NP_22}the <s>Escherichia coli</s>{/NP_22} {VP_act_23}chemosensory{/VP_act_23} {NP_P_24}<Bppf>proteins</Bppf>{/NP_P_24} , although {NP_25}it{/NP_25} {VP_act_26}lacks{/VP_act_26} {NP_27}homologues{/NP_27} of {NP_P_28}known <p>signal-terminating CheY-P phosphatases</p>{/NP_P_28} , {JP_29}such{/JP_29} as {NP_P_30}<p>CheZ</p> , <p>CheC</p> , <p>FliY</p> or <p>CheX</p>{/NP_P_30} .

{AV_31}Here{/AV_31} , {NP_32}we{/NP_32} {VP_act_33}demonstrate{/VP_act_33} that {NP_34}an unusual <p>CheA</p> homologue{/NP_34} , {NP_C_35}<c><p>CheA</p>(3)</c>{/NP_C_35} , {VP_pass_neg_36}is not only{/VP_pass_neg_36} {NP_C_37}a <c>phosphodonor</c>{/NP_C_37} for {NP_P_38}the principal <p>CheY protein</p>{/NP_P_38} , {NP_P_39}<p>CheY(6)</p>{/NP_P_39} , but {VP_act_40}is also is{/VP_act_40} {NP_P_41}a specific <p>phosphatase</p>{/NP_P_41} for {NP_B_42}<B><p>CheY</p>(6) -P</B>{/NP_B_42} .

{NP_43}This <p>phosphatase</p> activity{/NP_43} {VP_act_44}accelerates{/VP_act_44} {NP_45}<B><p>CheY</p>(6) -P</B> dephosphorylation{/NP_45} to {NP_46}a rate{/NP_46} {NP_47}that{/NP_47} {VP_pass_48}is comparable{/VP_pass_48} with {NP_49}the measured stimulus response time{/NP_49} of {AV_50}approximately{/AV_50} 1 s .

{NP_C_51}<c><p>CheA</p>(3)</c>{/NP_C_51} {VP_act_52}possesses{/VP_act_52} {AV_53}only{/AV_53} {CP_54}two{/CP_54} of {NP_PP_55}the five <Bppp>domains</Bppp>{/NP_PP_55} {VP_pass_56}found{/VP_pass_56} in {NP_PP_57}<pp>classical CheAs</pp>{/NP_PP_57} , {NP_PP_58}the <p>Hpt (P1)</p> and regulatory ( <B>P5</B> ) <Bppp>domains</Bppp>{/NP_PP_58} , {NP_59}which{/NP_59} {VP_pass_60}are joined{/VP_pass_60} by {NP_PP_61}a <pp><c>794-amino</c> acid sequence</pp>{/NP_PP_61} {NP_62}that{/NP_62} {VP_pass_63}is required{/VP_pass_63} for {NP_64}<p>phosphatase</p> activity{/NP_64} .

OUTPUT 1
PTM = ({VP_pass_67};phosphorylated)
Inducer = (-;-)
Kinase = ({NP_B_68}<p>CheA</p>{/NP_B_68};-)
	Method=rule: (kinase) for phrase=[{NP_B_68}<B><p>CheA</p>(4)</B>{/NP_B_68}0..3|<p>CheA</p>]
Substrate = (-;-)
	Method=features_(same_sentence) (substrate) for phrase=[{NP_C_66}<c><p>CheA</p>(3)</c>{/NP_C_66}0..3|<p>CheA</p>]
	Candidates (Substrate):
		Candidate="<p>CheA</p>" in "{NP_34}an unusual <p>CheA</p> homologue{/NP_34}" 	(Features:dist=-3|is-kinase_elsewhere|is-repeated|subject_subnc_modifier)
		Candidate="<p>phosphatase</p>" in "{NP_43}This <p>phosphatase</p> activity{/NP_43}" 	(Features:dist=-2|is-repeated|most-repeated|subject_main_modifier)
		Candidate="<p>CheY</p>" in "{NP_45}<B><p>CheY</p>(6) -P</B> dephosphorylation{/NP_45}" 	(Features:dist=-2|is-repeated)
		Candidate="<p>CheY</p>" in "{NP_B_42}<B><p>CheY</p>(6) -P</B>{/NP_B_42}" 	(Features:dist=-3|is-repeated)
		Candidate="<p>CheA</p>" in "{NP_B_68}<B><p>CheA</p>(4)</B>{/NP_B_68}" 	(Features:dist=0|is-kinase|is-repeated)
		Candidate="<p>CheA</p>" in "{NP_C_35}<c><p>CheA</p>(3)</c>{/NP_C_35}" 	(Features:dist=-3|is-kinase_elsewhere|is-repeated)
		Candidate="<p>CheA</p>" in "{NP_C_51}<c><p>CheA</p>(3)</c>{/NP_C_51}" 	(Features:dist=-1|is-kinase_elsewhere|is-repeated|subject_main_modifier)
		Candidate="<p>CheA</p>" in "{NP_C_66}<c><p>CheA</p>(3)</c>{/NP_C_66}" 	(Features:dist=0|is-kinase_elsewhere|is-repeated|subject_main_modifier)
		Candidate="<p>Hpt (P1)</p>" in "{NP_PP_58}the <p>Hpt (P1)</p> and regulatory ( <B>P5</B> ) <Bppp>domains</Bppp>{/NP_PP_58}" 	(Features:dist=-1|is-repeated)
		Candidate="<p>signal-terminating CheY-P phosphatases</p>" in "{NP_P_28}known <p>signal-terminating CheY-P phosphatases</p>{/NP_P_28}" 	(Features:dist=-4|is-repeated)
		Candidate="<p>CheZ</p>" in "{NP_P_30}<p>CheZ</p> , <p>CheC</p> , <p>FliY</p> or <p>CheX</p>{/NP_P_30}" 	(Features:dist=-4|is-repeated)
		Candidate="<p>FliY</p>" in "{NP_P_30}<p>CheZ</p> , <p>CheC</p> , <p>FliY</p> or <p>CheX</p>{/NP_P_30}" 	(Features:dist=-4|is-repeated)
		Candidate="<p>CheX</p>" in "{NP_P_30}<p>CheZ</p> , <p>CheC</p> , <p>FliY</p> or <p>CheX</p>{/NP_P_30}" 	(Features:dist=-4|is-repeated)
		Candidate="<p>CheC</p>" in "{NP_P_30}<p>CheZ</p> , <p>CheC</p> , <p>FliY</p> or <p>CheX</p>{/NP_P_30}" 	(Features:dist=-4|is-repeated)
		Candidate="{NP_P_38}the principal <p>CheY protein</p>{/NP_P_38}" 	(Features:dist=-3|is-repeated)
		Candidate="<p>CheY protein</p>" in "{NP_P_38}the principal <p>CheY protein</p>{/NP_P_38}" 	(Features:dist=-3|is-repeated)
		Candidate="<p>phosphatase</p>" in "{NP_P_41}a specific <p>phosphatase</p>{/NP_P_41}" 	(Features:dist=-3|is-repeated|most-repeated)
Site = (-;-;UNK)
	Method=rule: (site) for phrase=[{NP_PP_65}The <pp>P1 domain</pp>{/NP_PP_65}3..4|P1|1]

{NP_PP_65}The <pp>P1 domain</pp>{/NP_PP_65} of {NP_C_66}<c><p>CheA</p>(3)</c>{/NP_C_66} {VP_pass_67}is phosphorylated{/VP_pass_67} by {NP_B_68}<B><p>CheA</p>(4)</B>{/NP_B_68} , and {NP_69}it{/NP_69} {VP_act_70}subsequently acts{/VP_act_70} as {NP_C_71}a <c>phosphodonor</c>{/NP_C_71} for {NP_72}the <Bpf>response regulators</Bpf>{/NP_72} .

{NP_P_73}A <p>CheA(3) mutant protein</p>{/NP_P_73} without {NP_PP_74}the <pp><c>794-amino</c> acid region</pp>{/NP_PP_74} {VP_act_75}lacked{/VP_act_75} {NP_76}<p>phosphatase</p> activity{/NP_76} , {VP_act_77}retained{/VP_act_77} {NP_78}<c>phosphotransfer</c> function{/NP_78} , but {VP_act_neg_79}did not support{/VP_act_neg_79} {NP_80}chemotaxis{/NP_80} , {VP_act_81}suggesting{/VP_act_81} that {NP_82}the <p>phosphatase</p> activity{/NP_82} {VP_pass_83}may be required{/VP_pass_83} for {NP_84}chemotaxis{/NP_84} .

{VP_act_85}Using{/VP_act_85} {NP_86}a nested deletion approach{/NP_86} , {NP_87}we{/NP_87} {VP_act_88}showed{/VP_act_88} that {NP_PP_89}a <pp><c>200-amino</c> acid segment</pp>{/NP_PP_89} of {NP_C_90}<c><p>CheA</p>(3)</c>{/NP_C_90} {VP_pass_91}is required{/VP_pass_91} for {NP_92}<p>phosphatase</p> activity{/NP_92} .

OUTPUT 2
PTM = ({NP_96};phosphorylation)
Inducer = (-;-)
	Method=rule: (inducer) for phrase=[{NP_P_94}previously identified <p>nonhybrid histidine protein kinases</p>{/NP_P_94}20..51|<p>nonhybrid histidine protein kinases</p>]
Kinase = ({NP_P_94}<p>nonhybrid histidine protein kinases</p>{/NP_P_94};-)
	Method=inducer_is_kinase (kinase) for phrase=[{NP_P_94}previously identified <p>nonhybrid histidine protein kinases</p>{/NP_P_94}20..51|<p>nonhybrid histidine protein kinases</p>]
Substrate = (-;-)
Site = (-;-;UNK)

{NP_93}The <p>phosphatase</p> activity{/NP_93} of {NP_P_94}previously identified <p>nonhybrid histidine protein kinases</p>{/NP_P_94} {VP_act_95}depends{/VP_act_95} on {NP_96}the <pp>dimerization and histidine phosphorylation ( DHp ) domains</pp>{/NP_96} .

{AV_97}However{/AV_97} , {NP_C_98}<c><p>CheA</p>(3)</c>{/NP_C_98} {VP_act_99}lacks{/VP_act_99} {NP_PP_100}a <pp>DHp domain</pp>{/NP_PP_100} , {VP_act_101}suggesting{/VP_act_101} that {NP_102}its <p>phosphatase</p> mechanism{/NP_102} {VP_pass_103}is different{/VP_pass_103} from that of {NP_P_104}other <p>histidine protein kinases</p>{/NP_P_104} .


{NP_1}PMID{/NP_1} - {CP_2}19032871{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}The role{/NP_4} of {NP_5}FAK-ERK signal transduction pathway{/NP_5} in {NP_6}apoptosis{/NP_6} of {NP_7}hepatic stellate <Bpcl>cell</Bpcl>{/NP_7} ] .

{NP_8}AB{/NP_8} - {NP_9}OBJECTIVES{/NP_9} :

{VP_act_10}To investigate{/VP_act_10} {NP_11}the effects{/NP_11} of {NP_P_12}<p>FAK-related non-kinase ( FRNK )</p>{/NP_P_12} on {NP_13}the apoptosis{/NP_13} of {NP_S_14}<S>hepatic stellate cells ( HSC )</S>{/NP_S_14} in {NP_15}vitro{/NP_15} and on {NP_16}the extracellular signal-regulated kinase ( <p>ERK</p> ) signal transduction pathway{/NP_16} .

{NP_17}METHODS{/NP_17} : {NP_S_18}<S>HSC</S>{/NP_S_18} {VP_pass_19}were stimulated{/VP_pass_19} by {NP_P_20}<p>fibronectin ( FN )</p>{/NP_P_20} , and {AV_21}then{/AV_21} {NP_22}they{/NP_22} {VP_pass_23}were transfected{/VP_pass_23} with {NP_24}<p>FAK-related non-kinase ( FRNK )</p> plasmids{/NP_24} {VP_pass_25}mediated{/VP_pass_25} by {NP_26}cationic liposome{/NP_26} .

{NP_27}The apoptosis{/NP_27} of {NP_S_28}<p>FRNK</p> -induced <S>HSC</S>{/NP_S_28} {VP_pass_29}was examined{/VP_pass_29} by {NP_30}<p>annexin-V/propidium iodide double-labeled flow cytometry ( FCM )</p> , <c>gel</c> electrophoresis and transmission electron microscopy{/NP_30} .

{NP_31}Levels{/NP_31} of {NP_P_32}<p>FRNK</p>{/NP_P_32} , {NP_P_33}<p>FAK</p>{/NP_P_33} , {NP_P_B_34}<p>p-FAK</p> (<pp>Tyr397</pp>){/NP_P_B_34} , {NP_P_35}<p>ERK1</p> and <p>p-ERK</p>{/NP_P_35} in {NP_S_36}<S>HSC</S>{/NP_S_36} {VP_pass_37}were assayed{/VP_pass_37} by {NP_38}Western blot{/NP_38} on {NP_39}the <Bppf>protein</Bppf> level{/NP_39} , and by {NP_B_40}<B>RT-PCR</B>{/NP_B_40} on {NP_41}the mRNA level{/NP_41} .

{NP_42}RESULTS{/NP_42} : {NP_43}The expression{/NP_43} of {NP_P_44}<p>FRNK</p>{/NP_P_44} {VP_pass_45}was enhanced{/VP_pass_45} after {NP_46}<p>FRNK</p> plasmids{/NP_46} {VP_pass_47}were transiently transfected{/VP_pass_47} into {NP_S_48}the <S>HSC</S>{/NP_S_48} .

{NP_49}The apoptotic rate{/NP_49} of {NP_S_50}the <S>HSC</S>{/NP_S_50} {VP_act_51}exposed{/VP_act_51} to {NP_52}<p>FRNK</p> plasmids{/NP_52} for {NP_53}48 h{/NP_53} {VP_pass_54}was higher{/VP_pass_54} than that in {NP_55}the <B>non-FRNK</B> plasmid <Bpcf>group</Bpcf>{/NP_55} ( {NP_56}25.37%+/-1.92% vs 9.28%+/-1.05%{/NP_56} , {NP_B_57}<B>P less</B>{/NP_B_57} than {NP_58}0.01{/NP_58} ) , and {VP_pass_59}was accompanied{/VP_pass_59} by {NP_60}a significantly higher activity{/NP_60} of {NP_P_61}<p>caspase-3</p>{/NP_P_61} both in {NP_P_62}the <Bppf>protein</Bppf>{/NP_P_62} and in {NP_63}the mRNA levels{/NP_63} [ {NP_64}( 264.17+/-12.60 vs 185.82+/-9.69 ){/NP_64} , {NP_B_65}<B>P less</B>{/NP_B_65} than {NP_66}0.01{/NP_66} ; {NP_67}( 4.19+/-0.48 vs 1.07+/-0.27 ){/NP_67} , {NP_B_68}<B>P less</B>{/NP_B_68} than {NP_69}0.01]{/NP_69} .

After {NP_70}exposure{/NP_70} of {NP_S_71}<S>HSC</S>{/NP_S_71} to {NP_72}<p>FRNK</p> plasmids{/NP_72} , {VP_act_73}compared{/VP_act_73} with {NP_74}the <B>non-FRNK</B> plasmid <Bpcf>group</Bpcf>{/NP_74} , {NP_75}the expressions{/NP_75} of {NP_P_76}<p>p-FAK</p> , <p>ERK1</p> and <p>p-ERK</p>{/NP_P_76} in {NP_77}<Bppf>protein</Bppf> and mRNA levels{/NP_77} {VP_pass_78}were lower{/VP_pass_78} ; on {NP_79}the contrary{/NP_79} , {VP_act_80}compared{/VP_act_80} with {NP_81}the control <Bpcf>group</Bpcf>{/NP_81} , {NP_82}the expressions{/NP_82} of {NP_P_83}<p>p-FAK</p> , <p>ERK1</p> and <p>p-ERK</p>{/NP_P_83} in {NP_C_84}the <c>FN group</c>{/NP_C_84} {VP_pass_85}were higher{/VP_pass_85} .

OUTPUT 0
PTM = ({NP_90};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_88}<p>FRNK</p>{/NP_P_88}" 	(Features:dist=0|pparg)
Substrate = ({NP_P_91}<p>FAK</p>{/NP_P_91};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_91}<p>FAK</p>{/NP_P_91}]
Site = (-;-;UNK)

{NP_86}CONCLUSION{/NP_86} : {NP_87}The expression{/NP_87} of {NP_P_88}<p>FRNK</p>{/NP_P_88} {VP_pass_89}was enhanced{/VP_pass_89} and {NP_90}the phosphorylation{/NP_90} of {NP_P_91}<p>FAK</p>{/NP_P_91} {VP_pass_92}was inhibited{/VP_pass_92} after {NP_P_93}<p>FRNK</p>{/NP_P_93} {VP_pass_94}was transiently transfected{/VP_pass_94} into {NP_S_95}<S>HSC</S>{/NP_S_95} in {NP_96}vitro{/NP_96} .

{NP_P_97}<p>FRNK</p>{/NP_P_97} {VP_act_98}induces{/VP_act_98} {NP_99}apoptosis{/NP_99} of {NP_S_100}<S>HSC</S>{/NP_S_100} .

{NP_101}FAK-ERK signal transduction pathway{/NP_101} {VP_pass_102}perhaps is involved{/VP_pass_102} in {NP_103}the process{/NP_103} .


{NP_1}PMID{/NP_1} - {CP_2}19035092{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}<p>Akt</p> activation{/NP_4} {VP_act_5}mediates{/VP_act_5} {NP_6}<c>estrogen</c> -induced neuroprotection{/NP_6} against {NP_C_7}<c>beta amyloid</c>{/NP_C_7} ] .

{NP_8}AB{/NP_8} - {NP_9}OBJECTIVE{/NP_9} :

{VP_act_10}To investigate{/VP_act_10} {NP_11}the effects{/NP_11} of {NP_C_12}<c>estrogen 17beta-estradiol</c>{/NP_C_12} on {NP_13}<p>beta-amyloid protein 25-35 ( Abeta25-35 )</p>- induced neurotoxicity{/NP_13} and {NP_14}possible mechanism{/NP_14} {AV_15}thereof{/AV_15} .

{NP_16}METHODS{/NP_16} : {NP_17}Primary cortical neurons{/NP_17} {VP_pass_18}were obtained{/VP_pass_18} from {NP_19}the brain{/NP_19} of {NP_20}a <B>SD</B> <s>rat</s>{/NP_20} and {JP_21}cultured{/JP_21} and {VP_act_22}treated{/VP_act_22} with {NP_C_23}<p>Abeta25-35</p> and <c>17beta-estradiol</c>{/NP_C_23} .

{NP_24}I{/NP_24} {VP_act_25}order{/VP_act_25} {VP_act_26}to investigate{/VP_act_26} {NP_27}the possible mechanism{/NP_27} of {NP_28}antagonism{/NP_28} of {NP_C_29}<c>estrogen</c>{/NP_C_29} against {NP_30}the neurotoxicity{/NP_30} of {NP_P_31}<p>Abeta25-35</p>{/NP_P_31} , {NP_P_32}<p>Akt</p>{/NP_P_32} - {NP_33}I{/NP_33} , {NP_P_34}a specific <p>Akt inhibitor</p> and <p>ICI-182780</p>{/NP_P_34} , {NP_P_35}an <Bppf>inhibitor</Bppf>{/NP_P_35} of {NP_P_36}<p>estrogen receptor</p>{/NP_P_36} {VP_pass_37}were added{/VP_pass_37} before {NP_38}the addition{/NP_38} of {NP_C_39}<c>estrogen</c>{/NP_C_39} .

{NP_P_40}The <p>Abeta32-35</p>{/NP_P_40} {VP_act_41}induced{/VP_act_41} {NP_42}<S>cell</S> viability and <p>lactate dehydrogenase ( LDH )</p> release{/NP_42} into {NP_43}the <Bpcl>cell</Bpcl> media{/NP_43} {VP_pass_44}was detected{/VP_pass_44} with {NP_45}spectrophotometer{/NP_45} .

OUTPUT 0
PTM = ({NP_50};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_50}<p>Akt</p>{/NP_50};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_50}phosphorylated <p>Akt</p> , a <Bppf><Bpcl>cell</Bpcl> -protecting factor</Bppf> , and level{/NP_50}14..16|<p>Akt</p>]
Site = (-;-;UNK)

{VP_act_46}Western blotting{/VP_act_46} {VP_pass_47}was used{/VP_pass_47} {VP_act_48}to detect{/VP_act_48} {NP_49}the level{/NP_49} of {NP_50}phosphorylated <p>Akt</p> , a <Bppf><Bpcl>cell</Bpcl> -protecting factor</Bppf> , and level{/NP_50} of {NP_P_51}nonphosphorylated <p>Akt</p>{/NP_P_51} in {NP_52}different conditions{/NP_52} .

{NP_53}RESULTS{/NP_53} : {NP_P_54}20 <p>micromol/L Abeta25-35</p>{/NP_P_54} {VP_act_55}decreased{/VP_act_55} {NP_56}the <Bpcl>cell</Bpcl> viability{/NP_56} of {NP_57}the <s>rat</s> cortical neurons{/NP_57} to {NP_58}40.4%{/NP_58} ( {NP_59}P &lt{/NP_59} ; {NP_60}0.01{/NP_60} ) as {JP_61}compared{/JP_61} with {NP_62}the control <Bpcf>group</Bpcf>{/NP_62} and {NP_63}the <Bpcl>cell</Bpcl> viability{/NP_63} of {NP_64}the <Bpcf>group</Bpcf>{/NP_64} with {NP_65}the addition{/NP_65} of {NP_C_66}<c>17beta-estradiol</c>{/NP_C_66} {VP_pass_67}was{/VP_pass_67} {NP_68}84.2%{/NP_68} , {JP_69}significantly higher{/JP_69} than that of {NP_C_70}the <c><p>Abeta25-35</p> group</c>{/NP_C_70} ( {NP_71}P &lt{/NP_71} ; {NP_72}0.01{/NP_72} ) .

{NP_73}The LDH secretion level{/NP_73} of {NP_P_74}the <p>Abeta25-35</p>{/NP_P_74} {VP_pass_75}was{/VP_pass_75} {NP_76}172.5% as{/NP_76} {JP_77}high{/JP_77} as that of {NP_78}the control <Bpcf>group</Bpcf>{/NP_78} ( {NP_79}P &lt{/NP_79} ; {NP_80}0.01{/NP_80} ) , while that of {NP_C_81}the <c>17beta-estradiol preincubation group</c>{/NP_C_81} {VP_pass_82}was{/VP_pass_82} {NP_83}only 118.5%{/NP_83} that of {NP_84}the control <Bpcf>group</Bpcf>{/NP_84} ( {NP_85}P &lt{/NP_85} ; {NP_86}0.01{/NP_86} ) .

{NP_C_87}Both <p>Akt inhibitor</p> and <c><p>estrogen receptor</p> antagonist</c>{/NP_C_87} {VP_act_88}partially antagonized{/VP_act_88} {NP_89}<c>estrogen</c> 's protective effects{/NP_89} against {NP_P_90}<p>Abeta25-35</p>{/NP_P_90} in {NP_91}<Bpcl>cell</Bpcl> viability{/NP_91} .

OUTPUT 1
PTM = ({NP_94};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_92}<p>Abeta25-35</p>{/NP_P_92}" 	(Features:dist=0|subject_main)
		Candidate="<p>Abeta25-35</p>" in "{NP_P_92}<p>Abeta25-35</p>{/NP_P_92}" 	(Features:dist=0|subject_main|subject_main_modifier)
Substrate = ({NP_94}<p>Akt</p>{/NP_94};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_94}the phosphorylated <p>Akt</p> level{/NP_94}17..19|<p>Akt</p>]
Site = (-;-;UNK)

{NP_P_92}<p>Abeta25-35</p>{/NP_P_92} {VP_act_93}decreased{/VP_act_93} {NP_94}the phosphorylated <p>Akt</p> level{/NP_94} to {CP_95}69.5%{/CP_95} ( {NP_96}P &lt{/NP_96} ; {NP_97}0.01{/NP_97} ) , while {NP_98}<c>estrogen 17beta-estradiol</c> pretreatment{/NP_98} {VP_act_99}antagonized{/VP_act_99} {NP_100}this effect{/NP_100} to {CP_101}94.7%{/CP_101} ( {NP_102}P &lt{/NP_102} ; {NP_103}0.01{/NP_103} ) , and {NP_104}the addition{/NP_104} of {NP_P_105}<p>Akt inhibitor</p>{/NP_P_105} {VP_act_106}partially blocked{/VP_act_106} {NP_107}the <c>estrogen's</c> rescue effect{/NP_107} ( {NP_108}75.4%{/NP_108} , {NP_109}<B>P</B> &lt{/NP_109} ; {NP_110}0.05{/NP_110} ) .

OUTPUT 2
PTM = ({NP_113};phosphorylation)
	HasAgentTheme="<p>Akt</p>" in "{NP_113}<p>Akt</p> phosphorylation{/NP_113}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>estrogen receptor</p>" in "{NP_C_116}the <c><p>estrogen receptor</p> antagonist</c>{/NP_C_116}" 	(Features:dist=0)
Substrate = ({NP_113}<p>Akt</p>{/NP_113};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_113}<p>Akt</p> phosphorylation{/NP_113}0..2|<p>Akt</p>]
Site = (-;-;UNK)

OUTPUT 3
PTM = ({NP_114};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_113}<p>Akt</p>{/NP_113};-)
	Method=closer (substrate) for phrase=[{NP_113}<p>Akt</p> phosphorylation{/NP_113}0..2|<p>Akt</p>]
		From: {NP_113}<p>Akt</p> phosphorylation{/NP_113}0..2|<p>Akt</p>
Site = (-;-;UNK)

OUTPUT 4
PTM = ({NP_121};phosphorylation)
	HasAgentTheme="<p>Akt</p>" in "{NP_121}<p>Akt</p> phosphorylation{/NP_121}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_C_116}the <c><p>estrogen receptor</p> antagonist</c>{/NP_C_116}" 	(Features:dist=0)
		Candidate="<p>estrogen receptor</p>" in "{NP_C_116}the <c><p>estrogen receptor</p> antagonist</c>{/NP_C_116}" 	(Features:dist=0)
Substrate = ({NP_121}<p>Akt</p>{/NP_121};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_121}<p>Akt</p> phosphorylation{/NP_121}0..2|<p>Akt</p>]
Site = (-;-;UNK)

{NP_111}<c>Estrogen</c> treatment{/NP_111} {VP_act_112}alone increased{/VP_act_112} {NP_113}<p>Akt</p> phosphorylation{/NP_113} , but {NP_114}this phosphorylation{/NP_114} {VP_pass_115}could be partially blocked{/VP_pass_115} by {NP_C_116}the <c><p>estrogen receptor</p> antagonist</c>{/NP_C_116} , {NP_117}the latter{/NP_117} {AV_118}alone{/AV_118} {VP_act_119}had{/VP_act_119} {NP_120}no effect{/NP_120} on {NP_121}<p>Akt</p> phosphorylation{/NP_121} .

Under {NP_122}all circumstances{/NP_122} , {NP_123}the amount{/NP_123} of {NP_P_124}nonphosphorylated <p>Akt</p>{/NP_P_124} {VP_act_125}didn't{/VP_act_125} {NP_126}change{/NP_126} {AV_127}significantly{/AV_127} .

{NP_128}CONCLUSION{/NP_128} : {NP_C_129}The <c>estrogen 17beta-estradiol</c>{/NP_C_129} {VP_act_130}partially alleviates{/VP_act_130} {NP_131}the <p>Abeta25-35</p> -induced neurotoxicity and <p>Akt</p> activation{/NP_131} {VP_pass_132}may be involved{/VP_pass_132} in {NP_133}<c>estrogen</c> 's neuroprotective effect{/NP_133} .

{NP_P_134}<p>Estrogen receptor</p>{/NP_P_134} {VP_act_135}may play{/VP_act_135} {NP_136}a role{/NP_136} in {NP_C_137}<c>estrogen</c>{/NP_C_137} {VP_act_138}induced{/VP_act_138} {NP_139}<p>Akt</p> activation{/NP_139} .

NORM=akt
SYNONYM=Akt


{NP_1}PMID{/NP_1} - {CP_2}19035107{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}Correlative research{/NP_4} between {NP_5}<p>ERK1/2</p> cascade and <p>c-fos</p> expression{/NP_5} after {NP_6}hippocampal neuron epileptiform discharge{/NP_6} ] .

{NP_7}AB{/NP_7} - {NP_8}OBJECTIVE{/NP_8} :

{VP_act_9}To investigate{/VP_act_9} {NP_10}the correlation{/NP_10} between {NP_P_11}<p>ERK1/2</p> cascade and <p>c-fos</p>{/NP_P_11} after {NP_12}hippocampal neuron epileptiform discharge{/NP_12} .

{NP_13}METHODS{/NP_13} :

{NP_14}Hippocampal neurons{/NP_14} {VP_pass_15}were collected{/VP_pass_15} from {NP_16}<B>Wistar</B> rats{/NP_16} and {JP_17}cultured{/JP_17} in {NP_18}magnesium-free extra-cellular fluid{/NP_18} {VP_act_19}to establish{/VP_act_19} {NP_20}hippocampal neuron epileptiform discharge model{/NP_20} .

{AV_21}Then{/AV_21} {NP_22}the hippocampal neurons{/NP_22} {VP_pass_23}were divided{/VP_pass_23} into {NP_24}2 <Bpcf>groups</Bpcf>{/NP_24} :

{NP_25}<Bpcf>inhibitor group</Bpcf>{/NP_25} , {VP_act_26}added{/VP_act_26} with {NP_B_27}10 <B>micromol/L U0126</B>{/NP_B_27} , {NP_P_28}<Bppf>inhibitor</Bppf>{/NP_P_28} of {NP_29}<p>ERK 1/2</p> pathway{/NP_29} , and {NP_30}control <Bpcf>group</Bpcf>{/NP_30} without {NP_31}any treatment{/NP_31} , {VP_pass_32}got{/VP_pass_32} at {NP_33}0 min{/NP_33} ) .

OUTPUT 0
PTM = ({NP_P_40};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{VP_act_34}Using{/VP_act_34} {NP_35}double-label immunofluorescence{/NP_35} , {NP_36}laser scanning confocal microscopy{/NP_36} {VP_pass_37}was performed{/VP_pass_37} {VP_act_38}to detect{/VP_act_38} {NP_39}the disposition{/NP_39} of {NP_P_40}<p>phosphorylated-ERK1/2 ( p-ERK1/2 )</p> and <p>c-fos</p>{/NP_P_40} in {NP_41}the neurons{/NP_41} .

{VP_act_42}Western blotting{/VP_act_42} {VP_pass_43}was used{/VP_pass_43} {VP_act_44}to detect{/VP_act_44} {NP_45}the expression{/NP_45} of {NP_P_46}<p>p-ERK1/2</p> and <p>c-fos 0 min</p>{/NP_P_46} , {NP_47}30 min{/NP_47} , {NP_48}2 h{/NP_48} , {NP_49}6 h{/NP_49} , {NP_50}12 h{/NP_50} , and {NP_51}24 h{/NP_51} {VP_act_52}following{/VP_act_52} {NP_53}corresponding treatment RESULTS{/NP_53} : {NP_54}Double-label immunofluorescence examination{/NP_54} {VP_act_55}displayed{/VP_act_55} that there {VP_pass_56}was{/VP_pass_56} {NP_P_57}<p>p-ERK1/2</p>{/NP_P_57} in both {NP_58}the cytoplasm and nucleus{/NP_58} , but {NP_P_59}<p>c-fos</p>{/NP_P_59} in {NP_60}the nucleus{/NP_60} {AV_61}only{/AV_61} .

{VP_act_62}Western blotting{/VP_act_62} {VP_act_63}manifested{/VP_act_63} that {NP_P_64}<p>p-ERK1/2</p>{/NP_P_64} {VP_pass_65}was observed{/VP_pass_65} at {NP_66}each time points{/NP_66} in {NP_67}the model <Bpcf>group</Bpcf>{/NP_67} , and {NP_68}the expression pattern{/NP_68} of {NP_P_69}<p>c-fos</p>{/NP_P_69} {VP_pass_70}was{/VP_pass_70} the {JP_71}same{/JP_71} as {NP_P_72}<p>p-ERK1/2</p>{/NP_P_72} , {NP_73}which{/NP_73} {VP_act_74}peaked{/VP_act_74} {NP_75}30 min{/NP_75} after {NP_76}treatment{/NP_76} .

In {NP_77}the <Bpcf>inhibitor group</Bpcf>{/NP_77} , {NP_P_78}<p>p-ERK1/2</p>{/NP_P_78} {VP_pass_79}was inhibited{/VP_pass_79} {AV_80}completely{/AV_80} , and {NP_P_81}<p>c-fos</p>{/NP_P_81} {VP_pass_82}was decreased{/VP_pass_82} {AV_83}obviously{/AV_83} .

{NP_84}The <p>c-fos</p> expression levels{/NP_84} at {NP_85}different time points{/NP_85} of {NP_86}the <Bpcf>inhibitor group</Bpcf>{/NP_86} {VP_pass_87}were{/VP_pass_87} all {JP_88}significantly lower{/JP_88} than those of {NP_89}the model <Bpcf>group</Bpcf>{/NP_89} ( {NP_90}all <B>P</B> &lt{/NP_90} ; {NP_91}0.01{/NP_91} ) .

OUTPUT 1
PTM = ({NP_101};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_98}<p>c-fos</p>{/NP_P_98}" 	(Features:dist=0|in-title_elsewhere|pparg)
Substrate = ({NP_P_102}<p>ERK1/2</p>{/NP_P_102};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_102}<p>ERK1/2</p>{/NP_P_102}]
Site = (-;-;UNK)

{NP_92}CONCLUSION{/NP_92} : After {NP_93}hippocampal neuron epileptiform discharge{/NP_93} , {NP_P_94}<p>ERK1/2</p>{/NP_P_94} {VP_pass_95}is activated{/VP_pass_95} for {NP_96}a long time{/NP_96} , and {NP_97}the expression{/NP_97} of {NP_P_98}<p>c-fos</p>{/NP_P_98} {VP_pass_99}is downregulated{/VP_pass_99} by {VP_act_100}blocking{/VP_act_100} {NP_101}the phosphorylation{/NP_101} of {NP_P_102}<p>ERK1/2</p>{/NP_P_102} .


{NP_1}PMID{/NP_1} - {CP_2}19035116{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}Expression{/NP_4} of {NP_P_5}<B>nuclear export factor <p>CRM1</p></B> and <p>p27</p>{/NP_P_5} in {NP_6}glioma{/NP_6} ] .

{NP_7}AB{/NP_7} - {NP_8}OBJECTIVE{/NP_8} :

OUTPUT 0
PTM = ({NP_P_12};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_11}nuclear export factor <p>CRM1</p>{/NP_P_11}" 	(Features:dist=0|pparg)
		Candidate="<p>CRM1</p>" in "{NP_P_11}nuclear export factor <p>CRM1</p>{/NP_P_11}" 	(Features:dist=0|pparg)
		Candidate="Ser10" in "{NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12}" 	(Features:dist=0)
Substrate = ({NP_P_12}<p>p27</p>{/NP_P_12};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12}20..22|<p>p27</p>]
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12}26..28|<p>p27</p>]
Site = ({NP_P_12}10{/NP_P_12};{NP_P_12}Ser{/NP_P_12};UNK)
	Method=rule: (site) for phrase=[{NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12}0..4|Ser10|Ser10]

OUTPUT 1
PTM = ({NP_P_12};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_11}nuclear export factor <p>CRM1</p>{/NP_P_11}" 	(Features:dist=0|pparg)
		Candidate="<p>CRM1</p>" in "{NP_P_11}nuclear export factor <p>CRM1</p>{/NP_P_11}" 	(Features:dist=0|pparg)
		Candidate="Ser10" in "{NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12}" 	(Features:dist=0)
Substrate = ({NP_P_12}<p>p27</p>{/NP_P_12};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12}20..22|<p>p27</p>]
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12}26..28|<p>p27</p>]
Site = ({NP_P_12}10{/NP_P_12};{NP_P_12}Ser{/NP_P_12};UNK)
	Method=rule: (site) for phrase=[{NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12}0..4|Ser10|Ser10]

{VP_act_9}To investigate{/VP_act_9} {NP_10}the expression{/NP_10} of {NP_P_11}nuclear export factor <p>CRM1</p>{/NP_P_11} , {NP_P_12}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_12} in {NP_13}<s>human</s> gliomas{/NP_13} .

OUTPUT 2
PTM = ({NP_P_17};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_16}<p>CRM1</p>{/NP_P_16}" 	(Features:dist=0|pparg)
		Candidate="Ser10" in "{NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17}" 	(Features:dist=0)
Substrate = ({NP_P_17}<p>p27</p>{/NP_P_17};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17}20..22|<p>p27</p>]
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17}26..28|<p>p27</p>]
Site = ({NP_P_17}10{/NP_P_17};{NP_P_17}Ser{/NP_P_17};UNK)
	Method=rule: (site) for phrase=[{NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17}0..4|Ser10|Ser10]

OUTPUT 3
PTM = ({NP_P_17};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_16}<p>CRM1</p>{/NP_P_16}" 	(Features:dist=0|pparg)
		Candidate="Ser10" in "{NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17}" 	(Features:dist=0)
Substrate = ({NP_P_17}<p>p27</p>{/NP_P_17};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17}20..22|<p>p27</p>]
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17}26..28|<p>p27</p>]
Site = ({NP_P_17}10{/NP_P_17};{NP_P_17}Ser{/NP_P_17};UNK)
	Method=rule: (site) for phrase=[{NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17}0..4|Ser10|Ser10]

{NP_14}METHODS{/NP_14} : {NP_15}The expression{/NP_15} of {NP_P_16}<p>CRM1</p>{/NP_P_16} , {NP_P_17}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_17} {VP_pass_18}were investigated{/VP_pass_18} in {NP_19}70 cases{/NP_19} of {NP_20}<s>human</s> gliomas{/NP_20} and {NP_21}10 specimens{/NP_21} of {NP_22}the normal brain <Bpcl>tissue</Bpcl>{/NP_22} by {NP_23}<Bpcf>immunohistochemical</Bpcf> technique{/NP_23} and {NP_24}Western blot{/NP_24} .

OUTPUT 4
PTM = ({NP_P_30};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="Ser10" in "{NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30}" 	(Features:dist=0)
Substrate = ({NP_P_30}<p>p27</p>{/NP_P_30};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30}20..22|<p>p27</p>]
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30}26..28|<p>p27</p>]
Site = ({NP_P_30}10{/NP_P_30};{NP_P_30}Ser{/NP_P_30};UNK)
	Method=rule: (site) for phrase=[{NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30}0..4|Ser10|Ser10]

OUTPUT 5
PTM = ({NP_P_30};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="Ser10" in "{NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30}" 	(Features:dist=0)
Substrate = ({NP_P_30}<p>p27</p>{/NP_P_30};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30}20..22|<p>p27</p>]
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30}26..28|<p>p27</p>]
Site = ({NP_P_30}10{/NP_P_30};{NP_P_30}Ser{/NP_P_30};UNK)
	Method=rule: (site) for phrase=[{NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30}0..4|Ser10|Ser10]

{NP_25}RESULTS{/NP_25} : There {VP_pass_26}were{/VP_pass_26} {NP_27}significant differences{/NP_27} on {NP_28}the expression levels{/NP_28} of {NP_P_29}<p>CRM1</p>{/NP_P_29} , {NP_P_30}<pp>Ser10</pp> -phosphorylated <p>p27</p> and <p>p27</p>{/NP_P_30} among {NP_31}normal brain <Bpcl>tissue</Bpcl>{/NP_31} , {VP_act_32}gliomas{/VP_act_32} of {NP_B_33}grades <B>II</B>{/NP_B_33} and {NP_34}gliomas{/NP_34} of {NP_B_35}grades <B>III</B>{/NP_B_35} plus {NP_B_36}<B>IV</B>{/NP_B_36} ( {NP_37}P &lt{/NP_37} ; {NP_38}0.01{/NP_38} ) .

OUTPUT 6
PTM = ({NP_P_51};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_40}<p>CRM1</p>{/NP_P_40}" 	(Features:dist=0|pparg)
		Candidate="Ser10" in "{NP_P_51}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_51}" 	(Features:dist=0)
Substrate = ({NP_P_51}<p>p27</p>{/NP_P_51};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_51}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_51}20..22|<p>p27</p>]
Site = ({NP_P_51}10{/NP_P_51};{NP_P_51}Ser{/NP_P_51};UNK)
	Method=rule: (site) for phrase=[{NP_P_51}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_51}0..4|Ser10|Ser10]

{NP_39}The expression{/NP_39} of {NP_P_40}<p>CRM1</p>{/NP_P_40} in {NP_41}gliomas{/NP_41} {VP_pass_42}was inversely correlated{/VP_pass_42} with {NP_43}the expression{/NP_43} of {NP_P_44}<p>p27</p>{/NP_P_44} ( {NP_45}r(s){/NP_45} = {NP_46}-0.727{/NP_46} , {NP_47}<B>P</B> &lt{/NP_47} ; {NP_48}0.01{/NP_48} ) and {JP_49}positively correlated{/JP_49} with {NP_50}the expression{/NP_50} of {NP_P_51}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_51} ( {NP_52}r(s){/NP_52} = {CP_53}0.954{/CP_53} , {NP_54}<B>P</B> &lt{/NP_54} ; {NP_55}0.01{/NP_55} ) and {NP_P_56}<p>Ki-67</p>{/NP_P_56} ( {NP_57}r(s){/NP_57} = {CP_58}0.799{/CP_58} , {NP_59}<B>P</B> &lt{/NP_59} ; {NP_60}0.01{/NP_60} ) .

OUTPUT 7
PTM = ({NP_P_63};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="Ser10" in "{NP_P_63}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_63}" 	(Features:dist=0)
Substrate = ({NP_P_63}<p>p27</p>{/NP_P_63};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_63}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_63}20..22|<p>p27</p>]
Site = ({NP_P_63}10{/NP_P_63};{NP_P_63}Ser{/NP_P_63};UNK)
	Method=rule: (site) for phrase=[{NP_P_63}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_63}0..4|Ser10|Ser10]

{AV_61}Moreover{/AV_61} , {NP_62}the expression{/NP_62} of {NP_P_63}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_63} {VP_pass_64}was inversely correlated{/VP_pass_64} with {NP_P_65}<p>p27</p>{/NP_P_65} ( {NP_66}r(s){/NP_66} = {NP_67}-0.744{/NP_67} , {NP_68}<B>P</B> &lt{/NP_68} ; {NP_69}0.01{/NP_69} ) and {JP_70}positively correlated{/JP_70} with {NP_P_71}<p>Ki-67</p>{/NP_P_71} ( {NP_72}r(s){/NP_72} = {NP_73}0.785{/NP_73} , {NP_74}<B>P</B> &lt{/NP_74} ; {NP_75}0.01{/NP_75} ) .

OUTPUT 8
PTM = ({NP_P_80};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<Bppp>sites</Bppp>" in "{NP_PP_85}<Bppp>sites</Bppp>{/NP_PP_85}" 	(Features:dist=0)
		Candidate="Ser10" in "{NP_P_80}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_80}" 	(Features:dist=0)
Substrate = ({NP_P_80}<p>p27</p>{/NP_P_80};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_80}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_80}20..22|<p>p27</p>]
Site = ({NP_P_80}10{/NP_P_80};{NP_P_80}Ser{/NP_P_80};UNK)
	Method=rule: (site) for phrase=[{NP_P_80}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_80}0..4|Ser10|Ser10]

{NP_76}CONCLUSIONS{/NP_76} : {NP_P_77}<p>CRM1</p>{/NP_P_77} , through {VP_act_78}recognizing{/VP_act_78} and {NP_79}binding{/NP_79} with {NP_P_80}<pp>Ser10</pp> -phosphorylated <p>p27</p>{/NP_P_80} , {VP_act_81}may promote{/VP_act_81} {VP_act_82}moving{/VP_act_82} of {NP_P_83}<p>p27CRM1</p>{/NP_P_83} from its {VP_act_84}original locating{/VP_act_84} {NP_PP_85}<Bppp>sites</Bppp>{/NP_PP_85} ; {VP_act_86}act{/VP_act_86} as {NP_87}a critical signaling component{/NP_87} in {NP_88}the proliferative process{/NP_88} of {NP_89}glioma <Bpcl>cells</Bpcl>{/NP_89} and {AV_90}then{/AV_90} , {VP_act_91}plays{/VP_act_91} {NP_92}an important role{/NP_92} in {NP_93}the development{/NP_93} of {NP_94}gliomas{/NP_94} .

NORM=p 27
SYNONYM=p27


{NP_1}PMID{/NP_1} - {CP_2}19035120{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}Pilot study{/NP_4} of {NP_5}<p>PTEN</p> deletion{/NP_5} {VP_act_6}affecting{/VP_act_6} {NP_7}the expression{/NP_7} of {NP_B_8}<B>Cu/Zn SOD</B>{/NP_B_8} ] .

{NP_9}AB{/NP_9} - {NP_10}OBJECTIVE{/NP_10} :

{VP_act_11}To investigate{/VP_act_11} whether {NP_12}the deletion{/NP_12} of {NP_P_13}<p>PTEN</p>{/NP_P_13} {VP_act_14}affects{/VP_act_14} {NP_15}the expression{/NP_15} of {NP_B_16}<B>Cu/Zn SOD</B>{/NP_B_16} and {NP_17}the related biology{/NP_17} .

{NP_18}METHODS{/NP_18} : {NP_19}<Bppf>Protein</Bppf> and mRNA expression levels{/NP_19} of {NP_P_20}<p>PTEN</p>{/NP_P_20} , {NP_B_21}<B>P-Akt</B>{/NP_B_21} , {NP_B_22}<B>Cu/Zn SOD</B>{/NP_B_22} in {NP_23}the control{/NP_23} {VP_act_24}immortalized{/VP_act_24} {NP_S_25}wild type <s>mouse</s> embryonic <S>fibroblast cells</S> (<p>PTEN</p>+/+){/NP_S_25} and {NP_S_26}<S>PTEN-null cells ( PTEN-/- )</S>{/NP_S_26} {VP_pass_27}were evaluated{/VP_pass_27} by {NP_28}Western blot{/NP_28} and {NP_29}Northern blot{/NP_29} {AV_30}respectively{/AV_30} .

{NP_31}The level{/NP_31} of {NP_32}<c>superoxide</c> anions{/NP_32} {VP_pass_33}were detected{/VP_pass_33} {VP_act_34}using{/VP_act_34} {NP_35}fluorescent probes{/NP_35} .

{NP_36}The DNA damage{/NP_36} {VP_pass_37}was documented{/VP_pass_37} by {NP_38}single <c>cell alkalescence gel</c> assay{/NP_38} .

{NP_C_39}<c>MTT</c>{/NP_C_39} {VP_pass_40}was used{/VP_pass_40} {VP_act_41}to study{/VP_act_41} {NP_42}the effect{/NP_42} of {NP_P_43}<p>H2O2</p>{/NP_P_43} on {NP_44}the proliferation{/NP_44} of {NP_45}<Bpcl>cells</Bpcl>{/NP_45} .

{NP_46}RESULTS{/NP_46} : {NP_47}The expression{/NP_47} of {NP_B_48}<B>Cu/Zn SOD</B>{/NP_B_48} {VP_pass_49}was down regulated{/VP_pass_49} at {NP_50}both <Bppf>protein</Bppf> and mRNA levels{/NP_50} , and {NP_51}the level{/NP_51} of {NP_52}<c>superoxide</c> anions{/NP_52} {VP_pass_53}increased{/VP_pass_53} in {NP_S_54}the <S>PTEN-null cells ( PTEN-/- )</S>{/NP_S_54} .

OUTPUT 0
PTM = ({NP_55};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_56}<p>Akt kinase</p>{/NP_P_56};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_56}<p>Akt kinase</p>{/NP_P_56}]
Site = (-;-;UNK)

{NP_55}The phosphorylation level{/NP_55} of {NP_P_56}<p>Akt kinase</p>{/NP_P_56} {VP_pass_57}was up-regulated{/VP_pass_57} and {NP_58}the antiproliferative effect{/NP_58} of {NP_P_59}<p>H2O2</p>{/NP_P_59} {VP_pass_60}decreased{/VP_pass_60} in {NP_S_61}<S>PTEN-/- cells</S>{/NP_S_61} .

{AV_62}Furthermore{/AV_62} , {NP_63}DNA damage{/NP_63} {VP_pass_64}was observed{/VP_pass_64} {VP_pass_65}significantly severer{/VP_pass_65} in both {NP_P_66}the blank control and <p>H2O2</p>{/NP_P_66} {VP_act_67}treated{/VP_act_67} {NP_68}<Bpcf>groups</Bpcf>{/NP_68} than that in {NP_S_69}the <S><p>PTEN</p>+/+ cells</S>{/NP_S_69} .

{NP_70}CONCLUSIONS{/NP_70} : {NP_71}Deletion{/NP_71} of {NP_P_72}<p>PTEN</p>{/NP_P_72} {VP_act_73}affects{/VP_act_73} {NP_74}the expression{/NP_74} of {NP_B_75}<B>Cu/Zn SOD</B>{/NP_B_75} .

As {NP_76}a result{/NP_76} , {NP_77}<c>reactive oxygen species ( ROS )</c> keep{/NP_77} at {NP_78}a high level{/NP_78} , along with {NP_79}decrease{/NP_79} of {NP_80}accumulated oxidative damage{/NP_80} and {NP_81}the antiproliferative effect{/NP_81} of {NP_C_82}<c>ROS</c>{/NP_C_82} .


{NP_1}PMID{/NP_1} - {CP_2}19035139{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}Expression and activation{/NP_4} of {NP_B_5}<B>insulin receptor substrate -1</B>{/NP_B_5} in {NP_6}endometrial carcinoma{/NP_6} ] .

{NP_7}AB{/NP_7} - {NP_8}OBJECTIVE{/NP_8} :

OUTPUT 0
PTM = ({NP_10};phosphorylation)
	HasAgentTheme="<Bppf>protein</Bppf>" in "{NP_10}the mRNA , <Bppf>protein</Bppf> expression and <pp>tyrosine</pp> phosphorylation{/NP_10}"
Inducer = (-;-)
Kinase = (-;-)
	Method=agent|theme_but_substrate_is_known (kinase) for phrase=[{NP_10}the mRNA , <Bppf>protein</Bppf> expression and <pp>tyrosine</pp> phosphorylation{/NP_10}8..14|<Bppf>protein</Bppf>]
	Filtered={NP_10}the mRNA , <Bppf>protein</Bppf> expression and <pp>tyrosine</pp> phosphorylation{/NP_10}8..14|<Bppf>protein</Bppf>	(Category=generic)
	Method=agent|theme_but_substrate_is_known (kinase) for phrase=[{NP_10}the mRNA , <Bppf>protein</Bppf> expression and <pp>tyrosine</pp> phosphorylation{/NP_10}8..14|<Bppf>protein</Bppf>]
Substrate = ({NP_P_11}<p>insulin receptor substrate-1 ( IRS-1 )</p>{/NP_P_11};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_11}<p>insulin receptor substrate-1 ( IRS-1 )</p>{/NP_P_11}]
Site = (-;{NP_10}Tyr{/NP_10};UNK)
	Method=rule: (site) for phrase=[{NP_10}the mRNA , <Bppf>protein</Bppf> expression and <pp>tyrosine</pp> phosphorylation{/NP_10}15..22|tyrosine|Tyr]

{VP_act_9}To investigate{/VP_act_9} {NP_10}the mRNA , <Bppf>protein</Bppf> expression and <pp>tyrosine</pp> phosphorylation{/NP_10} of {NP_P_11}<p>insulin receptor substrate-1 ( IRS-1 )</p>{/NP_P_11} in {NP_12}endometrial carcinoma{/NP_12} .

{NP_13}METHODS{/NP_13} : {NP_14}Sixty-three <S>endometrial carcinoma ( EC )</S> patients{/NP_14} , {NP_15}21 <B>endometrial atypical hyperplasia ( AHE )</B> patients{/NP_15} and {NP_B_16}22 <B>normal control ( NE )</B>{/NP_B_16} {VP_act_17}entered{/VP_act_17} {NP_18}this study{/NP_18} .

{NP_19}Their clinical information{/NP_19} {VP_pass_20}were collected{/VP_pass_20} .

{VP_act_21}Fasting{/VP_act_21} {NP_22}serum <pp>C-peptide</pp> concentration{/NP_22} {VP_pass_23}was measured{/VP_pass_23} .

{NP_24}Expression{/NP_24} of {NP_P_25}<p>IRS-1</p>{/NP_P_25} in {NP_26}endometrium{/NP_26} {VP_pass_27}was examined{/VP_pass_27} by {NP_B_28}<B>RT-PCR</B>{/NP_B_28} and {NP_29}western blot{/NP_29} .

OUTPUT 1
PTM = ({NP_33};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>tyrosine</pp>" in "{NP_33}the <pp>tyrosine</pp> phosphorylation{/NP_33}" 	(Features:dist=0)
		Candidate="tyrosine" in "{NP_33}the <pp>tyrosine</pp> phosphorylation{/NP_33}" 	(Features:dist=0)
Substrate = ({NP_P_34}<p>IRS-1</p>{/NP_P_34};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_34}<p>IRS-1</p>{/NP_P_34}]
Site = (-;{NP_33}Tyr{/NP_33};UNK)
	Method=rule: (site) for phrase=[{NP_33}the <pp>tyrosine</pp> phosphorylation{/NP_33}3..10|tyrosine|Tyr]

{NP_30}Immunoprecipitation{/NP_30} {VP_pass_31}was used{/VP_pass_31} {VP_act_32}to measure{/VP_act_32} {NP_33}the <pp>tyrosine</pp> phosphorylation{/NP_33} of {NP_P_34}<p>IRS-1</p>{/NP_P_34} .

{NP_35}RESULTS{/NP_35} : {NP_36}C{/NP_36} - {NP_37}<Bppp>peptide</Bppp> concentration{/NP_37} in {NP_C_38}<c>EC group</c>{/NP_C_38} {VP_pass_39}was higher{/VP_pass_39} than that in {NP_C_40}<c>NE group</c>{/NP_C_40} [ {NP_B_41}( 3.2 +/- 1.1 ) vs ( 2.5 +/- 0.7 ) <B>microg/L</B>{/NP_B_41} , {NP_B_42}<B>P</B>{/NP_B_42} = {NP_43}0.007]{/NP_43} .

There {VP_pass_44}were{/VP_pass_44} {NP_45}no significant differences{/NP_45} in {NP_46}<p>IRS-1 mRNA</p> and <Bppf>protein</Bppf> expression{/NP_46} among {NP_47}the three <Bpcf>groups</Bpcf>{/NP_47} .

OUTPUT 2
PTM = ({NP_48};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<pp>Tyrosine</pp>" in "{NP_48}<pp>Tyrosine</pp> phosphorylation{/NP_48}" 	(Features:dist=0)
		Candidate="Tyrosine" in "{NP_48}<pp>Tyrosine</pp> phosphorylation{/NP_48}" 	(Features:dist=0)
Substrate = ({NP_P_49}<p>IRS-1</p>{/NP_P_49};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_49}<p>IRS-1</p>{/NP_P_49}]
Site = (-;{NP_48}Tyr{/NP_48};UNK)
	Method=rule: (site) for phrase=[{NP_48}<pp>Tyrosine</pp> phosphorylation{/NP_48}0..7|Tyrosine|Tyr]

{NP_48}<pp>Tyrosine</pp> phosphorylation{/NP_48} of {NP_P_49}<p>IRS-1</p>{/NP_P_49} in {NP_C_50}<c>EC group</c>{/NP_C_50} [ {NP_51}( 62 +/- 36 ) %]{/NP_51} {VP_pass_52}was higher{/VP_pass_52} than that in {NP_C_53}<c>AHE</c> and <c>NE groups</c>{/NP_C_53} [ {NP_54}( 53 <B>+/-34</B> ) %{/NP_54} and {NP_55}( 35 +/- 33 ) %{/NP_55} ; {NP_B_56}<B>P</B>{/NP_B_56} = {NP_57}0.048{/NP_57} , {NP_58}0.002]{/NP_58} .

{NP_59}<p>IRS-1</p> activation{/NP_59} in {NP_C_60}<c>AHE group</c>{/NP_C_60} {VP_pass_61}was also higher{/VP_pass_61} than {NP_62}normal control{/NP_62} ( {NP_63}P{/NP_63} = {NP_64}0.045{/NP_64} ) .

{NP_65}<p>IRS-1</p> activation{/NP_65} in {NP_66}endometrioid carcinoma{/NP_66} [ {NP_67}( 69 +/- 33 ) %]{/NP_67} {VP_pass_68}was higher{/VP_pass_68} than that in {NP_69}other histological types{/NP_69} [ {NP_70}( 34 +/- 31 ) %{/NP_70} ; {NP_71}t{/NP_71} = {NP_72}2.300{/NP_72} , {NP_B_73}<B>P</B>{/NP_B_73} = {NP_74}0.025]{/NP_74} .

OUTPUT 3
PTM = ({NP_75};phosphorylation)
	HasAgentTheme="<p>IRS-1</p>" in "{NP_75}<pp><p>IRS-1</p> tyrosine</pp> phosphorylation{/NP_75}"
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_75}<p>IRS-1</p>{/NP_75};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_75}<pp><p>IRS-1</p> tyrosine</pp> phosphorylation{/NP_75}0..4|<p>IRS-1</p>]
Site = (-;-;UNK)
	Candidates (Site):
		Candidate="{NP_75}<pp><p>IRS-1</p> tyrosine</pp> phosphorylation{/NP_75}" 	(Features:is-aa)

{NP_75}<pp><p>IRS-1</p> tyrosine</pp> phosphorylation{/NP_75} {VP_pass_76}was significantly higher{/VP_pass_76} in {NP_77}patients{/NP_77} with {NP_78}advanced stage{/NP_78} , {NP_79}high grade{/NP_79} , {NP_80}deep myometrial invasion{/NP_80} and {NP_81}pelvic lymph node metastasis{/NP_81} .

{NP_82}<p>IRS-1</p> activation{/NP_82} in {NP_83}endometrium{/NP_83} {VP_pass_84}was positively correlated{/VP_pass_84} with {NP_85}fasting serum <pp>C-peptide</pp> concentration{/NP_85} ( {NP_86}r{/NP_86} = {CP_87}0.491{/CP_87} , {NP_B_88}<B>P</B>{/NP_B_88} = {NP_89}0.001{/NP_89} ) .

{NP_90}CONCLUSIONS{/NP_90} : There {VP_act_91}is{/VP_act_91} {NP_92}excessive activation{/NP_92} of {NP_P_93}<p>IRS-1</p>{/NP_P_93} in {NP_94}endometrial carcinoma{/NP_94} and {NP_95}atypical hyperplasia{/NP_95} .

{NP_96}Activation{/NP_96} of {NP_P_97}<p>IRS-1</p>{/NP_P_97} in {NP_98}endometrial carcinoma{/NP_98} {VP_pass_99}is related{/VP_pass_99} with {NP_100}poor clinical-pathologic features{/NP_100} and {VP_act_101}may be{/VP_act_101} {NP_102}a prognostic predictor{/NP_102} for {NP_103}this tumor{/NP_103} .

{NP_104}Over-activation{/NP_104} of {NP_P_105}<p>IRS-1</p>{/NP_P_105} {VP_act_106}may be{/VP_act_106} {NP_107}an intermediate event{/NP_107} {VP_act_108}linking{/VP_act_108} {NP_109}the hyperinsulinemia and endometrial carcinoma{/NP_109} .

NORM=irs 1
SYNONYM=IRS-1
SYNONYM=insulin receptor substrate-1 ( IRS-1 )


{NP_1}PMID{/NP_1} - {CP_2}19035169{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}The role{/NP_4} of {NP_5}hepatic stellate <S>cells</S> <p>SSeCKS</p> expression{/NP_5} in {NP_6}liver fibrosis{/NP_6} ] .

{NP_7}AB{/NP_7} - {NP_8}OBJECTIVE{/NP_8} :

OUTPUT 0
PTM = ({NP_P_11};substrates)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{VP_act_9}To investigate{/VP_act_9} {NP_10}the change and effect{/NP_10} of {NP_P_11}<p>SSeCKS ( src suppressed c kinase substrates )</p>{/NP_P_11} in {NP_12}the activation{/NP_12} of {NP_S_13}<S>hepatic stellate cells ( HSCs )</S>{/NP_S_13} .

{NP_14}METHODS{/NP_14} : {NP_S_15}<S>HSCs</S>{/NP_S_15} {VP_pass_16}were isolated{/VP_pass_16} from {NP_17}normal <s>rats</s>{/NP_17} , {NP_18}the change{/NP_18} of {NP_19}<p>SSeCKS mRNA</p> expression{/NP_19} on {NP_S_20}<S>HSCs culture</S>{/NP_S_20} in {NP_21}vitro{/NP_21} {VP_pass_22}was determined{/VP_pass_22} {VP_act_23}using{/VP_act_23} {NP_24}real-time PCR{/NP_24} , {NP_25}<Bppf>protein</Bppf> level{/NP_25} {VP_pass_26}was determined{/VP_pass_26} by {NP_27}Western blot{/NP_27} and {NP_28}immunofluorescence methods{/NP_28} .

{NP_29}A <s>rat</s> model{/NP_29} of {NP_30}liver fibrosis{/NP_30} {VP_pass_31}was established{/VP_pass_31} .

{NP_32}The expression and location{/NP_32} of {NP_P_33}<p>SSeCKS</p> and <p>alpha-SMA ( alpha-smooth muscle actin )</p>{/NP_P_33} in {NP_34}liver <Bpcl>tissues</Bpcl>{/NP_34} {VP_pass_35}were detected{/VP_pass_35} by {NP_36}immunofluorescence methods{/NP_36} .

{NP_37}RESULTS{/NP_37} : {NP_38}<p>SSeCKS mRNA</p> expression{/NP_38} {VP_pass_39}was low{/VP_pass_39} in {NP_S_40}freshly isolated <S>HSCs cell</S>{/NP_S_40} and {NP_41}the expression{/NP_41} {VP_pass_42}increased{/VP_pass_42} in {NP_S_43}activated <S>HSCs</S>{/NP_S_43} in {NP_44}vitro{/NP_44} .

In {NP_45}liver <Bpcl>fibrosis tissue</Bpcl>{/NP_45} , {NP_46}the number{/NP_46} of {NP_S_47}<S>SSeCKS-positive cells</S>{/NP_S_47} {VP_pass_48}was increased{/VP_pass_48} and {NP_49}these <Bpcl>cells</Bpcl>{/NP_49} {VP_pass_50}were distributed{/VP_pass_50} along {NP_51}the sinusoids{/NP_51} {NP_52}which{/NP_52} {VP_act_53}also contained{/VP_act_53} {NP_P_54}<p>alpha-SMA positive cells</p>{/NP_P_54} .

{NP_55}CONCLUSION{/NP_55} : {NP_56}The expression{/NP_56} of {NP_P_57}<p>SSeCKS</p>{/NP_P_57} {VP_pass_58}was increased{/VP_pass_58} in {NP_S_59}activated <S>HSCs</S>{/NP_S_59} in {NP_60}vitro{/NP_60} .

{AV_61}Therefore{/AV_61} , {NP_P_62}<p>SSeCKS</p>{/NP_P_62} {VP_pass_63}may be involved{/VP_pass_63} in {NP_64}the liver inflammation and fibrosis{/NP_64} .


{NP_1}PMID{/NP_1} - {CP_2}19035280{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Persistent <s>adenovirus</s>-mediated <p>thymidine kinase gene</p> expression{/NP_4} in {NP_5}ovarian <Bpcl>cancer cells</Bpcl>{/NP_5} {VP_act_6}increases{/VP_act_6} {NP_7}<Bpcl>cell</Bpcl>{/NP_7} {VP_act_8}killing{/VP_act_8} {NP_9}efficacy{/NP_9} over {NP_10}time{/NP_10} .

{NP_11}AB{/NP_11} - {NP_12}<B>Adenovirus ( ADV )</B>- mediated <Bppf>gene</Bppf> therapy{/NP_12} with {NP_P_13}the <p>thymidine kinase ( TK ) gene</p>{/NP_P_13} under {NP_14}control{/NP_14} of {NP_15}the <s>Rous sarcoma virus ( RSV )</s> promotor{/NP_15} {VP_pass_16}followed{/VP_pass_16} by {NP_17}the administration{/NP_17} of {NP_C_18}<c>acyclovir</c>{/NP_C_18} {VP_pass_19}has been established{/VP_pass_19} in {NP_20}vitro{/NP_20} for {NP_21}the treatment{/NP_21} of {NP_22}ovarian <Bpcl>cancer cells</Bpcl>{/NP_22} and {VP_pass_23}has been used{/VP_pass_23} as {NP_24}the basis{/NP_24} for {NP_25}intraperitoneal phase I clinical trials{/NP_25} .

{NP_26}It{/NP_26} {VP_pass_27}is unclear{/VP_pass_27} how {JP_28}long{/JP_28} {NP_29}a significant degree{/NP_29} of {NP_30}<Bppf>transgene</Bppf> translation{/NP_30} {VP_pass_31}can be expected{/VP_pass_31} after {NP_32}<s>adenovirus</s>-mediated <p>TK</p> transduction{/NP_32} , {NP_33}where{/NP_33} {NP_34}the transcriptional <Bpf>complex</Bpf>{/NP_34} {VP_pass_35}is localized{/VP_pass_35} in {NP_36}the nucleus{/NP_36} in {NP_37}an episomal fashion{/NP_37} and {AV_38}thus{/AV_38} without {NP_39}stable integration{/NP_39} .

{NP_40}The possible interaction{/NP_40} of {NP_41}<c>acyclovir</c> pretreatment{/NP_41} with {NP_42}subsequent <B>ADV-RSV-TK</B> transduction{/NP_42} {VP_act_43}also remains{/VP_act_43} {VP_pass_44}to be elucidated{/VP_pass_44} .

{NP_45}<Bppf>Transgene</Bppf> expression and <Bpcl>cell</Bpcl>{/NP_45} {VP_act_46}killing{/VP_act_46} {NP_47}efficacy{/NP_47} {VP_pass_48}were analysed{/VP_pass_48} {VP_pass_49}based{/VP_pass_49} on {NP_50}multiplicity{/NP_50} of {NP_51}infection ( MOI ) and <B>MTT</B> assay{/NP_51} .

{NP_P_52}<p>Anti-TK-antibody 1397</p>{/NP_P_52} {VP_pass_53}was used{/VP_pass_53} for {NP_54}immunocytochemistry{/NP_54} and {NP_55}Western blot analysis{/NP_55} of {NP_56}<p>TK</p> expression{/NP_56} .

After {NP_57}transduction{/NP_57} with {NP_B_58}<B>ADV-RSV-TK</B>{/NP_B_58} at {NP_B_59}an <B>MOI</B>{/NP_B_59} of {CP_60}66{/CP_60} , {NP_61}<p>TK</p> translation{/NP_61} {VP_pass_62}increased{/VP_pass_62} {AV_63}strongly{/AV_63} in {NP_S_64}<p>MDH 2774</p> and <S><s>OVCAR-3 cell</s> lines</S>{/NP_S_64} during {NP_65}the initial 48 hours{/NP_65} .

{NP_66}Virtually constant expression{/NP_66} of {NP_P_67}the <p>TK transgene</p>{/NP_P_67} {VP_pass_68}was observed{/VP_pass_68} by {NP_69}Western blot{/NP_69} during {NP_70}eight days{/NP_70} .

{NP_71}<Bpcl>Cell</Bpcl>{/NP_71} {VP_act_72}killing{/VP_act_72} {NP_73}efficacy{/NP_73} {VP_pass_74}was increased{/VP_pass_74} by {NP_75}repeated daily administrations{/NP_75} of {NP_C_76}<c>acyclovir</c>{/NP_C_76} .

{NP_77}Pretreatment{/NP_77} with {NP_C_78}<c>acyclovir</c>{/NP_C_78} {VP_pass_neg_79}did not result{/VP_pass_neg_79} in {NP_80}significantly increased <Bpcl>cell</Bpcl>{/NP_80} {VP_act_81}killing{/VP_act_81} {NP_82}efficacy{/NP_82} .

{NP_83}No negative effect{/NP_83} of {NP_C_84}<c>acyclovir</c>{/NP_C_84} on {NP_85}<B>ADV-RSV-TK</B> transduction{/NP_85} {VP_pass_86}was observed{/VP_pass_86} .

{NP_87}The atleast week-long expression{/NP_87} of {NP_P_88}the <p>TK transgene</p>{/NP_P_88} with {NP_89}persistently increasing efficacy{/NP_89} of {NP_90}<Bpcl>cell</Bpcl>{/NP_90} {VP_act_91}killing{/VP_act_91} after <B>ADV</B> -mediated {NP_92}tumor <Bpcl>cell</Bpcl> transduction{/NP_92} {VP_act_93}provide{/VP_act_93} {NP_94}a realistic basis{/NP_94} for {NP_95}the development{/NP_95} of {NP_96}multicycle ADV -mediated <p>TK gene</p> therapy approaches{/NP_96} in {NP_97}the treatment{/NP_97} of {NP_98}ovarian cancer{/NP_98} .

OUTPUT 0
PTM = ({NP_102};substrate)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_99}Continuous <c>i.v.acyclovir</c> treatment{/NP_99} or {NP_100}daily oral <c>acyclovir-prodrug</c> therapy{/NP_100} {VP_act_101}might simplify{/VP_act_101} {NP_102}the <Bppf>substrate</Bppf> regimen{/NP_102} for {NP_P_103}the <p>TK gene</p>{/NP_P_103} .


{NP_1}PMID{/NP_1} - {CP_2}19035284{/CP_2}

OUTPUT 0
PTM = ({NP_4};Dephosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_3}TI{/NP_3} - {NP_4}Dephosphorylation{/NP_4} of {NP_P_5}<Bppf>cancer protein</Bppf>{/NP_P_5} by {NP_P_6}<p>tyrosine phosphatases</p>{/NP_P_6} in {NP_7}response{/NP_7} to {NP_8}<Bpf>analogs</Bpf>{/NP_8} of {VP_act_9}luteinizing{/VP_act_9} {NP_P_10}<p>hormone -releasing hormone</p> and <p>somatostatin</p>{/NP_P_10} .

OUTPUT 1
PTM = ({NP_12};phosphorylation)
	HasAgentTheme="<Bppf>Protein</Bppf>" in "{NP_12}<Bppf>Protein</Bppf> phosphorylation/dephosphorylation{/NP_12}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_PP_13}<pp>tyrosine residues</pp>{/NP_PP_13}" 	(Features:dist=0)
		Candidate="tyrosine" in "{NP_PP_13}<pp>tyrosine residues</pp>{/NP_PP_13}" 	(Features:dist=0)
Substrate = (-;-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_12}<Bppf>Protein</Bppf> phosphorylation/dephosphorylation{/NP_12}0..6|<Bppf>Protein</Bppf>]
	Filtered={NP_12}<Bppf>Protein</Bppf> phosphorylation/dephosphorylation{/NP_12}0..6|<Bppf>Protein</Bppf>	(Category=generic)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_12}<Bppf>Protein</Bppf> phosphorylation/dephosphorylation{/NP_12}0..6|<Bppf>Protein</Bppf>]
Site = (-;-;UNK)
	Method=rule: (site) for phrase=[{NP_PP_13}<pp>tyrosine residues</pp>{/NP_PP_13}0..7|tyrosine|Tyr]

{NP_11}AB{/NP_11} - {NP_12}<Bppf>Protein</Bppf> phosphorylation/dephosphorylation{/NP_12} of {NP_PP_13}<pp>tyrosine residues</pp>{/NP_PP_13} {VP_act_14}is{/VP_act_14} {NP_15}an important regulatory mechanism{/NP_15} in {NP_16}<Bpcl>cell</Bpcl> growth and differentiation{/NP_16} .

{AV_17}Previously{/AV_17} {NP_18}it{/NP_18} {VP_pass_19}has been reported{/VP_pass_19} that {NP_B_20}<B>RC-160</B>{/NP_B_20} , {NP_21}an <Bpf>octapeptide analog</Bpf>{/NP_21} of {NP_P_22}<p>somatostatin</p>{/NP_P_22} , and {NP_PP_23}<pp>[D-Trp6</pp>]<p>LHRH</p>{/NP_PP_23} , {NP_24}an <Bpcf>agonist</Bpcf>{/NP_24} of {NP_P_25}<p>luteinizing hormone-releasing hormone ( LHRH )</p>{/NP_P_25} , {VP_act_26}stimulate{/VP_act_26} {NP_27}<Bppf>receptor</Bppf> -mediated activity{/NP_27} of {NP_P_28}<p>tyrosine phosphatases ( PTP )</p>{/NP_P_28} and {VP_act_29}reverse{/VP_act_29} {NP_30}growth promotion{/NP_30} of {NP_31}the tyrosine kinase ( PTK ) class{/NP_31} of {NP_P_32}<Bppf>oncogenes</Bppf>{/NP_P_32} in {NP_33}tumor <Bpcl>cells</Bpcl>{/NP_33} .

OUTPUT 2
PTM = ({NP_36};phosphorylation)
	HasAgentTheme="<Bppf>protein</Bppf>" in "{NP_36}<Bppf>protein</Bppf> phosphorylation{/NP_36}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>LHRH</p>" in "{NP_PP_35}<B>RC-160</B> and <pp>[D-Trp6</pp>]<p>LHRH</p>{/NP_PP_35}" 	(Features:dist=0|subject_main_modifier)
Substrate = (-;-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_36}<Bppf>protein</Bppf> phosphorylation{/NP_36}0..6|<Bppf>protein</Bppf>]
	Filtered={NP_36}<Bppf>protein</Bppf> phosphorylation{/NP_36}0..6|<Bppf>protein</Bppf>	(Category=generic)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_36}<Bppf>protein</Bppf> phosphorylation{/NP_36}0..6|<Bppf>protein</Bppf>]
Site = (-;-;UNK)

{NP_34}The effect{/NP_34} of {NP_PP_35}<B>RC-160</B> and <pp>[D-Trp6</pp>]<p>LHRH</p>{/NP_PP_35} on {NP_36}<Bppf>protein</Bppf> phosphorylation{/NP_36} {VP_pass_37}was further examined{/VP_pass_37} in {NP_38}surgical specimens{/NP_38} of {NP_39}<s>human</s> carcinomas{/NP_39} .

{NP_40}<Bppf>Protein</Bppf> extracts{/NP_40} of {NP_41}<s>human</s> ovarian , liver , breast and prostate tumor samples{/NP_41} {VP_pass_42}were preincubated{/VP_pass_42} with {NP_P_43}<p>epidermal growth factor ( EGF )</p>{/NP_P_43} ( {NP_B_44}10 ( -7 ) <B>M</B>{/NP_B_44} ) with or without {NP_B_45}<pp>[D-Trp6</pp>]<p>LHRH</p> or <B>RC-160</B>{/NP_B_45} ( {NP_B_46}10 ( -6 ) <B>M</B>{/NP_B_46} ) at {NP_47}25 degrees C{/NP_47} for {NP_48}2 h{/NP_48} , {VP_pass_49}followed{/VP_pass_49} by {NP_50}incubation{/NP_50} for {NP_51}10 min{/NP_51} with {NP_P_52}<p>[gamma-32p]ATP</p>{/NP_P_52} .

OUTPUT 3
PTM = ({NP_60};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_C_53}<c>SDS-PAGE</c>{/NP_C_53} , {NP_54}Western{/NP_54} {VP_act_55}blotting{/VP_act_55} , {NP_56}autoradiography{/NP_56} and {NP_57}densitometry{/NP_57} {VP_pass_58}were then used{/VP_pass_58} {VP_act_59}to quantify{/VP_act_59} {NP_60}the phosphorylation level{/NP_60} of {NP_61}individual <Bppf>protein</Bppf> bands{/NP_61} .

OUTPUT 4
PTM = ({NP_68};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_62}It{/NP_62} {VP_pass_63}was found{/VP_pass_63} that {NP_P_64}<p>EGF</p>{/NP_P_64} {VP_act_65}enhanced{/VP_act_65} , and {NP_B_66}<pp>[D-Trp6</pp>]<p>LHRH</p> and <B>RC-160</B>{/NP_B_66} {VP_act_67}reduced{/VP_act_67} {NP_68}phosphorylation{/NP_68} of {NP_69}a prominent <B>300-kDa</B> band{/NP_69} .

{NP_P_70}Two <Bppf>proteins</Bppf> ( <B>65 and 60 kDa</B> ){/NP_P_70} , {VP_pass_71}involved{/VP_pass_71} in {NP_72}growth control{/NP_72} in {NP_73}tumor <Bpcl>cell lines</Bpcl>{/NP_73} , {VP_pass_74}were also identified{/VP_pass_74} in {NP_75}this study{/NP_75} .

OUTPUT 5
PTM = ({NP_77};substrate)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>PTP</p>" in "{NP_P_78}induced <p>PTK</p> and <p>PTP</p>{/NP_P_78}" 	(Features:dist=0)
		Candidate="<p>PTK</p>" in "{NP_P_78}induced <p>PTK</p> and <p>PTP</p>{/NP_P_78}" 	(Features:dist=0)
Substrate = (-;-)
	Method=rule:1.2.23.1.1.1 (substrate) for phrase=[{NP_77}<Bppf>substrate</Bppf> phosphorylation{/NP_77}0..8|<Bppf>substrate</Bppf>]
	Filtered={NP_77}<Bppf>substrate</Bppf> phosphorylation{/NP_77}0..8|<Bppf>substrate</Bppf>	(Category=generic)
	Method=rule:1.2.23.1.1.1 (substrate) for phrase=[{NP_77}<Bppf>substrate</Bppf> phosphorylation{/NP_77}0..8|<Bppf>substrate</Bppf>]
Site = (-;-;UNK)

{NP_76}The homology{/NP_76} of {NP_77}<Bppf>substrate</Bppf> phosphorylation{/NP_77} between {NP_P_78}induced <p>PTK</p> and <p>PTP</p>{/NP_P_78} in {NP_79}the presence{/NP_79} of {NP_P_80}<Bppf>hormones</Bppf>{/NP_P_80} {VP_act_81}provided{/VP_act_81} {NP_82}evidence{/NP_82} that {NP_P_83}these <Bppf>substrates</Bppf>{/NP_P_83} {VP_act_84}might be identical{/VP_act_84} or {VP_pass_85}related{/VP_pass_85} in {NP_86}tumors{/NP_86} .

{NP_87}These findings{/NP_87} , along with {NP_88}the previous <Bpcl>cell culture</Bpcl> results{/NP_88} , {VP_act_89}suggest{/VP_act_89} that {NP_90}many solid tumors{/NP_90} {VP_act_91}may respond{/VP_act_91} to {NP_92}treatment{/NP_92} with {NP_93}<Bpf>analogues</Bpf>{/NP_93} of {NP_P_94}<p>somatostatin</p> and <p>LHRH</p>{/NP_P_94} .

{AV_95}Collectively{/AV_95} , {NP_96}the results{/NP_96} {VP_act_97}further support{/VP_act_97} {NP_98}the hypothesis{/NP_98} that {NP_99}these 60-{/NP_99} , {CP_100}65{/CP_100} - and {NP_P_101}<Bppf>300-kDa protein substrates</Bppf>{/NP_P_101} {VP_pass_102}may be involved{/VP_pass_102} in {NP_103}growth-message transduction{/NP_103} .


{NP_1}PMID{/NP_1} - {CP_2}19035289{/CP_2}

OUTPUT 0
PTM = ({NP_13};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_3}TI{/NP_3} - {NP_4}Growth inhibition{/NP_4} of {NP_5}<s>human</s> <p>MDA-mB-231</p> breast <Bpcl>cancer cells</Bpcl>{/NP_5} by {NP_6}delta-tocotrienol{/NP_6} {VP_pass_7}is associated{/VP_pass_7} with {NP_8}loss{/NP_8} of {NP_9}<p>cyclin D1/CDK4</p> expression{/NP_9} and {VP_act_10}accompanying{/VP_act_10} {NP_11}changes{/NP_11} in {NP_12}the state{/NP_12} of {NP_13}phosphorylation{/NP_13} of {NP_P_14}the retinoblastoma tumor suppressor <Bppf>gene product</Bppf>{/NP_P_14} .

{NP_15}AB{/NP_15} - {NP_16}Tocotrienols{/NP_16} , {NP_17}a <Bpcf>subgroup</Bpcf>{/NP_17} within {NP_B_18}the <B>vitamin E family</B>{/NP_B_18} of {NP_19}<Bpcf>compounds</Bpcf>{/NP_19} , {VP_act_20}have shown{/VP_act_20} {NP_21}antiproliferative{/NP_21} and {NP_22}anticancer properties{/NP_22} , {AV_23}however{/AV_23} , {NP_24}the molecular basis{/NP_24} of {NP_25}these effects{/NP_25} {VP_act_26}remains{/VP_act_26} {VP_pass_27}to be elucidated{/VP_pass_27} .

OUTPUT 1
PTM = ({NP_34};phosphorylation)
	HasAgentTheme="<p>retinoblastoma protein ( Rb )</p>" in "{NP_34}the <p>retinoblastoma protein ( Rb )</p> levels and phosphorylation status{/NP_34}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>DNA -binding protein</p>" in "{NP_P_42}a <p>DNA -binding protein</p>{/NP_P_42}" 	(Features:dist=0)
Substrate = ({NP_34}<p>retinoblastoma protein ( Rb )</p>{/NP_34};-)
	Method=agent_or_theme_and_known_as_neither_(default) (substrate) for phrase=[{NP_34}the <p>retinoblastoma protein ( Rb )</p> levels and phosphorylation status{/NP_34}3..27|<p>retinoblastoma protein ( Rb )</p>]
Site = (-;-;UNK)

In {NP_28}this study{/NP_28} , {NP_29}the effect{/NP_29} of {NP_30}3-tocotrienol{/NP_30} on {NP_31}cell cycle arrest{/NP_31} {VP_pass_32}was assessed{/VP_pass_32} by {VP_act_33}studying{/VP_act_33} {NP_34}the <p>retinoblastoma protein ( Rb )</p> levels and phosphorylation status{/NP_34} , {VP_act_35}levels{/VP_act_35} of {NP_P_36}<p>E2F</p>{/NP_P_36} ( {NP_P_37}a <Bppf>transcription factor</Bppf>{/NP_P_37} {VP_pass_38}critically involved{/VP_pass_38} in {NP_39}the <B>G1/S-phase</B> transition{/NP_39} of {NP_40}the mammalian <Bpcl>cell</Bpcl> cycle{/NP_40} ; {VP_act_41}originally identified{/VP_act_41} as {NP_P_42}a <p>DNA -binding protein</p>{/NP_P_42} {JP_43}essential{/JP_43} for {NP_44}early region 1A -dependent activation{/NP_44} of {NP_PP_45}the <s>adenovirus</s> <Bppp>promoter</Bppp>{/NP_PP_45} {VP_act_46}designated{/VP_act_46} {NP_B_47}<B>E2</B>{/NP_B_47} ) , and {NP_48}other <Bpcl>cell</Bpcl> cycle{/NP_48} {VP_act_49}controlling{/VP_act_49} {NP_P_50}<Bppf>proteins</Bppf>{/NP_P_50} in {NP_51}<p>estrogen receptor -negative MDA-MB-231</p> breast <Bpcl>cancer cells</Bpcl>{/NP_51} .

{NP_52}The cell growth assay{/NP_52} {VP_act_53}demonstrated{/VP_act_53} that {NP_54}exposure{/NP_54} of {NP_S_55}the <s><S><p>MDA-MB-231</p> cells</S></s>{/NP_S_55} to {NP_56}6-tocotrienol ( 1-20 microM ){/NP_56} {VP_pass_57}resulted{/VP_pass_57} in {NP_58}a dose{/NP_58} - and {NP_59}time -dependent inhibition{/NP_59} of {NP_60}<Bpcl>cell</Bpcl> growth{/NP_60} as {JP_61}compared{/JP_61} with {NP_62}vehicle{/NP_62} {VP_act_63}treated{/VP_act_63} {NP_64}<Bpcl>cells</Bpcl>{/NP_64} and {NP_65}the magnitude{/NP_65} of {NP_66}growth inhibition{/NP_66} {VP_pass_67}was higher{/VP_pass_67} at {NP_68}10 and 20 microM treatment{/NP_68} for {NP_69}48 and 72 h{/NP_69} .

OUTPUT 2
PTM = ({NP_70};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = ({NP_P_71}<p>Rb</p>{/NP_P_71};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_71}<p>Rb</p>{/NP_P_71}]
Site = (-;-;UNK)

{NP_70}The phosphorylation status{/NP_70} of {NP_P_71}<p>Rb</p>{/NP_P_71} {VP_act_72}plays{/VP_act_72} {NP_73}a central role{/NP_73} in {NP_74}the control{/NP_74} of {NP_75}the <Bpcl>cell</Bpcl> cycle{/NP_75} at {NP_B_76}the <B>G0/G1-phase</B>{/NP_B_76} .

OUTPUT 3
PTM = ({NP_80};phosphorylation)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_77}delta-Tocotrienol treatment{/NP_77} {VP_act_78}reduced{/VP_act_78} {NP_P_79}the total <p>Rb</p>{/NP_P_79} and {NP_80}its phosphorylation{/NP_80} at {NP_81}the <pp>Ser780</pp> , <pp>Ser795</pp> , <pp>Ser 807/811</pp> and <pp>Thr826</pp> positions{/NP_81} in {NP_82}a dose{/NP_82} - and {NP_83}time -dependent fashion{/NP_83} .

OUTPUT 4
PTM = ({NP_85};phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_92}<p>cyclin-dependant kinase 4 ( CDK4 )</p>{/NP_P_92};-)
	Method=from_other_triggers_in_the_same_sentence (kinase) for phrase=[{NP_P_92}its regulatory partner <p>cyclin-dependant kinase 4 ( CDK4 )</p>{/NP_P_92}20..48|<p>cyclin-dependant kinase 4 ( CDK4 )</p>]
Substrate = ({NP_P_86}<p>Rb</p>{/NP_P_86};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_86}<p>Rb</p>{/NP_P_86}]
Site = (-;-;UNK)
	Method=site_in_argument_proteins (site) for phrase=[{NP_P_92}its regulatory partner <p>cyclin-dependant kinase 4 ( CDK4 )</p>{/NP_P_92}42..42| 4|4]

OUTPUT 5
PTM = ({NP_95};phosphorylation)
Inducer = (-;-)
Kinase = ({NP_P_92}<p>cyclin-dependant kinase 4 ( CDK4 )</p>{/NP_P_92};-)
	Method=link (kinase) for phrase=[{NP_P_92}its regulatory partner <p>cyclin-dependant kinase 4 ( CDK4 )</p>{/NP_P_92}]
		From: {NP_93}which{/NP_93}
		Path: refer
Substrate = ({NP_P_96}<p>Rb</p>{/NP_P_96};-)
	Method=rule:1.2.1.1.0.1 (substrate) for phrase=[{NP_P_96}<p>Rb</p>{/NP_P_96}]
Site = ({NP_PP_97}780{/NP_PP_97};{NP_PP_97}Ser{/NP_PP_97};UNK)
({NP_PP_97}795{/NP_PP_97};{NP_PP_97}Ser{/NP_PP_97};UNK)
({NP_PP_97}807{/NP_PP_97};{NP_PP_97}Ser{/NP_PP_97};UNK)
({NP_PP_97}811{/NP_PP_97};{NP_PP_97}Ser{/NP_PP_97};UNK)
({NP_PP_98}826{/NP_PP_98};{NP_PP_98}Thr{/NP_PP_98};UNK)
	Method=rule: (site) for phrase=[{NP_PP_97}<pp>Ser780</pp> , <pp>Ser795</pp> , <pp>Ser 807/811</pp>{/NP_PP_97}0..5|Ser780|Ser7807..12|Ser795|Ser79514..23|Ser 807/811|Ser807,811]
	Method=rule: (site) for phrase=[{NP_PP_98}<pp>Thr826</pp>{/NP_PP_98}0..5|Thr826|Thr826]

{NP_84}The <Bppp>site</Bppp> -specific inhibition{/NP_84} of {NP_85}the phosphorylation{/NP_85} of {NP_P_86}<p>Rb</p>{/NP_P_86} by {NP_87}delta-tocotrienol{/NP_87} {VP_pass_88}was tightly associated{/VP_pass_88} with {NP_89}a marked reduction{/NP_89} in {NP_90}the expression{/NP_90} of {NP_P_91}<p>cyclin D1</p>{/NP_P_91} and {NP_P_92}its regulatory partner <p>cyclin-dependant kinase 4 ( CDK4 )</p>{/NP_P_92} , {NP_93}which{/NP_93} {VP_pass_94}is responsible{/VP_pass_94} for {NP_95}the phosphorylation{/NP_95} of {NP_P_96}<p>Rb</p>{/NP_P_96} at {NP_PP_97}<pp>Ser780</pp> , <pp>Ser795</pp> , <pp>Ser 807/811</pp>{/NP_PP_97} and {NP_PP_98}<pp>Thr826</pp>{/NP_PP_98} .

OUTPUT 6
PTM = ({NP_107};phosphorylation)
	HasAgentTheme="<p>Rb</p>" in "{NP_107}<p>Rb</p> phosphorylation and inhibition{/NP_107}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="{NP_P_102}<p>E2F</p>{/NP_P_102}" 	(Features:dist=0|pparg)
Substrate = ({NP_107}<p>Rb</p>{/NP_107};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_107}<p>Rb</p> phosphorylation and inhibition{/NP_107}0..1|<p>Rb</p>]
Site = (-;-;UNK)

In {NP_99}addition{/NP_99} , {VP_act_100}delta-tocotrienol also reduced{/VP_act_100} {NP_101}the expression{/NP_101} of {NP_P_102}<p>E2F</p>{/NP_P_102} {NP_103}that{/NP_103} {VP_act_104}occurred{/VP_act_104} {AV_105}simultaneously{/AV_105} with {NP_106}the loss{/NP_106} of {NP_107}<p>Rb</p> phosphorylation and inhibition{/NP_107} of {NP_108}cell cycle progression{/NP_108} .

{AV_109}Interestingly{/AV_109} , {VP_act_110}delta-tocotrienol also caused{/VP_act_110} {NP_111}a marked reduction{/NP_111} in {NP_112}the expression{/NP_112} of {NP_P_113}G2/M regulatory <Bppf>proteins</Bppf>{/NP_P_113} {VP_act_114}including{/VP_act_114} {NP_P_115}<p>cyclin B1</p> and <p>CDK1</p>{/NP_P_115} .

OUTPUT 7
PTM = ({NP_132};phosphorylation)
	HasAgentTheme="<p>Rb</p>" in "{NP_132}<pp>site</pp> -specific <p>Rb</p> phosphorylation{/NP_132}"
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>MDA-MB-231</p>" in "{NP_P_126}<s>human</s> breast <S>cancer cell line</S> <p>MDA-MB-231</p>{/NP_P_126}" 	(Features:dist=0)
Substrate = ({NP_132}<p>Rb</p>{/NP_132};-)
	Method=agent_or_theme_but_known_as_substrate (substrate) for phrase=[{NP_132}<pp>site</pp> -specific <p>Rb</p> phosphorylation{/NP_132}13..14|<p>Rb</p>]
Site = (-;-;{NP_132}<pp>site</pp>{/NP_132})

To the {JP_116}best{/JP_116} of {NP_117}our knowledge{/NP_117} , {NP_118}this study{/NP_118} {VP_pass_119}was{/VP_pass_119} the {JP_120}first{/JP_120} to {NP_121}reveal{/NP_121} that {NP_122}the target{/NP_122} of <Bpcl>cell</Bpcl> proliferative {NP_123}inhibitory action{/NP_123} of {JP_124}delta-tocotrienol{/JP_124} in {NP_125}a model{/NP_125} <p>estrogen receptor</p> -negative {NP_P_126}<s>human</s> breast <S>cancer cell line</S> <p>MDA-MB-231</p>{/NP_P_126} {VP_pass_127}is mediated{/VP_pass_127} by {NP_128}the loss{/NP_128} of {NP_P_129}<p>cyclin D1</p>{/NP_P_129} and {VP_act_130}associated{/VP_act_130} {NP_131}suppression{/NP_131} of {NP_132}<pp>site</pp> -specific <p>Rb</p> phosphorylation{/NP_132} , {VP_act_133}suggesting{/VP_act_133} {NP_134}its future development{/NP_134} and {NP_135}use{/NP_135} as {NP_136}an anticancer agent{/NP_136} .

NORM=rb
SYNONYM=Rb
SYNONYM=retinoblastoma protein ( Rb )


{NP_1}PMID{/NP_1} - {CP_2}19035298{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Promotion{/NP_4} of {NP_5}the self-renewal capacity{/NP_5} of {NP_6}<s>human</s> acute <Bpcl>leukemia cells</Bpcl>{/NP_6} by {NP_P_7}<p>Wnt3A</p>{/NP_P_7} .

{NP_8}AB{/NP_8} - {NP_9}BACKGROUND{/NP_9} :

{NP_10}<p>Wnt/beta-catenin</p> signaling{/NP_10} {VP_pass_11}is involved{/VP_pass_11} in {NP_12}the growth{/NP_12} of {NP_13}various types{/NP_13} of {NP_14}<Bpcl>cancer cells</Bpcl>{/NP_14} .

{NP_P_15}<p>Wnt3A</p>{/NP_P_15} {VP_pass_16}has been reported{/VP_pass_16} {VP_act_17}to promote{/VP_act_17} {NP_18}the self-renewal{/NP_18} of {NP_19}hematopoietic stem <Bpcl>cells</Bpcl>{/NP_19} .

{NP_20}MATERIALS{/NP_20} AND {NP_21}METHODS{/NP_21} : {NP_22}The effects{/NP_22} of {NP_P_23}recombinant <p>Wnt3A protein</p>{/NP_P_23} on {NP_24}the in vitro growth{/NP_24} of {NP_P_25}four <p>acute myeloid leukemia ( AML )</p>{/NP_P_25} and {NP_S_26}four acute <S>T-lymphoblastic leukemia ( T-ALL ) cell lines</S>{/NP_S_26} {VP_pass_27}was examined{/VP_pass_27} .

{NP_28}RESULTS{/NP_28} : {NP_29}<p>Wnt3A</p> stimulation{/NP_29} either {VP_act_30}had{/VP_act_30} {NP_31}no effect{/NP_31} on , or {VP_act_32}slightly suppressed{/VP_act_32} , {NP_33}the short-term growth{/NP_33} of {NP_34}these <Bpcl>cell lines</Bpcl>{/NP_34} .

In {NP_35}three <Bpcl>cell lines</Bpcl>{/NP_35} , {NP_P_36}<p>Wnt3A</p>{/NP_P_36} {VP_act_37}promoted{/VP_act_37} {NP_38}clonogenic <Bpcl>cell</Bpcl> recovery{/NP_38} after {NP_39}<Bpcl>suspension culture</Bpcl>{/NP_39} , {VP_act_40}suggesting{/VP_act_40} {NP_41}the promotion{/NP_41} of {NP_42}the self-renewal capacity{/NP_42} of {NP_43}leukemic stem or <Bpcl>progenitor cells</Bpcl>{/NP_43} .

OUTPUT 0
PTM = ({NP_P_48};phosphorylated)
Inducer = (-;-)
Kinase = (-;-)
	Candidates (Kinase):
		Candidate="<p>Wnt3A</p>" in "{NP_46}<p>Wnt3A</p> stimulation{/NP_46}" 	(Features:dist=0|in-title_elsewhere|subject_subnc_modifier)
		Candidate="<p>Wnt3A</p>" in "{NP_53}<p>Wnt3A</p> stimulation{/NP_53}" 	(Features:dist=0|in-title_elsewhere)
Substrate = ({NP_P_48}<p>beta-catenin</p>{/NP_P_48};-)
	Method=rule:1.4.2.1.2 (substrate) for phrase=[{NP_P_48}phosphorylated <p>beta-catenin</p>{/NP_P_48}14..25|<p>beta-catenin</p>]
Site = (-;-;UNK)

{NP_44}Immunoblot analysis{/NP_44} {VP_act_45}showed{/VP_act_45} that {NP_46}<p>Wnt3A</p> stimulation{/NP_46} {VP_act_47}reduced{/VP_act_47} {NP_P_48}phosphorylated <p>beta-catenin</p>{/NP_P_48} and {VP_act_49}increased{/VP_act_49} {NP_P_50}<p>beta-catenin</p>{/NP_P_50} in {NP_51}these <Bpcl>cells</Bpcl>{/NP_51} , {VP_act_52}indicating{/VP_act_52} that {NP_53}<p>Wnt3A</p> stimulation{/NP_53} {VP_act_54}activated{/VP_act_54} {NP_55}<p>Wnt/beta-catenin</p> signaling{/NP_55} .

{NP_56}CONCLUSION{/NP_56} : {NP_57}<p>Wnt3A</p> stimulation{/NP_57} {VP_act_neg_58}did not promote{/VP_act_neg_58} {NP_59}the growth{/NP_59} of {NP_60}whole <Bpcl>cell</Bpcl> populations{/NP_60} , but {VP_act_61}did promote{/VP_act_61} {NP_62}the self-renewal{/NP_62} of {NP_63}leukemic <Bpcl>stem/progenitor cells</Bpcl>{/NP_63} in {NP_S_64}some <p>AML</p> and <S>T-ALL cell lines</S>{/NP_S_64} .


{NP_1}PMID{/NP_1} - {CP_2}19035329{/CP_2}

{NP_3}TI{/NP_3} - [ {NP_4}Molecular evolution and correlation{/NP_4} of {NP_P_5}<p>HN</p>{/NP_P_5} and {NP_P_6}P <Bppf>gene</Bppf>{/NP_P_6} among {NP_7}the field Newcastle disease viruses{/NP_7} ] .

{NP_8}AB{/NP_8} - {NP_9}The goal{/NP_9} of {NP_10}this study{/NP_10} {VP_act_11}is{/VP_act_11} {VP_act_12}to research{/VP_act_12} {NP_13}the genetic characteristics and relationship{/NP_13} between {NP_P_14}<p>HN</p> and <p>P genes</p>{/NP_P_14} of {NP_B_15}<s><B>NDV</B></s>{/NP_B_15} .

OUTPUT 0
PTM = ({NP_P_19};Phosphoprotein)
Inducer = (-;-)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;UNK)

{NP_PP_16}The nucleotide <Bppp>sequence</Bppp>{/NP_PP_16} and {NP_PP_17}deduced <Bppp>amino acid sequence</Bppp>{/NP_PP_17} {VP_pass_18}were analyzed{/VP_pass_18} for {NP_P_19}the <p>Hemagglutinin-neuramindase ( HN )</p> and <p>Phosphoprotein (P) gene</p>{/NP_P_19} of {NP_20}twelve field{/NP_20} {VP_act_21}isolates{/VP_act_21} of {NP_B_22}<B><s>Newcastle disease virus</s> ( NDV )</B>{/NP_B_22} during {CP_23}1997-2005{/CP_23} in {NP_B_24}<B>China</B>{/NP_B_24} .

{NP_PP_25}The <p>HN</p> and <pp><p>P gene</p> sequences</pp>{/NP_PP_25} of {NP_S_26}fifteen <S><s>NDV</s> reference strains</S>{/NP_S_26} from {NP_B_27}<B>GenBank</B>{/NP_B_27} {VP_pass_28}were also used{/VP_pass_28} in {NP_29}this study{/NP_29} .

{NP_30}The molecular evolution distance{/NP_30} of {NP_31}nucleotides{/NP_31} and {NP_PP_32}<Bppp>amino acids</Bppp>{/NP_PP_32} {VP_pass_33}were calculated{/VP_pass_33} by {NP_34}<B>MEGA 4.0</B> software{/NP_34} , and {NP_35}analysis{/NP_35} of {NP_36}variance{/NP_36} and {NP_37}correlations{/NP_37} {VP_pass_38}were analyzed{/VP_pass_38} by {NP_39}<B>SPSS11.0</B> software{/NP_39} among {NP_PP_40}different length <Bppp>sequences</Bppp>{/NP_PP_40} of {NP_P_41}the <p>HN gene</p> or <p>P gene</p>{/NP_P_41} .

{NP_42}The nucleotide and <Bppp>amino acids</Bppp> correlation{/NP_42} of {NP_P_43}<p>HN</p> and <p>P gene</p>{/NP_P_43} {VP_pass_44}were analyzed{/VP_pass_44} {AV_45}respectively{/AV_45} .

{NP_46}The correlation{/NP_46} of {NP_47}evolution distance{/NP_47} and {NP_48}isolation year{/NP_48} {VP_pass_49}were also calculated{/VP_pass_49} .

{NP_50}The results{/NP_50} {VP_act_51}indicated{/VP_act_51} that there {VP_pass_52}were{/VP_pass_52} {NP_53}difference{/NP_53} and {NP_54}good correlation{/NP_54} of {NP_55}nucleotide{/NP_55} and {NP_PP_56}<Bppp>amino acid</Bppp>{/NP_PP_56} among {NP_PP_57}different length <Bppp>sequences</Bppp>{/NP_PP_57} of {NP_P_58}the <p>HN gene</p> or <p>P gene</p>{/NP_P_58} .

{NP_59}These results{/NP_59} {VP_act_60}revealed{/VP_act_60} that {NP_P_61}the <p>HN</p> and <p>P gene</p>{/NP_P_61} of {NP_B_62}<s><B>NDV</B></s>{/NP_B_62} {VP_act_63}have{/VP_act_63} {NP_64}the different response{/NP_64} to {NP_65}selective pressure{/NP_65} {VP_act_66}to adopt{/VP_act_66} to {NP_67}landscape{/NP_67} and {NP_68}closely relationship{/NP_68} on {NP_69}heredity mutations{/NP_69} .

{NP_70}Nucleotide variations{/NP_70} of {NP_P_71}<p>HN</p> and <p>P gene</p>{/NP_P_71} {VP_act_72}have{/VP_act_72} {NP_73}relationship{/NP_73} with {NP_74}isolation year{/NP_74} of {NP_75}<Bpcl>strains</Bpcl>{/NP_75} .


{NP_1}PMID{/NP_1} - {CP_2}19035848{/CP_2}

{NP_3}TI{/NP_3} - {NP_4}Optimization{/NP_4} of {NP_5}a homogeneous assay{/NP_5} for {NP_P_6}<Bppf>kinase inhibitors</Bppf>{/NP_P_6} in {NP_7}plant extracts{/NP_7} .

{NP_8}AB{/NP_8} - To {VP_act_9}identify{/VP_act_9} {NP_P_10}natural and original <Bppf>kinase inhibitors</Bppf>{/NP_P_10} from {NP_11}plant extracts{/NP_11} , {NP_12}we{/NP_12} {VP_act_13}have developed{/VP_act_13} and {VP_act_14}compared{/VP_act_14} {NP_P_15}a heterogeneous <p>enzyme-linked immunosorbent assay ( ELISA )</p>{/NP_P_15} and {NP_16}a homogeneous time-resolved fluorescence{/NP_16} ( {NP_B_17}<B>HTRF</B>{/NP_B_17} , {NP_B_18}<B>Cisbio International</B>{/NP_B_18} , {NP_B_19}<B>Bagnols/Ceze</B>{/NP_B_19} , {NP_B_20}<B>France</B>{/NP_B_20} ) {NP_21}assay{/NP_21} .

OUTPUT 0
PTM = ({NP_P_23};substrate)
Inducer = (-;-)
Kinase = ({NP_P_23}<p>ATP</p>{/NP_P_23};-)
	Method=rule:1.16.1 (kinase) for phrase=[{NP_P_23}the <Bppf><p>ATP</p> substrate</Bppf>{/NP_P_23}3..5|<p>ATP</p>]
Substrate = (-;-)
Site = (-;-;UNK)

{NP_22}<Bppf>Kinase</Bppf> affinity{/NP_22} for {NP_P_23}the <Bppf><p>ATP</p> substrate</Bppf>{/NP_P_23} {VP_pass_24}was determined{/VP_pass_24} in {NP_25}both assays{/NP_25} , and {NP_26}the same <B>[<p>ATP</p>]/ATP Km</B> ratio{/NP_26} {VP_pass_27}was used{/VP_pass_27} in {NP_28}each case{/NP_28} {VP_act_29}to enable{/VP_act_29} {NP_30}the identification{/NP_30} of {NP_P_31}<p>ATP</p> competitive and noncompetitive <Bppf>inhibitors</Bppf>{/NP_P_31} .

{NP_32}Assays{/NP_32} {VP_pass_33}were then used{/VP_pass_33} {VP_act_34}to screen{/VP_act_34} {NP_35}the same collection{/NP_35} of {NP_36}<Bpcf>chemical compounds</Bpcf> and plant extracts{/NP_36} .

{NP_37}The intra-assay correlation analysis{/NP_37} of {NP_38}each technology{/NP_38} {VP_act_39}showed{/VP_act_39} {NP_40}a very good screening precision{/NP_40} in {NP_B_41}<B>HTRF</B>{/NP_B_41} and an {JP_42}acceptable{/JP_42} {CP_43}one{/CP_43} in {NP_P_44}<p>ELISA</p>{/NP_P_44} .

When {NP_45}the two methods{/NP_45} {VP_pass_46}were compared{/VP_pass_46} , {NP_47}a poor correlation{/NP_47} {VP_pass_48}was obtained{/VP_pass_48} with a {VP_act_49}higher hit{/VP_act_49} {NP_50}rate{/NP_50} in {NP_P_51}the <p>ELISA</p>{/NP_P_51} .

{NP_52}We{/NP_52} {AV_53}then{/AV_53} {VP_act_54}performed{/VP_act_54} {NP_55}a detailed study{/NP_55} of {NP_56}the <p>ELISA</p> hits{/NP_56} and {VP_act_57}showed{/VP_act_57} that {NP_58}they{/NP_58} {VP_act_59}also presented{/VP_act_59} {NP_60}a strong antioxidant activity{/NP_60} , {VP_act_61}associated{/VP_act_61} with {NP_62}high adsorption{/NP_62} into {NP_63}microplate wells{/NP_63} , {NP_64}which{/NP_64} {VP_act_65}interfered{/VP_act_65} with {NP_66}the <s>horseradish</s> peroxidase-based detection system{/NP_66} .

{NP_67}These hits{/NP_67} {VP_pass_68}were then flagged{/VP_pass_68} as {NP_69}false-positives{/NP_69} .

{NP_70}We{/NP_70} {VP_act_71}also showed{/VP_act_71} that {NP_72}many plant extracts{/NP_72} {VP_act_73}presented{/VP_act_73} {NP_74}this kind{/NP_74} of {NP_75}activity{/NP_75} and that {NP_76}this interference{/NP_76} {VP_act_77}could explain{/VP_act_77} {NP_78}the lack{/NP_78} of {NP_79}correlation{/NP_79} between {NP_80}the assays{/NP_80} .

{NP_81}These findings{/NP_81} {VP_act_82}suggest{/VP_act_82} that {NP_83}assay design{/NP_83} {VP_pass_84}should be carefully adapted{/VP_pass_84} to {NP_85}the substances{/NP_85} {VP_pass_86}to be screened{/VP_pass_86} and that {NP_87}interferences{/NP_87} {VP_pass_88}should be extensively considered{/VP_pass_88} before {NP_89}any assay development process and comparison studies{/NP_89} .

In {NP_90}spite{/NP_90} of {NP_91}a few interferences{/NP_91} , {NP_92}our results{/NP_92} {VP_act_93}showed{/VP_act_93} that {NP_94}a homogeneous-phase assay{/NP_94} like {NP_95}the <B>HTRF</B> assay{/NP_95} {VP_pass_96}could be more efficiently used{/VP_pass_96} for {NP_97}plant extract screening{/NP_97} than {NP_98}a heterogeneous-phase assay{/NP_98} like {NP_P_99}<p>ELISA</p>{/NP_P_99} .


